RNA Interactome of Polycomb Repressive Complex 1 (PRC1)

ABSTRACT

This invention relates to polycomb-associated RNAs, libraries and fragments of those RNAs, inhibitory nucleic acids and methods and compositions for targeting RNAs, and methods of use thereof.

CLAIM OF PRIORITY

This application is a continuation of U.S. patent application Ser. No. 15/558,974, filed Sep. 15, 2017, which is a U.S. National Phase Application under 35 U.S.C. § 371 of International Patent Application No. PCT/US2016/022778, filed on Mar. 17, 2016, which claims the benefit of U.S. Provisional Patent Application Ser. No. 62/134,361, filed on Mar. 17, 2015. The entire contents of the foregoing are hereby incorporated by reference.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government support under Grant No. RO1-DA36895 awarded by the National Institutes of Health. The Government has certain rights in the invention.

TECHNICAL FIELD

This invention relates to the RNA interactome of Polycomb Repressive Complex 1 (PRC1) and methods of using inhibitory nucleic acids that bind RNAs and inhibit the PRC1-RNA interaction to modulate gene expression.

BACKGROUND

Transcriptome analyses have suggested that, although only 1-2% of the mammalian genome is protein-coding, 70-90% is transcriptionally active (Carninci et al., 2005; Kapranov et al., 2007; Mercer et al., 2009). Ranging from 100 nt to >100 kb, these transcripts are largely unknown in function, may originate within or between genes, and may be conserved and developmentally regulated (Kapranov et al., 2007; Guttman et al., 2009). Recent discoveries argue that a subset of these transcripts play crucial roles in epigenetic regulation.

RNA-mediated recruitment is especially attractive for Polycomb proteins. First identified in Drosophila as homeotic regulators, Polycomb proteins are conserved from flies to mammals and control many aspects of development (Ringrose and Paro, 2004; Boyer et al., 2006; Lee et al., 2006; Schuettengruber et al., 2007; Pietersen and van Lohuizen, 2008; Schwartz and Pirrotta, 2008).

Polycomb Repressive Complex 1 (PRC1) is the enzymatic complex that ubiquitylates histone H2A at lysine 119 (H2AK119Ub). In mammals, it is composed of multiple variable subunits, including (1) the catalytic subunit, Ring1b or Ring1a; (2) Bmi1 (which can be PCGF1, PCGF2, PCGF3, PCGF5, or PCGF6); (3) PH1 (or PH2, PH3); and (4) CBX2, 4, 6, 7, or 8. Action of PRC1 on chromatin results in chromatin compaction and transcriptional repression. The classical PRC1 complex exists in two forms in which either CBX and MPH or RYBP subunits associate with the catalytic core subunits RING1A/B and PCGF2/4. The PRC1 interacting protein, SCMLH1/2/3, is only weakly associated/substoichiometric and is considered an accessory factor, rather than a core component. The RanBP-ZF domain present in RYBP/YAF2 has an RNA binding function in some related proteins but apparently not in RYBP/YAF2. See, e.g., Brockdorff, RNA 19:429-442 (2013); Yap et al., Mol Cell. 38(5):662-74 (2010).

Although PRC1 binds thousands of sites in the mammalian genome, how PRC1 is targeted to chromatin has remained a mystery. YY1 and the H3K27me3 chromatin mark may recruit PRC1 in some contexts, but they are unlikely to be the general or only mechanisms. RNA-mediated targeting is another potential mechanism. PRC1 is known to interact with at least one RNA, ANRIL, likely via the chromodomain (CD) of the CBX7 protein (Yap et al., Mol Cell. 38(5):662-74 (2010)). ANRIL is an antisense non-coding RNA (ncRNA) at the INK4b/ARF/INK4a locus (Pasmant et al., Cancer Res 67: 3963-3969 (2007)). How many RNAs interact with PRC1 and whether they are a general recruiting tool for PRC1 has not previously been determined.

SUMMARY

A new ‘denaturing’ CLIP-seq method was developed using the biotin-avidin method, which enables washes in high salt and urea (i.e., protein denaturing conditions). Because the exemplified system includes two protein tags, FLAG and biotin, purification can be performed with either tag or conducted as a tandem affinity purification (e.g., FLAG purification first, followed by biotin pulldown). For the denaturing method, the biotin tag is preferably used. During CLIP, because the interacting RNAs are UV-crosslinked to RNA-binding proteins in a covalent fashion, the RNA-protein interactions survive the wash conditions, whereas nonspecific, low-affinity interactions are not preserved. These methods were used to identify genome-wide pools of polycomb repressive complex 1 (PRC1)-interacting RNAs (referred to herein as the “PRC1 transcriptome” or “PRC1 RNA interactome”) in several cell types, including embryonic stem cells and human fibroblast cells.

The results of the studies described herein demonstrated that PRC1 binds both noncoding RNA and coding RNA. The transcriptome includes antisense, intergenic, and promoter-associated transcripts, as well as many unannotated RNAs. A large number of transcripts occur within imprinted regions, oncogene and tumor suppressor loci, and stem-cell-related bivalent domains. Further evidence is provided that inhibitory oligonucleotides that specifically bind to these PRC1-interacting RNAs can successfully modulate gene expression in a variety of separate and independent examples, presumably by inhibiting PRC1-associated effects. PRC1 binding sites can be classified into several groups, including (i) 3′ untranslated region [3′ UTR], (ii) promoter-associated, (iii) gene body, (iv) antisense, and (v) intergenic. Inhibiting the PRC1-RNA interactions can lead to either activation or repression, depending on context.

Also provided herein are methods for isolating RNA sequences that interact with a selected protein, e.g., with chromatin complexes, in a cell; the methods include providing a cell expressing (i) a biotin ligase, e.g., BirA, and (ii) the protein of interest comprising a biotinylation sequence; exposing the cells to UV-crosslinking; lysing the cells, isolating protein-RNA complexes from the lysed cells, e.g., using avidin purification, e.g., streptavidin beads; washing the complexes in protein-denaturing conditions, e.g., high salt and detergent, e.g., using 8 M urea+0.1% SDS; and isolating the protein-RNA complexes.

In one aspect, described herein are methods for isolating RNA sequences that interact with a selected protein, e.g., with chromatin complexes. The methods include providing a cell expressing (i) a biotin ligase, e.g., BirA, and (ii) the protein of interest comprising a biotinylation sequence; exposing the cells to UV-crosslinking to crosslink the proteins to RNA, to create protein-RNA complexes; lysing the cells to obtain a sample comprising the protein-RNA complexes; isolating protein-RNA complexes from the lysed cells, e.g., using avidin purification, e.g., streptavidin beads; washing the complexes in protein-denaturing conditions, e.g., high salt and detergent, e.g., using 8 M urea+0.1% SDS; and isolating the protein-RNA complexes.

In some embodiments, the methods include optionally preparing a plurality of validated cDNAs complementary to the pool of ribonucleic acids (RNAs) that bind to the protein of interest; these methods include synthesizing DNA complementary to the RNAs to provide an initial population of cDNAs; PCR-amplifying, if necessary, using strand-specific primers; purifying the initial population of cDNAs to obtain a purified population of cDNAs that are at least about 20 nucleotides (nt) in length, e.g., at least 25, 50, 75, 100, 150, 200, or 250 nt in length; sequencing at least part or substantially all of the purified population of cDNAs; aligning reads to a reference genome and retaining only those that are aligned; selecting high-confidence cDNA sequences, optionally, based on criteria that (1) the candidate transcript has a minimum read density in reads per kilobase per million reads (RPKM) terms (e.g., above a desired threshold); and/or (2) the candidate transcript is enriched in the wildtype library versus a suitable control library (such as an IgG pulldown library or a protein-null pulldown library); thereby preparing the plurality of cDNAs. In some embodiments, the cDNAs are synthesized using strand-specific adaptors.

In some embodiments, the method is used to prepare a library representing a transcriptome associated with the protein of interest.

In some embodiments, the methods further include sequencing substantially all of the cDNAs.

In another aspect the invention features an inhibitory nucleic acid that specifically binds to, or is complementary to a region of an RNA that is known to bind to Polycomb repressive complex 1 (PRC1), wherein the sequence of the region is selected from the group consisting of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) as set forth in Tables 1-3. Without being bound by a theory of invention, these inhibitory nucleic acids are able to interfere with the binding of and function of PRC1, by preventing recruitment of PRC1 to a specific chromosomal locus. For example, data herein shows that a single administration of inhibitory nucleic acids designed to specifically bind a RNA can alter expression of a gene associated with the RNA. Data provided herein also indicate that putative ncRNA binding sites for PRC1 show no conserved primary sequence motif, making it possible to design specific inhibitory nucleic acids that will interfere with PRC1 interaction with a single ncRNA, without generally disrupting PRC1 interactions with other ncRNAs. Further, data provided herein support that RNA can recruit PRC1 in a cis fashion, repressing gene expression at or near the specific chromosomal locus from which the RNA was transcribed, thus making it possible to design inhibitory nucleic acids that inhibit the function of PRC1 and increase the expression of a specific target gene.

In some embodiments, the inhibitory nucleic acid is provided for use in a method of modulating expression of a “gene targeted by the PRC1-binding RNA” (e.g., an intersecting or nearby gene, as set forth in Tables 1-3 below), meaning a gene whose expression is regulated by the PRC1-binding RNA. The term “PRC1-binding RNA” or “RNA that binds PRC1” is used interchangeably with “PRC1-associated RNA” and “PRC1-interacting RNA”, and refers to an RNA transcript or a region thereof (e.g., a Peak as described below) that binds the PRC1 complex, directly or indirectly. Such binding may be determined by dCLIP-SEQ techniques described herein using a component of the PRC1 complex, e.g., PRC1 itself. SEQ ID NOs: 1 to 5893 represent human RNA sequences containing portions that have been experimentally determined to bind PRC1 using the dCLIP-seq method described herein; SEQ ID NOs: 17416 to 36368 represent murine RNA sequences containing portions that have been experimentally determined to bind PRC1 using the dCLIP-seq method described herein; and SEQ ID NOs: 5894 to 17415 represent or human RNA sequences corresponding to the murine RNA sequences.

Such methods of modulating gene expression may be carried out in vitro, ex vivo, or in vivo. Tables 1-3 display genes targeted by the PRC1-binding RNA; the SEQ ID NOS: of the PRC1-associated RNA are set forth in the same row as the gene name. In some embodiments, the inhibitory nucleic acid is provided for use in a method of treating disease, e.g. a disease category as described herein. The treatment may involve modulating expression (either up or down) of a gene targeted by the PRC1-binding RNA, preferably upregulating gene expression. The inhibitory nucleic acid may be formulated as a sterile composition for parenteral administration. It is understood that any reference to uses of compounds throughout the description contemplates use of the compound in preparation of a pharmaceutical composition or medicament for use in the treatment of a disease. Thus, as one nonlimiting example, this aspect of the invention includes use of such inhibitory nucleic acids in the preparation of a medicament for use in the treatment of disease, wherein the treatment involves upregulating expression of a gene targeted by the PRC1-binding RNA.

Diseases, disorders or conditions that may be treated according to the invention include cardiovascular, metabolic, inflammatory, bone, neurological or neurodegenerative, pulmonary, hepatic, kidney, urogenital, bone, cancer, and/or protein deficiency disorders.

In a related aspect, the invention features a process of preparing an inhibitory nucleic acid that modulates gene expression, the process comprising the step of synthesizing an inhibitory nucleic acid of between 5 and 40 bases in length, or about 8 to 40, or about 5 to 50 bases in length, optionally single stranded, that specifically binds, or is complementary to, an RNA sequence that has been identified as binding to PRC1, optionally an RNA of any of Tables 1-3 or any one of SEQ ID NOs: 1 to 5893, or 5894 to 17415, or 17416 to 36368. This aspect of the invention may further comprise the step of identifying the RNA sequence as binding to PRC1, optionally through the dCLIP-seq method described herein.

In a further aspect of the present invention a process of preparing an inhibitory nucleic acid that specifically binds to an RNA that binds to Polycomb repressive complex 1 (PRC1) is provided, the process comprising the step of designing and/or synthesizing an inhibitory nucleic acid of between 5 and 40 bases in length, or about 8 to 40, or about 5 to 50 bases in length, optionally single stranded, that specifically binds to an RNA sequence that binds to PRC1, optionally an RNA of any of Tables 1-3 or any one of SEQ ID NOs: 1 to 5893, or 5894 to 17415, or 17416 to 36368.

In some embodiments prior to synthesizing the inhibitory nucleic acid the process further comprises identifying an RNA that binds to PRC1.

In some embodiments the RNA has been identified by a method involving identifying an RNA that binds to PRC1.

In some embodiments the inhibitory nucleic acid is at least 80% complementary to a contiguous sequence of between 5 and 40 bases, or about 8 to 40, or about 5 to 50 bases in said RNA sequence that binds to PRC1. In some embodiments the sequence of the designed and/or synthesized inhibitory nucleic acid is based on a said RNA sequence that binds to PRC1, or a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 bases, or about 5 to 50 bases.

In some embodiments the sequence of the designed and/or synthesized inhibitory nucleic acid is based on a nucleic acid sequence that is complementary to said RNA sequence that binds to PRC1, or is complementary to a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 base pairs, or about 5 to 50 base pairs.

The designed and/or synthesized inhibitory nucleic acid may be at least 80% complementary to (optionally one of at least 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) the portion of the RNA sequence to which it binds or targets, or is intended to bind or target. In some embodiments it may contain 1, 2 or 3 base mismatches compared to the portion of the target RNA sequence or its complement respectively. In some embodiments it may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.

The inhibitory nucleic acid or portion of RNA sequence that binds to PRC1 may have a length of one of at least 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 bases, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases. Where the inhibitory nucleic acid is based on an RNA sequence that binds to PRC1, a nucleic acid sequence that is complementary to said RNA sequence that binds to PRC1 or a portion of such a sequence, it may be based on information about that sequence, e.g. sequence information available in written or electronic form, which may include sequence information contained in publicly available scientific publications or sequence databases.

In some embodiments, the isolated single stranded oligonucleotide is of 5 to 40 nucleotides in length and has a region of complementarity that is complementary with at least 5 contiguous nucleotides of the PRC1-binding RNA that inhibits expression of the target gene, wherein the oligonucleotide is complementary to and binds specifically within a PRC1-binding region of the PRC1-binding RNA and interferes with binding of PRC1 to the PRC1-binding region without inducing degradation of the PRC1-binding RNA (e.g., wherein the PRC1-binding region has a nucleotide sequence identified using a denaturing cross-linking immunoprecipitation procedure using an a biotin-tagged PRC1 as described herein), and without interfering with binding of PRC2 to a PRC2-binding region of the RNA (as described in WO 2012/087983 or WO 2012/065143, wherein the PRC2-binding region has a nucleotide sequence protected from nucleases during an RNA immunoprecipitation procedure using an antibody directed against PRC2), optionally wherein the PRC1-binding RNA is transcribed from a sequence of the chromosomal locus of the target gene, and optionally wherein a decrease in recruitment of PRC1 to the target gene in the cell following delivery of the single stranded oligonucleotide to the cell, compared with an appropriate control cell to which the single stranded oligonucleotide has not been delivered, indicates effectiveness of the single stranded oligonucleotide.

Where the design and/or synthesis involves design and/or synthesis of a sequence that is complementary to a nucleic acid described by such sequence information the skilled person is readily able to determine the complementary sequence, e.g. through understanding of Watson-Crick base pairing rules which form part of the common general knowledge in the field.

In the methods described above the RNA that binds to PRC1 may be, or have been, identified, or obtained, by a method that involves identifying RNA that binds to PRC1.

Such methods may involve the following steps: providing a sample containing nuclear ribonucleic acids, contacting the sample with an agent that binds specifically to PRC1 or a subunit thereof, allowing complexes to form between the agent and protein in the sample, partitioning the complexes, synthesizing nucleic acid that is complementary to nucleic acid present in the complexes.

If necessary, the method may further comprise the steps of amplifying the synthesized nucleic acid, and/or purifying the nucleic acid (or amplified nucleic acid), and/or sequencing the nucleic acids so obtained, and/or filtering/analysing the nucleic acids so obtained to identify high-probability PRC1 (or subunit thereof)-interacting transcripts.

In one embodiment the method involves the dCLIP-Seq method described herein.

In accordance with the above, in some embodiments the RNA that binds to PRC1 may be one that is known to bind PRC1, e.g. information about the sequence of the RNA and/or its ability to bind PRC1 is available to the public in written or electronic form allowing the design and/or synthesis of the inhibitory nucleic acid to be based on that information. As such, an RNA that binds to PRC1 may be selected from known sequence information and used to inform the design and/or synthesis of the inhibitory nucleic acid.

In other embodiments the RNA that binds to PRC1 may be identified as one that binds PRC1 as part of the method of design and/or synthesis.

In preferred embodiments design and/or synthesis of an inhibitory nucleic acid involves manufacture of a nucleic acid from starting materials by techniques known to those of skill in the art, where the synthesis may be based on a sequence of an RNA (or portion thereof) that has been selected as known to bind to Polycomb repressive complex 2.

Methods of design and/or synthesis of an inhibitory nucleic acid may involve one or more of the steps of:

Identifying and/or selecting a portion of an RNA sequence that binds to PRC1 (e.g., as shown in Tables 1-3);

Designing a nucleic acid sequence having a desired degree of sequence identity or complementarity to an RNA sequence that binds to PRC1 or a portion thereof;

Synthesizing a nucleic acid to the designed sequence;

Mixing the synthesized nucleic acid with at least one pharmaceutically acceptable diluent, carrier or excipient to form a pharmaceutical composition or medicament.

Inhibitory nucleic acids so designed and/or synthesized may be useful in method of modulating gene expression as described herein.

As such, the process of preparing an inhibitory nucleic acid may be a process that is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene targeted by the RNA binds to PRC1.

Thus, provided herein are methods for isolating RNA sequences that interact with a selected protein, e.g., with chromatin complexes, in a cell. The methods include providing a cell expressing (i) a biotin ligase, e.g., BirA, and (ii) the protein of interest comprising a biotinylation sequence; exposing the cells to UV-crosslinking; lysing the cells, isolating protein-RNA complexes from the lysed cells, e.g., using avidin purification, e.g., streptavidin beads; washing the complexes in protein-denaturing conditions, e.g., high salt and detergent, e.g., using 8 M urea+0.1% SDS; and isolating the protein-RNA complexes. In some embodiments, the methods include labelling the RNA in the RNA-protein complexes, e.g., by phosphorylation using ³²P-ATP. In some embodiments, the methods include purifying the RNA-protein complexes, preparing cDNA from the RNA, and deep sequencing the cDNA to identify the RNA sequences bound to the protein.

Also provided are kits for use in the methods described herein; these kits include an expression vector comprising a sequence encoding a biotin ligase, and an expression vector comprising a sequence encoding a biotinylation sequence, and optionally one or more buffers. In some embodiments, the the buffers include one or more of a high stringency denaturing buffer, e.g., comprising 8 M urea (range: 5-10 M, 6-10M, 7-10M, 7-9M, or 7.5-8.5M) plus 0.1% SDS (range: 0.0-2.0%); a wash buffer (e.g., PBS+2% SDS; and a high salt wash buffer (e.g., PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS).

In yet another aspect, the invention provides isolated nucleic acids comprising a sequence referred to in any of Tables 1-3, or a fragment comprising at least 20 nt thereof. In some or any embodiments, the invention provides an isolated nucleic acid comprising (a) an RNA sequence as set forth in Tables 1-3 that targets a proto-oncogene or oncogene as set forth in Tables 1-3, or (b) a fragment of (a) that is at least 20 bases in length that retains PRC1-binding activity, or (c) a derivative of (a) or (b) that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous thereto, or (d) a nucleic acid of (a), (b), or (c) in which one or more bases has been replaced with a base of similar base-pairing capacity, such as replacing U with T. In preferred embodiments, the isolated nucleic acid of (a), (b) or (c) is for use in a method of decreasing expression of an oncogene. In some embodiments, the isolated nucleic acid is synthetic. In some embodiments, the isolated RNA comprises a SEQ ID NO. associated with Pvt1 in Tables 1-3. Pvt1 is known in the art to be disrupted in some cases of Burkitt's lymphoma as well as in plasmacytomas (e.g., by translocations from another chromosome). Therefore, Pvt1 is likely to act by targeting PRC1 to c-Myc in order to repress its expression. Accordingly, exogenous administration of any of the RNA sequences associated with Pvt1 in Tables 1-3, or inhibitory nucleic acids complementary thereto, could rescue Pvt1 loss-of-function phenotypes contributing to various cancers.

In a further aspect, the invention provides methods for decreasing expression of an oncogene in a cell. In some embodiments, the methods include contacting the cell with a PRC1-binding fragment described in any of Tables 1-3, or a nucleic acid sequence that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous to a PRC1-binding fragment as referred to in any of Tables 1-3. In exemplary methods, the RNA a nucleic acid in which one or more bases has been replaced with a base of similar base-pairing capacity, such as replacing U with T. PRC1-binding fragments of murine or orthologous ncRNAs, including human ncRNA, which retain the ncRNA's ability to bind PRC1, are contemplated.

In yet another aspect, the invention features methods for increasing expression of a tumor suppressor in a mammal, e.g. human, in need thereof. The methods include administering to said mammal an inhibitory nucleic acid that specifically binds, or is complementary, to a human PRC1-interacting RNA corresponding to a tumor suppressor locus of any of Tables 1-3 or a human RNA corresponding to an imprinted gene of any of Tables 1-3, or a related naturally occurring RNA that is othologous or at least 90%, (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%%, or 100%) identical over at least 15 (e.g., at least 20, 21, 25, 30, 100) nucoleobases thereof, in an amount effective to increase expression of the tumor suppressor or growth suppressing gene. It is understood that one method of determining human orthologous RNA that corresponds to murine RNA is to identify a corresponding human sequence at least 90% identical (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to at least 15 nucleobases of the murine sequence (or at least 20, 21, 25, 30, 40, 50, 60, 70, 80, 90 or 100 nucleobases).

In an additional aspect, the invention provides methods for inhibiting or suppressing tumor growth in a mammal, e.g. human, with cancer, comprising administering to said mammal an inhibitory nucleic acid that specifically binds, or is complementary, to a human PRC1-interacting RNA corresponding to a tumor suppressor locus of any of Tables 1-3, or a human RNA corresponding to an imprinted gene of any of Tables 1-3, or a related naturally-occurring RNA that is orthologous or at least 90%, (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical over at least 15 (e.g., at least 20, 21, 25, 30, 50, 70, 100) nucleobases thereof, in an amount effective to suppress or inhibit tumor growth.

In another aspect, the invention features methods for treating a mammal, e.g., a human, with cancer comprising administering to said mammal an inhibitory nucleic acid that specifically binds, or is complementary, to a human RNA corresponding to a tumor suppressor locus of any of Tables 1-3, or a human RNA corresponding to an imprinted gene of Tables 1-3, or a related naturally occurring RNA that is orthologous or at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical over at least 15 (e.g., at least 20, 21, 25, 30, 50, 70, 100) nucleobases thereof, in a therapeutically effective amount.

Also provided herein are inhibitory nucleic acids that specifically bind, or are complementary to, a region of an RNA that is known to bind to Polycomb repressive complex 1 (PRC1), wherein the sequence of the region is selected from the group consisting of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) as set forth in Tables 1-3, for use in the treatment of disease, wherein the treatment involves modulating expression of a gene targeted by the RNA, wherein the inhibitory nucleic acid is between 5 and 40 bases in length, and wherein the inhibitory nucleic acid is formulated as a sterile composition.

Further described herein are processs for preparing an inhibitory nucleic acid that specifically binds, or is complementary to, an RNA that is known to bind to Polycomb repressive complex 1 (PRC1), selected from the group consisting of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) as set forth in Tables 1-3; the processes include the step of designing and/or synthesizing an inhibitory nucleic acid of between 5 and 40 bases in length, optionally single stranded, that specifically binds to a region of the RNA that binds PRC1.

In some embodiments, the sequence of the designed and/or synthesized inhibitory nucleic acid is a nucleic acid sequence that is complementary to said RNA sequence that binds to PRC1, or is complementary to a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs.

In some embodiments, the inhibitory nucleic acid is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene targeted by the RNA binds to PRC1.

In some embodiments, the modulation is increasing expression of a gene and the region of the RNA that binds PRC1 can be in intergenic space mapping to a noncoding RNA, antisense to the coding gene, or in the promoter, 3′UTR, 5′UTR, exons, and introns of a coding gene.

In some embodiments, the modulation is decreasing expression of a gene and the region of the RNA that binds PRC1 can be in intergenic space mapping to a noncoding RNA, antisense to the coding gene, or in the promoter, 3′UTR, 5′UTR, exons, and introns of a coding gene.

In some embodiments, the modulation is to influence gene expression by altering splicing of a gene and the region of the RNA that binds PRC1 can be in intergenic space mapping to a noncoding RNA, antisense to the coding gene, or in the promoter, 3′UTR, 5′UTR, exons, and introns of a coding gene.

Also provided herein are sterile compositions comprising an inhibitory nucleic acid that specifically binds, or is complementary to, an RNA sequence of any one of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) and is capable of modulating expression of a gene targeted by the RNA as set forth in Tables 1-3.

In some embodiments, the composition is for parenteral administration. In some embodiments, the RNA sequence is in the 3′UTR of a gene, and the inhibitory nucleic acid is capable of upregulating or downregulating expression of a gene targeted by the RNA.

Also provided herein is an inhibitory nucleic acid for use in the treatment of disease, wherein said inhibitory nucleic acid specifically binds, or is complementary to, an RNA sequence of any one of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human), and wherein the treatment involves modulating expression of a gene targeted by the RNA according to Tables 1-3.

The present disclosure also provides methods for modulating gene expression in a cell or a mammal comprising administering to the cell or the mammal an inhibitory nucleic acid that specifically binds, or is complementary to, an RNA sequence of any one of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human) or 17416 to 36368 (mouse), in an amount effective for modulating expression of a gene targeted by the RNA according to Table 1-3.

In addition, provided herein are inhibitory nucleic acids of about 5 to 50 bases in length that specifically bind, or are complementary to, a fragment of at least five consecutive bases within any of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human) or 17416 to 36368 (mouse), optionally for use in the treatment of disease, wherein the treatment involves modulating expression of a gene targeted by the RNA.

In addition, provided are methods for modulating expression of a gene comprising administering to a mammal an inhibitory nucleic acid as described herein in an amount effective for modulating expression of a gene targeted by the RNA as set forth in Tables 1-3.

In some embodiments, the modulation is upregulating or downregulating gene expression, optionally wherein the gene targeted by the RNA is selected from the group set forth in Tables 1-3, and wherein the RNA sequence is listed in the same row as the gene.

In some embodiments, the inhibitory nucleic acid is 5 to 40 bases in length (optionally 12-30, 12-28, or 12-25 bases in length).

In some embodiments, the inhibitory nucleic acid is 10 to 50 bases in length.

In some embodiments, the inhibitory nucleic acid comprises a base sequence at least 90% complementary to at least 10 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases at least 80% or 90% complementary to, e.g., at least 5-30, 10-30, 15-30, 20-30, 25-30 or 5-40, 10-40, 15-40, 20-40, 25-40, or 30-40 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases with up to 3 mismatches (e.g., up to 1, or up to 2 mismatches) in complementary base pairing over 10, 15, 20, 25 or 30 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases at least 80% complementary to at least 10 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases with up to 3 mismatches over 15 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid is single stranded.

In some embodiments, the inhibitory nucleic acid is double stranded.

In some embodiments, the inhibitory nucleic acid comprises one or more modifications comprising: a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof.

In some embodiments, the inhibitory nucleic acid is an antisense oligonucleotide, LNA molecule, PNA molecule, ribozyme or siRNA.

In some embodiments, the inhibitory nucleic acid is double stranded and comprises an overhang (optionally 2-6 bases in length) at one or both termini.

In some embodiments, the inhibitory nucleic acid is selected from the group consisting of antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, micro RNAs (miRNAs); small, temporal RNAs (stRNA), and single- or double-stranded RNA interference (RNAi) compounds.

In some embodiments, the RNAi compound is selected from the group consisting of short interfering RNA (siRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); and small activating RNAs (saRNAs).

In some embodiments, the antisense oligonucleotide is selected from the group consisting of antisense RNAs, antisense DNAs, and chimeric antisense oligonucleotides.

In some embodiments, the modified internucleoside linkage comprises at least one of: alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, or combinations thereof.

In some embodiments, the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety. In some embodiments, the inhibitory nucleic acids include 2′-OMe, 2′-F, LNA, PNA, FANA, ENA or morpholino modifications.

Further provided are sterile compositions comprising an isolated nucleic acid that is a mouse RNA sequence of any one of any one of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human) or 17416 to 36368 (mouse), or a fragment thereof at least 20 bases in length that retains PRC1-binding activity.

Also provided are isolated nucleic acids for use in a method of decreasing expression of an oncogene, comprising an RNA sequence as set forth in Tables 1-3 that targets a proto-oncogene or oncogene as set forth in Tables 1-3, or a fragment thereof at least 20 bases in length that retains PRC1-binding activity.

In addition, provided are methods for decreasing expression of an oncogene in a cell, the method comprising contacting the cell with an RNA sequence as set forth in Tables 1-3 that targets an oncogene as set forth in Tables 1-3, or a fragment thereof at least 20 bases in length that retains PRC1-binding activity.

Further, provided herein are methods of inducing expression of a target gene in a cell, the method comprising delivering to the cell a single stranded oligonucleotide of 5 to 40 nucleotides in length having a region of complementarity that is complementary with at least 5 contiguous nucleotides of a PRC1-binding RNA that inhibits expression of the target gene, wherein the oligonucleotide is complementary to and binds specifically to the PRC1-binding RNA, and wherein the PRC1-binding RNA is transcribed from a sequence of the chromosomal locus of the target gene.

In some embodiments, the RNA is a non-codingRNA.

In some embodiments, the methods include detecting expression of the PRC1-binding RNA in the cell, wherein expression of the PRC1-binding RNA in the cell indicates that the single stranded oligonucleotide is suitable for increasing expression of the target gene in the cell.

In some embodiments, the methods include detecting a change in expression of the target gene following delivery of the single stranded oligonucleotide to the cell, wherein an increase in expression of the target gene compared with an appropriate control cell indicates effectiveness of the single stranded oligonucleotide.

In some embodiments, the methods include detecting a change in recruitment of PRC1 to the target gene in the cell following delivery of the single stranded oligonucleotide to the cell, wherein a decrease in recruitment compared with an appropriate control cell indicates effectiveness of the single stranded oligonucleotide.

In some embodiments, the cell is in vitro.

In some embodiments, the cell is in vivo.

In some embodiments, at least one nucleotide of the oligonucleotide is a modified nucleotide.

In some embodiments, the PRC1-binding RNA is transcribed from the same strand as the target gene in a genomic region containing the target gene.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to an exon.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from the same strand as the target gene within a chromosomal region within −2.0 kb to +0.001 kb of the transcription start site of the target gene.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from the opposite strand of the target gene within a chromosomal region within −0.5 to +0.1 kb of the transcription start site of the target gene.

In some embodiments, the oligonucleotide has complementarity to the PRC1-binding RNA in a region of the PRC1-binding RNA that forms a stem-loop structure.

In some embodiments, at least one nucleotide of the oligonucleotide is an RNA or DNA nucleotide.

In some embodiments, at least one nucleotide of the oligonucleotide is a ribonucleic acid analogue comprising a ribose ring having a bridge between its 2′-oxygen and 4′-carbon.

In some embodiments, the ribonucleic acid analogue comprises a methylene bridge between the 2′-oxygen and the 4′-carbon.

In some embodiments, at least one nucleotide of the oligonucleotide comprises a modified sugar moiety.

In some embodiments, the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety.

In some embodiments, the oligonucleotide comprises at least one modified internucleoside linkage.

In some embodiments, the at least one modified internucleoside linkage is selected from phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

In some embodiments, the oligonucleotide is configured such that hybridization of the single stranded oligonucleotide to the PRC1-binding RNA does not activate an RNAse H pathway in the cell.

In some embodiments, the oligonucleotide is configured such that hybridization of the single stranded oligonucleotide to the PRC1-binding RNA does not induce substantial cleavage or degradation of the PRC1-binding RNA in the cell.

In some embodiments, the oligonucleotide is configured such that hybridization of the single stranded oligonucleotide to the PRC1-binding RNA interferes with interaction of the RNA with PRC1 in the cell.

In some embodiments, the target gene is a protein-coding gene.

In some embodiments, the chromosomal locus of the target gene is an endogenous gene of an autosomal chromosome.

In some embodiments, the cell is a cell of a male subject.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to an intron-exon junction or an intron.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a translation initiation region or a translation termination region.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a promoter.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a 5′-UTR.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a 3′-UTR.

In some or any embodiments, the inhibitory nucleic acid is an oligomeric base compound or oligonucleotide mimetic that hybridizes to at least a portion of the target nucleic acid and modulates its function. In some or any embodiments, the inhibitory nucleic acid is single stranded or double stranded. A variety of exemplary inhibitory nucleic acids are known and described in the art. In some examples, the inhibitory nucleic acid is an antisense oligonucleotide, locked nucleic acid (LNA) molecule, peptide nucleic acid (PNA) molecule, ribozyme, siRNA, antagomirs, external guide sequence (EGS) oligonucleotide, microRNA (miRNA), small, temporal RNA (stRNA), or single- or double-stranded RNA interference (RNAi) compounds. It is understood that the term “LNA molecule” refers to a molecule that comprises at least one LNA modification; thus LNA molecules may have one or more locked nucleotides (conformationally constrained) and one or more non-locked nucleotides. It is also understood that the term “LNA” includes a nucleotide that comprises any constrained sugar that retains the desired properties of high affinity binding to complementary RNA, nuclease resistance, lack of immune stimulation, and rapid kinetics. Exemplary constrained sugars include those listed below. Similarly, it is understood that the term “PNA molecule” refers to a molecule that comprises at least one PNA modification and that such molecules may include unmodified nucleotides or internucleoside linkages.

In some or any embodiments, the inhibitory nucleic acid comprises at least one nucleotide and/or nucleoside modification (e.g., modified bases or with modified sugar moieties), modified internucleoside linkages, and/or combinations thereof. Thus, inhibitory nucleic acids can comprise natural as well as modified nucleosides and linkages. Examples of such chimeric inhibitory nucleic acids, including hybrids or gapmers, are described below.

In some embodiments, the inhibitory nucleic acid comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. In some embodiments, the modified internucleoside linkage comprises at least one of: alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, or combinations thereof. In some embodiments, the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety. Other examples of modifications include locked nucleic acid (LNA), peptide nucleic acid (PNA), arabinonucleic acid (ANA), optionally with 2′-F modification, 2′-fluoro-D-Arabinonucleic acid (FANA), phosphorodiamidate morpholino oligomer (PMO), ethylene-bridged nucleic acid (ENA), optionally with 2′-0,4′-C-ethylene bridge, and bicyclic nucleic acid (BNA). Yet other examples are described below and/or are known in the art.

In some embodiments, the inhibitory nucleic acid is 5-40 bases in length (e.g., 12-30, 12-28, 12-25). The inhibitory nucleic acid may also be 10-50, or 5-50 bases length. For example, the inhibitory nucleic acid may be one of any of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases in length. In some embodiments, the inhibitory nucleic acid is double stranded and comprises an overhang (optionally 2-6 bases in length) at one or both termini. In other embodiments, the inhibitory nucleic acid is double stranded and blunt-ended. In some embodiments, the inhibitory nucleic acid comprises or consists of a sequence of bases at least 80% or 90% complementary to, e.g., at least 5, 10, 15, 20, 25 or 30 bases of, or up to 30 or 40 bases of, the target RNA, or comprises a sequence of bases with up to 3 mismatches (e.g., up to 1, or up to 2 mismatches) over 10, 15, 20, 25 or 30 bases of the target RNA.

Thus, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 80% complementary to at least 10 contiguous bases of the target RNA, or at least 80% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 80% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 80% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 80% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 80% complementary to at least 40 contiguous bases of the target RNA. Moreover, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 90% complementary to at least 10 contiguous bases of the target RNA, or at least 90% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 90% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 90% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 90% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 90% complementary to at least 40 contiguous bases of the target RNA. Similarly, the inhibitory nucleic acid can comprise or consist of a sequence of bases fully complementary to at least 5, 10, or 15 contiguous bases of the target RNA.

Complementarity can also be referenced in terms of the number of mismatches in complementary base pairing, as noted above. Thus, the inhibitory nucleic acid can comprise or consist of a sequence of bases with up to 3 mismatches over 10 contiguous bases of the target RNA, or up to 3 mismatches over 15 contiguous bases of the target RNA, or up to 3 mismatches over 20 contiguous bases of the target RNA, or up to 3 mismatches over 25 contiguous bases of the target RNA, or up to 3 mismatches over 30 contiguous bases of the target RNA. Similarly, the inhibitory nucleic acid can comprise or consist of a sequence of bases with up to 2 mismatches over 10 contiguous bases of the target RNA, or up to 2 mismatches over 15 contiguous bases of the target RNA, or up to 2 mismatches over 20 contiguous bases of the target RNA, or up to 2 mismatches over 25 contiguous bases of the target RNA, or up to 2 mismatches over 30 contiguous bases of the target RNA. Similarly, the the inhibitory nucleic acid can comprise or consist of a sequence of bases with one mismatch over 10, 15, 20, 25 or 30 contiguous bases of the target RNA.

As such, in some embodiments the inhibitory nucleic acid comprises or consists of a sequence of bases about 5 to 40, or 8 to 40, or 10 to 50, or 5 to 50 bases in length, comprising a base sequence at least 80% complementary to (optionally one of at least 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) a contiguous sequence of at least 5 to 40 bases, or 8 to 40, or 10 to 50, or 5 to 50 bases (optionally one of at least 10, 15, 20, 25 or 30 bases, or one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases) of the target RNA. Thus, in some embodiments the inhibitory nucleic acid may comprise or consist of a sequence of at least 5 to 40, or 8 to 40, or 5 to 50, or 10 to 50, bases (optionally one of at least 10, 15, 20, 25 or 30 bases, or one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases) having at least 80% identity to (optionally one of at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to) a contiguous sequence of bases of the same length of an antisense nucleic acid that is completely complementary in sequence to the target RNA. In some embodiments the sequence of the inhibitory nucleic acid may contain 1, 2 or 3 mismatches in complementary base pairing compared to the target ncRNA sequence, over 10, 15, 20, 25 or 30 bases (optionally one of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 bases) of the target RNA.

In some or any embodiments, the inhibitory nucleic acid is 5 to 40, or 8 to 40, or 10 to 50 bases in length (e.g., 12-30, 12-28, 12-25, 5-25, or 10-25, bases in length), and comprises a sequence of bases with up to 3 mismatches in complementary base pairing over 15 bases of, or up to 2 mismatches over 10 bases.

In some embodiments, gene expression is modulated in a cell. In some embodiments, the cell is a cancer cell, e.g., a tumor cell, in vitro or in vivo, e.g., in a subject. In other embodiments, the cell is a stem cell that is contacted with the inhibitory nucleic acid, PRC1-binding ncRNA, or fragment thereof, ex vivo, for example to enhance pluripotency, enhance differentiation, or induce the stem cell to differentiate to a particular cell type, e.g. nerve, neuron, dopaminergic neuron, muscle, skin, heart, kidney, liver, lung, neuroendocrine, retinal, retinal pigment epithelium, pancreatic alpha or beta cells, hematopoietic, chondrocyte, bone cells and/or blood cells (e.g., T-cells, B-cells, macrophages, erythrocytes, platelets, and the like).

In an additional aspect, the invention provides methods for enhancing pluripotency of a stem cell. The methods include contacting the cell with an inhibitory nucleic acid that specifically binds, or is complementary, to a nucleic acid sequence that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homologous to a PRC1-binding fragment thereof, as referred to in Tables 1-3. PRC1-binding fragments of murine or orthologous RNAs, including human RNAs, are contemplated in the aforementioned method.

In a further aspect, the invention features methods for enhancing differentiation of a stem cell, the method comprising contacting the cell with an inhibitory nucleic acid that specifically binds, or is complementary, to a PRC1-binding RNA sequence as set forth in SEQ ID NOS. 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver].

In some embodiments, the stem cell is an embryonic stem cell. In some embodiments, the stem cell is an iPS cell or an adult stem cell.

In an additional aspect, the invention provides sterile compositions including an inhibitory nucleic acid that specifically binds to or is at least 90% complementary to (e.g., at least 5, 10, 15, 20, 25 or 30 bases of, or up to 30 or 40 bases of) a sequence listed in any of Tables 1-3, or any one of SEQ ID NOs: 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver], or a related naturally occurring RNA at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to at least 15 (e.g., at least 20, 21, 25, 30, 100) nucleobases of an ncRNA of any of Tables 1-3 or any one of SEQ ID NOs: 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver], for parenteral administration. In some embodiments, the inhibitory nucleic acid is selected from the group consisting of antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, micro RNAs (miRNAs); small, temporal RNAs (stRNA), and single- or double-stranded RNA interference (RNAi) compounds. In some embodiments, the RNAi compound is selected from the group consisting of short interfering RNA (siRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); and small activating RNAs (saRNAs).

In some embodiments, the antisense oligonucleotide is selected from the group consisting of antisense RNAs, antisense DNAs, chimeric antisense oligonucleotides, and antisense oligonucleotides.

In some embodiments, the inhibitory nucleic acid comprises one or more modifications comprising: a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof. In some embodiments, the modified internucleoside linkage comprises at least one of: alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, or combinations thereof. In some embodiments, the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety. Other examples of modifications include locked nucleic acid (LNA), peptide nucleic acid (PNA), arabinonucleic acid (ANA), optionally with 2′-F modification, 2′-fluoro-D-Arabinonucleic acid (FANA), phosphorodiamidate morpholino oligomer (PMO), ethylene-bridged nucleic acid (ENA), optionally with 2′-0,4′-C-ethylene bridge, and bicyclic nucleic acid (BNA). Yet other examples are described below and/or are known in the art.

PRC1-binding fragments of any of the RNA sequences set forth in the sequence listing as summarized below are contemplated. In some aspects, the fragments may recruit PRC1 and enhance PRC1 activity, thereby repressing gene expression, while in other instances the fragments may interfere with PRC1 activity by masking the ncRNA-binding sites on PRC1. In particular, the invention features uses of fragments of the RNA below to modulate expression of any of the genes set forth in Tables 1-3, for use in treating a disease, disorder, condition or association (whether in the “opposite strand” column or the “same strand” column).

Moreover, inhibitory nucleic acids that specifically bind to any of the RNA peaks set forth in the sequence listing as summarized below, any one of SEQ ID NOs: 1 to 5893, 5894 to 17415, or 17416 to 36368, are also contemplated. In particular, the invention features uses of these inhibitory nucleic acids to upregulate expression of any of the genes set forth in Tables 1-3, for use in treating a disease, disorder, condition or association known in the art (whether in the “opposite strand” column or the “same strand”); upregulations of a set of genes grouped together in any one of the categories is contemplated. In some embodiments it is contemplated that expression may be increased by at least about 15-fold, 20-fold, 30-fold, 40-fold, 50-fold or 100-fold, or any range between any of the foregoing numbers. In other experiments, increased mRNA expression has been shown to correlate to increased protein expression.

Thus, in various aspects, the invention features inhibitory nucleic acids that specifically bind to any of the RNA sequences of any of Tables 1-3, for use in modulating expression of a group of reference genes that fall within any one or more of the categories set forth in the tables, and for treating corresponding diseases, disorders or conditions.

In another aspect, the invention also features inhibitory nucleic acids that specifically bind, or are complementary, to any of the RNA sequences of SEQ ID NOS: 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver], whether in the “opposite strand” column or the “same strand” column of Tables 1-3. In some embodiments, the inhibitory nucleic acid is provided for use in a method of modulating expression of a gene targeted by the PRC1-binding RNA (e.g., an intersecting or nearby gene, as set forth in any of Tables 1-4 below). Such methods may be carried out in vitro, ex vivo, or in vivo. In some embodiments, the inhibitory nucleic acid is provided for use in methods of treating disease, e.g. as described below. The treatments may involve modulating expression (either up or down) of a gene targeted by the PRC1-binding RNA, preferably upregulating gene expression. In some embodiments, the inhibitory nucleic acid is formulated as a sterile composition for parenteral administration. Thus, in one aspect the invention describes a group of inhibitory nucleic acids that specifically bind, or are complementary to, a group of RNA sequences, i.e., Peaks, in any one of Tables 1, 2, or 3. In particular, the invention features uses of such inhibitory nucleic acids to upregulate expression of any of the reference genes set forth in Tables 1-3, for use in treating a disease, disorder, or condition.

It is understood that inhibitory nucleic acids of the invention may be complementary to, or specifically bind to, Peaks, or regions adjacent to (within 100, 200, 300, 400, or 500 nts of) Peaks, as shown in Tables 1-3.

Also provided herein are methods for treating a subject with MECP2 Duplication Syndrome. The methods include administering a therapeutically effective amount of an inhibitory nucleic acid targeting a PRC1-binding region on Mecp2 RNA, e.g., an inhibitory nucleic acid targeting a sequence within the 3′UTR of Mecp2. In some embodiments, inhibitory nucleic acid comprises any of SEQ ID NOs:36399 to 36404.

Further provided herein are methods for treating a subject with systemic lupus erythematosus. The methods include administering a therapeutically effective amount of an inhibitory nucleic acid targeting a PRC1-binding region on IRAK1 RNA, e.g., an inhibitory nucleci acid targeting a sequence within the 3′UTR of IRAK1.

In some embodiments, the inhibitory nucleic acid comprises any of SEQ ID NOs:36396 to 36398.

In some embodiments, the inhibitory nucleic acid comprises at least one locked nucleotide.

Also provided herein are inhibitory nucleic acids targeting a PRC1-binding region on Mecp2 RNA, preferably wherein the PRC1 binding region comprises SEQ ID NO:5876 or 5877, and/or preferably an inhibitory nucleic acid targeting a sequence within the 3′UTR of Mecp2, for use in treating a subject with MECP2 Duplication Syndrome, e.g., comprising any of SEQ ID NOs:36399 to 36404.

In addition, provided herein are inhibitory nucleic acids targeting a PRC1-binding region on IRAK1 RNA, preferably wherein the PRC1 binding region comprises SEQ ID NO:5874 or 5875, and/or preferably an inhibitory nucleic acid targeting a sequence within the 3′UTR of IRAK1, for use in treating a subject with systemic lupus erythematosus, e.g., an inhibitory nucleic acid comprising any of SEQ ID NOs:36396 to 36398.

In some or any embodiments, the inhibitory nucleic acids are, e.g., about 5 to 40, about 8 to 40, or 10 to 50 bases, or 5 to 50 bases in length. In some embodiments, the inhibitory nucleic acid comprises or consists of a sequence of bases at least 80% or 90% complementary to, e.g., at least 5, 10, 15, 20, 25 or 30 bases of, or up to 30 or 40 bases of, the target RNA (e.g., any one of SEQ ID NOs: 1 to 36,368), or comprises a sequence of bases with up to 3 mismatches (e.g., up to 1, or up to 2 mismatches) over 10, 15, 20, 25 or 30 bases of the target RNA.

Thus, as noted above, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 80% complementary to at least 10, or 10-30 or 10-40 contiguous bases of the target RNA, or at least 80% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 80% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 80% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 80% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 80% complementary to at least 40 contiguous bases of the target RNA. Moreover, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 90% complementary to at least 5, or 5-30 or 5-40 or 8-40 contiguous bases of the target RNA, or at least 90% complementary to at least 10, or 10-30, or 10-40 contiguous bases of the target RNA, or at least 90% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 90% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 90% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 90% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 90% complementary to at least 40 contiguous bases of the target RNA. Similarly, the inhibitory nucleic acid can comprise or consist of a sequence of bases fully complementary to at least 5, 10, or 15 contiguous bases of the target RNA. It is understood that some additional non-complementary bases may be included. It is understood that inhibitory nucleic acids that comprise such sequences of bases as described may also comprise other non-complementary bases. For example, an inhibitory nucleic acid can be 20 bases in total length but comprise a 15 base portion that is fully complementary to 15 bases of the target RNA. Similarly, an inhibitory nucleic acid can be 20 bases in total length but comprise a 15 base portion that is at least 80% complementary to 15 bases of the target RNA.

Complementarity can also be referenced in terms of the number of mismatches in complementary base pairing, as noted above. Thus, the inhibitory nucleic acid can comprise or consist of a sequence of bases with up to 3 mismatches over 10 contiguous bases of the target RNA, or up to 3 mismatches over 15 contiguous bases of the target RNA, or up to 3 mismatches over 20 contiguous bases of the target RNA, or up to 3 mismatches over 25 contiguous bases of the target RNA, or up to 3 mismatches over 30 contiguous bases of the target RNA. Similarly, the inhibitory nucleic acid can comprise or consist of a sequence of bases with up to 2 mismatches over 10 contiguous bases of the target RNA, or up to 2 mismatches over 15 contiguous bases of the target RNA, or up to 2 mismatches over 20 contiguous bases of the target RNA, or up to 2 mismatches over 25 contiguous bases of the target RNA, or up to 2 mismatches over 30 contiguous bases of the target RNA. Similarly, the the inhibitory nucleic acid can comprise or consist of a sequence of bases with one mismatch over 10, 15, 20, 25 or 30 contiguous bases of the target RNA.

In some or any of the embodiments of inhibitory nucleic acids described herein (e.g. in the summary, detailed description, or examples of embodiments) or the processes for designing or synthesizing them, the inhibitory nucleic acids may optionally exclude (a) any LNA that disrupts binding of PRC2 to an RNA, e.g., as describe in WO 2012/087983 or WO 2012/065143; (b) any one or more of the specific inhibitory nucleic acids made or actually disclosed (i.e. specific chemistry, single or double-stranded, specific modifications, and specific base sequence), set forth in WO 2012/065143 or WO 2012/087983; and/or the general base sequence of any one or more of the inhibitory nucleic acids of (b); and/or (c) the group of inhibitory nucleic acids that specifically bind or are complementary to the same specific portion of RNA (a stretch of contiguous bases) as any one or more of the inhibitory nucleic acids of (a); as disclosed in any one or more of the following publications: as targeting ANRIL RNA (as described in Yap et al., Mol Cell. 2010 Jun. 11; 38(5):662-74) HOTAIR RNA (Rinn et al., 2007), Tsix, RepA, or Xist RNAs ((Zhao et al., 2008) [SEQ ID NOs: 936166-936170 of WO 2012/087983], or (Sarma et al., 2010) [SEQ ID NOs: 936177-936186 of WO 2012/087983] or (Zhao et al., 2010) [SEQ ID NOs: 936187-936188 of WO 2012/087983] or (Prasnath et al., 2005) [SEQ ID NOs: 936173-936176 of WO 2012/087983] or (Shamovsky et al., 2006) [SEQ ID NO: 936172 of WO 2012/087983] or (Mariner et al., 2008) [SEQ ID NO: 936171 of WO 2012/087983] or (Sunwoo et al., 2008) or (Bernard et al., 2010) [SEQ ID NO: 936189 of WO 2012/087983]; or as targeting short RNAs of 50-200 nt that are identified as candidate PRC2 regulators (Kanhere et al., 2010); or (Kuwabara et al., US 2005/0226848) [SEQ ID NOs: 936190-936191 of WO 2012/087983] or (Li et al., US 2010/0210707) [SEQ ID NOs: 936192-936227 of WO 2012/087983] or (Corey et al., U.S. Pat. No. 7,709,456) [SEQ ID NOs: 936228-936245] or (Mattick et al., WO 2009/124341), or (Corey et al., US 2010/0273863) [SEQ ID NOs: 936246-936265 of WO 2012/087983], or (Wahlstedt et al., US 2009/0258925) [SEQ ID NOs: 935060-935126 of WO 2012/087983], or BACE: US 2009/0258925 [SEQ ID NOs: 935060-935126 of WO 2012/087983]; ApoA1: US 2010/0105760/EP235283 [SEQ ID NOs: 935127-935299 of WO 2012/087983], P73, p53, PTEN, WO 2010/065787 A2/EP2370582 [SEQ ID NOs: 935300-935345 of WO 2012/087983]; SIRT1: WO 2010/065662 A2/EP09831068 [SEQ ID NOs: 935346-935392 of WO 2012/087983]; VEGF: WO 2010/065671 A2/EP2370581 [SEQ ID NOs: 935393-935403 of WO 2012/087983]; EPO: WO 2010/065792 A2/EP09831152 [SEQ ID NOs: 935404-935412 of WO 2012/087983]; BDNF: WO2010/093904 [SEQ ID NOs: 935413-935423 of WO 2012/087983], DLK1: WO 2010/107740 [SEQ ID NOs: 935424-935430 of WO 2012/087983]; NRF2/NFE2L2: WO 2010/107733 [SEQ ID NOs: 935431-935438 of WO 2012/087983]; GDNF: WO 2010/093906 [SEQ ID NOs: 935439-935476 of WO 2012/087983]; SOX2, KLF4, Oct3A/B, “reprogramming factors: WO 2010/135329 [SEQ ID NOs: 935477-935493 of WO 2012/087983]; Dystrophin: WO 2010/129861 [SEQ ID NOs: 935494-935525 of WO 2012/087983]; ABCA1, LCAT, LRP1, ApoE, LDLR, ApoA1: WO 2010/129799 [SEQ ID NOs: 935526-935804 of WO 2012/087983]; HgF: WO 2010/127195 [SEQ ID NOs: 935805-935809 of WO 2012/087983]; TTP/Zfp36: WO 2010/129746[SEQ ID NOs: 935810-935824 of WO 2012/087983]; TFE3, IRS2: WO 2010/135695 [SEQ ID NOs: 935825-935839 of WO 2012/087983]; RIG1, MDAS, IFNA1: WO 2010/138806 [SEQ ID NOs: 935840-935878 of WO 2012/087983]; PON1: WO 2010/148065 [SEQ ID NOs: 935879-935885 of WO 2012/087983]; Collagen: WO/2010/148050 [SEQ ID NOs: 935886-935918 of WO 2012/087983]; DyrklA, Dscrl, “Down Syndrome Gene”: WO/2010/151674 [SEQ ID NOs: 935919-935942 of WO 2012/087983]; TNFR2: WO/2010/151671 [SEQ ID NOs: 935943-935951 of WO 2012/087983]; Insulin: WO/2011/017516 [SEQ ID NOs: 935952-935963 of WO 2012/087983]; ADIPOQ: WO/2011/019815 [SEQ ID NOs: 935964-935992 of WO 2012/087983]; CHIP: WO/2011/022606 [SEQ ID NOs: 935993-936004 of WO 2012/087983]; ABCB1: WO/2011/025862 [SEQ ID NOs: 936005-936014 of WO 2012/087983]; NEUROD1, EUROD1, HNF4A, MAFA, PDX, KX6, “Pancreatic development gene”: WO/2011/085066 [SEQ ID NOs: 936015-936054 of WO 2012/087983]; MBTPS1: WO/2011/084455 [SEQ ID NOs: 936055-936059 of WO 2012/087983]; SHBG: WO/2011/085347 [SEQ ID NOs: 936060-936075 of WO 2012/087983]; IRF8: WO/2011/082409 [SEQ ID NOs: 936076-936080 of WO 2012/087983]; UCP2: WO/2011/079263 [SEQ ID NOs: 936081-936093 of WO 2012/087983]; HGF: WO/2011/079261 [SEQ ID NOs: 936094-936104 of WO 2012/087983]; GH: WO/2011/038205 [SEQ ID NOs: 936105-936110 of WO 2012/087983]; IQGAP: WO/2011/031482 [SEQ ID NOs: 936111-936116 of WO 2012/087983]; NRF1: WO/2011/090740 [SEQ ID NOs: 936117-936123 of WO 2012/087983]; P63: WO/2011/090741 [SEQ ID NOs: 936124-936128 of WO 2012/087983]; RNAseHl: WO/2011/091390 [SEQ ID NOs: 936129-936140 of WO 2012/087983]; ALOX12B: WO/2011/097582 [SEQ ID NOs: 936141-936146 of WO 2012/087983]; PYCR1: WO/2011/103528 [SEQ ID NOs: 936147-936151 of WO 2012/087983]; CSF3: WO/2011/123745 [SEQ ID NOs: 936152-936157 of WO 2012/087983]; FGF21: WO/2011/127337 [SEQ ID NOs: 936158-936165 of WO 2012/087983]; SIRTUIN (SIRT): WO2011/139387 [SEQ ID NOs: 936266-936369 and 936408-936425 of WO 2012/087983]; PAR4: WO2011/143640 [SEQ ID NOs: 936370-936376 and 936426 of WO 2012/087983]; LHX2: WO2011/146675 [SEQ ID NOs: 936377 936388 and 936427-936429 of WO 2012/087983]; BCL2L11: WO2011/146674 [SEQ ID NO: 936389-936398 and 936430-936431 of WO 2012/087983]; MSRA: WO2011/150007 [SEQ ID NOs: 936399-936405 and 936432 of WO 2012/087983]; ATOH1: WO2011/150005 [SEQ ID NOs: 936406-936407 and 936433 of WO 2012/087983] of which each of the foregoing is incorporated by reference in its entirety herein. In some or any of the embodiments, optionally excluded from the invention are of inhibitory nucleic acids that specifically bind to, or are complementary to, any one or more of the following regions: Nucleotides 1-932 of SEQ ID NO: 935128 of WO 2012/087983; Nucleotides 1-1675 of SEQ ID NO: 935306 of WO 2012/087983; Nucleotides 1-518 of SEQ ID NO: 935307 of WO 2012/087983; Nucleotides 1-759 of SEQ ID NO: 935308 of WO 2012/087983; Nucleotides 1-25892 of SEQ ID NO: 935309 of WO 2012/087983; Nucleotides 1-279 of SEQ ID NO: 935310 of WO 2012/087983; Nucleotides 1-1982 of SEQ ID NO: 935311 of WO 2012/087983; Nucleotides 1-789 of SEQ ID NO: 935312 of WO 2012/087983; Nucleotides 1-467 of SEQ ID NO: 935313 of WO 2012/087983; Nucleotides 1-1028 of SEQ ID NO: 935347 of WO 2012/087983; Nucleotides 1-429 of SEQ ID NO: 935348 of WO 2012/087983; Nucleotides 1-156 of SEQ ID NO: 935349 of WO 2012/087983; Nucleotides 1-593 of SEQ ID NO:935350 of WO 2012/087983; Nucleotides 1-643 of SEQ ID NO: 935395 of WO 2012/087983; Nucleotides 1-513 of SEQ ID NO: 935396 of WO 2012/087983; Nucleotides 1-156 of SEQ ID NO: 935406 of WO 2012/087983; Nucleotides 1-3175 of SEQ ID NO: 935414 of WO 2012/087983; Nucleotides 1-1347 of SEQ ID NO: 935426 of WO 2012/087983; Nucleotides 1-5808 of SEQ ID NO: 935433 of WO 2012/087983; Nucleotides 1-237 of SEQ ID NO: 935440 of WO 2012/087983; Nucleotides 1-1246 of SEQ ID NO: 935441 of WO 2012/087983; Nucleotides 1-684 of SEQ ID NO: 935442 of WO 2012/087983; Nucleotides 1-400 of SEQ ID NO: 935473 of WO 2012/087983; Nucleotides 1-619 of SEQ ID NO: 935474 of WO 2012/087983; Nucleotides 1-813 of SEQ ID NO: 935475 of WO 2012/087983; Nucleotides 1-993 of SEQ ID NO: 935480 of WO 2012/087983; Nucleotides 1-401 of SEQ ID NO: 935480 of WO 2012/087983; Nucleotides 1-493 of SEQ ID NO: 935481 of WO 2012/087983; Nucleotides 1-418 of SEQ ID NO: 935482 of WO 2012/087983; Nucleotides 1-378 of SEQ ID NO: 935496 of WO 2012/087983; Nucleotides 1-294 of SEQ ID NO: 935497 of WO 2012/087983; Nucleotides 1-686 of SEQ ID NO: 935498 of WO 2012/087983; Nucleotides 1-480 of SEQ ID NO: 935499 of WO 2012/087983; Nucleotides 1-501 of SEQ ID NO: 935500 of WO 2012/087983; Nucleotides 1-1299 of SEQ ID NO: 935533 of WO 2012/087983; Nucleotides 1-918 of SEQ ID NO: 935534 of WO 2012/087983; Nucleotides 1-1550 of SEQ ID NO: 935535 of WO 2012/087983; Nucleotides 1-329 of SEQ ID NO: 935536 of WO 2012/087983; Nucleotides 1-1826 of SEQ ID NO: 935537 of WO 2012/087983; Nucleotides 1-536 of SEQ ID NO: 935538 of WO 2012/087983; Nucleotides 1-551 of SEQ ID NO: 935539 of WO 2012/087983; Nucleotides 1-672 of SEQ ID NO: 935540 of WO 2012/087983; Nucleotides 1-616 of SEQ ID NO: 935541 of WO 2012/087983; Nucleotides 1-471 of SEQ ID NO: 935542 of WO 2012/087983; Nucleotides 1-707 of SEQ ID NO: 935543 of WO 2012/087983; Nucleotides 1-741 of SEQ ID NO: 935544 of WO 2012/087983; Nucleotides 1-346 of SEQ ID NO: 935545 of WO 2012/087983; Nucleotides 1-867 of SEQ ID NO: 935546 of WO 2012/087983; Nucleotides 1-563 of SEQ ID NO: 935547 of WO 2012/087983; Nucleotides 1-970 of SEQ ID NO: 935812 of WO 2012/087983; Nucleotides 1-1117 of SEQ ID NO: 935913 of WO 2012/087983; Nucleotides 1-297 of SEQ ID NO: 935814 of WO 2012/087983; Nucleotides 1-497 of SEQ ID NO: 935827 of WO 2012/087983; Nucleotides 1-1267 of SEQ ID NO: 935843 of WO 2012/087983; Nucleotides 1-586 of SEQ ID NO: 935844 of WO 2012/087983; Nucleotides 1-741 of SEQ ID NO: 935845 of WO 2012/087983; Nucleotides 1-251 of SEQ ID NO: 935846 of WO 2012/087983; Nucleotides 1-681 of SEQ ID NO: 935847 of WO 2012/087983; Nucleotides 1-580 of SEQ ID NO: 935848 of WO 2012/087983; Nucleotides 1-534 of SEQ ID NO: 935880 of WO 2012/087983; Nucleotides 1-387 of SEQ ID NO: 935889 of WO 2012/087983; Nucleotides 1-561 of SEQ ID NO: 935890 of WO 2012/087983; Nucleotides 1-335 of SEQ ID NO: 935891 of WO 2012/087983; Nucleotides 1-613 of SEQ ID NO: 935892 of WO 2012/087983; Nucleotides 1-177 of SEQ ID NO: 935893 of WO 2012/087983; Nucleotides 1-285 of SEQ ID NO: 935894 of WO 2012/087983; Nucleotides 1-3814 of SEQ ID NO: 935921 of WO 2012/087983; Nucleotides 1-633 of SEQ ID NO: 935922 of WO 2012/087983; Nucleotides 1-497 of SEQ ID NO: 935923 Nucleotides 1-545 of SEQ ID NO: 935924 of WO 2012/087983; Nucleotides 1-413 of SEQ ID NO: 935950 of WO 2012/087983; Nucleotides 1-413 of SEQ ID NO: 935951 of WO 2012/087983; Nucleotides 1-334 of SEQ ID NO: 935962 of WO 2012/087983; Nucleotides 1-582 of SEQ ID NO: 935963 of WO 2012/087983; Nucleotides 1-416 of SEQ ID NO: 935964 of WO 2012/087983; Nucleotides 1-3591 of SEQ ID NO: 935990 of WO 2012/087983; Nucleotides 1-875 of SEQ ID NO: 935991 of WO 2012/087983; Nucleotides 1-194 of SEQ ID NO: 935992 of WO 2012/087983; Nucleotides 1-2074 of SEQ ID NO: 936003 of WO 2012/087983; Nucleotides 1-1237 of SEQ ID NO: 936004 of WO 2012/087983; Nucleotides 1-4050 of SEQ ID NO: 936013 of WO 2012/087983; Nucleotides 1-1334 of SEQ ID NO: 936014 of WO 2012/087983; Nucleotides 1-1235 of SEQ ID NO: 936048 of WO 2012/087983; Nucleotides 1-17,964 of SEQ ID NO: 936049 of WO 2012/087983; Nucleotides 1-50,003 of SEQ ID NO: 936050 of WO 2012/087983; Nucleotides 1-486 of SEQ ID NO: 936051 of WO 2012/087983; Nucleotides 1-494 of SEQ ID NO: 936052 of WO 2012/087983; Nucleotides 1-1992 of SEQ ID NO: 936053 of WO 2012/087983; Nucleotides 1-1767 of SEQ ID NO: 936054 of WO 2012/087983; Nucleotides 1-1240 of SEQ ID NO: 936059 of WO 2012/087983; Nucleotides 1-3016 of SEQ ID NO: 936074 of WO 2012/087983; Nucleotides 1-1609 of SEQ ID NO: 936075 of WO 2012/087983; Nucleotides 1-312 of SEQ ID NO: 936080 of WO 2012/087983; Nucleotides 1-243 of SEQ ID NO: 936092 of WO 2012/087983; Nucleotides 1-802 of SEQ ID NO: 936093 of WO 2012/087983; Nucleotides 1-514 of SEQ ID NO: 936102 of WO 2012/087983; Nucleotides 1-936 of SEQ ID NO: 936103 of WO 2012/087983; Nucleotides 1-1075 of SEQ ID NO: 936104 of WO 2012/087983; Nucleotides 1-823 of SEQ ID NO: 936110 of WO 2012/087983; Nucleotides 1-979 of SEQ ID NO: 936116 of WO 2012/087983; Nucleotides 1-979 of SEQ ID NO: 936123 of WO 2012/087983; Nucleotides 1-288 of SEQ ID NO: 936128 of WO 2012/087983; Nucleotides 1-437 of SEQ ID NO: 936137 of WO 2012/087983; Nucleotides 1-278 of SEQ ID NO: 936138 of WO 2012/087983; Nucleotides 1-436 of SEQ ID NO: 936139 of WO 2012/087983; Nucleotides 1-1140 of SEQ ID NO: 936140 of WO 2012/087983; Nucleotides 1-2082 of SEQ ID NO: 936146 of WO 2012/087983; Nucleotides 1-380 of SEQ ID NO: 936151 of WO 2012/087983; Nucleotides 1-742 of SEQ ID NO: 936157 of WO 2012/087983; Nucleotides 1-4246 of SEQ ID NO: 936165 of WO 2012/087983; Nucleotides 1-1028 of SEQ ID NO: 936408 of WO 2012/087983; Nucleotides 1-429 of SEQ ID NO: 936409 of WO 2012/087983; Nucleotides 1-508 of SEQ ID NO: 936410 of WO 2012/087983; Nucleotides 1-593 of SEQ ID NO: 936411 of WO 2012/087983; Nucleotides 1-373 of SEQ ID NO: 936412 of WO 2012/087983; Nucleotides 1-1713 of SEQ ID NO: 936413 of WO 2012/087983; Nucleotides 1-660 of SEQ ID NO:936414 of WO 2012/087983; Nucleotides 1-589 of SEQ ID NO: 936415 of WO 2012/087983; Nucleotides 1-726 of SEQ ID NO: 936416 of WO 2012/087983; Nucletides 1-320 of SEQ ID NO: 936417 of WO 2012/087983; Nucletides 1-616 of SEQ ID NO: 936418 of WO 2012/087983; Nucletides 1-492 of SEQ ID NO: 936419 of WO 2012/087983; Nucletides 1-428 of SEQ ID NO: 936420 of WO 2012/087983; Nucletides 1-4041 of SEQ ID NO: 936421 of WO 2012/087983; Nucletides 1-705 of SEQ ID NO: 936422 of WO 2012/087983; Nucletides 1-2714 of SEQ ID NO: 936423 of WO 2012/087983; Nucletides 1-1757 of SEQ ID NO: 936424 of WO 2012/087983; Nucletides 1-3647 of SEQ ID NO: 936425 of WO 2012/087983; Nucleotides 1-354 of SEQ ID NO: 936426 of WO 2012/087983; Nucleotides 1-2145 of SEQ ID NO: 936427, Nucleotides 1-606 of SEQ ID NO: 936428 of WO 2012/087983; Nucleotides 1-480 of SEQ ID NO: 936429 of WO 2012/087983; Nucleotides 1-3026 of SEQ ID NO: 936430 of WO to 2012/087983; Nucleotides 1-1512 of SEQ ID NO: 936431 of WO 2012/087983; Nucleotides 1-3774 of SEQ ID NO: 936432 of WO 2012/087983; Nucleotides 1-589 of SEQ ID NO: 936433.

In some of the embodiments of inhibitory nucleic acids described herein, or processes for designing or synthesizing them, the inhibitory nucleic acids will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to the PRC1-binding RNA that is transcribed from the same strand as a protein coding reference gene. The inhibitory nucleic acid may bind to a region of the PRC1-binding RNA, that originates within or overlaps an intron, exon, intron-exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein-coding sense-strand of a reference gene (refGene).

In some or any of the embodiments of inhibitory nucleic acids described herein, or processes for designing or syntheisizing them, the inhibitory nucleic acids will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to a PRC1 binding RNA that transcribed from the opposite strand (the antisense-strand) of a protein-coding reference gene.

The inhibitory nucleic acids described herein may be modified, e.g. comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof. In addition, the inhibitory nucleic acids can exhibit one or more of the following properties: do not induce substantial cleavage or degradation of the target RNA; do not cause substantially complete cleavage or degradation of the target RNA; do not activate the RNAse H pathway; do not activate RISC; do not recruit any Argonaute family protein; are not cleaved by Dicer; do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; may have improved endosomal exit; do interfere with interaction of ncRNA with PRC1, preferably the Ezh2 subunit but optionally the Suz12, Eed, RbAp46/48 subunits or accessory factors such as Jarid2; do decrease histone H3-lysine27 methylation and/or do upregulate gene expression. In some or any of the embodiments of inhibitory nucleic acids described herein, or processes for designing or synthesizing them, the inhibitory nucleic acids may optionally exclude those that bind DNA of a promoter region, as described in Kuwabara et al., US 2005/0226848 or Li et al., US 2010/0210707 or Corey et al., U.S. Pat. No. 7,709,456 or Mattick et al., WO 2009/124341, or those that bind DNA of a 3′ UTR region, as described in Corey et al., US 2010/0273863.

Inhibitory nucleic acids that are designed to interact with RNA to modulate gene expression are a distinct subset of base sequences from those that are designed to bind a DNA target (e.g., are complementary to the underlying genomic DNA sequence from which the RNA is transcribed).

This application incorporates by reference the entire disclosures of U.S. provisional Nos. 61/425,174 filed on Dec. 20, 2010, and 61/512,754 filed on Jul. 28, 2011, and International Patent Application Nos. PCT/US2011/060493, filed Nov. 12, 2011, and PCT/US2011/065939, filed on Dec. 19, 2011.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.

REFERENCE TO SEQUENCE LISTING

This application includes a Sequence Listing in .txt format, filed herewith as SL.txt, a file of 67.2 MB. The entire content of this file is hereby incorporated by reference.

DESCRIPTION OF DRAWINGS

FIGS. 1A-B are schematics of exemplary denaturing CLIP (dCLIP) pull-down methods (1A) and library preparation methods (1B).

FIGS. 2A-C show four test genes for effects of disrupting PRC1-3′UTR interactions. IGV screenshots shown for three Chromobox Homolog 7 (CBX7)-binding RNAs: (2A) Mouse DDB1 and CUL4 Associated Factor 12-Like 1 (Dcaf12L1); (2B) Mouse Calmodulin 2 (Calm2); (2C) Mouse methyl CpG binding protein 2 (Mecp2). For each gene, the RNA-seq profile shows the FPKM expression values of each gene. CLIP-seq profiles are then shown for various biological replicates (e.g., Cbx7 #1, #2, #3). For Dcaf12L1 and Calm2, statistically significant peaks (“Peak”, as called by PeakRanger software) shown as bars under each replicate's track. Two control (tag-only libraries) are shown for each gene. Only the relevant strand is shown (Watson or Crick). Note highly reproducible CLIP profiles and very clean control libraries. ASO LNA mixmers used for knockoff ananlysis are shown as black bars. The mixmers were pooled for the transfections.

FIGS. 3A-C are graphs showing gene upregulation as a result of disrupting PRC1-3′UTR interactions. 16.7 ES cells were nucleofected with pooled mixmer LNAs against Calmodulin 2 (Calm2) (leftmost bars) or DDB1 and CUL4 Associated Factor 12-Like 1 (Dcafl2L1) (middle bars); Dual-specific phosphatase 9 (Dusp9) was used as a negative control (right bars). Cells were harvested after 24 hours and whole cell RNA was used for quantitative gene expression analysis using real-time RT-PCR. Expression of specific transcripts was normalized to beta-actin as a reference gene.

FIGS. 4A-B shows the test gene, Tsix, and results of knocking off PRC1 from Tsix RNA. (4A) The RNA-seq profile shows the Fragments Per Kilobase of transcript per Million mapped reads (FPKM) expression values of each gene. CLIP-seq profiles are then shown for two biological replicates (Cbx7 #1, #2), with corresponding statistically significant peaks (“Peak”, as called by PeakRanger software) shown as bars under each replicate's track. Two control (tag-only libraries) are shown for each gene. Antisense oligonucleotide (ASO) LNA mixmers used for knockoff ananlysis are shown as black bars. The mixmers were pooled for the transfections. Only the Watson strand is shown in the figure. (4B) Tsix RNA is a repressor ofXist expression. Here we hypothesized that Tsix recruits PRC1 to repress Xist expression. The RT-qPCR analysis performed 6 hours after administering Tsix LNAs support this interaction. Xist upregulation was achieved specifically.

Table 1: Human CBX7-RNA binding sites as determined by denaturing CLIP-seq analysis in Human 293 cells. All coordinates in hg19. The columns (c) correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C6, nearest gene name. c7, gene categories as defined in Example 2.

Table 2: Human LiftOver sequences corresponding to CBX7-RNA binding sites as determined by denaturing CLIP-seq analysis in mouse ES cells shown. All coordinates in hg19. CBX7-binding sites derived from CLIP-seq performed in the mouse ES cell line, 16.7, as shown in Table 3, are translated from mouse mm9 to human hg19 coordinates.

Table 3: Mouse CBX7-RNA binding sites as determined by denaturing CLIP-seq analysis in ES cells derived from Mus musculus. All coordinates in mm9. CLIP-seq performed in the mouse ES cell line, EL 16.7. CBX7 binding sites in the RNA are shown.

DETAILED DESCRIPTION

The new ‘denaturing’ CLIP-seq (dCLIP-seq) method, which utilizes a biotin tag to enable purification of RNA-protein complexes under denaturing conditions to increase the specificity of the purification scheme, was used to capture a genome-wide pool of transcripts (>30 nt) that bind with the PRC1 complex via the CBX7 subunit. Transcriptome characterization has identified classes of medically significant targets. Many if not all of the mouse PRC1-transcripts identified herein were shown by LiftOver analysis to have direct counterparts in the human epigenome.

As demonstrated herein, at least a subset of RNAs directly interacts with PRC1 in vivo and, in many cases, the interacting subunit is a CBX protein, e.g., CBX7. In some cases, the interacting subunit is CBX2, 4, 6, or 8. CBX7 is generally expressed earlier in development in less-differentiated cells, while CBX2, 4, 6, 8 are expressed in more differentiated cells and may be more tissue-specific. The CBX family is likely to have highly overlapping RNA interactomes, because the proteins are highly similar to each other and have RNA-binding domains.

The present analysis suggests that both cis and trans mechanisms may be utilized by RNAs in the PRC1 RNA interactome. As shown herein, PRC1 has a number of different cis-regulatory effects. PRC1 binding sites can be classified into several groups, including (i) 3′ untranslated region (3′ UTR), (ii) promoter-associated, (iii) gene body, (iv) antisense, and (v) intergenic. Disrupting the interaction between PRC1 and a binding RNA could lead to either activation or repression. For example, targeting the PRC1 binding sites within the 3′ UTR of Calm2 and Dcaf1211 results in upregulation of these coding genes (FIG. 3 ). Calm2 is a member of the calmodulin gene family, with three distinct calmodulin genes throughout the genome that encode an identical protein. CALM2 is a calcium binding protein that plays a role in signaling pathways, cell cycle progression and proliferation. Mutations are associated with long-QT syndrome (LQTS, life-threatening ventricular arrhythmias) with delayed neurodevelopment and epilepsy. By contrast, targeting various regions within Mecp2 and IRAK1 resulted in gene downregulation (FIGS. 5A-B). The present methods may be especially useful when one aims to titrate down but not eliminate gene expression, such as in the case of MECP2 Duplication Syndrome (a disease in which the MECP2 gene is duplicated and causes an Rett Syndrome-like disorder) or for treating autoimmune or inflammatory diseases, such as systemic lupus erythematosis (SLE), for which IRAK1 (interleukin 1 associated kinase 1) has been implicated.

As used herein, the 3′UTR is the last exon of a protein coding gene that usually includes the last few translated codons and the rest of the untranslated 3′ end of the mRNA encoded by the gene.

The evidence presented herein further demonstrates that RNA cofactors are a general feature of Polycomb regulation and that inhibitory nucleic acids as described herein that target RNAs in the PRC1 RNA interactome can successfully modulate (e.g., upregulate) gene expression, with effects dependent on the target site in the interacting transcript. The effects are presumed to be caused by inhibiting PRC1-RNA interactions. Genes in cis, in either antisense-strand orientation or same strand orientation, and extending 1 kb or more, e.g. 5 or 20 kb, from the location of the PRC1-binding RNA, can be regulated. Because chromatin modifiers such as PRC1 play a central role in maintaining stem cell pluripotency and in cancer, a genome-wide profile of regulatory RNAs will be a valuable resource in the quest to diagnose and treat disease. To downregulate gene expression, targeting RNA-PRC1 interactions by antisense oligonucleotides provides an alternative approach to RNAi methods, when one aims to titrate down but not eliminate gene expression, such as in the case of MECP2 Duplication Syndrome (a disease in which the MECP2 gene is duplicated and causes an Rett Syndrome-like disorder) or for treating autoimmune or inflammatory diseases, such as systemic lupus erythematosis (SLE), for which IRAK1 (interleukin 1 associated kinase 1) has been implicated.

Denaturing CLIP-Seq Methods (dCLIP-Seq)

Described herein are methods for pulling down RNAs that bind to a protein of interest, to produce libraries of those RNAs, and to identify regions of the RNAs to which the proteins bind. These methods were used to identify RNAs that bind the CBX7 portion of the PRC1 complex, but can be used with any proteins known or suspected to bind RNA. In some embodiments, the methods include the steps shown in FIGS. 1A and/or 1B; one of skill in the art will appreciate that other techniques can be substituted for those shown. These include conventional CLIP (see, e.g., Davidovich et al., Mol Cell. 2015 Feb. 5; 57(3):552-8), HITS-CLIP (Darnell, Wiley Interdiscip Rev RNA. 2010 September-October; 1(2): 266-286), PAR-CLIP, iCLIP (huppertz et al., Methods. 2014 February; 65(3): 274-287), and native RIP (Zhao et al., Mol Cell. 2010 Dec. 22; 40(6):939-53).

In preferred embodiments, the methods are practiced using cells, e.g., mammalian cells, that express the bacterial biotin ligase BirA, and an RNA-binding protein of interest, e.g., CBX2, CBX4, CBX6, CBX7, or CBX8, fused to a biotinylation tag sequence. In some embodiments, the BirA and RNA binding protein are on separate vectors, preferably separate vectors with different selectable markers, e.g., different antibiotic resistance genes, or different fluorescent proteins. In some embodiments, the BirA is expressed from a first vector under neomycin resistance, and the protein of interest fused to a biotinylation tag sequence is expressed from a second vector under puromycin resistance. Biotinylation tag sequences are known in the art, see, e.g., Schatz, Biotechnology (N Y). 1993 October; 11(10):1138-43; Tucker and Grisshammer, Biochem J. 1996 Aug. 1; 317 (Pt 3):891-9; and Beckett et al., Protein Sci. 1999 April; 8(4):921-9. An exemplary biotinylation sequence is GLNDIFEAQKIEWHE (SEQ ID NO: 36369); other sequences are known in the art, e.g., GLNDIFEAQKIEWH (SEQ ID NO: 36370); and others as disclosed in Beckett et al., Protein Science 1999, 8:921-929, e.g., in FIG. 5 and Table 2 therein. Sequences for BirA are also known in the art; see, e.g., Howard et al., Gene. 1985; 35(3):321-31. An exemplary protein sequence for BirA is as follows:

(SEQ ID NO: 36371)         10         20         30         40 MKDNTVPLKL IALLANGEFH SGEQLGETLG MSRAAINKHI         50         60         70         80 QTLRDWGVDV FTVPGKGYSL PEPIQLLNAK QILGQLDGGS         90        100        110        120 VAVLPVIDST NQYLLDRIGE LKSGDACIAE YQQAGRGRRG        130        140        150        160 RKWFSPFGAN LYLSMFWRLE QGPAAAIGLS LVIGIVMAEV        170        180        190        200 LRKLGADKVR VKWPNDLYLQ DRKLAGILVE LTGKTGDAAQ        210        220        230        240 IVIGAGINMA MRRVEESVVN QGWITLQEAG INLDRNTLAA        250        260        270        280 MLIRELRAAL ELFEQEGLAP YLSRWEKLDN FINRPVKLII        290        300        310        320 GDKEIFGISR GIDKQGALLL EQDGIIKPWM GGEISLRSAE K Additional exemplary sequences include those at GenBank Acc. No. NP_418404.1 and YP_491483.1; exemplary coding sequences can be found at NC_000913.3 and NC_007779.1.

Cells are crosslinked by exposure to ultraviolet (UV) light (e.g., preferably 254 nm, but a range of 200 nm to 400 nm may be possible), cellular lysates are prepared, then DNAsed to solubilize the chromatin, and protein-RNA complexes are pulled down using streptavidin beads. Importantly, the samples are then washed, preferably with a high stringency wash, e.g., using 8 M urea (range: 5-10 M, 6-10M, 7-10M, 7-9M, or 7.5-8.5M)+0.1% SDS (range: 0.0-2.0%). Other detergents may be used as substitutes for SDS, including Triton X-100 and NP40. Samples can then be further washed, e.g., in PBS+2% SDS and further in high salt buffer (e.g., PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS; variations on salt/detergent conditions are possible). Under such suitable stringent conditions, most proteins are denatured, resulting in the loss of the nonspecific RNA-protein interactions. Only the extremely high-affinity biotin-avidin interaction survives. Thus, these steps can be used to effectively remove the vast majority of background RNA, resulting in extremely clean “peaks” of binding. The samples are then treated with DNAse to remove contaminating DNA. The RNA is phosphorylated using P32-ATP and run on SDS-PAGE and transferred onto membrane. Bands corresponding to the protein-RNA complex are then excised and eluted for cDNA preparation.

In some embodiments, the methods include contacting the sample with an agent, e.g., an antibody, that binds specifically to an RNA-binding protein or protein complex such as PRC1, e.g., to CBX7.

In some embodiments, the methods include some or all of the following: isolating the complexes; synthesizing DNA complementary to the RNAs to provide an initial population of cDNAs; PCR-amplifying, if necessary, using strand-specific primers; purifying the initial population of cDNAs to obtain a purified population of cDNAs that are at least 20 nucleotides (nt) in length; and high-throughput sequencing the purified population of cDNAs. Homopolymer reads are filtered, and reads matching the mitochondrial genome and ribosomal RNAs are excluded from all subsequent analyses. Reads that align to a reference genome with <1 mismatch are retained, excluding homopolymers, reads that align to the mitochondrial genome, and ribosomal RNAs. High probability PRC1-interacting transcripts are then called based on criteria that reads were significantly enriched in the wildtype library versus control library (such as a protein-null or tag-only control library, a minus-crosslinking library, or library made from an IgG pulldown done in parallel) for any given transcript. For example, under one set of criteria published in Zhao et al., 2010, the transcripts were enriched 3:1 in the wildtype library over the EZH2-null library, and each transcript had an RPKM minimum of 0.4. The criteria can be adjusted up or down based on empirical control data suggesting what cutoffs could be reasonably used. Statistical methods may also be used to call enrichment or “peaks” (binding sites) in the PRC1 library relative to control libraries, as has been used for the peaks called herein.

In general, to construct dCLIP-seq libraries, RNAs are extracted from the gel using standard techniques. To capture all RNAs (not just polyA RNAs) and to preserve strand information, 3′end-specific adapter is ligated to the extracted RNA fragments followed by hybridization with reverse transcription primer specific to 3′end adaptor and ligation of second adaptor specific to 5′ end. The subsequent reverse transcription step creates first strand cDNA sequence that contains sequences complementary to the 3′ and 5′ adapters. The resulting PCR using 3′- and 5′-adaptor specific primer pairs is then performed to amplify the cDNAs and the products sequenced via standard methods of high throughput sequencing. Prior to sequencing, a size-selection step is incorporated in which amplified PCR products of desired sizes are excised after separation by gel electrophoresis (e.g., on a Nu-Sieve agarose gel or in an acrylamide gel) in order to remove an undesirable side products such as adapter dimers.

Kits

Provided herein are kits for use in the dCLIP-seq methods described herein. The kits can include, but are not limited to, an expression vector for expressing the bacterial biotin ligase BirA in a cell type of interest, and an expression vector for expressing RNA-binding proteins of interest, e.g., mammalian (e.g., human or mouse) RNA-binding proteins of interest PRC1 components such as CBX2, CBX4, CBX6, CBX7, CBX8, or RYPB fused in-frame to a Flag-biotinylation tag sequence. In addition to PRC1 components, PRC2 components (EZH2, EZH1, SUZ12, etc) or any other RNA-binding protein (ATRX, YY1, CTCF, as three examples) may be used as bait and fused in frame to the biotin tag. In some embodiments, the kits include buffers, e.g., a high stringency denaturing buffer, e.g., comprising 8 M urea (range: 5-10 M, 6-10M, 7-10M, 7-9M, or 7.5-8.5M) plus 0.1% SDS (range: 0.0-2.0%); wash buffer (e.g., PBS+2% SDS; high salt wash buffer (e.g., PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS. Other detergents may be used as substitutes for SDS, including Triton X-100 and NP40; variations on salt conditions are also possible. In some embodiments, the kits include cells expressing BirA.

PRC1-Interacting RNAs and RNA Libraries

The present invention includes the individual PRC1-binding regions of RNAs described herein, as well as libraries of RNAs produced by methods described herein. In some embodiments, the libraries are in solution, or are lyophilized. In some embodiments, the libraries are bound to a substrate, e.g., wherein each member of the library is bound to an individually addressable member, e.g., an individual area on an array (e.g., a microarray), or a bead. The PRC1 RNA interactome consists of both coding and noncoding transcripts. Non-coding PRC1-interacting RNA transcripts may also include a protein-coding sequence of bases, e.g., a distinct transcript that overlaps in position with a protein-coding reference gene (e.g., the gene whose expression is modulated in cis).

In one embodiment, an RNA includes a nucleotide sequence that is at least about 85% or more homologous or identical to the entire length of an RNA sequence shown herein, e.g., in any of Tables 1-4, or a fragment comprising at least 20 nt thereof (e.g., at least 25, 30, 35, 40, 50, 60, 70, 80, 90, or 100 nt thereof, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50% or more of the full length RNA). In some embodiments, the nucleotide sequence is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homologous or identical to an RNA sequence shown herein.

Mouse-to-human LiftOver analysis and analysis in the UCSC genome browser of syntenic positions indicate the existence of similar transcripts in the human genome. This process and LiftOver chains are generally described in Kent et al., Proc. Nat'l Acad. Sci., 100(20) 11484-11489 (2003). Given the geographic and sequence similarities between the mouse and human transcripts, we believe that a similar number of PRC1-interacting transcripts occur in the human system. The data suggest that many if not all of the mouse PRC1-transcripts have direct counterparts in the human epigenome. Such direct counterparts in other species are termed “orthologous” herein.

RNAs may be functionally conserved without being highly conserved at the level of overall nucleotide identity. For example, mouse Xist shows only 76% overall nucleotide identity with human XIST using sliding 21-bp windows, or an overall sequence identity of only 60%. However, within specific functional domains, the degree of conservation can be >70% between different mammalian species. The crucial motif in some RNAs (e.g., Repeat A of XIST) is the secondary structures formed by the repeat. An RNA interacting with PRC1 may therefore be similarly low in overall conservation but still have conservation in secondary structure within specific domains of the RNA, and thereby demonstrate functional conservation with respect to recruitment of PRC1.

Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

To determine the percent identity of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%. The nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein nucleic acid “identity” is equivalent to nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

For purposes of the present invention, the comparison of sequences and determination of percent identity between two sequences can be accomplished using a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

There are several potential uses for the RNAs described herein in the expanded PRC1 transcriptome: The RNAs themselves, or antagomirs and small molecules designed against them, can be utilized to modulate expression (either up or down) of Polycomb target genes.

In various related aspects, including with respect to the targeting of RNAs by LNA molecule, PRC1-binding RNAs can include endogenous coding and non-coding cellular RNAs, including but not limited to those RNAs that are greater than 60 nt in length, e.g., greater than 100 nt, e.g., greater than 200 nt, have no positive-strand open reading frames greater than 100 amino acids in length, are identified as ncRNAs by experimental evidence, and are distinct from known (smaller) functional-RNA classes (including but not limited to ribosomal, transfer, and small nuclear/nucleolar RNAs, siRNA, piRNA, and miRNA). See, e.g., Lipovich et al., “MacroRNA underdogs in a microRNA world: Evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA” Biochimica et Biophysica Acta (2010) doi:10.1016/j.bbagrm.2010.10.001; Ponting et al., Cell 136(4):629-641 (2009), Jia et al., RNA 16 (8) (2010) 1478-1487, Dinger et al., Nucleic Acids Res. 37 1685 (2009) D122-D126 (database issue); and references cited therein. ncRNAs have also been referred to as, and can include, long non-coding RNA, long RNA, large RNA, macro RNA, intergenic RNA, and NonCoding Transcripts.

The methods described herein can be used to target both coding and non-coding RNAs. Known classes of RNAs include large intergenic non-coding RNAs (lincRNAs, see, e.g., Guttman et al., Nature. 2009 Mar. 12; 458(7235):223-7. Epub 2009 Feb. 1, which describes over a thousand exemplary highly conserved large non-coding RNAs in mammals; and Khalil et al., PNAS 106(28)₁₁₆₇₅-11680 (2009)); promoter associated short RNAs (PASRs; see, e.g., Seila et al., Science. 2008 Dec. 19; 322(5909):1849-51. Epub 2008 Dec. 4; Kanhere et al., Molecular Cell 38, 675-688, (2010)); endogenous antisense RNAs (see, e.g., Numata et al., BMC Genomics. 10:392 (2009); Okada et al., Hum Mol Genet. 17(11):1631-40 (2008); Numata et al., Gene 392(1-2):134-141 (2007); and Rosok and Sioud, Nat Biotechnol. 22(1):104-8 (2004)); and RNAs that bind chromatin modifiers such as PRC2 and LSD1 (see, e.g., Tsai et al., Science. 2010 Aug. 6; 329(5992):689-93. Epub 2010 Jul. 8; and Zhao et al., Science. 2008 Oct. 31; 322(5902):750-6).

Exemplary ncRNAs include XIST, TSIX, SRA1, and KCNQ1OT1. The sequences for more than 17,000 long human ncRNAs can be found in the NCode™ Long ncRNA Database on the Invitrogen website. Additional long ncRNAs can be identified using, e.g., manual published literature, Functional Annotation of Mouse (FANTOM3) project, Human Full-length cDNA Annotation Invitational (H-Invitational) project, antisense ncRNAs from cDNA and EST database for mouse and human using a computation pipeline (Zhang et al., Nucl. Acids Res. 35 (suppl 1): D156-D161 (2006); Engstrom et al., PLoS Genet. 2:e47 (2006)), human snoRNAs and scaRNAs derived from snoRNA-LBME-db, RNAz (Washietl et al. 2005), Noncoding RNA Search (Torarinsson, et al. 2006), and EvoFold (Pedersen et al. 2006).

Methods of Modulating Gene Expression

The RNAs described herein, including fragments thereof that are at least 20 nt in length, and inhibitory nucleic acids and small molecules targeting (e.g., complementary to) them, can be used to modulate gene expression in a cell, e.g., a cancer cell, a stem cell, or other normal cell types for gene or epigenetic therapy. The cells can be in vitro, including ex vivo, or in vivo (e.g., in a subject who has cancer, e.g., a tumor).

The methods described herein can be used for modulating expression of oncogenes and tumor suppressors in cells, e.g., cancer cells. For example, to decrease expression of an gene (e.g., an oncogene or imprinted gene) in a cell, the methods include introducing into the cell an inhibitory nucleic acid or small molecule that specifically binds, or is complementary, to a PRC1-binding region of an RNA that increases expression of the gene, e.g., an oncogene and/or an imprinted gene, set forth in Tables 1-3. As another example, to increase expression of a gene, e.g., a tumor suppressor, in a cell, the methods include introducing into the cell an inhibitory nucleic acid or small molecule that specifically binds, or is complementary, to a PRC1-binding region of an RNA that decreases expression of the gene, e.g., of a tumor suppressor gene, set forth in Tables 1-3, e.g., in subjects with cancer, e.g., lung adenocarcinoma patients.

In general, the methods include introducing into the cell an inhibitory nucleic acid that specifically binds, or is complementary, to a region of an RNA that modulated expression of a gene as set forth in Tables 1-3.

In preferred embodiments, the inhibitory nucleic acid binds to a region within or near (e.g., within 100, 200, 300, 400, 500, 600, 700, 1K, 2K, or 5K bases of) a PRC1-binding region of the RNA as set forth in Tables 1-3. The empirically-identified “peaks,” which are believed to represent PRC1-binding regions are shown in Table 1, with 500 nts of sequence on each side, so that in some the methods can include targeting a sequence as shown in one of the sequences in Tables 1-3, or a sequence that is between 500 nts from the start and 500 nts of the end of a sequence shown in Tables 1-3, or between 400 nts from the start and 400 nts of the end, 300 nts from the start and 300 nts of the end, between 200 nts from the start and 200 nts of the end, or between 100 nts from the start and 100 nts of the end, of a sequence shown in Tables 1-3. A nucleic acid that binds “specifically” binds primarily to the target RNA or related RNAs to inhibit regulatory function of the RNA but not of other non-target RNAs. The specificity of the nucleic acid interaction thus refers to its function (e.g., inhibiting the PRC1-associated repression of gene expression) rather than its hybridization capacity. Inhibitory nucleic acids may exhibit nonspecific binding to other sites in the genome or other RNAs, without interfering with binding of other regulatory proteins and without causing degradation of the non-specifically-bound RNA. Thus this nonspecific binding does not significantly affect function of other non-target RNAs and results in no significant adverse effects.

These methods can be used to treat a cancer in a subject by administering to the subject a composition (e.g., as described herein) comprising a PRC1-binding fragment of an RNA as described herein and/or an inhibitory nucleic acid that binds to an RNA (e.g., an inhibitory nucleic acid that binds to an RNA that inhibits a tumor suppressor, or cancer-suppressing gene, or imprinted gene and/or other growth-suppressing genes in any of Tables 1-3). Examples of cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.

As used herein, treating includes “prophylactic treatment” which means reducing the incidence of or preventing (or reducing risk of) a sign or symptom of a disease in a patient at risk for the disease, and “therapeutic treatment”, which means reducing signs or symptoms of a disease, reducing progression of a disease, reducing severity of a disease, in a patient diagnosed with the disease. With respect to cancer, treating includes inhibiting tumor cell proliferation, increasing tumor cell death or killing, inhibiting rate of tumor cell growth or metastasis, reducing size of tumors, reducing number of tumors, reducing number of metastases, increasing 1-year or 5-year survival rate.

As used herein, the terms “cancer”, “hyperproliferative” and “neoplastic” refer to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.

The terms “cancer” or “neoplasms” include malignancies of the various organ systems, such as affecting lung (e.g. small cell, non-small cell, squamous, adenocarcinoma), breast, thyroid, lymphoid, gastrointestinal, genito-urinary tract, kidney, bladder, liver (e.g. hepatocellular cancer), pancreas, ovary, cervix, endometrium, uterine, prostate, brain, as well as adenocarcinomas which include malignancies such as most colon cancers, colorectal cancer, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.

The term “carcinoma” is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. In some embodiments, the disease is renal carcinoma or melanoma. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term also includes carcinosarcomas, e.g., which include malignant tumors composed of carcinomatous and sarcomatous tissues. An “adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.

The term “sarcoma” is art recognized and refers to malignant tumors of mesenchymal derivation.

Additional examples of proliferative disorders include hematopoietic neoplastic disorders. As used herein, the term “hematopoietic neoplastic disorders” includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Preferably, the diseases arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia and acute megakaryoblastic leukemia. Additional exemplary myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) Crit Rev. in Oncol./Hemotol. 11:267-97); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Sternberg disease.

In some embodiments, specific cancers that can be treated using the methods described herein include, but are not limited to: breast, lung, prostate, CNS (e.g., glioma), salivary gland, prostate, ovarian, and leukemias (e.g., ALL, CML, or AML). Associations of these genes with a particular cancer are known in the art, e.g., as described in Futreal et al., Nat Rev Cancer. 2004; 4; 177-83; and The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Bamford et al., Br J Cancer. 2004; 91; 355-8; see also Forbes et al., Curr Protoc Hum Genet. 2008; Chapter 10; Unit 10.11, and the COSMIC database, e.g., v. 50 (Nov. 30, 2010).

In addition, the methods described herein can be used for modulating (e.g., enhancing or decreasing) pluripotency of a stem cell and to direct stem cells down specific differentiation pathways to make endoderm, mesoderm, ectoderm, and their developmental derivatives. To increase, maintain, or enhance pluripotency, the methods include introducing into the cell an inhibitory nucleic acid that specifically binds to, or is complementary to, a PRC1-binding site on a non-coding RNA as set forth in any of Tables 1-3. Stem cells useful in the methods described herein include adult stem cells (e.g., adult stem cells obtained from the inner ear, bone marrow, mesenchyme, skin, fat, liver, muscle, or blood of a subject, e.g., the subject to be treated); embryonic stem cells, or stem cells obtained from a placenta or umbilical cord; progenitor cells (e.g., progenitor cells derived from the inner ear, bone marrow, mesenchyme, skin, fat, liver, muscle, or blood); and induced pluripotent stem cells (e.g., iPS cells).

Furthermore, the present methods can be used to treat Systemic Lupus erythematosus (SLE), an autoimmune disease that affects 1.5 million Americans (16,000 new cases per year). Ages 10-50 are the most affected, with more sufferers being female than male. SLE is a multi-organ disease; the effects include arthritis, joint pain & swelling, chest pain, fatigue, general malaise, hair loss, mouth sores, sensitivity to light, skin rash, and swollen lymph nodes. Current treatments include corticosteroids, immunosuppressants, and more recently belimumab (an inhibitor of B cell activating factor).

The causes of SLE are probably multiple, including HLA haplotypes. The interleukin 1 receptor associated kinase 1 (IRAK1) has been implicated in some patients. IRAK1 is X-linked (possibly explaining the female predominance of the disease) and is involved in immune response to foreign antigens and pathogens. IRAK1 has been associated with SLE in both adult and pediatric forms. Overexpression of IRAK1 in animal models causes SLE, and knocking out IRAK1 in mice alleviates symptoms of SLE. See, e.g., Jacob et al., Proc Natl Acad Sci USA. 2009 Apr. 14; 106(15):6256-61. The present methods can include treating a subject with SLE by administering an inhibitory nucleic acid that is complementary to a PRC1-binding region on IRAK1 RNA, e.g., an LNA targeting the 3′ UTR, e.g., as shown in Table 4.

The present methods can also be used to treat MECP2 Duplication Syndrome in a subject. This condition is characterized by mental retardation, weak muscle tone, and feeding difficulties, as well as poor/absent speech, seizures, and muscle spasticity. There are more reported cases in males than in females; female carriers may have skewed XCI. There is a 50% mortality rate by age 25 associated with this condition, which accounts for 1-2% of X-linked mental retardation. The real rate of incidence is unknown, as many go undiagnosed. Genetically, the cause is duplication (even triplication) of MECP2 gene. There is no current treatment. The present methods can include treating a subject with MECP2 Duplication Syndrome by administering an inhibitory nucleic acid that is complementary to a PRC1-binding region on Mecp2 RNA, e.g., an LNA targeting the 3′UTR of Mecp2 as shown in FIG. 2C, e.g., as shown in Table 4.

In some embodiments, the methods described herein include administering a composition, e.g., a sterile composition, comprising an inhibitory nucleic acid that is complementary to a PRC1-binding region on an RNA described herein, e.g., as set forth in any of Tables 1-3, or SEQ ID NOS:1-5893 (human) or 5894-17415 (human LiftOver). Inhibitory nucleic acids for use in practicing the methods described herein can be an antisense or small interfering RNA, including but not limited to an shRNA or siRNA. In some embodiments, the inhibitory nucleic acid is a modified nucleic acid polymer (e.g., a locked nucleic acid (LNA) molecule). The present methods can include administration of a

Inhibitory nucleic acids have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Inhibitory nucleic acids can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.

For therapeutics, an animal, preferably a human, suspected of having cancer is treated by administering an RNA or inhibitory nucleic acid in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of an RNA or inhibitory nucleic acid as described herein.

Inhibitory Nucleic Acids Inhibitory nucleic acids useful in the present methods and compositions include antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, molecules comprising modified bases, locked nucleic acid molecules (LNA molecules), antagomirs, peptide nucleic acid molecules (PNA molecules), and other oligomeric compounds or oligonucleotide mimetics which hybridize to at least a portion of the target nucleic acid and modulate its function. In some embodiments, the inhibitory nucleic acids include antisense RNA, antisense DNA, chimeric antisense oligonucleotides, antisense oligonucleotides comprising modified linkages, interference RNA (RNAi), short interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); small activating RNAs (saRNAs), or combinations thereof. See, e.g., WO 2010040112.

In the present methods, the inhibitory nucleic acids are preferably designed to target a specific region of the RNA that binds to PRC1, as described herein (see Tables 1-3). These “inhibitory” nucleic acids are believed to work by inhibiting the interaction between the RNA and PRC1, and as described herein can be used to modulate expression of a gene.

In some embodiments, the inhibitory nucleic acids are 10 to 50, 13 to 50, or 13 to 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies oligonucleotides having antisense (complementary) portions of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length, or any range therewithin. It is understood that non-complementary bases may be included in such inhibitory nucleic acids; for example, an inhibitory nucleic acid 30 nucleotides in length may have a portion of 15 bases that is complementary to the targeted RNA. In some embodiments, the oligonucleotides are 15 nucleotides in length. In some embodiments, the antisense or oligonucleotide compounds of the invention are 12 or 13 to 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies inhibitory nucleic acids having antisense (complementary) portions of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, or any range therewithin.

Preferably the inhibitory nucleic acid comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

In some embodiments, the inhibitory nucleic acids are chimeric oligonucleotides that contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. Chimeric inhibitory nucleic acids of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference.

In some embodiments, the inhibitory nucleic acid comprises at least one nucleotide modified at the 2′ position of the sugar, most preferably a 2′-O-alkyl, 2′-O-alkyl-O-alkyl or 2′-fluoro-modified nucleotide. In other preferred embodiments, RNA modifications include 2′-fluoro, 2′-amino and 2′ O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3′ end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher Tm (i.e., higher target binding affinity) than; 2′-deoxyoligonucleotides against a given target.

A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide; these modified oligos survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones, particularly CH₂—NH—O—CH₂, CH, ˜N(CH₃)˜O˜CH₂ (known as a methylene(methylimino) or MMI backbone], CH₂—O—N(CH₃)—CH₂, CH₂—N(CH₃)—N(CH₃)—CH₂ and 0-N(CH₃)— CH₂—CH₂ backbones, wherein the native phosphodiester backbone is represented as O— P— O— CH); amide backbones (see De Mesmaeker et al. Ace. Chem. Res. 1995, 28:366-374); morpholino backbone structures (see Summerton and Weller, U.S. Pat. No. 5,034,506); peptide nucleic acid (PNA) backbone (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., Science 1991, 254, 1497). Phosphorus-containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3′alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′; see U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.

Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503-4510); Genesis, volume 30, issue 3, 2001; Heasman, J., Dev. Biol., 2002, 243, 209-214; Nasevicius et al., Nat. Genet., 2000, 26, 216-220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).

Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc., 2000, 122, 8595-8602.

Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts; see U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264, 562; 5, 264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

Modified oligonucleotides are also known that include oligonucleotides that are based on or constructed from arabinonucleotide or modified arabinonucleotide residues. Arabinonucleosides are stereoisomers of ribonucleosides, differing only in the configuration at the 2′-position of the sugar ring. In some embodiments, a 2′-arabino modification is 2′-F arabino. In some embodiments, the modified oligonucleotide is 2′-fluoro-D-arabinonucleic acid (FANA) (as described in, for example, Lon et al., Biochem., 41:3457-3467, 2002 and Min et al., Bioorg. Med. Chem. Lett., 12:2651-2654, 2002; the disclosures of which are incorporated herein by reference in their entireties). Similar modifications can also be made at other positions on the sugar, particularly the 3′ position of the sugar on a 3′ terminal nucleoside or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide.

PCT Publication No. WO 99/67378 discloses arabinonucleic acids (ANA) oligomers and their analogues for improved sequence specific inhibition of gene expression via association to complementary messenger RNA.

Other preferred modifications include ethylene-bridged nucleic acids (ENAs) (e.g., International Patent Publication No. WO 2005/042777, Morita et al., Nucleic Acid Res., Suppl 1:241-242, 2001; Surono et al., Hum. Gene Ther., 15:749-757, 2004; Koizumi, Curr. Opin. Mol. Ther., 8:144-149, 2006 and Horie et al., Nucleic Acids Symp. Ser (Oxf), 49:171-172, 2005; the disclosures of which are incorporated herein by reference in their entireties). Preferred ENAs include, but are not limited to, 2′-O,4′-C-ethylene-bridged nucleic acids.

Examples of LNAs are described in WO 2008/043753 and include compounds of the following formula.

where X and Y are independently selected among the groups —O—,

—S—, —N(H)—, N(R)—,—CH2- or —CH— (if part of a double bond),

—CH₂—O—, —CH₂—S—, —CH₂—N(H)—, —CH₂—N(R)—, —CH₂—CH₂— or —CH₂—CH— (if part of a double bond),

—CH═CH—, where R is selected from hydrogen and C₁₋₄-alkyl; Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety; and the asymmetric groups may be found in either orientation.

Preferably, the LNA used in the oligomer of the invention comprises at least one LNA unit according any of the formulas

wherein Y is —O—, —S—, —NH—, or N(R^(H)); Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety, and RH is selected from hydrogen and C₁₋₄-alkyl.

Preferably, the Locked Nucleic Acid (LNA) used in the oligomeric compound, such as an antisense oligonucleotide, of the invention comprises at least one nucleotide comprises a Locked Nucleic Acid (LNA) unit according any of the formulas shown in Scheme 2 of PCT/DK2006/000512.

Preferably, the LNA used in the oligomer of the invention comprises internucleoside linkages selected from -0-P(O)₂—O—, —O—P(O,S)—O—, -0-P(S)₂—O—, —S—P(O)₂—O—, —S—P(O,S)—O—, —S—P(S)₂—O—, -0-P(O)₂—S—, —O—P(O,S)—S—, —S—P(O)₂—S—, —O—PO(R^(H))—O—, O—PO(OCH₃)—O—, —O—PO(NR^(H))—O—, —O—PO(OCH₂CH₂S—R)—O—, —O—PO(BH₃)—O—, —O—PO(NHR^(H))—O—, —O—P(O)₂—NR^(H)—, —NR^(H)—P(O)₂—O—, —NR^(H)—CO—O—, where R^(H) is selected from hydrogen and C₁₋₄-alkyl.

Specifically preferred LNA units are shown in scheme 2:

The term “thio-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from S or —CH2-S—. Thio-LNA can be in both beta-D and alpha-L-configuration.

The term “amino-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from —N(H)—, N(R)—, CH₂—N(H)—, and —CH₂—N(R)— where R is selected from hydrogen and C₁₋₄-alkyl. Amino-LNA can be in both beta-D and alpha-L-configuration.

The term “oxy-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above represents —O— or —CH₂—O—. Oxy-LNA can be in both beta-D and alpha-L-configuration.

The term “ena-LNA” comprises a locked nucleotide in which Y in the general formula above is —CH₂—O— (where the oxygen atom of —CH₂—O— is attached to the 2′-position relative to the base B).

LNAs are described in additional detail below.

One or more substituted sugar moieties can also be included, e.g., one of the following at the 2′ position: OH, SH, SCH₃, F, OCN, OCH₃ OCH₃, OCH₃ O(CH₂)n CH₃, O(CH₂)n NH₂ or O(CH₂)n CH₃ where n is from 1 to about 10; Ci to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF3; OCF3; O—, S—, or N-alkyl; O-, S-, or N-alkenyl; SOCH3; SO2 CH3; ONO2; NO2; N3; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy [2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl)] (Martin et al, Helv. Chim. Acta, 1995, 78, 486). Other preferred modifications include 2′-methoxy (2′-O—CH₃), 2′-propoxy (2′-OCH₂ CH₂CH₃) and 2′-fluoro (2′-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.

Inhibitory nucleic acids can also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2′ deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, isocytosine, pseudoisocytosine, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 5-propynyluracil, 8-azaguanine, 7-deazaguanine, N6 (6-aminohexyl)adenine, 6-aminopurine, 2-aminopurine, 2-chloro-6-aminopurine and 2,6-diaminopurine or other diaminopurines. See, e.g., Kornberg, “DNA Replication,” W. H. Freeman & Co., San Francisco, 1980, pp 75-77; and Gebeyehu, G., et al. Nucl. Acids Res., 15:4513 (1987)). A “universal” base known in the art, e.g., inosine, can also be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2<0>C. (Sanghvi, in Crooke, and Lebleu, eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions.

It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

In some embodiments, both a sugar and an internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, Science, 1991, 254, 1497-1500.

Inhibitory nucleic acids can also include one or more nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Further, nucleobases comprise those disclosed in U.S. Pat. No. 3,687,808, those disclosed in “The Concise Encyclopedia of Polymer Science And Engineering”, pages 858-859, Kroschwitz, ed. John Wiley & Sons, 1990; those disclosed by Englisch et al., Angewandle Chemie, International Edition, 1991, 30, page 613, and those disclosed by Sanghvi, Chapter 15, Antisense Research and Applications,” pages 289-302, Crooke, and Lebleu, eds., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2<0>C (Sanghvi, et al., eds, “Antisense Research and Applications,” CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications. Modified nucleobases are described in U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175, 273; 5, 367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.

In some embodiments, the inhibitory nucleic acids are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. For example, one or more inhibitory nucleic acids, of the same or different types, can be conjugated to each other; or inhibitory nucleic acids can be conjugated to targeting moieties with enhanced specificity for a cell type or tissue type. Such moieties include, but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S— tritylthiol (Manoharan et al, Ann. N. Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937). See also U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552, 538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486, 603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762, 779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082, 830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5, 245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391, 723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5, 565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599, 928 and 5,688,941, each of which is herein incorporated by reference.

These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety. See, e.g., U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

The inhibitory nucleic acids useful in the present methods are sufficiently complementary to the target RNA, e.g., hybridize sufficiently well and with sufficient biological functional specificity, to give the desired effect. “Complementary” refers to the capacity for pairing, through base stacking and specific hydrogen bonding, between two sequences comprising naturally or non-naturally occurring (e.g., modified as described above) bases (nucleosides) or analogs thereof. For example, if a base at one position of an inhibitory nucleic acid is capable of hydrogen bonding with a base at the corresponding position of an RNA, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required. As noted above, inhibitory nucleic acids can comprise universal bases, or inert abasic spacers that provide no positive or negative contribution to hydrogen bonding. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing). It is understood that for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Nichols et al., Nature, 1994; 369:492-493 and Loakes et al., Nucleic Acids Res., 1994; 22:4039-4043. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U, or T. See Watkins and SantaLucia, Nucl. Acids Research, 2005; 33 (19): 6258-6267.

In some embodiments, the location on a target RNA to which an inhibitory nucleic acids hybridizes is defined as a region to which a protein binding partner binds, as shown in Tables 1-3. Routine methods can be used to design an inhibitory nucleic acid that binds to this sequence with sufficient specificity. In some embodiments, the methods include using bioinformatics methods known in the art to identify regions of secondary structure, e.g., one, two, or more stem-loop structures, or pseudoknots, and selecting those regions to target with an inhibitory nucleic acid. For example, methods of designing oligonucleotides similar to the inhibitory nucleic acids described herein, and various options for modified chemistries or formats, are exemplified in Lennox and Behlke, Gene Therapy (2011) 18: 1111-1120, which is incorporated herein by reference in its entirety, with the understanding that the present disclosure does not target miRNA ‘seed regions’.

While the specific sequences of certain exemplary target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional target segments are readily identifiable by one having ordinary skill in the art in view of this disclosure. Target segments 5-500 nucleotides in length comprising a stretch of at least five (5) consecutive nucleotides within the protein binding region, or immediately adjacent thereto, are considered to be suitable for targeting as well. Target segments can include sequences that comprise at least the 5 consecutive nucleotides from the 5 ‘-terminus of one of the protein binding regions (the remaining nucleotides being a consecutive stretch of the same RNA beginning immediately upstream of the 5’-terminus of the binding segment and continuing until the inhibitory nucleic acid contains about 5 to about 100 nucleotides). Similarly preferred target segments are represented by RNA sequences that comprise at least the 5 consecutive nucleotides from the 3 ‘-terminus of one of the illustrative preferred target segments (the remaining nucleotides being a consecutive stretch of the same RNA beginning immediately downstream of the 3’-terminus of the target segment and continuing until the inhibitory nucleic acid contains about 5 to about 100 nucleotides). One having skill in the art armed with the sequences provided herein will be able, without undue experimentation, to identify further preferred protein binding regions to target with complementary inhibitory nucleic acids.

In the context of the present disclosure, hybridization means base stacking and hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. Complementary, as the term is used in the art, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a RNA molecule, then the inhibitory nucleic acid and the RNA are considered to be complementary to each other at that position. The inhibitory nucleic acids and the RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other through their bases. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the inhibitory nucleic acid and the RNA target. For example, if a base at one position of an inhibitory nucleic acid is capable of hydrogen bonding with a base at the corresponding position of a RNA, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required.

It is understood in the art that a complementary nucleic acid sequence need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. A complementary nucleic acid sequence for purposes of the present methods is specifically hybridizable when binding of the sequence to the target RNA molecule interferes with the normal function of the target RNA to cause a loss of activity (e.g., inhibiting PRC1-associated repression with consequent up-regulation of gene expression) and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target RNA sequences under conditions in which avoidance of the non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency. For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30° C., more preferably of at least about 37° C., and most preferably of at least about 42° C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30° C. in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37° C. in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42° C. in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25° C., more preferably of at least about 42° C., and even more preferably of at least about 68° C. In a preferred embodiment, wash steps will occur at 25° C. in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 68° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

In general, the inhibitory nucleic acids useful in the methods described herein have at least 80% sequence complementarity to a target region within the target nucleic acid, e.g., 90%, 95%, or 100% sequence complementarity to the target region within an RNA. For example, an antisense compound in which 18 of 20 nucleobases of the antisense oligonucleotide are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity of an inhibitory nucleic acid with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656). Antisense and other compounds of the invention that hybridize to an RNA are identified through routine experimentation. In general the inhibitory nucleic acids must retain specificity for their target, i.e., either do not directly bind to, or do not directly significantly affect expression levels of, transcripts other than the intended target.

Target-specific effects, with corresponding target-specific functional biological effects, are possible even when the inhibitory nucleic acid exhibits non-specific binding to a large number of non-target RNAs. For example, short 8 base long inhibitory nucleic acids that are fully complementary to a RNA may have multiple 100% matches to hundreds of sequences in the genome, yet may produce target-specific effects, e.g. upregulation of a specific target gene through inhibition of PRC1 activity. 8-base inhibitory nucleic acids have been reported to prevent exon skipping with with a high degree of specificity and reduced off-target effect. See Singh et al., RNA Biol., 2009; 6(3): 341-350. 8-base inhibitory nucleic acids have been reported to interfere with miRNA activity without significant off-target effects. See Obad et al., Nature Genetics, 2011; 43: 371-378.

For further disclosure regarding inhibitory nucleic acids, please see US2010/0317718 (antisense oligos); US2010/0249052 (double-stranded ribonucleic acid (dsRNA)); US2009/0181914 and US2010/0234451 (LNA molecules); US2007/0191294 (siRNA analogues); US2008/0249039 (modified siRNA); and WO2010/129746 and WO2010/040112 (inhibitory nucleic acids).

Antisense

In some embodiments, the inhibitory nucleic acids are antisense oligonucleotides. Antisense oligonucleotides are typically designed to block expression of a DNA or RNA target by binding to the target and halting expression at the level of transcription, translation, or splicing. Antisense oligonucleotides of the present invention are complementary nucleic acid sequences designed to hybridize under stringent conditions to an RNA in vitro, and are expected to inhibit the activity of PRC1 in vivo. Thus, oligonucleotides are chosen that are sufficiently complementary to the target, i.e., that hybridize sufficiently well and with sufficient biological functional specificity, to give the desired effect.

Modified Base, Including Locked Nucleic Acids (LNAs)

In some embodiments, the inhibitory nucleic acids used in the methods described herein comprise one or more modified bonds or bases. Modified bases include phosphorothioate, methylphosphonate, peptide nucleic acids, or locked nucleic acids (LNAs). Preferably, the modified nucleotides are part of locked nucleic acid molecules, including [alpha]-L-LNAs. LNAs include ribonucleic acid analogues wherein the ribose ring is “locked” by a methylene bridge between the 2′-oxgygen and the 4′-carbon—i.e., oligonucleotides containing at least one LNA monomer, that is, one 2′-O,4′-C-methylene-β-D-ribofuranosyl nucleotide. LNA bases form standard Watson-Crick base pairs but the locked configuration increases the rate and stability of the basepairing reaction (Jepsen et al., Oligonucleotides, 14, 130-146 (2004)). LNAs also have increased affinity to base pair with RNA as compared to DNA. These properties render LNAs especially useful as probes for fluorescence in situ hybridization (FISH) and comparative genomic hybridization, as knockdown tools for miRNAs, and as antisense oligonucleotides to target mRNAs or other RNAs, e.g., RNAs as described herien.

The modified base/LNA molecules can include molecules comprising 10-30, e.g., 12-24, e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in the RNA. The modified base/LNA molecules can be chemically synthesized using methods known in the art.

The modified base/LNA molecules can be designed using any method known in the art; a number of algorithms are known, and are commercially available (e.g., on the internet, for example at exiqon.com). See, e.g., You et al., Nuc. Acids. Res. 34:e60 (2006); McTigue et al., Biochemistry 43:5388-405 (2004); and Levin et al., Nuc. Acids. Res. 34:e142 (2006). For example, “gene walk” methods, similar to those used to design antisense oligos, can be used to optimize the inhibitory activity of a modified base/LNA molecule; for example, a series of oligonucleotides of 10-30 nucleotides spanning the length of a target RNA can be prepared, followed by testing for activity. Optionally, gaps, e.g., of 5-10 nucleotides or more, can be left between the LNAs to reduce the number of oligonucleotides synthesized and tested. GC content is preferably between about 30₇60%. General guidelines for designing modified base/LNA molecules are known in the art; for example, LNA sequences will bind very tightly to other LNA sequences, so it is preferable to avoid significant complementarity within an LNA molecule. Contiguous runs of three or more Gs or Cs, or more than four LNA residues, should be avoided where possible (for example, it may not be possible with very short (e.g., about 9-10 nt) oligonucleotides). In some embodiments, the LNAs are xylo-LNAs.

For additional information regarding LNA molecules see U.S. Pat. Nos. 6,268,490; 6,734,291; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,060,809; 7,084,125; and 7,572,582; and U.S. Pre-Grant Pub. Nos. 20100267018; 20100261175; and 20100035968; Koshkin et al. Tetrahedron 54, 3607-3630 (1998); Obika et al. Tetrahedron Lett. 39, 5401-5404 (1998); Jepsen et al., Oligonucleotides 14:130-146 (2004); Kauppinen et al., Drug Disc. Today 2(3):287-290 (2005); and Ponting et al., Cell 136(4):629-641 (2009), and references cited therein.

As demonstrated herein and previously (see, e.g., WO 2012/065143 and WO 2012/087983, incorporated herein by reference), LNA molecules can be used as a valuable tool to manipulate and aid analysis of RNAs. Advantages offered by an LNA molecule-based system are the relatively low costs, easy delivery, and rapid action. While other inhibitory nucleic acids may exhibit effects after longer periods of time, LNA molecules exhibit effects that are more rapid, e.g., a comparatively early onset of activity, are fully reversible after a recovery period following the synthesis of new RNA, and occur without causing substantial or substantially complete RNA cleavage or degradation. One or more of these design properties may be desired properties of the inhibitory nucleic acids of the invention. Additionally, LNA molecules make possible the systematic targeting of domains within much longer nuclear transcripts. Although a PNA-based system has been described earlier, the effects on Xi were apparent only after 24 hours (Beletskii et al., Proc Natl Acad Sci USA. 2001; 98:9215-9220). The LNA technology enables high-throughput screens for functional analysis of non-coding RNAs and also provides a novel tool to manipulate chromatin states in vivo for therapeutic applications.

In various related aspects, the methods described herein include using LNA molecules to target RNAs for a number of uses, including as a research tool to probe the function of a specific RNA, e.g., in vitro or in vivo. The methods include selecting one or more desired RNAs, designing one or more LNA molecules that target the RNA, providing the designed LNA molecule, and administering the LNA molecule to a cell or animal. The methods can optionally include selecting a region of the RNA and designing one or more LNA molecules that target that region of the RNA.

Aberrant imprinted gene expression is implicated in several diseases including Long QT syndrome, Beckwith-Wiedemann, Prader-Willi, and Angelman syndromes, as well as behavioral disorders and carcinogenesis (see, e.g., Falls et al., Am. J. Pathol. 154:635-647 (1999); Lalonde, Annu Rev Genet 30:173-195 (1996); Hall Annu Rev Med. 48:35-44 (1997)). LNA molecules can be created to treat such imprinted diseases. As one example, the long QT Syndrome can be caused by a K+ gated Calcium-channel encoded by Kcnql. This gene is regulated by its antisense counterpart, the long noncoding RNA, Kcnqlotl (Pandey et al., Mol Cell. 2008 Oct. 24; 32(2):232-46). Disease arises when Kcnqlotl is aberrantly expressed. LNA molecules can be created to downregulate Kcnqlotl, thereby restoring expression of Kcnql. As another example, LNA molecules could inhibit RNA cofactors for polycomb complex chromatin modifiers to reverse the imprinted defect.

From a commercial and clinical perspective, the timepoints between about 1 to 24 hours potentially define a window for epigenetic reprogramming. The advantage of the LNA system is that it works quickly, with a defined half-life, and is therefore reversible upon degradation of LNAs, at the same time that it provides a discrete timeframe during which epigenetic manipulations can be made. By targeting nuclear long RNAs, LNA molecules or similar polymers, e.g., xylo-LNAs, might be utilized to manipulate the chromatin state of cells in culture or in vivo, by transiently eliminating the regulatory RNA and associated proteins long enough to alter the underlying locus for therapeutic purposes. In particular, LNA molecules or similar polymers that specifically bind to, or are complementary to, PRC1-binding RNA can prevent recruitment of PRC1 to a specific chromosomal locus, in a gene-specific fashion.

LNA molecules might also be administered in vivo to treat other human diseases, such as but not limited to cancer, neurological disorders, infections, inflammation, and myotonic dystrophy. For example, LNA molecules might be delivered to tumor cells to downregulate the biologic activity of a growth-promoting or oncogenic long nuclear RNA (e.g., Gt12 or MALAT1 (Luo et al., Hepatology. 44(4):1012-24 (2006)), a RNA associated with metastasis and is frequently upregulated in cancers). Repressive RNAs downregulating tumor suppressors can also be targeted by LNA molecules to promote reexpression. For example, expression of the INK4b/ARF/INK4a tumor suppressor locus is controlled by Polycomb group proteins including PRC1 and PRC1 and repressed by the antisense noncoding RNA ANRIL (Yap et al., Mol Cell. 2010 Jun. 11; 38(5):662-74). PRC1-binding regions described herein in ANRIL can be targeted by LNA molecules to promote reexpression of the INK4b/ARF/INK4a tumor suppressor. Some ncRNAs may be positive regulators of oncogenes. Such “activating ncRNAs” have been described recently (e.g., Jpx (Tian et al., Cell. 143(3):390-403 (2010) and others (from et al., Cell. 143(1):46-58 (2010)). Therefore, LNA molecules could be directed at these activating ncRNAs to downregulate oncogenes. LNA molecules could also be delivered to inflammatory cells to downregulate regulatory ncRNA that modulate the inflammatory or immune response. (e.g., LincRNA-Cox2, see Guttman et al., Nature. 458(7235):223-7. Epub 2009 Feb. 1 (2009)).

In still other related aspects, the LNA molecules targeting PRC1-binding regions in RNAs described herein can be used to create animal or cell models of conditions associated with altered gene expression (e.g., as a result of altered epigenetics).

The methods described herein may also be useful for creating animal or cell models of other conditions associated with aberrant imprinted gene expression, e.g., as noted above.

In various related aspects, the results described herein demonstrate the utility of LNA molecules for targeting RNA, for example, to transiently disrupt chromatin for purposes of reprogramming chromatin states ex vivo. Because LNA molecules stably displace RNA for hours and chromatin does not rebuild for hours thereafter, LNA molecules create a window of opportunity to manipulate the epigenetic state of specific loci ex vivo, e.g., for reprogramming of hiPS and hESC prior to stem cell therapy. For example, Gt12 controls expression of DLK1, which modulates the pluripotency of iPS cells. Low Gt12 and high DLK1 is correlated with increased pluripotency and stability in human iPS cells. Thus, LNA molecules targeting Gt12 can be used to inhibit differentiation and increase pluripotency and stability of iPS cells.

See also PCT/US11/60493, which is incorporated by reference herein in its entirety.

Interfering RNA, Including siRNA/shRNA

In some embodiments, the inhibitory nucleic acid sequence that is complementary to an RNA can be an interfering RNA, including but not limited to a small interfering RNA (“siRNA”) or a small hairpin RNA (“shRNA”). Methods for constructing interfering RNAs are well known in the art. For example, the interfering RNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e., each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double stranded structure); the antisense strand comprises nucleotide sequence that is complementary to a nucleotide sequence in a target nucleic acid molecule or a portion thereof (i.e., an undesired gene) and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Alternatively, interfering RNA is assembled from a single oligonucleotide, where the self-complementary sense and antisense regions are linked by means of nucleic acid based or non-nucleic acid-based linker(s). The interfering RNA can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises a nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The interfering can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an active siRNA molecule capable of mediating RNA interference.

In some embodiments, the interfering RNA coding region encodes a self-complementary RNA molecule having a sense region, an antisense region and a loop region. Such an RNA molecule when expressed desirably forms a “hairpin” structure, and is referred to herein as an “shRNA.” The loop region is generally between about 2 and about 10 nucleotides in length. In some embodiments, the loop region is from about 6 to about 9 nucleotides in length. In some embodiments, the sense region and the antisense region are between about 15 and about 20 nucleotides in length. Following post-transcriptional processing, the small hairpin RNA is converted into a siRNA by a cleavage event mediated by the enzyme Dicer, which is a member of the RNase III family. The siRNA is then capable of inhibiting the expression of a gene with which it shares homology. For details, see Brummelkamp et al., Science 296:550-553, (2002); Lee et al, Nature Biotechnol., 20, 500-505, (2002); Miyagishi and Taira, Nature Biotechnol 20:497-500, (2002); Paddison et al. Genes & Dev. 16:948-958, (2002); Paul, Nature Biotechnol, 20, 505-508, (2002); Sui, Proc. Natl. Acad. Sd. USA, 99(6), 5515-5520, (2002); Yu et al. Proc NatlAcadSci USA 99:6047-6052, (2002).

The target RNA cleavage reaction guided by siRNAs is highly sequence specific. In general, siRNA containing a nucleotide sequences identical to a portion of the target nucleic acid are preferred for inhibition. However, 100% sequence identity between the siRNA and the target gene is not required to practice the present invention. Thus the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence. For example, siRNA sequences with insertions, deletions, and single point mutations relative to the target sequence have also been found to be effective for inhibition. Alternatively, siRNA sequences with nucleotide analog substitutions or insertions can be effective for inhibition. In general the siRNAs must retain specificity for their target, i.e., must not directly bind to, or directly significantly affect expression levels of, transcripts other than the intended target.

Ribozymes

In some embodiments, the inhibitory nucleic acids are ribozymes. Trans-cleaving enzymatic nucleic acid molecules can also be used; they have shown promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037). Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional.

In general, enzymatic nucleic acids with RNA cleaving activity act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

Several approaches such as in vitro selection (evolution) strategies (Orgel, 1979, Proc. R. Soc. London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages, (Joyce, 1989, Gene, 82, 83-87; Beaudry et al., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al, 1994, TIBTECH 12, 268; Bartel et al, 1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al, 1995, FASEB J., 9, 1183; Breaker, 1996, Curr. Op. Biotech., 1, 442). The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme, for example, functions with a catalytic rate (kcat) of about 1 min⁻¹ in the presence of saturating (10 MM) concentrations of Mg²⁺ cofactor. An artificial “RNA ligase” ribozyme has been shown to catalyze the corresponding self-modification reaction with a rate of about 100 min⁻¹. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min⁻¹.

Making and Using Inhibitory Nucleic Acids

The nucleic acid sequences used to practice the methods described herein, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, can be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/generated recombinantly. If desired, nucleic acid sequences of the invention can be inserted into delivery vectors and expressed from transcription units within the vectors. The recombinant vectors can be DNA plasmids or viral vectors. Generation of the vector construct can be accomplished using any suitable genetic engineering techniques well known in the art, including, without limitation, the standard techniques of PCR, oligonucleotide synthesis, restriction endonuclease digestion, ligation, transformation, plasmid purification, and DNA sequencing, for example as described in Sambrook et al. Molecular Cloning: A Laboratory Manual. (1989)), Coffin et al. (Retroviruses. (1997)) and “RNA Viruses: A Practical Approach” (Alan J. Cann, Ed., Oxford University Press, (2000)).

Preferably, inhibitory nucleic acids of the invention are synthesized chemically. Nucleic acid sequences used to practice this invention can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Pat. No. 4,458,066; WO/2008/043753 and WO/2008/049085, and the references cited therein.

Nucleic acid sequences of the invention can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide modification. For example, nucleic acid sequences of the invention includes a phosphorothioate at least the first, second, or third internucleotide linkage at the 5′ or 3′ end of the nucleotide to sequence. As another example, the nucleic acid sequence can include a 2′-modified nucleotide, e.g., a 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), or 2′-O—N-methylacetamido (2′-O—NMA). As another example, the nucleic acid sequence can include at least one 2′-O-methyl-modified nucleotide, and in some embodiments, all of the nucleotides include a 2′-O-methyl modification. In some embodiments, the nucleic acids are “locked,” i.e., comprise nucleic acid analogues in which the ribose ring is “locked” by a methylene bridge connecting the 2′-O atom and the 4′-C atom (see, e.g., Kaupinnen et al., Drug Disc. Today 2(3):287-290 (2005); Koshkin et al., J. Am. Chem. Soc., 120(50):13252-13253 (1998)). For additional modifications see US 20100004320, US 20090298916, and US 20090143326.

It is understood that any of the modified chemistries or formats of inhibitory nucleic acids described herein can be combined with each other, and that one, two, three, four, five, or more different types of modifications can be included within the same molecule.

Techniques for the manipulation of nucleic acids used to practice this invention, such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook et al., Molecular Cloning; A Laboratory Manual 3d ed. (2001); Current Protocols in Molecular Biology, Ausubel et al., eds. (John Wiley & Sons, Inc., New York 2010); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); Laboratory Techniques In Biochemistry And Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).

Pharmaceutical Compositions

The methods described herein can include the administration of pharmaceutical compositions and formulations comprising inhibitory nucleic acid sequences designed to target an RNA.

In some embodiments, the compositions are formulated with a pharmaceutically acceptable carrier. The pharmaceutical compositions and formulations can be administered parenterally, topically, orally or by local administration, such as by aerosol or transdermally. The pharmaceutical compositions can be formulated in any way and can be administered in a variety of unit dosage forms depending upon the condition or disease and the degree of illness, the general medical condition of each patient, the resulting preferred method of administration and the like. Details on techniques for formulation and administration of pharmaceuticals are well described in the scientific and patent literature, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005.

The inhibitory nucleic acids can be administered alone or as a component of a pharmaceutical formulation (composition). The compounds may be formulated for administration, in any convenient way for use in human or veterinary medicine. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Formulations of the compositions of the invention include those suitable for intradermal, inhalation, oral/nasal, topical, parenteral, rectal, and/or intravaginal administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient (e.g., nucleic acid sequences of this invention) which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, e.g., intradermal or inhalation. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect, e.g., an antigen specific T cell or humoral response.

Pharmaceutical formulations of this invention can be prepared according to any method known to the art for the manufacture of pharmaceuticals. Such drugs can contain sweetening agents, flavoring agents, coloring agents and preserving agents. A formulation can be admixtured with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture. Formulations may comprise one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, on patches, in implants, etc.

Pharmaceutical formulations for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in appropriate and suitable dosages. Such carriers enable the pharmaceuticals to be formulated in unit dosage forms as tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Pharmaceutical preparations for oral use can be formulated as a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores. Suitable solid excipients are carbohydrate or protein fillers include, e.g., sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxy-methylcellulose; and gums including arabic and tragacanth; and proteins, e.g., gelatin and collagen. Disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Push-fit capsules can contain active agents mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active agents can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Aqueous suspensions can contain an active agent (e.g., nucleic acid sequences of the invention) in admixture with excipients suitable for the manufacture of aqueous suspensions, e.g., for aqueous intradermal injections. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Formulations can be adjusted for osmolarity.

In some embodiments, oil-based pharmaceuticals are used for administration of nucleic acid sequences of the invention. Oil-based suspensions can be formulated by suspending an active agent in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these. See e.g., U.S. Pat. No. 5,716,928 describing using essential oils or essential oil components for increasing bioavailability and reducing inter- and intra-individual variability of orally administered hydrophobic pharmaceutical compounds (see also U.S. Pat. No. 5,858,401). The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid. As an example of an injectable oil vehicle, see Minto (1997) J. Pharmacol. Exp. Ther. 281:93-102.

Pharmaceutical formulations can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent. In alternative embodiments, these injectable oil-in-water emulsions of the invention comprise a paraffin oil, a sorbitan monooleate, an ethoxylated sorbitan monooleate and/or an ethoxylated sorbitan trioleate.

The pharmaceutical compounds can also be administered by in intranasal, intraocular and intravaginal routes including suppositories, insufflation, powders and aerosol formulations (for examples of steroid inhalants, see e.g., Rohatagi (1995) J. Clin. Pharmacol. 35:1187-1193; Tjwa (1995) Ann. Allergy Asthma Immunol. 75:107-111). Suppositories formulations can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at body temperatures and will therefore melt in the body to release the drug. Such materials are cocoa butter and polyethylene glycols.

In some embodiments, the pharmaceutical compounds can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

In some embodiments, the pharmaceutical compounds can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug which slowly release subcutaneously; see Rao (1995) J. Biomater Sci. Polym. Ed. 7:623-645; as biodegradable and injectable gel formulations, see, e.g., Gao (1995) Pharm. Res. 12:857-863 (1995); or, as microspheres for oral administration, see, e.g., Eyles (1997) J. Pharm. Pharmacol. 49:669-674.

In some embodiments, the pharmaceutical compounds can be parenterally administered, such as by intravenous (IV) administration or administration into a body cavity or lumen of an organ. These formulations can comprise a solution of active agent dissolved in a pharmaceutically acceptable carrier. Acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter. These formulations may be sterilized by conventional, well known sterilization techniques. The formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs. For IV administration, the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol. The administration can be by bolus or continuous infusion (e.g., substantially uninterrupted introduction into a blood vessel for a specified period of time).

In some embodiments, the pharmaceutical compounds and formulations can be lyophilized. Stable lyophilized formulations comprising an inhibitory nucleic acid can be made by lyophilizing a solution comprising a pharmaceutical of the invention and a bulking agent, e.g., mannitol, trehalose, raffinose, and sucrose or mixtures thereof. A process for preparing a stable lyophilized formulation can include lyophilizing a solution about 2.5 mg/mL protein, about 15 mg/mL sucrose, about 19 mg/mL NaCl, and a sodium citrate buffer having a pH greater than 5.5 but less than 6.5. See, e.g., U.S. 20040028670.

The compositions and formulations can be delivered by the use of liposomes. By using liposomes, particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the active agent into target cells in vivo. See, e.g., U.S. Pat. Nos. 6,063,400; 6,007,839; Al-Muhammed (1996) J. Microencapsul. 13:293-306; Chonn (1995) Curr. Opin. Biotechnol. 6:698-708; Ostro (1989) Am. J. Hosp. Pharm. 46:1576-1587. As used in the present invention, the term “liposome” means a vesicle composed of amphiphilic lipids arranged in a bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

Liposomes can also include “sterically stabilized” liposomes, i.e., liposomes comprising one or more specialized lipids. When incorporated into liposomes, these specialized lipids result in liposomes with enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860.

The formulations of the invention can be administered for prophylactic and/or therapeutic treatments. In some embodiments, for therapeutic applications, compositions are administered to a subject who is need of reduced triglyceride levels, or who is at risk of or has a disorder described herein, in an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of the disorder or its complications; this can be called a therapeutically effective amount. For example, in some embodiments, pharmaceutical compositions of the invention are administered in an amount sufficient to decrease serum levels of triglycerides in the subject.

The amount of pharmaceutical composition adequate to accomplish this is a therapeutically effective dose. The dosage schedule and amounts effective for this use, i.e., the dosing regimen, will depend upon a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.

The dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, i.e., the active agents' rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g., Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58:611-617; Groning (1996) Pharmazie 51:337-341; Fotherby (1996) Contraception 54:59-69; Johnson (1995) J. Pharm. Sci. 84:1144-1146; Rohatagi (1995) Pharmazie 50:610-613; Brophy (1983) Eur. J. Clin. Pharmacol. 24:103-108; Remington: The Science and Practice of Pharmacy, 21st ed., 2005). The state of the art allows the clinician to determine the dosage regimen for each individual patient, active agent and disease or condition treated. Guidelines provided for similar compositions used as pharmaceuticals can be used as guidance to determine the dosage regiment, i.e., dose schedule and dosage levels, administered practicing the methods of the invention are correct and appropriate.

Single or multiple administrations of formulations can be given depending on for example: the dosage and frequency as required and tolerated by the patient, the degree and amount of therapeutic effect generated after each administration (e.g., effect on tumor size or growth), and the like. The formulations should provide a sufficient quantity of active agent to effectively treat, prevent or ameliorate conditions, diseases or symptoms.

In alternative embodiments, pharmaceutical formulations for oral administration are in a daily amount of between about 1 to 100 or more mg per kilogram of body weight per day. Lower dosages can be used, in contrast to administration orally, into the blood stream, into a body cavity or into a lumen of an organ. Substantially higher dosages can be used in topical or oral administration or administering by powders, spray or inhalation. Actual methods for preparing parenterally or non-parenterally administrable formulations will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington: The Science and Practice of Pharmacy, 21st ed., 2005.

Various studies have reported successful mammalian dosing using complementary nucleic acid sequences. For example, Esau C., et al., (2006) Cell Metabolism, 3(2):87-98 reported dosing of normal mice with intraperitoneal doses of miR-122 antisense oligonucleotide ranging from 12.5 to 75 mg/kg twice weekly for 4 weeks. The mice appeared healthy and normal at the end of treatment, with no loss of body weight or reduced food intake. Plasma transaminase levels were in the normal range (AST ¾ 45, ALT ¾ 35) for all doses with the exception of the 75 mg/kg dose of miR-122 ASO, which showed a very mild increase in ALT and AST levels. They concluded that 50 mg/kg was an effective, non-toxic dose. Another study by Krützfeldt J., et al., (2005) Nature 438, 685-689, injected anatgomirs to silence miR-122 in mice using a total dose of 80, 160 or 240 mg per kg body weight. The highest dose resulted in a complete loss of miR-122 signal. In yet another study, locked nucleic acid molecules (“LNA molecules”) were successfully applied in primates to silence miR-122. Elmen J., et al., (2008) Nature 452, 896-899, report that efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg-1 LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals.

In some embodiments, the methods described herein can include co-administration with other drugs or pharmaceuticals, e.g., compositions for providing cholesterol homeostasis. For example, the inhibitory nucleic acids can be co-administered with drugs for treating or reducing risk of a disorder described herein.

EXAMPLES

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

Example 1. A Denaturing CLIP-Seq Method for Identifying RNA Interactomes of Chromatin Complexes with High Specificity

PRC1 is Polycomb Repressive Complex 1, a Polycomb complex that is biochemically distinct from PRC2. PRC1 is the ezymatic complex that ubiquitylates histone H2A at lysine 119 (H2AK119Ub). Action of PRC1 on chromatin results in chromatin compaction and transcriptional repression. Although PRC1 binds thousands of sites in the mammalian genome, how PRC1 is targeted to chromatin has remained a mystery. YY1 may recruit PRC1 in some contexts, but is unlikely to be the general mechanism. RNA-mediated targeting is another potential mechanism. PRC1 is known to interact with at least one RNA—ANRIL (Yap et al., Mol Cell. 2010 Jun. 11; 38(5):662-74). This example describes methods that were developed to determing how many RNAs interact with PRC1 and whether they are a general recruiting tool for PRC1.

These “denaturing” CLIP-seq methods (also referred to herein as dCLIP-seq) utilize a biotin tag to enable purification of RNA-protein complexes under denaturing conditions to increase the specificity of the purification scheme. As shown in FIGS. 1A-B, for the to denaturing CLIP method, cell lines stably expressing two vectors were prepared: vector #1-expressing bacterial biotin ligase BirA under neomycin resistance; and vector #2—expressing a protein of interest (here, PRC1) fused to a biotinylation tag or control vector under puromycin resistance. Both human HEK 293 kidney cells and mouse 16.7 ES cells were used. Cells were crosslinked by exposure to ultraviolet (UV) light (254 nm) at 150-400 mJ/cm² on ice depending on cell layer thickness, cellular lysates are prepared, then treated with DNAse to solubilize the chromatin, and protein-RNA complexes were pulled down using streptavidin beads. Importantly, the samples were then washed with a high stringency wash using 8 M urea+0.1% SDS (range: 0.0-2.0%) at room temperature. Samples were then further washed in PBS+2% SDS and further in high salt buffer (PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS), each at room temperature. Under such stringent conditions, most proteins are denatured, resulting in the loss of the nonspecific RNA-protein interactions. Only the extremely high-affinity biotin-avidin interaction survives. Thus, these steps can be used to effectively remove the vast majority of background RNA, resulting in extremely clean “peaks” of binding. The samples are then treated with DNAse to remove contaminating DNA. The RNA was phosphorylated using ³²P-ATP and run on SDS-PAGE and transferred onto a membrane. Broad bands corresponding to the RNA-PRC1 complex were identified by the presence of radioactive labeling (hot smear on the membrane) and then excised and eluted for cDNA preparation preparation prior to deep sequencing.

Peaks (high-frequency sequences, believed to correlate with protein binding sites on the RNA), were called by the following methods. About 40 million paired-end 50 nucleotide (nt) reads were generated for every dCLIP-seq sample. Adaptor sequences were trimmed with either Trim Galore! v0.3.3 (for dCLIP-seq; stringency 15 and allowed error rate 0.2), or cutadapt (v1.0). Identical sequences (PCR duplicates) were removed by custom programs prior to alignment. To account for the M. mus (mus)/M. castaneus (cas) hybrid character of mouse 16.7 ES cell line used for a dCLIP-seq, reads were first aligned to custom mus/129 and cas genomes, and then mapped back to the reference mm9 genome (Pinter et al., Genome Res 22, 1864-1876, 2012). For dCLIP-seq data obtained from human HEK293 cell line, alignments were performed to hg19 human reference genome. All alignments were performed with Tophat (v2.0.11) (Kim et al., Genome Biol 14, R36, 2013). Post-processing of alignments was performed with custom scripts using SAMtools (Li et al., Bioinformatics 25, 2078-2079, 2009), and BEDtools v2.17.0 (Quinlan and Hall, Bioinformatics 26, 841-842, 2010). These included accounting, alignment file-type conversion, extracting and sorting reads (SAMtools), and obtaining wig coverage files (SAMtools depth).

Fragment per million (fpm) wig files were then created by scaling uniquely aligned wig files to total number of fragments per million in each library (determined by SAMtools flagstat combining reads “with itself and mate mapped” and “singletons”). Then consecutive wig entries of equal coverage were merged forming bed files that were used for peak calling. The peak caller software peakranger (v. 16) (Uren et al., Bioinformatics 28, 3013-3020, 2012) was used. The software peakranger requires an even distribution of watson/crick entries, so prior to calling, strand specific bed file entries were randomized for strand. The software peakranger was called with arguments ranger −p 0.01—format bed—gene_annot_file (either mm9 or hg19 appropriate), −d experiment and −c mock-transfected control, to find narrow peaks with p-value 0.01 or less. To extract more uniquely aligned reads, a second round of peak calling was performed from the mus track, this time including “pegged” reads attained using tophat2 with the option −g 100. Pegged reads are singletons extracted from the reps track where the locus of one end is fixed locus and other varies. We then merged the results with the previous method.

Example 2. Human CBX7-RNA Binding Sites as Determined by Denaturing CLIP-Seq Analysis in Human 293 Cells

CLIP-seq performed in human female embryonic kidney fibroblast line, HEK293, as described above in Example 1. CBX7 binding sites in the RNA are shown in Table 1. Peaks were called from uniquely mapped reads using the software peakranger (p=0.01). The resulting strand specific bed files were then converted to their respective strands. To produce non-overlapping peaks, entries, from two biological replicate bed files were expanded by 500 nucleotides on each side and merged. The envelope of 500 bases was added because RNA-protein interactions could be affected by changes in nucleic acid folding nearby, which in turn could cause allosteric effects on the RNA-protein interaction. Then the closest gene was determined for each entry (bedtools closest) and categorized as “Imprinted” gene, “Oncogene”, and/or “Tumor Suppressor”.

Our analysis turned up 5893 binding sites in RNA for human CBX7. The columns (c) in Table 1 correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C₆, nearest gene name. c7, gene categories as defined in the following way.

The hexadecimal code is used in Table 1 to indicate the number of categories satisfied by each gene: The 4 bit represents an Imprinted gene (IM). The 2 bit represents an Oncogene (OC). The 1 bit represents a Tumor Suppressor (TS). The hexadecimal code can be translated to binary. Each bit represents the condition (1) or absence (0) of the condition.

Thus:

Value binary meaning 0x1 0 0 1 TS 0x2 0 1 0 OC 0x3 0 1 1 TS and OC 0x4 1 0 0 IM 0x5 1 0 1 IM and TS 0x6 1 1 0 IM and OC 0x7 1 1 1 IM and OC and TS

Example 3. Mouse CBX7-RNA Binding Sites as Determined by Denaturing CLIP-Seq Analysis in ES Cells Derived from Mus musculus

CLIP-seq was performed as described in Example 1 in the mouse ES cell line, EL 16.7. CBX7 binding sites in the RNA are shown in Table 3. Peaks were called from uniquely mapped reads using the software peakranger (p=0.01). The resulting strand specific bed files were then converted to their respective strand. To produce non-overlapping peaks entries, 3 biological replicates of undifferentiated and 1 biological replicate of day 7-differentiated ES cells were expanded by 500 nucleotides on each side and merged. The envelope of 500 bases was added because RNA-protein interactions could be affected by changes in nucleic acid folding nearby, which in turn could cause allosteric effects on the RNA-protein interaction. Then the closest gene was determined for each entry (bedtools closest) and categorized as “Imprinted” gene, “Oncogene”, and/or “Tumor Suppressor”.

Our analysis revealed 18,953 binding sites (peaks) in RNA for mouse ES cells. The columns (c) in Table 3 correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C6, nearest gene name. c7, gene categories as defined above in Example 2.

Example 4. Human LiftOver Sequences Corresponding to CBX7-RNA Binding Sites as Determined by Denaturing CLIP-Seq Analysis in Mouse ES Cells

CBX7-binding sites shown in Table 2 were derived from dCLIP-seq performed in the mouse ES cell line, 16.7, as shown in Table 3, translated from mouse mm9 to human hg19 coordinates. The software UCSC Liftover was used to convert mouse mm9 coordinates from the mouse sub-sheet to human hg19 in the human liftover sub-sheet, prior to the envelope extension and merge step. The analysis led to 11,522 binding sites in human RNA. The columns (c) in Table 2 correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C6, nearest gene name. c7, gene categories as defined in Example 2.

Example 5. Targeting the PRC1-RNA Interaction to Modulate Gene Expression

Analysis of the results described above indicated that PRC1 binding sites can be classified into several groups, including (i) 3′ untranslated region [3′ UTR], (ii) promoter-associated, (iii) gene body, (iv) antisense, and (v) intergenic. In order to block the identified interactions between Cbx7 and specific RNA transcripts, antisense oligonucleotides (ASO) LNAs were administered to cells in culture, to determine whether targeting the interaction between PRC1 and each of these RNA classes would change gene expression in cis.

First, the effects of disrupting PRC1-3′UTR interactions were examined. Potential Cbx7 binding sites (identified as described above) that were within 3′UTRs of three selected transcripts were identified based on CLIP-seq data, including (FIG. 2A) Mouse DDB1 and CUL4 Associated Factor 12-Like 1 (Dcaf12L1); (FIG. 2B) Mouse Calmodulin 2 (Calm2); (FIG. 2C) Mouse Mecp2; and Human IRAK1. 22-mer mixmer LNAs targeting selected binding sites (FIG. 3 ) were designed with the following sequences:

TABLE 4 Sequences of LNAs targeting Dusp9, Dcaf12L1, IRAK1, Mecp2, and Calm2 Target LNA SEQ ID Gene LNA I.D sequence NO: Dusp9 Dusp9-1- CCTACAGTTCC 36372 a AAGAAGTCTAA Dusp9-1- GAAGCAGGAAG 36373 b GAGTCTACACG Dusp9-2- CAGTTTGACCA 36374 a CCCTCAGTCAC Dusp9-2- AAAGAAACAGT 36375 b CAGGGCACCAG Dusp9-3- CACAGGTATTG 36376 a CCAGCTCCAGG Dusp9-3- CACACACACAG 36377 b AGTCTACAACG Dcaf12L1 Dcaf12L1- CCTGTCTGCCA 36378 1 TACATTCTACA Dcaf12L1- GCTCAGACTTC 36379 2 TTCCTTTGCAC Dcaf12L1- GTAACAGATCT 36380 3 ATTCTACTTGA Dcaf12L1- CATTATCTCTA 36381 4-a TTTATCTGAAC Dcaf12L1- GGAGAAAACCA 36382 4-b ATCTATCCGCA Calm2 Calm2-1- GCCAGAGTAAG 36383 a CCACATGCAAC Calm2-1- TTAGATGTGCA 36384 b GACGGGCTTAG Calm2-2- TTACAGCTCCA 36385 a CACTTCAACAA C Calm2-2- ACATGCTGACA 36386 b GTTCCTAAAAG Scrambled LNA-Scr GTGTAACACGT 36387 control CTATACGCCCA Tsix Tsix- AGAGTACAGTT 36388 region-1 AACAAGCTGGG T Tsix- TGTTTTGTGAC 36389 region-2 AGGGATTCT Tsix- TTCTTCCTTGC 36390 region- ATTGTGTCTA 3a Tsix- GGTGTGTCCTA 36391 region- TGGTCCTATGT 3b Tsix- CCATGTAACAG 36392 region- AATGTTGAGAT 3c Tsix- CATAATCTGTG 36393 region- ACCAGTACCTC 4a Tsix- CATCAGAAGAG 36394 region- GTTAGATAT 4b Tsix- TGGAGGCAGGT 36395 region- GGATTTCTAAC 4c IRAK1 IRAK1-a CCAACATGCGC 36396 CAGCCTCCTCA IRAK1-b AAGTGCTGGGA 36397 TTACAGGCGTG IRAK1-c ATCATGACTCA 36398 CTGCAGCCTCG Mecp2 Mecp2- TCGCTATACCA 36399 reg1-a CAGTCCACAGG Mecp2- TGAAGCAGAGA 36400 reg1-b GCAGGAAGAAG Mecp2- ACACCTCAAAT 36401 reg1-c CTCAAGAGGCT Mecp2- GATTACTCCCT 36402 reg2-a AGAGCAAGGCC Mecp2- CACAAGGAAAG 36403 reg2-b GGCTCGGCACA Mecp2- CCACTTCCCTC 36404 reg2-c CCTTCAAATGC

Phosphate residues were replaced with phosphorothioate residues for increased stability. Multiple LNA oligonucleotides (LNAs) targeting the same transcript were pooled together to the final concentration of 50 μM. Following trypsinization and feeder removal, a total of 2×10⁶ EL16.7 mouse ES cells were resuspended in 100 μM of ES cell nucleofector solution (Lonza) supplemented with 2 μM LNAs. The cells were transfected using the A-030 program. A 0.5 mL of culture medium was added to the cells and 250 μL of this suspension was plated on gelatinized 6-well tissue culture dish with 2 ml of fibroblast-conditioned media. Per time point, whole cell RNA was extracted using a Trizol reagent and expression of the target genes was estimated using quantitative real-time RT-PCR (normalized to beta-actin as a reference gene).

The effect of LNAs on gene expression was represented as a ratio between specific LNAs and scrambled control. The results are shown in FIGS. 3 and 5A-B. To test the specificity of LNA pools, two unrelated amplicons were tested for every LNA pool along with a specific one. There was a specific increase in Dcaf12L1 gene expression 24 hrs after nucleofection with the Dcaf12L1-specific LNA pool as compared to unrelated Calm2 or to Dusp9 genes (FIG. 3 , right). The same was true for the LNA pool against Calm2, which resulted in a specific increase in Calm2 mRNA levels as compared to unrelated Dsup9 and Dcaf12L1 genes 24 hrs after nucleofection (FIG. 3 , left). These results indicate that targeting the RNA interaction with PRC1 lead to an increase in gene expression.

In contrast, LNAs targeting Mecp2 and IRAK1 interaction with PRC1-binding RNA resulted in gene downregulation, presumably as a result of disrupting PRC1 RNA interactions. Mouse embryonic fibroblasts (MEFs) were nucleofected with pooled LNAs and harvested after 24 hours for qRT-PCR analysis of Mecp2 expression. Downregulation was seen after Mecp2-specific LNA treatment, but not seen with LNAs against Tsix or scrambled control. In addition, human PC3 cells were transfected with pooled IRAK1-specific LNA or control scrambled LNA, then harvested after 24 hours or 36 hours for qRT-PCR analysis of IRAK1 expression. Specific downregulation was seen for IRAK1-specific LNA. Thus, these LNAs caused downregulation but not elimination of gene expression in cis. Thus, targeting 3′ UTR-PRC1 interactions by antisense oligonucleotides provides an alternative approach to RNAi methods and may be especially useful when one aims to titrate down but not eliminate gene expression, such as in the case of MECP 2 Duplication Syndrome.

Second, we examined the effects of disrupting PRC1-antisense RNA interactions. As an example, Tsix RNA is antisense to Xist and binds PRC1 via CBX7 at both Tsix's 5′ and 3′ ends. Tsix RNA is a known repressor ofXist expression but the mechanisms of repression have not be fully elucidated. Here we hypothesized that Tsix in part recruits PRC1 to repress Xist expression. Targeting Tsix RNA with ASO mixmers led to increased Xist expression even after just 6 hours of treatment (FIG. 4A,B), consistent with a derepression of Xist when PRC1 cannot be recruited. Furthermore, ANRIL is antisense to INK4a and interacts with CBX7. Targeting ANRIL is expected to lead to derepression of the linked coding gene INK4a, consistent with loss of ANRIL-PRC1 interactions. Thus, antisense RNAs interact with PRC1 and serve as recruiting tools for PRC1 in cis.

Third, we examined the effects of disrupting PRC1-intergenic RNA interactions. Genes can either be turned up or down. For example, Xist is a CBX7 target. Xist recruits PRC1 via CBX7 to the rest of the X-chromosome. Targeting Xist binding sites is expected to prevent PRC1 recruitment and leads to failure of X-inactivation or higher likelihood of X-reactivation. As an opposite example, Pvt1 is a long noncoding RNA located next to c-Myc and is a frequent site of translocations in B-cell lymphomas (e.g., Burkitt's). Pvt1 and to cMyc are both associated with oncogenesis. Pvt1 appears to be a positive regulator of cMyc expression. Our analysis shows that Pvt1 is a PRC1 target. Pvt1 may recruit PRC1 and result in upregulation of cMyc.

These data indicate that PRC1-RNA interactions may serve different functions within cells and genes may be up- or down-regulated by disrupting these CBX7-RNA interactions.

Gene SEQ ID NO. Chromosome Start (bp) Stop (bp) strand Nearest gene category 1 chr1 840144 841315 + SAMD11 0x0 2 chr1 852326 853425 − LOC100130417 0x0 3 chr1 864967 866163 + SAMD11 0x0 4 chr1 879290 880468 − NOC2L 0x0 5 chr1 893660 894797 − NOC2L 0x0 6 chr1 933795 934971 − HES4 0x0 7 chr1 939820 940963 + ISG15 0x1 8 chr1 941875 943019 + ISG15 0x1 9 chr1 990208 992002 + AGRN 0x0 10 chr1 1018302 1019453 − C1orf159 0x0 11 chr1 1042955 1044169 − C1orf159 0x0 12 chr1 1155610 1156790 − SDF4 0x0 13 chr1 1221945 1223142 + SCNN1D 0x0 14 chr1 1240971 1242078 − ACAP3 0x0 15 chr1 1244270 1245370 − ACAP3 0x0 16 chr1 1244824 1245997 − PUSL1 0x0 17 chr1 1250751 1251923 − CPSF3L 0x0 18 chr1 1253901 1255113 − CPSF3L 0x0 19 chr1 1257950 1259068 − CPSF3L 0x0 20 chr1 1270872 1272024 − DVL1 0x4 21 chr1 1287069 1288262 + TAS1R3 0x0 22 chr1 1327280 1328568 − CCNL2 0x0 23 chr1 1482465 1483678 − SSU72 0x0 24 chr1 1497825 1498974 − SSU72 0x0 25 chr1 1499242 1500446 − SSU72 0x0 26 chr1 1531126 1532227 − C1orf233 0x0 27 chr1 1534005 1535150 − C1orf233 0x0 28 chr1 1554365 1555575 + MIB2 0x0 29 chr1 1717245 1718531 − GNB1 0x0 30 chr1 2087331 2088452 + PRKCZ 0x0 31 chr1 2186545 2187672 + SKI 0x0 32 chr1 2258187 2259377 − MORN1 0x0 33 chr1 2970525 2971680 − FU42875 0x0 34 chr1 3696643 3697775 − LRRC47 0x0 35 chr1 3712359 3713583 − LRRC47 0x0 36 chr1 5221620 5222816 + AJAP1 0x0 37 chr1 6244753 6246027 − RPL22 0x6 38 chr1 6257275 6258424 − RPL22 0x6 39 chr1 6283411 6284533 − ICMT 0x0 40 chr1 6438381 6439534 − ACOT7 0x0 41 chr1 6584050 6585244 − NOL9 0x0 42 chr1 6605037 6606171 − NOL9 0x0 43 chr1 6651267 6652348 − KLHL21 0x0 44 chr1 6695045 6696146 − DNAJC11 0x1 45 chr1 6709976 6711146 − DNAJC11 0x1 46 chr1 6844973 6846190 + CAMTA1 0x1 47 chr1 8387551 8388748 + SLC45A1 0x0 48 chr1 8411950 8413097 − RERE 0x0 49 chr1 8556917 8558157 − RERE 0x0 50 chr1 8667679 8668827 − RERE 0x0 51 chr1 8922743 8923838 − ENO1 0x0 52 chr1 8924945 8926044 − ENO1 0x0 53 chr1 8926640 8927823 − ENO1 0x0 54 chr1 9364627 9365824 + SPSB1 0x0 55 chr1 9648465 9649637 + TMEM201 0x0 56 chr1 9797015 9798190 − CLSTN1 0x0 57 chr1 10006837 10008034 + NMNAT1 0x0 58 chr1 10210619 10211845 + UBE4B 0x1 59 chr1 10212128 10213323 + UBE4B 0x1 60 chr1 10219898 10221032 + UBE4B 0x1 61 chr1 10437072 10438185 + KIF1B 0x1 62 chr1 10517254 10518437 − DFFA 0x0 63 chr1 10519910 10521155 − DFFA 0x0 64 chr1 11082896 11084096 + TARDBP 0x0 65 chr1 11086612 11087712 + TARDBP 0x0 66 chr1 11114167 11115339 − SRM 0x0 67 chr1 11166821 11168000 − MTOR 0x0 68 chr1 11190033 11191197 − MTOR 0x0 69 chr1 11845848 11847032 − MTHFR 0x0 70 chr1 11967643 11968911 + PLOD1 0x0 71 chr1 11969319 11970555 − KIAA2013 0x0 72 chr1 12024759 12025894 + PLOD1 0x0 73 chr1 12071654 12072919 + MFN2 0x0 74 chr1 12081168 12082397 + MIIP 0x0 75 chr1 12337286 12338484 + VPS13D 0x0 76 chr1 12496061 12497240 − DHRS3 0x0 77 chr1 12534409 12535606 + VPS13D 0x0 78 chr1 12828806 12829927 + PRAMEF12 0x0 79 chr1 15931136 15932327 + DDI2 0x0 80 chr1 16046315 16047483 + PLEKHM2 0x0 81 chr1 16158644 16159843 − FU37453 0x0 82 chr1 16163602 16164745 + SPEN 0x0 83 chr1 16176405 16177587 + SPEN 0x0 84 chr1 16198975 16200210 + SPEN 0x0 85 chr1 16202208 16203403 + SPEN 0x0 86 chr1 16256261 16257458 + SPEN 0x0 87 chr1 16263796 16264969 + SPEN 0x0 88 chr1 16265815 16266883 + SPEN 0x0 89 chr1 16780855 16781964 − CROCCP3 0x0 90 chr1 16846525 16847742 − CROCCP3 0x0 91 chr1 16871860 16873033 − NBPF1 0x0 92 chr1 17004176 17005430 − ESPNP 0x0 93 chr1 17053194 17054426 + MIR3675 0x0 94 chr1 17186168 17187363 + CROCC 0x2 95 chr1 17187862 17189092 + CROCC 0x2 96 chr1 17733274 17734587 − RCC2 0x0 97 chr1 17748766 17749972 − RCC2 0x0 98 chr1 19207589 19208765 − ALDH4A1 0x0 99 chr1 19407485 19408666 − UBR4 0x0 100 chr1 19467661 19468839 − UBR4 0x0 101 chr1 19480827 19482021 − UBR4 0x0 102 chr1 19510062 19511162 − UBR4 0x0 103 chr1 19518563 19519634 − UBR4 0x0 104 chr1 19625557 19627771 − AKR7A2 0x0 105 chr1 19934145 19935669 + C1orf151-NBL1 0x0 106 chr1 19934145 19935669 + MINOS1 0x0 107 chr1 21068879 21070073 − HP1BP3 0x0 108 chr1 21101451 21102605 − HP1BP3 0x0 109 chr1 21112219 21113345 − HP1BP3 0x0 110 chr1 21180924 21182129 − EIF4G3 0x0 111 chr1 21219529 21220598 − EIF4G3 0x0 112 chr1 21357497 21358722 − EIF4G3 0x0 113 chr1 21368009 21369192 − EIF4G3 0x0 114 chr1 21469103 21470320 − EIF4G3 0x0 115 chr1 21483420 21484575 − EIF4G3 0x0 116 chr1 21499884 21501032 − EIF4G3 0x0 117 chr1 22022042 22023220 − USP48 0x0 118 chr1 22090919 22092045 − USP48 0x0 119 chr1 22175614 22176789 − H5PG2 0x0 120 chr1 22418197 22419329 + CDC42 0x2 121 chr1 22438373 22439541 + CDC42 0x2 122 chr1 23604893 23606066 − HNRNPR 0x0 123 chr1 23611267 23612409 − HNRNPR 0x0 124 chr1 23636297 23637464 − HNRNPR 0x0 125 chr1 23664466 23665686 − HNRNPR 0x0 126 chr1 23696173 23697372 + C1orf213 0x0 127 chr1 24018563 24019764 + RPL11 0x0 128 chr1 24035667 24036809 + RPL11 0x0 129 chr1 24053341 24054440 + TCEB3 0x0 130 chr1 24055464 24056625 + TCEB3 0x0 131 chr1 24086902 24088096 − LOC100506963 0x0 132 chr1 24121383 24122585 + LYPLA2 0x0 133 chr1 24321543 24322767 + PNRC2 0x0 134 chr1 24795527 24796626 + NIPAL3 0x0 135 chr1 25168610 25169758 + CLIC4 0x0 136 chr1 25686991 25688242 + TMEM50A 0x0 137 chr1 26142500 26144914 + SEPN1 0x0 138 chr1 26226551 26228033 − STMN1 0x0 139 chr1 26799856 26800971 + HMGN2 0x0 140 chr1 27212259 27213402 − GPN2 0x0 141 chr1 27435519 27436813 − SLC9A1 0x0 142 chr1 27586882 27588101 + WDTC1 0x0 143 chr1 27632491 27633959 + WDTC1 0x0 144 chr1 27730967 27732179 − WASF2 0x0 145 chr1 27732345 27740500 − WASF2 0x0 146 chr1 28240102 28241240 − RPA2 0x0 147 chr1 28298923 28300079 − EYA3 0x0 148 chr1 28352695 28353858 − EYA3 0x0 149 chr1 28833307 28835831 + RCC1 0x0 150 chr1 28833307 28835831 + SNHG3 0x0 151 chr1 28904692 28908087 − SNHG12 0x0 152 chr1 28904692 28908087 − SNORA16A 0x0 153 chr1 28904692 28908087 − SNORA44 0x0 154 chr1 28904692 28908087 − SNORA61 0x0 155 chr1 28904692 28908087 − SNORD99 0x0 156 chr1 28974564 28975822 + RNU11 0x0 157 chr1 29247305 29248543 + EPB41 0x1 158 chr1 29308535 29309673 − TMEM200B 0x0 159 chr1 29444554 29446232 + EPB41 0x1 160 chr1 29474230 29475417 − SRSF4 0x0 161 chr1 29480719 29481895 − SRSF4 0x0 162 chr1 30305391 30306547 − MECR 0x0 163 chr1 31316149 31317342 + LOC100129196 0x0 164 chr1 31467449 31468593 − PUM1 0x0 165 chr1 31478154 31479311 − PUM1 0x0 166 chr1 32203368 32204547 − BAI2 0x1 167 chr1 32228432 32229591 − BAI2 0x1 168 chr1 32507902 32509306 + KHDRBS1 0x0 169 chr1 32640327 32641537 + KPNA6 0x0 170 chr1 32661663 32662812 + TXLNA 0x0 171 chr1 32689077 32690271 + EIF3I 0x0 172 chr1 32800031 32801234 − MARCKSL1 0x0 173 chr1 33051782 33052957 − ZBTB8A 0x0 174 chr1 33086866 33088028 − Z8TB8OS 0x0 175 chr1 33474529 33475637 − AK2 0x0 176 chr1 33765318 33766520 + ZNF362 0x0 177 chr1 34029443 34030618 − CSMD2 0x0 178 chr1 35316677 35317863 − C1orf212 0x0 179 chr1 35648193 35650636 − SFPQ 0x2 180 chr1 35651800 35652899 − SFPQ 0x2 181 chr1 35656343 35657533 − SFPQ 0x2 182 chr1 36031642 36032886 + NCDN 0x0 183 chr1 36063797 36064965 − PSMB2 0x0 184 chr1 36307953 36309152 + EIF2C4 0x0 185 chr1 36388167 36389851 + EIF2C1 0x0 186 chr1 36614384- 36615568 − TRAPPC3 0x0 187 chr1 36807748 36808925 − STK40 0x0 188 chr1 39469513 39470715 + AKIRIN1 0x0 189 chr1 39493910 39495136 + NDUFS5 0x0 190 chr1 40029630 40030729 − PABPC4 0x0 191 chr1 40032527 40033665 − PABPC4 0x0 192 chr1 40032527 40033665 − SNORA55 0x0 193 chr1 40041718 40042871 − PABPC4 0x0 194 chr1 40413156 40414381 + MFSD2A 0x1 195 chr1 40428168 40429524 + MFSD2A 0x1 196 chr1 40537396 40538555 + CAP1 0x0 197 chr1 40537899 40539087 − PPT1 0x0 198 chr1 40598294 40599496 + RLF 0x0 199 chr1 40930541 40931733 + ZNF643 0x0 200 chr1 41476871 41478119 + CTPS 0x0 201 chr1 41608008 41609172 − SCMH1 0x0 202 chr1 41919561 41920665 + LOC100507178 0x0 203 chr1 42641695 42642843 − FOXJ3 0x0 204 chr1 42643332 42644469 − FOXJ3 0x0 205 chr1 43161880 43162989 + YBX1 0x0 206 chr1 43167147 43168350 + YBX1 0x0 207 chr1 44125402 44126640 + KDM4A 0x0 208 chr1 44170298 44171502 + KDM4A 0x0 209 chr1 44369888 44371081 + ST3GAL3 0x0 210 chr1 44371265 44372436 + ST3GAL3 0x0 211 chr1 44442659 44443906 + ATP6V0B 0x0 212 chr1 44911247 44912431 + RNF220 0x0 213 chr1 45062534 45063657 − TMEM53 0x0 214 chr1 45186916 45188147 − TMEM53 0x0 215 chr1 45196159 45197386 − BEST4 0x0 216 chr1 45240987 45242949 + RPS8 0x0 217 chr1 45240987 45242949 + SNORD46 0x0 218 chr1 45240987 45242949 + SNORD55 0x0 219 chr1 45242965 45244687 + RPS8 0x0 220 chr1 45242965 45244687 + SNORD38A 0x0 221 chr1 45242965 45244687 + SNORD38B 0x0 222 chr1 45284993 45286220 − PTCH2 0x1 223 chr1 46125981 46127259 − GPBP1L1 0x0 224 chr1 46148262 46149412 − GPBP1L1 0x0 225 chr1 46654276 46655502 − POMGNT1 0x0 226 chr1 46859410 46860537 + FAAH 0x0 227 chr1 47745459 47746710 − STIL 0x0 228 chr1 47774668 47775846 − STIL 0x0 229 chr1 49275861 49277039 − BEND5 0x0 230 chr1 51049850 51051026 − FAF1 0x0 231 chr1 51189287 51190509 − FAF1 0x0 232 chr1 51715868 51717079 − TTC39A 0x0 233 chr1 51787282 51788462 − TTC39A 0x0 234 chr1 52379262 52380464 − RAB3B 0x0 235 chr1 52438512 52439715 + BTF3L4 0x0 236 chr1 52826661 52827803 − CC2D1B 0x0 237 chr1 52837435 52838617 − ORC1 0x2 238 chr1 53336515 53337624 + ZYG11A 0x0 239 chr1 53349000 53350130 + ZYG11A 0x0 240 chr1 53367018 53368216 + ZYG11A 0x0 241 chr1 53491985 53493213 + SCP2 0x0 242 chr1 53716288 53717467 − LRP8 0x0 243 chr1 55315885 55317555 − DHCR24 0x0 244 chr1 57129718 57130907 + PRKAA2 0x0 245 chr1 59248014 59249266 − JUN 0x2 246 chr1 60868316 60869493 + HOOK1 0x0 247 chr1 61663674 61664848 + NFIA 0x0 248 chr1 63182476 63183613 − DOCK7 0x0 249 chr1 65008049 65009293 + CACHD1 0x0 250 chr1 65234621 65235845 + RAVER2 0x0 251 chr1 65523304 65524453 − MIR101-1 0x1 252 chr1 65523304 65524453 − MIR3671 0x0 253 chr1 67873676 67875700 − SERBP1 0x0 254 chr1 67878205 67879389 − SERBP1 0x0 255 chr1 67887368 67888559 − SERBP1 0x0 256 chr1 68166950 68168313 − GNG12 0x0 257 chr1 68273081 68274225 − GNG12 0x0 258 chr1 70067427 70068625 + LRRC7 0x0 259 chr1 70686727 70688033 + SRSF11 0x2 260 chr1 76252214 76253404 + RABGGTB 0x0 261 chr1 76252214 76253404 + SNORD45C 0x0 262 chr1 77554193 77555417 − PIGK 0x0 263 chr1 78170124 78171311 − USP33 0x0 264 chr1 78410310 78411448 − FUBP1 0x2 265 chr1 78434297 78435474 − FUBP1 0x2 266 chr1 82403020 82404264 + LPHN2 0x2 267 chr1 84570348 84571545 + PRKACB 0x0 268 chr1 84966968 84968146 − GNG5 0x0 269 chr1 85330676 85331965 − LPAR3 0x0 270 chr1 85610552 85611775 − SYDE2 0x0 271 chr1 86057408 86058620 + CYR61 0x0 272 chr1 86079240 86080418 − ZNHIT6 0x0 273 chr1 87426543 87427773 + HS2ST1 0x0 274 chr1 87511146 87512431 + HS2ST1 0x0 275 chr1 89255594 89256826 + PKN2 0x0 276 chr1 89259619 89260755 + PKN2 0x0 277 chr1 89270987 89272231 + PKN2 0x0 278 chr1 90341079 90342295 + LRRC8D 0x0 279 chr1 90472119 90473511 + ZNF326 0x0 280 chr1 91363596 91364776 − ZNF644 0x0 281 chr1 91852202 91853725 − HFM1 0x0 282 chr1 92326566 92327783 − TGFBR3 0x1 283 chr1 92724108 92725226 − GLMN 0x0 284 chr1 92975994 92977194 − EVI5 0x0 285 chr1 93588727 93590210 + MTF2 0x0 286 chr1 93618375 93619763 − TMED5 0x0 287 chr1 93803508 93804686 − LOC100131564 0x0 288 chr1 93810953 93812167 + DR1 0x0 289 chr1 94312549 94313776 + MIR760 0x0 290 chr1 94899930 94901140 + ABCD3 0x0 291 chr1 95401336 95402708 + LOC729970 0x0 292 chr1 96690973 96692200 + PTBP2 0x0 293 chr1 96911938 96913259 + PTBP2 0x0 294 chr1 98628031 98629273 + LOC729987 0x0 295 chr1 100139712 100140929 + PALMD 0x0 296 chr1 100547299 100548483 + HIAT1 0x0 297 chr1 101486719 101487914 − DPH5 0x0 298 chr1 102251585 102252999 − OLFM3 0x0 299 chr1 103507706 103508886 − COL11A1 0x2 300 chr1 108112882 108114057 − VAV3 0x0 301 chr1 109241985 109243695 + PRPF38B 0x0 302 chr1 109604746 109605960 − TAF13 0x0 303 chr1 109642240 109643797 + SCARNA2 0x0 304 chr1 109852954 109854306 − SORT1 0x0 305 chr1 110563994 110565230 + AHCYL1 0x0 306 chr1 110881918 110883020 + RBM15 0x2 307 chr1 110889786 110890938 + RBM15 0x2 308 chr1 111983105 111984257 − WDR77 0x0 309 chr1 112001663 112002811 + ATP5F1 0x0 310 chr1 112186658 112187879 + RAP1A 0x1 311 chr1 112198778 112199981 + RAP1A 0x1 312 chr1 113212803 113214334 + CAPZA1 0x0 313 chr1 113454053 113456912 − SLC16A1 0x0 314 chr1 113459502 113460782 − SLC16A1 0x0 315 chr1 113552218 113553398 + LRIG2 0x0 316 chr1 113711026 113712272 + LRIG2 0x0 317 chr1 114216414 114217630 + MAGI3 0x0 318 chr1 115248058 115249362 − NRAS 0x2 319 chr1 115259278 115261005 − CSDE1 0x0 320 chr1 115259278 115261005 − NRAS 0x2 321 chr1 115268298 115269476 − CSDE1 0x0 322 chr1 115269811 115271040 + SYCP1 0x0 323 chr1 115272477 115273735 − CSDE1 0x0 324 chr1 115277451 115278611 − CSDE1 0x0 325 chr1 116915330 116916732 + ATP1A1 0x0 326 chr1 116926045 116927247 + ATP1A1 0x0 327 chr1 116932313 116933518 + ATP1A1 0x0 328 chr1 116946522 116947737 + ATP1A1 0x0 329 chr1 117452059 117453257 + PTGFRN 0x0 330 chr1 117640591 117641790 + TTF2 0x0 331 chr1 117910253 117911401 + MAN1A2 0x0 332 chr1 117944308 117945714 + MAN1A2 0x0 333 chr1 117993522 117994752 + MAN1A2 0x0 334 chr1 118530435 118531631 − SPAG17 0x0 33S chr1 120543418 120544633 − NOTCH2 0x2 336 chr1 144055799 144057061 + SRGAP2P2 0x0 337 chr1 144857432 144858775 − PDE4DIP 0x2 338 chr1 144881054 144882227 − PDE4DIP 0x2 339 chr1 144900376 144901530 − PDE4DIP 0x2 340 chr1 144921748 144923136 − PDE4DIP 0x2 341 chr1 145115870 145116991 + SEC22B 0x0 312 chr1 145382265 145383487 + NBPF10 0x0 343 chr1 145394939 145396145 − POLR3GL 0x0 344 chr1 145508701 145509914 + RBM8A 0x0 34S chr1 145510390 145511633 + RBM8A 0x0 346 chr1 145577621 145578843 + PIAS3 0x0 347 chr1 146555618 146556791 − LOC728989 0x0 348 chr1 147510499 147511710 − PDZK1P1 0x0 349 chr1 147825129 147826328 + GPR89C 0x0 350 chr1 147993651 147994895 + GPR89C 0x0 351 chr1 148240938 148242186 + NBPF15 0x0 352 chr1 148247512 148248779 + NBPF15 0x0 353 chr1 148344173 148345590 − PPIAL4D 0x0 354 chr1 148344173 148345590 − PPIAL4F 0x0 355 chr1 149193532 149194786 − HIST2H2BF 0x0 356 chr1 149223492 149224764 − HIST2H2BF 0x0 357 chr1 149229993 149231191 − HIST2H2BF 0x0 358 chr1 149294107 149295294 − HIST2H2BF 0x0 359 chr1 149298025 149299210 − HIST2H2BF 0x0 360 chr1 149513523 149514749 − HIST2H2BF 0x0 361 chr1 149803642 149804974 + HIST2H4A 0x0 362 chr1 149803642 149804974 + HIST2H4B 0x0 363 chr1 149822551 149824705 + HIST2H2AA3 0x0 364 chr1 149822551 149824705 + HIST2H2AA4 0x0 365 chr1 149822551 149824705 + HIST2H3A 0x0 366 chr1 149822551 149824705 + HIST2H3C 0x0 367 chr1 149857574 149858794 − HIST2H2BE 0x0 368 chr1 149858006 149859450 + HIST2H2AC 0x0 369 chr1 150190301 150191593 − ANP32E 0x0 370 chr1 150208744 150210050 + CA14 0x0 371 chr1 150324926 150326093 + PRPF3 0x0 372 chr1 150418223 150419437 + RPRD2 0x0 373 chr1 150445729 150446920 + RPRD2 0x0 374 chr1 150464353 150465522 + TARS2 0x0 375 chr1 150470489 150471707 + TARS2 0x0 376 chr1 150548808 150549982 − MCL1 0x0 377 chr1 150592648 150593816 − ENSA 0x0 378 chr1 150594619 150595719 − ENSA 0x0 379 chr1 150815378 150816598 − ARNT 0x2 380 chr1 150901999 150903198 + SETDB1 0x0 381 chr1 150937624 150938971 − CERS2 0x0 382 chr1 151024631 151025836 − CDC42SE1 0x0 383 chr1 151148459 151149816 − TMOD4 0x0 384 chr1 151148459 151149816 − VPS72 0x0 385 chr1 151214030 151215213 + PIP5K1A 0x0 386 chr1 151377945 151379168 − POGZ 0x0 387 chr1 151415600 151416737 − POGZ 0x0 388 chr1 151424674 151425882 − POGZ 0x0 389 chr1 151669554 151671784 + SNX27 0x0 390 chr1 153608927 153610327 + CHTOP 0x0 391 chr1 153637282 153638518 − ILF2 0x0 392 chr1 153949216 153950397 − JTB 0x0 393 chr1 154179204 154180520 − C1orf43 0x0 394 chr1 154223078 154224555 + UBAP2L 0x0 395 chr1 154229465 154230671 + UBAP2L 0x0 396 chr1 154231629 154232898 + UBAP2L 0x0 397 chr1 154554155 154556592 − ADAR 0x0 398 chr1 154573661 154574860 − ADAR 0x0 399 chr1 154744040 154745218 − KCNN3 0x2 400 chr1 155092389 155093588 + EFNA1 0x1 401 chr1 155216724 155217968 − FAM189B 0x0 402 chr1 155222866 155224055 − FAM189B 0x0 403 chr1 155238484 155239665 − CLK2 0x0 404 chr1 155281808 155283956 + FDPS 0x0 405 chr1 155387707 155388905 − ASH1L 0x0 406 chr1 155392166 155393369 − ASH1L 0x0 407 chr1 155628831 155630008 − YY1AP1 0x0 408 chr1 155717315 155718435 − GON4L 0x0 409 chr1 155734656 155735997 − GON4L 0x0 410 chr1 155889121 155890387 − SNORA42 0x0 411 chr1 155895194 155896426 − KIAA0907 0x0 412 chr1 155895194 155896426 − SCARNA4 0x0 413 chr1 155978393 155979751 − SSR2 0x0 414 chr1 156005184 156006501 − UBQLN4 0x0 415 chr1 156046144 156047385 − MEX3A 0x0 416 chr1 156049971 156051157 − MEX3A 0x0 417 chr1 156083983 156085214 + LMNA 0x0 418 chr1 156711443 156713262 − HDGF 0x0 419 chr1 159147726 159148925 + CADM3 0x1 420 chr1 159887640 159888903 − TAGLN2 0x0 421 chr1 160247969 160249354 − PEX19 0x0 422 chr1 160323451 160324651 + NCSTN 0x0 423 chr1 160964965 160966160 − F11R 0x0 424 chr1 160967011 160968217 − F11R 0x0 425 chr1 161140861 161142038 − B4GALT3 0x0 426 chr1 161195560 161196876 + TOMM40L 0x0 427 chr1 161287359 161288596 + SDHC 0x2 428 chr1 161296677 161298830 + SDHC 0x2 429 chr1 161409368 161410591 − C1orf192 0x0 430 chr1 161500321 161501624 + HSPA6 0x4 431 chr1 161581923 161583137 + HSPA7 0x0 432 chr1 161590868 161592139 + HSPA7 0x0 433 chr1 162470267 162471488 + UHMK1 0x0 434 chr1 164569061 164570291 + PBX1 0x2 435 chr1 165825882 165827031 + UCK2 0x0 436 chr1 165878681 165880175 + UCK2 0x0 437 chr1 166245062 166246377 − FAM78B 0x0 438 chr1 166716741 166718458 + POGK 0x0 439 chr1 166822396 166823563 + POGK 0x0 440 chr1 167876363 167877573 − ADCY10 0x0 441 chr1 168024779 168025960 − GPR161 0x0 442 chr1 168218537 168219697 + SFT2D2 0x0 443 chr1 169894169 169895391 − KIFAP3 0x0 444 chr1 171470726 171471915 + PRRC2C 0x0 445 chr1 171509758 171510953 + PRRC2C 0x0 446 chr1 173760137 173761357 + KLHL20 0x0 447 chr1 173832715 173837436 − GAS5 0x1 448 chr1 173832715 173837436 − SNORD44 0x0 449 chr1 173832715 173837436 − SNORD47 0x0 450 chr1 173832715 173837436 − SNORD74 0x0 451 chr1 173832715 173837436 − SNORD75 0x0 452 chr1 173832715 173837436 − SNORD76 0x0 453 chr1 173832715 173837436 − SNORD77 0x0 454 chr1 173832715 173837436 − SNORD78 0x0 455 chr1 173832715 173837436 − SNORD79 0x0 456 chr1 173832715 173837436 − SNORD80 0x0 457 chr1 173832715 173837436 − SNORD81 0x0 458 chr1 173903892 173905070 − RC3H1 0x0 459 chr1 173906989 173908288 − RC3H1 0x0 460 chr1 174158307 174159546 + RABGAP1L 0x0 461 chr1 178567950 178569162 + C1orf220 0x0 462 chr1 178842862 178844097 + RALGPS2 0x0 463 chr1 178886248 178887421 + RALGPS2 0x0 464 chr1 179189773 179190983 − ABL2 0x2 465 chr1 179813512 179814723 − TOR1AIP2 0x0 466 chr1 179833159 179835492 − TOR1AIP2 0x0 467 chr1 180080290 180081489 + CEP350 0x0 468 chr1 180245669 180246855 − LOC100527964 0x0 469 chr1 180737011 180738229 + XPR1 0x0 470 chr1 180751452 180752652 + XPR1 0x0 471 chr1 180944787 180946000 − STX6 0x0 472 chr1 182352152 182354225 − GLUL 0x0 473 chr1 182357155 182358347 − GLUL 0x0 474 chr1 182822589 182823780 + DHX9 0x0 475 chr1 182843646 182844797 + DHX9 0x0 476 chr1 183451618 183452866 + SMG7 0x0 477 chr1 183521166 183522365 + SMG7 0x0 478 chr1 183599093 183600275 − ARPC5 0x0 479 chr1 185029958 185031201 + RNF2 0x0 480 chr1 185266746 185267923 − IVNS1ABP 0x0 481 chr1 186341227 186342433 + C1orf27 0x0 482 chr1 190328252 190329522 − FAM5C 0x0 483 chr1 193054036 193055950 + TROVE2 0x0 484 chr1 194881379 194882556 − KCNT2 0x0 485 chr1 196246079 196247256 − KCNT2 0x0 486 chr1 196454168 196455378 − KCNT2 0x0 487 chr1 197123904 197125081 − ZBTB41 0x2 488 chr1 198189561 198190790 + NEK7 0x0 489 chr1 201104044 201105241 − TMEM9 0x0 490 chr1 201263563 201264762 + PKP1 0x0 491 chr1 201844844 201846017 + IPO9 0x0 492 chr1 201846540 201847715 + IPO9 0x0 493 chr1 202102898 202104120 − ARL8A 0x0 494 chr1 202112029 202113216 − ARL8A 0x0 495 chr1 202428654 202429874 + PPP1R12B 0x0 496 chr1 203292770 203293990 + BTG2 0x1 497 chr1 203765008 203766264 + ZC3H11A 0x0 498 chr1 204061645 204062843 + SOX13 0x0 499 chr1 204082926 204084098 + SOX13 0x0 500 chr1 204475098 204476336 + MDM4 0x2 501 chr1 204475595 204476748 − PIK3C2B 0x0 502 chr1 204506187 204507372 + MDM4 0x2 503 chr1 204522274 204523452 + MDM4 0x2 504 chr1 204530962 204532206 − LRRN2 0x0 505 chr1 205217339 205218722 + TMCC2 0x0 506 chr1 205273122 205274318 − NUAK2 0x0 507 chr1 205592298 205593497 − ELK4 0x2 508 chr1 205682685 205686265 − NUCKS1 0x0 509 chr1 205686535 205687953 − NUCKS1 0x0 510 chr1 205718529 205719853 − NUCKS1 0x0 511 chr1 206518541 206519779 + SRGAP2 0x0 512 chr1 206895521 206896732 + MAPKAPK2 0x0 513 chr1 206905648 206907237 + MAPKAPK2 0x0 514 chr1 207285121 207286300 + C4BPA 0x0 515 chr1 210029291 210030488 + DIEXF 0x0 516 chr1 211712199 211713383 − SLC30A1 0x0 517 chr1 212265961 212267203 + DTL 0x0 518 chr1 212273532 212274725 + DTL 0x0 519 chr1 212792678 212793986 + ATF3 0x0 520 chr1 212964633 212965882 + TATDN3 0x0 521 chr1 214371742 214372972 + SMYD2 0x0 522 chr1 214529737 214530959 − PTPN14 0x4 523 chr1 215758835 215760082 + KCTD3 0x0 524 chr1 216707533 216708744 − ESRRG 0x0 525 chr1 216938284 216939482 + SPATA17 0x0 526 chr1 217781474 217782701 − GPATCH2 0x0 527 chr1 219464873 219466060 + LYPIAL1 0x0 528 chr1 220290576 220291740 + RNU5F-1 0x0 529 chr1 220343726 220344909 − RAB3GAP2 0x0 530 chr1 220373343 220374520 − MIR664 0x0 531 chr1 220373343 220374520 − SNORA36B 0x0 532 chr1 220411787 220412985 − RAB3GAP2 0x0 533 chr1 224186371 224187597 + FBXO28 0x0 534 chr1 224458091 224459318 − NVL 0x0 535 chr1 224487715 224488892 − NVL 0x0 536 chr1 224621339 224622694 − WDR26 0x0 537 chr1 224632047 224633294 + CNIH4 0x0 538 chr1 225227059 225228271 + DNAH14 0x0 539 chr1 225395058 225396267 + DNAH14 0x0 540 chr1 225589675 225591446 − LBR 0x0 541 chr1 225683421 225684835 − ENAH 0x0 542 chr1 225699878 225701146 − ENAH 0x0 543 chr1 225832972 225834130 − ENAH 0x0 544 chr1 225839667 225840854 − ENAH 0x0 545 chr1 225840886 225842085 − ENAH 0x0 546 chr1 225976535 225978191 + SRP9 0x0 547 chr1 226053350 226054557 − TMEM63A 0x0 548 chr1 226231274 226232493 + H3F3A 0x0 549 chr1 226308957 226310189 + H3F3A 0x0 550 chr1 226308957 226310189 + H3F3AP4 0x0 551 chr1 226332364 226333539 − ACBD3 0x0 552 chr1 226548198 226550310 − PARP1 0x0 553 chr1 226633087 226634318 + C1orf95 0x0 554 chr1 226764909 226766092 + C1orf95 0x0 555 chr1 227174238 227175480 + ADCK3 0x0 556 chr1 228246176 228247405 + WNT3A 0x0 557 chr1 228268372 228269597 − C1orf35 0x0 558 chr1 228286031 228287395 + ARF1 0x1 559 chr1 228460035 228461227 + OBSCN 0x6 560 chr1 228464213 228465383 + OBSCN 0x6 561 chr1 228479225 228480392 + OBSCN 0x6 562 chr1 228588834 228589997 − TRIM11 0x0 563 chr1 228742937 228744191 + RHOU 0x0 564 chr1 228763318 228764571 − HIST3H2A 0x0 565 chr1 228822584 228823835 + DUSP5P 0x0 566 chr1 229452464 229453715 + SPHAR 0x0 567 chr1 229829043 229830261 + URB2 0x0 568 chr1 230376361 230377564 + GALNT2 0x0 569 chr1 231076229 231077435 − TTC13 0x0 570 chr1 231089569 231090749 − TTC13 0x0 571 chr1 231113282 231114478 − TTC13 0x0 572 chr1 231400510 231401943 + GNPAT 0x0 573 chr1 231694808 231696046 + TSNAX 0x0 574 chr1 231694808 231696046 + TSNAX-DISC1 0x0 575 chr1 231990122 231991288 + DISC1 0x0 576 chr1 233514316 233515555 + KIAA1804 0x2 577 chr1 233518262 233519476 + KIAA1804 0x2 578 chr1 233520067 233521316 + KIAA1804 0x2 579 chr1 234492209 234493429 − TARBP1 0x0 580 chr1 234496426 234497849 + C1orf31 0x0 581 chr1 234563407 234565919 − TARBP1 0x0 582 chr1 234585710 234586893 − TARBP1 0x0 583 chr1 234605372 234606597 − TARBP1 0x0 584 chr1 234610314 234611484 − TARBP1 0x0 585 chr1 234613342 234614518 − TARBP1 0x0 586 chr1 234741314 234743389 − IRF2BP2 0x0 587 chr1 234745312 234746411 − IRF2BP2 0x0 588 chr1 235272366 235273548 − TOMM20 0x0 589 chr1 235273910 235275525 − TOMM20 0x0 590 chr1 235290593 235291716 − SNORA14B 0x0 591 chr1 235460844 235462024 − ARID4B 0x0 592 chr1 235601456 235602682 + TBCE 0x0 593 chr1 235796415 235797938 − GNG4 0x0 594 chr1 236380467 236381595 − ERO1LB 0x0 595 chr1 236430556 236431809 + GPR137B 0x0 596 chr1 236646542 236647719 + EDARADD 0x0 597 chr1 236706956 236708213 − HEATR1 0x0 598 chr1 236961224 236962464 + MTR 0x0 599 chr1 236975460 236976657 + MTR 0x0 600 chr1 237007214 237008501 + MTR 0x0 601 chr1 237765743 237767229 + RYR2 0x2 602 chr1 243663467 243665403 − AKT3 0x2 603 chr1 244586559 244587735 − ADSS 0x0 604 chr1 244871059 244872312 + PPPDE1 0x0 605 chr1 245013374 245014444 − HNRNPU 0x2 606 chr1 245016406 245017772 − HNRNPU 0x2 607 chr1 245020748 245021936 − HNRNPU 0x2 608 chr1 245026904 245028090 − HNRNPU 0x2 609 chr1 245106873 245108219 + EFCAB2 0x0 610 chr1 245382092 245383296 + KIF26B 0x0 611 chr1 246197368 246198550 − SMYD3 0x0 612 chr1 246349541 246350748 − SMYD3 0x0 613 chr1 246636841 246638018 − SMYD3 0x0 614 chr1 247318878 247320068 − ZNF124 0x0 615 chr1 247322465 247323700 − ZNF124 0x0 616 chr1 247326069 247327168 − ZNF124 0x0 617 chr1 247453655 247454860 − ZNF496 0x0 618 chr1 247613596 247614816 + NLRP3 0x2 619 chr1 249167501 249168976 + ZNF672 0x0 620 chr10 327413 328640 − DIP2C 0x0 621 chr10 666729 667894 − DIP2C 0x0 622 chr10 717319 718546 − DIP2C 0x0 623 chr10 851188 852361 − LARP4B 0x0 624 chr10 857811 858983 − LARP4B 0x0 625 chr10 897946 899153 − LARP4B 0x0 626 chr10 915522 916733 − LARP4B 0x0 627 chr10 1037878 1039077 + GTPBP4 0x1 628 chr10 1177466 1178635 + WDR37 0x0 629 chr10 3143076 3144273 + PFKP 0x2 630 chr10 5498718 5499855 + NET1 0x0 631 chr10 5894873 5896267 − ANKRD16 0x0 632 chr10 7284973 7286228 − SFMBT2 0x4 633 chr10 7318329 7319540 − SFMBT2 0x4 634 chr10 7327265 7328458 − SFMBT2 0x4 635 chr10 7361094 7362349 − SFMBT2 0x4 636 chr10 7388629 7389823 − SFMBT2 0x4 637 chr10 7884436 7885634 + TAF3 0x0 638 chr10 8034661 8035813 + TAF3 0x0 639 chr10 10817881 10819050 − SFTA1P 0x0 640 chr10 11375072 11376197 + CELF2 0x0 641 chr10 11529210 11530389 − USP6NL 0x0 642 chr10 12139258 12140488 + DHTKD1 0x0 643 chr10 12141598 12142790 + DHTKD1 0x0 644 chr10 12193739 12194931 + SEC61A2 0x0 645 chr10 13769281 13770472 + PRPF18 0x0 646 chr10 15254670 15255759 − FAM171A1 0x0 647 chr10 15677400 15678528 − ITGA8 0x0 648 chr10 15885198 15886387 − FAM188A 0x1 649 chr10 16512344 16513511 + PTER 0x0 650 chr10 16517452 16518631 + PTER 0x0 651 chr10 17271274 17272447 + VIM 0x0 652 chr10 17278801 17280000 + VIM 0x0 653 chr10 17658065 17659244 − PTPLA 0x0 654 chr10 17693625 17694846 + StAM 0x0 655 chr10 18731218 18732413 + CACNB2 0x0 656 chr10 18969440 18970539 + ARL5B 0x0 657 chr10 21442123 21443301 − C10orf113 0x0 658 chr10 21453958 21455156 + LOC100128511 0x0 659 chr10 21934560 21935750 + MLLT10 0x0 660 chr10 21944578 21945780 + MLLT10 0x0 661 chr10 21974309 21975409 + MLLT10 0x0 662 chr10 22221492 22222711 + MLLT10 0x0 663 chr10 22517892 22519075 − EBLN1 0x0 664 chr10 27046890 27048090 + PDSS1 0x0 665 chr10 27112344 27113521 − ABI1 0x2 666 chr10 27414860 27416037 − YME1L1 0x0 667 chr10 27422424 27423599 − YME1L1 0x0 668 chr10 27430769 27431910 − YME1L1 0x0 669 chr10 27484861 27486047 − ACBD5 0x0 670 chr10 27529727 27530930 − ACBD5 0x0 671 chr10 27828011 27829181 + RAB18 0x0 672 chr10 28840201 28841312 + WAC 0x0 673 chr10 28896605 28897768 + WAC 0x0 674 chr10 30601620 30602784 − MTPAP 0x0 675 chr10 32197132 32198312 − ARHGAP12 0x0 676 chr10 32298882 32300844 − KIF5B 0x2 677 chr10 32307631 32308819 − KIF5B 0x2 678 chr10 32599864 32601121 − EPC1 0x2 679 chr10 33532312 33533462 − NRP1 0x0 680 chr10 34682668 34684029 − PARD3 0x0 681 chr10 34931805 34940500 − PARD3 0x0 682 chr10 35005954 35007146 − PARD3 0x0 683 chr10 35674327 35675517 + CCNY 0x0 684 chr10 38104286 38105423 − ZNF248 0x0 685 chr10 38410549 38411702 + ZNF37A 0x2 686 chr10 38726021 38727193 + LOC399744 0x0 687 chr10 42987909 42989114 + LOC848S6 0x0 688 chr10 43047320 43048711 − ZNF37BP 0x0 689 chr10 45950107 45951270 − MARCH8 0x0 690 chr10 48205645 48206744 + AGAP9 0x0 691 chr10 49862031 49863217 − ARHGAP22 0x0 692 chr10 50910581 50911972 − OGDHL 0x0 693 chr10 51387116 51388251 + MSMB 0x1 694 chr10 51591654 51592946 − TIMM23 0x0 695 chr10 51748030 51749191 + AGAP6 0x0 696 chr10 52141798 52142974 − SGMS1 0x0 697 chr10 52789097 52790200 + PRKG1 0x0 698 chr10 52938396 52939541 + PRKG1 0x0 699 chr10 52980093 52981305 + PRKG1 0x0 700 chr10 52999596 53000733 + MIR605 0x0 701 chr10 53089007 53090231 + MIR605 0x0 702 chr10 53134151 53135349 + MIR605 0x0 703 chr10 53342480 53343660 + PRKG1 0x0 704 chr10 53412101 53413200 + PRKG1 0x0 70S chr10 53426903 53428121 + PRKG1 0x0 706 chr10 57419102 57420322 − ZWINT 0x0 707 chr10 57526788 57528007 − ZWINT 0x0 708 chr10 58117180 58118473 − ZWINT 0x0 709 chr10 61550012 61551187 − CCDC6 0x0 710 chr10 61646660 61647838 − CCDC6 0x0 711 chr10 61799473 61800681 − ANK3 0x2 712 chr10 62471757 62472934 − ANK3 0x2 713 chr10 62553173 62554457 − CDK1 0x0 714 chr10 62670575 62671753 − RHOBTB1 0x0 715 chr10 63447839 63449050 + C10orf107 0x0 716 chr10 63976408 63977620 − RTKN2 0x0 717 chr10 65006684 65007886 − JMJD1C 0x0 718 chr10 65256338 65257454 − JMJD1C 0x0 719 chr10 65283600 65284816 + REEP3 0x0 720 chr10 65358845 65360025 + REEP3 0x0 721 chr10 65381754 65383090 + REEP3 0x0 722 chr10 67420760 67421880 − CTNNA3 0x4 723 chr10 69090896 69092095 − CTNNA3 0x4 724 chr10 69523738 69525755 + SIRT1 0x0 725 chr10 69556175 69557381 − DNAJC12 0x0 726 chr10 70101826 70103014 + HNRNPH3 0x0 727 chr10 70128501 70129686 − RUFY2 0x0 728 chr10 70153037 70154136 − RUFY2 0x0 729 chr10 70227468 70228610 − DNA2 0x0 730 chr10 70286378 70287515 − SLC25A16 0x0 731 chr10 70416334 70417482 + TET1 0x0 732 chr10 70425287 70426442 + TET1 0x0 733 chr10 70458278 70459445 + TET1 0x0 734 chr10 70514348 70515593 + CCAR1 0x0 735 chr10 70514348 70515593 + SNORD98 0x0 736 chr10 70521337 70522505 + CCAR1 0x0 737 chr10 70526118 70527353 + CCAR1 0x0 738 chr10 70547382 70548611 + CCAR1 0x0 739 chr10 70719311 70720548 + DDX21 0x0 740 chr10 70742633 70743716 + DDX21 0x0 741 chr10 71213672 71214905 + TSPAN15 0x0 742 chr10 71968827 71969932 − PPA1 0x0 743 chr10 72090161 72091301 − LRRC20 0x0 744 chr10 72179181 72180412 + EIF4EBP2 0x0 745 chr10 72182095 72183256 + EIF4EBP2 0x0 746 chr10 72186344 72188291 + EIF4EBP2 0x0 747 chr10 72226248 72227487 + KIAA1274 0x0 748 chr10 72327126 72328451 + KIAA1274 0x0 749 chr10 72603792 72604923 + SGPL1 0x0 750 chr10 72638485 72639719 + SGPL1 0x0 751 chr10 73059524 73060994 + UNC5B 0x1 752 chr10 73575664 73577723 − PSAP 0x0 753 chr10 73769977 73771076 + CHST3 0x0 754 chr10 73771572 73773721 + CHST3 0x0 755 chr10 74226979 74228171 − MICU1 0x0 756 chr10 74645466 74646663 + MCU 0x0 757 chr10 74761035 74762200 − P4HA1 0x0 758 chr10 74853987 74855251 − P4HA1 0x0 759 chr10 75008449 75009792 − MRPS16 0x0 760 chr10 75262821 75263997 − USP54 0x0 761 chr10 75433909 75435129 − AGAP5 0x0 762 chr10 75456729 75457933 − AGAP5 0x0 763 chr10 75536646 75537837 + FUT11 0x0 764 chr10 75545273 75546461 + KIAA0913 0x0 765 chr10 75558239 75559455 + KIAA0913 0x0 766 chr10 75623611 75624834 − CAMK2G 0x0 767 chr10 75828203 75829447 + VCL 0x1 768 chr10 76102005 76103155 + ADK 0x0 769 chr10 76602446 76603781 + KAT6B 0x2 770 chr10 76870831 76872021 + SAMD8 0x0 771 chr10 76936412 76937545 + SAMD8 0x0 772 chr10 76983205 76984301 + VDAC2 0x0 773 chr10 76994299 76995499 − COMTD1 0x0 774 chr10 76995165 76996322 + VDAC2 0x0 775 chr10 77160413 77161591 − ZNF503 0x0 776 chr10 77550216 77551415 + C10orf11 0x0 777 chr10 79514310 79515493 − DLG5 0x2 778 chr10 79550701 79552113 − DLG5 0x2 779 chr10 79580656 79581853 − DLG5 0x2 780 chr10 79729156 79730355 − POLR3A 0x2 781 chr10 79794606 79795831 + RPS24 0x0 782 chr10 79796462 79797625 + RPS24 0x0 783 chr10 79799824 79800997 + RPS24 0x0 784 chr10 80146596 80147772 − POLR3A 0x2 785 chr10 81572099 81573257 − SFTPD 0x0 786 chr10 81686310 81687409 + MBL1P 0x0 787 chr10 81885271 81886500 + PLAC9 0x0 788 chr10 85911939 85913402 + GHITM 0x0 789 chr10 87571839 87573088 − GRID1 0x2 790 chr10 87811722 87812914 + LOC100507470 0x0 791 chr10 88126165 88127381 + OPN4 0x0 792 chr10 88256073 88257291 − WAPAL 0x0 793 chr10 88266884 88268077 − WAPAL 0x0 794 chr10 88648778 88650011 + BMPR1A 0x2 795 chr10 89312084 89313511 + MINPP1 0x0 796 chr10 89512707 89513915 − ATAD1 0x0 797 chr10 89542693 89544610 − ATAD1 0x0 798 chr10 89727592 89728794 + PTEN 0x1 799 chr10 90999167 91000389 + LIPA 0x0 800 chr10 91144482 91145707 − SLC16A12 0x0 801 chr10 92986428 92987533 + PCGF5 0x0 802 chr10 93576218 93577444 + TNKS2 0x0 803 chr10 93756841 93758040 + BTAF1 0x0 804 chr10 94044068 94045250 − CPEB3 0x0 805 chr10 94092672 94093873 + MARCH5 0x0 806 chr10 94193802 94195017 − MARK2P9 0x0 807 chr10 94685206 94686408 + EXOC6 0x0 808 chr10 96108489 96109640 − NOC3L 0x0 809 chr10 96117423 96118595 − NOC3L 0x0 810 chr10 96122067 96123244 − NOC3L 0x0 811 chr10 96349622 96350815 + HELLS 0x0 812 chr10 96362603 96364743 + HELLS 0x0 813 chr10 96370239 96371467 + HELLS 0x0 814 chr10 97888941 97890188 + ZNF518A 0x2 815 chr10 98038160 98039356 + DNTT 0x0 816 chr10 98281270 98282442 − TM9SF3 0x0 817 chr10 98352618 98353841 − PIK3AP1 0x0 818 chr10 98560827 98562069 − PIK3AP1 0x0 819 chr10 98619000 98620163 + LCOR 0x0 820 chr10 98697481 98698689 + LCOR 0x0 821 chr10 99200150 99201299 − EXOSC1 0x0 822 chr10 99211300 99212538 + ZDHHC16 0x0 823 chr10 99220768 99221879 − MMS19 0x0 824 chr10 99257035 99258187 − MMS19 0x0 825 chr10 99434051 99435229 − AVPI1 0x2 826 chr10 99486666 99487852 + MARVELD1 0x0 827 chr10 99620012 99621179 + GOLGA7B 0x0 828 chr10 101106408 101107648 + CNNM1 0x0 829 chr10 101189707 101190895 − GOT1 0x0 830 chr10 101198213 101199432 + CNNM1 0x0 831 chr10 101446019 101447252 + ENTPD7 0x0 832 chr10 101909566 101910739 − ERLIN1 0x0 833 chr10 101996380 101997710 − CWF19L1 0x0 834 chr10 101996380 101997710 − SNORA12 0x0 835 chr10 102012574 102013761 − CWF19L1 0x0 836 chr10 102121124 102123864 + SCD 0x0 837 chr10 102123929 102124967 + SCD 0x0 838 chr10 102312573 102313722 + HIF1AN 0x0 839 chr10 102510249 102511465 + PAX2 0x0 840 chr10 102588417 102589613 + PAX2 0x0 841 chr10 102740219 102741347 − MRPL43 0x0 842 chr10 102746626 102747726 − MRPL43 0x0 843 chr10 102826216 102827396 + KAZALD1 0x0 844 chr10 103066793 103067972 − BTRC 0x0 845 chr10 103124035 103125312 − LBX1 0x0 846 chr10 103432736 103433950 − FBXW4 0x0 847 chr10 103732741 103733962 − C10orf76 0x0 848 chr10 103870177 103871418 − LDB1 0x6 849 chr10 103903555 103904683 + PPRC1 0x0 850 chr10 104350740 104351950 + SUFU 0x1 851 chr10 104391364 104392863 + SUFU 0x1 852 chr10 104618319 104619522 + C10orf32 0x0 853 chr10 104618319 104619522 + C10orf32-AS3MT 0x0 854 chr10 104703041 104704186 + CNNM2 0x0 855 chr10 104841572 104842768 + CNNM2 0x0 856 chr10 104929881 104931142 − NT5C2 0x0 857 chr10 104936094 104937308 + LOC729020 0x0 858 chr10 104966476 104967641 − NT5C2 0x0 859 chr10 105071657 105072830 − PCGF6 0x0 860 chr10 105236366 105237543 − CALHM3 0x0 861 chr10 105354565 105355675 − SH3PXD2A 0x0 862 chr10 105359058 105360157 − SH3PXO2A 0x0 863 chr10 105402766 105403933 − SH3PXD2A 0x0 864 chr10 105753471 105754685 + SLK 0x0 865 chr10 105797373 105798600 + SLK 0x0 866 chr10 108729213 108730449 + SORCS3 0x0 867 chr10 111825059 111826221 + ADD3 0x0 868 chr10 112045697 112046917 + MXI1 0x1 869 chr10 112541004 112542127 + RBM20 0x0 870 chr10 112556693 112557891 + RBM20 0x0 871 chr10 112601898 112603122 − LOC282997 0x0 872 chr10 114300308 114301485 + VTI1A 0x2 873 chr10 114430666 114431996 + VTI1A 0x2 874 chr10 114575897 114577131 + VTI1A 0x2 875 chr10 114803679 114804834 + TCF7L2 0x1 876 chr10 114810783 114812085 + TCF7L2 0x1 877 chr10 114832960 114834173 + TCF7L2 0x1 878 chr10 114994467 114995686 + TCF7L2 0x1 879 chr10 116191291 116192572 − ABLIM1 0x0 880 chr10 116192892 116194131 − ABLIM1 0x0 881 chr10 116194170 116195533 − ABLIM1 0x0 882 chr10 116482750 116483970 + FAM160B1 0x0 883 chr10 116726306 116727502 + TRUB1 0x0 884 chr10 118432853 118434126 − HSPA12A 0x0 885 chr10 118659202 118660345 − KIAA1598 0x0 886 chr10 118672336 118673543 − KIAA1598 0x0 887 chr10 119040865 119042286 − PDZD8 0x0 888 chr10 119133806 119134993 − PDZD8 0x0 889 chr10 119613911 119615133 − RAB11FIP2 0x0 890 chr10 120444662 120445977 − C10orf46 0x0 891 chr10 120801317 120802788 − EIF3A 0x2 892 chr10 120827133 120828353 + NANOS1 0x0 893 chr10 120829962 120831338 − EIF3A 0x2 894 chr10 120928180 120929329 − PRDX3 0x0 895 chr10 121334411 121335594 − TIAL1 0x0 896 chr10 121335956 121337136 − TIAL1 0x0 897 chr10 121608403 121609588 − MCMBP 0x0 898 chr10 123310751 123311964 − FGFR2 0x2 899 chr10 123324439 123325692 − FGFR2 0x2 900 chr10 123663896 123665105 − ATE1 0x0 901 chr10 123718953 123720157 − NSMCE4A 0x0 902 chr10 124913829 124915052 + BUB3 0x0 903 chr10 124924070 124925428 + BUB3 0x0 904 chr10 124934702 124936353 + BUB3 0x0 905 chr10 124991437 124992665 + BUB3 0x0 906 chr10 125025863 125027036 + BUB3 0x0 907 chr10 125114673 125115921 + BUB3 0x0 908 chr10 125164937 125166171 + BUB3 0x0 909 chr10 125198504 125199751 + GPR26 0x0 910 chr10 125664056 125665258 − CPXM2 0x0 911 chr10 125774837 125776019 − CHST15 0x0 912 chr10 125830388 125831664 − CHST15 0x0 913 chr10 126308995 126312062 − FAM53B 0x0 914 chr10 126369856 126371487 − FAM53B 0x0 915 chr10 126464474 126465618 − METTL10 0x0 916 chr10 126475775 126476905 − METTL10 0x0 917 chr10 126496071 126497298 + FAM175B 0x0 918 chr10 126700536 126701714 − CTBP2 0x1 919 chr10 126800984 126802132 − CTBP2 0x1 920 chr10 126816411 126817597 − CTBP2 0x1 921 chr10 127411064 127412263 + C10orf137 0x2 922 chr10 127705459 127706666 − ADAM12 0x2 923 chr10 128854346 128855588 + DOCK1 0x0 924 chr10 129894800 129896956 − MKI67 0x0 925 chr10 129905232 129906521 − MKI67 0x0 926 chr10 129913111 129914504 − MKI67 0x0 927 chr10 131634425 131635894 − EBF3 0x0 928 chr10 131642924 131644143 + MGMT 0x0 929 chr10 132107642 132108887 + GLRX3 0x0 930 chr10 132179372 132180570 − LOC387723 0x0 931 chr10 134109868 134111045 − STK32C 0x0 932 chr10 134754867 134756042 − TTC40 0x0 933 chr10 135095771 135096937 − TUBGCP2 0x0 934 chr10 135115703 135116996 − TUBGCP2 0x0 935 chr10 135121757 135122955 − TUBGCP2 0x0 936 chr10 135222774 135224017 + MTG1 0x0 937 chr11 290224 291416 + ATHL1 0x0 938 chr11 439910 441128 − ANO9 0x0 939 chr11 642177 643361 − DEAF1 0x0 940 chr11 671065 672334 − DEAF1 0x0 941 chr11 769924 771342 − PDDC1 0x0 942 chr11 790565 791735 − SLC25A22 0x0 943 chr11 809719 810944 + RPLP2 0x0 944 chr11 811175 813388 + RPLP2 0x0 945 chr11 811175 813388 + SNORA52 0x0 946 chr11 988708 989919 + AP2A2 0x0 947 chr11 1773934 1775128 − CTSD 0x0 948 chr11 2393292 2394489 + CD81 0x4 949 chr11 2417707 2419006 + CD81 0x4 950 chr11 2984521 2985619 − SNORA54 0x0 951 chr11 3383623 3384799 − ZNF195 0x0 952 chr11 3716135 3717338 − NUP98 0x2 953 chr11 6631438 6632537 − TAF10 0x0 954 chr11 8125426 8126565 + TUB 0x0 955 chr11 8538631 8539771 − STK33 0x0 956 chr11 8689247 8690420 − TRIM66 0x0 957 chr11 8705244 8706446 + RPL27A 0x0 958 chr11 8705244 8706446 + SNORA3 0x0 959 chr11 8706452 8707671 + RPL27A 0x0 960 chr11 8706452 8707671 + SNORA45 0x0 961 chr11 9310545 9311720 − TMEM41B 0x0 962 chr11 9431002 9432103 + IPO7 0x0 963 chr11 9449754 9451088 + IPO7 0x0 964 chr11 9449754 9451088 + SNORA23 0x0 965 chr11 9461513 9462627 + IPO7 0x0 966 chr11 9609488 9610703 + WEE1 0x0 967 chr11 10264434 10265657 − SBF2 0x0 968 chr11 10529526 10530696 − MIR4485 0x0 969 chr11 10529526 10530696 − MTRNR2L8 0x0 970 chr11 10818436 10819796 − EIF4G2 0x0 971 chr11 10822497 10823700 − EIF4G2 0x0 972 chr11 10822497 10823700 − SNORD97 0x0 973 chr11 12962124 12963416 + TEAD1 0x0 974 chr11 13434590 13435724 − BTBD10 0x0 975 chr11 13440526 13441707 − BTBd10 0x0 976 chr11 14478587 14479807 − COPB1 0x0 977 chr11 16760098 16761286 + C11or158 0x0 978 chr11 16995727 16997058 − PLEKHA7 0x0 979 chr11 17095623 17098089 − RPS13 0x0 980 chr11 17098092 17099231 − RPS13 0x0 981 chr11 17225281 17226466 − PIK3C2A 0x0 982 chr11 17399390 17400490 + B7H6 0x0 983 chr11 18428322 18429599 + LDHA 0x0 984 chr11 19422875 19424100 − NAV2-AS4 0x0 985 chr11 22248369 22249579 + ANO5 0x0 986 chr11 22709343 22710553 + GAS2 0x0 987 chr11 22795836 22797053 + GAS2 0x0 988 chr11 23427115 23428335 + GAS2 0x0 989 chr11 28191782 28193016 + METTL15 0x0 990 chr11 28592373 28593592 + METTL15 0x0 991 chr11 32608006 32609259 + EIF3M 0x0 992 chr11 33100090 33101473 + LINC00294 0x0 993 chr11 33160995 33162510 − CSTF3 0x0 994 chr11 33690488 33691795 + C11orf41 0x0 995 chr11 34073293 34074505 + CAPRIN1 0x0 996 chr11 34117590 34118706 + CAPRIN1 0x0 997 chr11 34121064 34122602 + CAPRIN1 0x0 998 chr11 34368183 34369357 − ABTB2 0x0 999 chr11 35473459 35474657 − PAMR1 0x0 1000 chr11 36248223 36249497 + LDLRAD3 0x0 1001 chr11 38594065 38595243 + C11orf74 0x0 1002 chr11 43465120 43466265 + TTC17 0x0 1003 chr11 43701813 43703100 + HSD17B12 0x0 1004 chr11 43710889 43712096 + HSD17B12 0x0 1005 chr11 43713719 43714879 + HSD17B12 0x0 1006 chr11 44104241 44105440 + ACCS 0x0 1007 chr11 44147814 44149025 + EXT2 0x1 1008 chr11 44950191 44951341 + TSPAN18 0x0 1009 chr11 44953860 44955070 − TP53I11 0x0 1010 chr11 45923521 45924726 + MAPK8IP1 0x0 1011 chr11 46449763 46450915 − AMBRA1 0x0 1012 chr11 46514646 46515836 − AMBRA1 0x0 1013 chr11 46699392 46700538 − ARHGAP1 0x0 1014 chr11 46772535 46773582 − CKAP5 0x0 1015 chr11 47489352 47490908 − CELF1 0x0 1016 chr11 47499886 47501080 − CELF1 0x0 1017 chr11 47509722 47511032 − CELF1 0x0 1018 chr11 47600235 47601463 + NDUFS3 0x0 1019 chr11 47799968 47801080 − NUP160 0x0 1020 chr11 47833349 47834567 − NUP160 0x0 1021 chr11 50048802 50050001 + OR4C13 0x2 1022 chr11 57083573 57084694 − TNKS1BP1 0x0 1023 chr11 57092908 57094413 − SSRP1 0x0 1024 chr11 57101422 57102590 − SSRP1 0x0 1025 chr11 57507709 57508876 + C11orf31 0x0 1026 chr11 57507709 57508876 + TMX2 0x0 1027 chr11 57538522 57539710 + CTNND1 0x1 1028 chr11 57575280 57576487 + CTNND1 0x1 1029 chr11 57575280 57575487 + TMX2-CTNND1 0x0 1030 chr11 57585111 57586193 + CTNND1 0x1 1031 chr11 57585111 57586193 + TMX2-CTNND1 0x0 1032 chr11 58385311 58385651 + ZFP91 0x0 1033 chr11 59382267 59383461 − OSBP 0x0 1034 chr11 60657745 60658974 − PRPF19 0x0 1035 chr11 60673362 60574576 − PRPF19 0x0 1036 chr11 60905662 60907001 − VPS37C 0x0 1037 chr11 61080978 61082137 − DDB1 0x0 1038 chr11 61094557 61095688 − DDB1 0x0 1039 chr11 61103262 61104457 + DAK 0x0 1040 chr11 61116305 61117482 − CYBASC3 0x0 1041 chr11 61171066 61172241 − CPSF7 0x0 1042 chr11 61570746 61572017 − FADS1 0x0 1043 chr11 61633292 61634749 + FADS2 0x0 1044 chr11 61731955 61733169 − FTH1 0x0 1045 chr11 61918917 61920151 + INCENP 0x0 1046 chr11 62326613 62327797 − EEF1G 0x0 1047 chr11 62326613 62327797 − MIR3654 0x0 1048 chr11 62328614 62329742 − EEF1G 0x0 1049 chr11 62334335 62335539 − EEF1G 0x0 1050 chr11 62360207 62361316 − MTA2 0x2 1051 chr11 62364348 62365556 − MTA2 0x2 1052 chr11 62383240 62384372 − B3GAT3 0x0 1053 chr11 62400036 62401262 − GANAB 0x0 1054 chr11 62431867 62433201 − C11orf48 0x0 1055 chr11 62432354 62433550 − METTL12 0x0 1056 chr11 62432354 62433550 + SNORA57 0x0 1057 chr11 62489249 62490426 + HNRNPUL2 0x0 1058 chr11 62489249 62490426 − HNRNPUL2-BSCL2 0x0 1059 chr11 62510820 62512038 + TTC9C 0x0 1060 chr11 62532031 62533274 + POLR2G 0x0 1061 chr11 62542758 62543857 + TAF6L 0x0 1062 chr11 62549124 62550223 + TAF6L 0x0 1063 chr11 62567012 62568190 − NXF1 0x2 1064 chr11 62608541 62609849 − WDR74 0x0 1065 chr11 62618968 62621378 − SNHG1 0x0 1066 chr11 62618968 62621378 − SNORD22 0x0 1067 chr11 62618968 62621378 − SNORD29 0x0 1068 chr11 62618968 62621378 − SNORD30 0x0 1069 chr11 62618968 62621378 − SNORD31 0x0 1070 chr11 62622051 62623625 − SNHG1 0x0 1071 chr11 62622051 62623625 − SNORD25 0x0 1072 chr11 62622051 62623625 − SNORD26 0x0 1073 chr11 62622051 62623625 − SNORD27 0x0 1074 chr11 62622051 62623625 − SNORD28 0x0 1075 chr11 63423115 63424290 − ATL3 0x0 1076 chr11 63596428 63597649 + C11orf84 0x0 1077 chr11 63785551 63786757 − MACROD1 0x0 1078 chr11 64005477 64006741 + VEGFB 0x0 1079 chr11 64013805 64014998 − PPP1R14B 0x0 1080 chr11 64018832 64019978 + PLCB3 0x1 1081 chr11 64063003 64064157 + KCNK4 0x0 1082 chr11 64083247 64084373 + ESRRA 0x0 1083 chr11 64083656 64084870 − TRMT112 0x0 1084 chr11 64532206 64533405 − SF1 0x0 1085 chr11 64574182 64575360 − MEN1 0x1 1086 chr11 64845803 64846957 − CDCA5 0x0 1087 chr11 64878887 64880037 + C11orf2 0x0 1088 chr11 64878887 64880037 + TM7SF2 0x0 1089 chr11 64880221 64881320 + TM7SF2 0x0 1090 chr11 64914487 64915767 + MRPL49 0x0 1091 chr11 64978362 64979722 + CAPN1 0x0 1092 chr11 65197873 65199078 + NEAT1 0x0 1093 chr11 65202147 65203375 + NEAT1 0x0 1094 chr11 65205474 65206618 + MIR612 0x0 1095 chr11 65211102 65213301 + MIR612 0x0 1096 chr11 65267086 65272491 + MALAT1 0x0 1097 chr11 65272670 65273959 + MALAT1 0x0 1098 chr11 65303924 65305111 + SCYL1 0x0 1099 chr11 65318518 65319691 − LTBP3 0x0 1100 chr11 65340337 65341462 + FAM89B 0x0 1101 chr11 65382895 65384217 + PCNXL3 0x0 1102 chr11 65403876 65405283 + PCNXL3 0x0 1103 chr11 65420601 65421743 − RELA 0x0 1104 chr11 65606663 65607901 + SNX32 0x0 1105 chr11 65621762 65623097 − CFL1 0x0 1106 chr11 65657684 65658871 + CCDC85B 0x0 1107 chr11 65732857 65734198 + SART1 0x0 1108 chr11 66040462 66041680 + RAB1B 0x4 1109 chr11 66115021 66116249 + TMEM151A 0x0 1110 chr11 66412944 66414301 + RBM14-RBM4 0x0 1111 chr11 66412944 66414301 + RBM4 0x0 1112 chr11 66458249 66459396 − SPTBN2 0x0 1113 chr11 66477558 66478690 − SPTBN2 0x0 1114 chr11 66998612 66999821 + KDM2A 0x0 1115 chr11 67129304 67130537 + LOC100130987 0x0 1116 chr11 67171122 67172325 + PPP1CA 0x1 1117 chr11 67888092 67889195 − CHKA 0x0 1118 chr11 68114944 68116240 + LRP5 0x2 1119 chr11 68124695 68125868 + LRP5 0x2 1120 chr11 68178330 68179614 + LRP5 0x2 1121 chr11 68380749 68381958 + PPP6R3 0x0 1122 chr11 68457842 68459072 + GAL 0x0 1123 chr11 69465610 69466793 + CCND1 0x2 1124 chr11 69468028 69469207 + CCND1 0x2 1125 chr11 70260296 70261444 + CTTN 0x0 1126 chr11 70266096 70267236 + CTTN 0x0 1127 chr11 70281342 70282887 + CTTN 0x0 1128 chr11 70487751 70488908 − SHANK2 0x0 1129 chr11 71719638 71720823 − NUMA1 0x2 1130 chr11 72396112 72397289 − ARAP1 0x0 1131 chr11 72465381 72466597 − STARD10 0x0 1132 chr11 72533951 72535153 + ATG16L2 0x0 1133 chr11 73089519 73090913 + RELT 0x0 1134 chr11 73102560 73103766 + RELT 0x0 1135 chr11 73113207 73114421 − FAM168A 0x0 1136 chr11 73292950 73294141 − FAM168A 0x0 1137 chr11 73471139 73472306 − RA86A 0x0 1138 chr11 73686049 73687204 − UCP2 0x0 1139 chr11 73692040 73693221 − UCP2 0x0 1140 chr11 74395754 74397001 + POLD3 0x0 1141 chr11 74459371 74460563 + RNF169 0x0 1142 chr11 74548402 74549680 + RNF169 0x0 1143 chr11 74953752 74954991 + LOC100507050 0x0 1144 chr11 74973123 74974469 − ARRB1 0x0 1145 chr11 75114637 75115718 + RPS3 0x0 1146 chr11 75114637 75115718 + SNORD15B 0x0 1147 chr11 75116122 75117284 + RPS3 0x0 1148 chr11 75946310 75947433 − WNT11 0x1 1149 chr11 76188233 76189474 + C11orf30 0x2 1150 chr11 77445397 77446524 − RSF1 0x0 1151 chr11 77596958 77598370 + C11or167 0x0 1152 chr11 78203348 78204744 − NARS2 0x0 1153 chr11 78281988 78283213 − NARS2 0x0 1154 chr11 79158852 79160049 + USP35 0x0 1155 chr11 82400096 82401484 + C11orf82 0x0 1156 chr11 85194521 85195729 + TMEM126B 0x0 1157 chr11 85372133 85373311 − CREBZF 0x0 1158 chr11 85374978 85376093 − CREBZF 0x0 1159 chr11 85955600 85956820 + EED 0x0 1160 chr11 86781990 86783149 + TMEM135 0x0 1161 chr11 87035894 87037074 + TMEM135 0x0 1162 chr11 87173935 87175142 + TMEM135 0x0 1163 chr11 88115883 88117057 + TYR 0x0 1164 chr11 88601325 88602522 − GRM5 0x2 1165 chr11 90016508 90017736 + NAALAD2 0x0 1166 chr11 92628475 92629717 + FAT3 0x2 1167 chr11 93430080 93431249 + KIAA1731 0x0 1168 chr11 93431321 93432559 + KIAA1731 0x0 1169 chr11 93454277 93455631 + KIAA1731 0x0 1170 chr11 93454277 93455631 + SCARNA9 0x0 1171 chr11 93463172 93467318 − MIR1304 0x0 1172 chr11 93463172 93467318 − SNORA1 0x0 1173 chr11 93463172 93467318 − SNORA18 0x0 1174 chr11 93463172 93467318 − SNORA25 0x0 1175 chr11 93463172 93467318 − SNORA32 0x0 1176 chr11 93463172 93467318 − SNORA8 0x0 1177 chr11 93463172 93467318 − SNORD5 0x0 1178 chr11 93463172 93467318 − SNORD6 0x0 1179 chr11 93467776 93468906 − SNORA40 0x0 1180 chr11 93471932 93473313 − TAF1D 0x0 1181 chr11 93710378 93711559 − VSTM5 0x0 1182 chr11 93951439 93952636 − GPR83 0x0 1183 chr11 94150949 94152169 − MRE11A 0x2 1184 chr11 94191674 94192852 − MRE11A 0x2 1185 chr11 94626721 94627940 + AMOTL1 0x0 1186 chr11 94901765 94902876 − SESN3 0x0 1187 chr11 94905459 94906618 − SESN3 0x0 1188 chr11 95825694 95826915 − MAML2 0x2 1189 chr11 97636450 97637649 − CCDC82 0x0 1190 chr11 102165160 102166359 + BIRC3 0x2 1191 chr11 102267092 102268404 − TMEM123 0x0 1192 chr11 103002798 103004000 + DYNC2H1 0x2 1193 chr11 103027441 103028540 + DYNC2H1 0x2 1194 chr11 103174765 103176006 + DYNC2H1 0x2 1195 chr11 105633446 105634654 + GRIA4 0x0 1196 chr11 105968338 105969437 + AASDHPPT 0x0 1197 chr11 108002424 108003642 + ACAT1 0x0 1198 chr11 108047167 108048374 − NPAT 0x0 1199 chr11 108344138 108345359 − KDELC2 0x0 1200 chr11 108788410 108789619 + DDX10 0x0 1201 chr11 110100605 110101959 − RDX 0x0 1202 chr11 110165437 110166631 − RDX 0x0 1203 chr11 111611018 111612348 − PPP2R1B 0x1 1204 chr11 111630786 111631964 − PPP2R1B 0x1 1205 chr11 111692090 111693298 − ALG9 0x0 1206 chr11 111911615 111912858 + DLAT 0x0 1207 chr11 113692674 113693849 − USP28 0x2 1208 chr11 113737800 113739046 + HTR3B 0x0 1209 chr11 114293964 114295180 + RBM7 0x0 1210 chr11 115046086 115047511 − CADM1 0x1 1211 chr11 115148719 115149902 − CADM1 0x1 1212 chr11 115342456 115343604 − CADM1 0x1 1213 chr11 115471774 115472976 + FAM55B 0x0 1214 chr11 115692620 115693820 − APOC3 0x0 1215 chr11 117708156 117709359 − FXYD6 0x0 1216 chr11 118279246 118280394 + ATP5L 0x0 1217 chr11 118342606 118343847 + MLL 0x2 1218 chr11 118393102 118394257 + MLL 0x2 1219 chr11 118427130 118428283 − IFT46 0x0 1220 chr11 118470924 118472083 + ARCN1 0x0 1221 chr11 118527620 118528782 + PHLDB1 0x0 1222 chr11 118619817 118620995 − DDX6 0x0 1223 chr11 118894521 118895926 − SLC37A4 0x0 1224 chr11 118914425 118916307 − HYOU1 0x0 1225 chr11 118964055 118965438 − H2AFX 0x0 1226 chr11 120219784 120220989 + ARHGEF12 0x1 1227 chr11 120346835 120347953 + ARHGEF12 0x1 1228 chr11 120356530 120357629 + ARHGEF12 0x1 1229 chr11 120901672 120902820 − TBCEL 0x0 1230 chr11 122928226 122929337 − HSPA8 0x0 1231 chr11 122929463 122930664 − HSPA8 0x0 1232 chr11 123050799 123052002 − CLMP 0x0 1233 chr11 123595631 123596826 − ZNF202 0x0 1234 chr11 123634095 123635377 + GRAMD1B 0x0 1235 chr11 124505785 124507034 + TBRG1 0x1 1236 chr11 124923736 124924915 − TMEM218 0x0 1237 chr11 125169906 125171066 + PKNOX2 0x0 1238 chr11 125453376 125454570 + EI24 0x1 1239 chr11 125490149 125491346 + STT3A 0x0 1240 chr11 125547115 125548337 + CHEK1 0x1 1241 chr11 126076638 126077817 − RPUSD4 0x0 1242 chr11 126147179 126148335 + FOXRED1 0x0 1243 chr11 129297040 129298265 + BARX2 0x0 1244 chr11 130013182 130015087 + APLP2 0x0 1245 chr11 133768160 133769577 − LOC283174 0x0 1246 chr11 133768160 133769577 − MIR4697 0x0 1247 chr11 133775128 133776296 − LOC283174 0x0 1248 chr11 133801584 133802941 − IGSF9B 0x0 1249 chr11 133905644 133907090 − IGSF9B 0x0 1250 chr11 134207878 134209110 + GLB1L2 0x0 1251 chr11 134244503 134245731 + GLB1L2 0x0 1252 chr12 364481 365671 − SLC6A13 0x0 1253 chr12 392498 393756 − KDMSA 0x2 1254 chr12 413102 414299 + CCDC77 0x0 1255 chr12 973775 975079 + WNK1 0x0 1256 chr12 1038335 1039518 − RAD52 0x0 1257 chr12 1136736 1137951 + ERC1 0x2 1258 chr12 2364481 2365782 + CACNA1C 0x0 1259 chr12 2675917 2677086 + CACNA1C 0x0 1260 chr12 2912189 2913544 + FKBP4 0x0 1261 chr12 2927125 2928323 + ITFG2 0x0 1262 chr12 2986248 2987433 + C12orf32 0x0 1263 chr12 2997913 2999053 + C12orf32 0x0 1264 chr12 3008519 3009671 + TULP3 0x0 1265 chr12 3079751 3080900 + TEAD4 0x0 1266 chr12 3153592 3154803 + TEAD4 0x0 1267 chr12 4399756 4400906 + CCND2 0x2 1268 chr12 4411084 4412957 + CCND2 0x2 1269 chr12 4772532 4773729 + NDUFA9 0x0 1270 chr12 6618969 6620370 + NCAPD2 0x0 1271 chr12 6618969 6620370 + SCARNA10 0x0 1272 chr12 6626244 6627393 + NCAPD2 0x0 1273 chr12 6646283 6647637 + GAPDH 0x0 1274 chr12 6652008 6653217 − IFFO1 0x0 1275 chr12 6678923 6680015 − CHD4 0x2 1276 chr12 6690067 6691369 − CHD4 0x2 1277 chr12 6690067 6691369 − SCARNA11 0x0 1278 chr12 6709165 6710346 − CHD4 0x2 1279 chr12 6775774 6776986 − ZNF384 0x2 1280 chr12 6879192 6880496 + PTMS 0x2 1281 chr12 7052424 7053623 + C12orf57 0x0 1282 chr12 7074110 7075210 − PHB2 0x0 1283 chr12 7076077 7077300 − PHB2 0x0 1284 chr12 7076077 7077300 − SCARNA12 0x0 1285 chr12 7079104 7080280 − PHB2 0x0 1286 chr12 7362702 7363899 + PEX5 0x0 1287 chr12 9451079 9452259 + LOC642846 0x0 1288 chr12 9572828 9574121 − DDX12P 0x0 1289 chr12 10865278 10866425 − CSDA 0x0 1290 chr12 11283034 11284164 − TAS2R30 0x0 1291 chr12 12396929 12398082 − LRP6 0x0 1292 chr12 12693877 12695074 − DUSP16 0x0 1293 chr12 12843359 12844568 + CDKN1B 0x2 1294 chr12 12882447 12883597 + APOLD1 0x0 1295 chr12 13349667 13350884 + EMP1 0x1 1296 chr12 14553333 14554482 + ATF7IP 0x0 1297 chr12 14576917 14578148 + ATF7IP 0x0 1298 chr12 16034899 16035998 + STRAP 0x0 1299 chr12 19459402 19460532 + PLEKHA5 0x0 1300 chr12 19609180 19610356 − PLCZ1 0x0 1301 chr12 19646275 19647461 + AEBP2 0x0 1302 chr12 19667021 19668250 + AEBP2 0x0 1303 chr12 19787207 19788406 + AEBP2 0x0 1304 chr12 20703858 20705060 + PDE3A 0x0 1305 chr12 21787731 21789097 − LDHB 0x0 1306 chr12 21796330 21797498 − LDHB 0x0 1307 chr12 21806910 21808112 − LDHB 0x0 1308 chr12 22841550 22842755 − ETNK1 0x0 1309 chr12 24302800 24303994 − SOX5 0x2 1310 chr12 25359335 25360441 − KRAS 0x2 1311 chr12 26799681 26800860 − ITPR2 0x0 1312 chr11 27182459 27183558 + MED21 0x0 1313 chr12 28416937 28418091 + CCDC91 0x0 1314 chr12 29318753 29320044 + FAR2 0x0 1315 chr12 31255183 31256382 + DDX11 0x2 1316 chr12 32329775 32330974 + BICD1 0x0 1317 chr12 34358128 34359328 + ALG10 0x0 1318 chr12 38554688 38555905 − CPNE8 0x0 1319 chr12 38556667 38557854 − CPNE8 0x0 1320 chr12 40306319 40307450 − SLC2A13 0x2 1321 chr12 41291889 41293092 + CNTN1 0x2 1322 chr12 42802927 42804130 + PPHLN1 0x0 1323 chr12 44112475 44113668 − PUS7L 0x0 1324 chr11 46210804 46211974 − ARID2 0x1 1325 chr12 46348079 46349248 − SCAF11 0x0 1326 chr12 46578570 46579679 − SLC38A1 0x0 1327 chr12 46580852 46583054 − SLC38A1 0x0 1328 chr12 46662262 46663408 − SLC38A1 0x0 1329 chr12 46753993 46755126 − SLC38A2 0x0 1330 chr12 47028778 47029926 + MIR4698 0x0 1331 chr12 48211842 48213021 − HDAC7 0x0 1332 chr12 48361676 48362943 + TMEM106C 0x0 1333 chr12 48929861 48931073 − LALBA 0x0 1334 chr11 49047617 49048857 − KANSL2 0x0 1335 chr12 49047617 49048857 − MIR1291 0x0 1336 chr12 49047617 49048857 − SNORA34 0x0 1337 chr12 49049902 49051113 − SNORA2A 0x0 1338 chr12 49053651 49054832 − KANSL2 0x0 1339 chr12 49318110 49319282 − FKBP11 0x0 1340 chr12 49329445 49332620 − ARF3 0x0 1341 chr12 49414410 49415621 − MLL2 0x2 1342 chr12 49435603 49436758 − MLL2 0x2 1343 chr12 49529532 49530765 + TUBA1C 0x0 1344 chr12 49548759 49550000 + TUBA1C 0x0 1345 chr12 49666456 49667619 + TUBA1C 0x0 1346 chr12 49920100 49921328 + SPATS2 0x0 1347 chr12 49985589 49986795 + PRPF40B 0x0 1348 chr12 50128781 50130000 − FMNL3 0x2 1349 chr12 50134767 50135968 + TMBIM6 0x0 1350 chr12 50145699 50146862 + TMBIM6 0x0 1351 chr12 50156264 50157519 + TMBIM6 0x0 1352 chr12 50157722 50158819 + TMBIM6 0x0 1353 chr12 50184490 50185694 − NCKAP5L 0x0 1354 chr12 50491552 50492780 + SMARCD1 0x2 1355 chr12 50849813 50851143 + LARP4 0x0 1356 chr12 51090319 51091513 + DIP28 0x0 1357 chr12 51498676 51499900 − TFCP2 0x0 1358 chr12 51634102 51635201 + DAZAP2 0x0 1359 chr12 51636316 51637386 + DAZAP2 0x0 1360 chr12 52401840 52403056 + GRASP 0x0 1361 chr12 53415744 53416893 + EIF4B 0x0 1362 chr12 53427832 53429067 + EIF4B 0x0 1363 chr12 53434475 53435740 + EIF4B 0x0 1364 chr12 53440754 53442110 − LOC283335 0x0 1365 chr12 53677339 53678467 + ESPL1 0x2 1366 chr12 53861998 53863198 + PCBP2 0x0 1367 chr12 53872702 53873900 + PCBP2 0x0 1368 chr12 53925841 53927016 − ATF7 0x0 1369 chr12 53959188 53960365 − ATF7 0x0 1370 chr12 54058406 54059659 − ATP5G2 0x0 1371 chr12 54105636 54106848 − CALCOCO1 0x0 1372 chr12 54116856 54118029 − CALCOCO1 0x0 1373 chr12 54624276 54625822 − CBX5 0x0 1374 chr12 54624276 54625822 − MIR3198-2 0x0 1375 chr12 54626334 54627796 − CBX5 0x0 1376 chr12 54632554 54633647 − CBX5 0x0 1377 chr12 54678040 54679244 + HNRNPA1 0x0 1378 chr12 54678040 54679244 + HNRNPA1P10 0x0 1379 chr12 54680244 54681745 + HNRNPA1 0x0 1380 chr12 54744020 54745227 + COPZ1 0x0 1381 chr12 56144734 56145888 + GDF11 0x0 1382 chr12 56214650 56215827 − DNAJC14 0x0 1383 chr12 56319123 56320301 − WIBG 0x0 1384 chr12 56509912 56511132 + RPL41 0x0 1385 chr12 56529980 56531185 + ESYT1 0x0 1386 chr12 56554648 56555864 + MYL6 0x0 1387 chr12 56567925 56569100 − SMARCC2 0x0 1388 chr12 56574409 56575535 − SMARCC2 0x0 1389 chr12 56631521 56633609 − ANKRD52 0x0 1390 chr12 56650675 56651839 − ANKRD52 0x0 1391 chr12 56665418 56666553 − CS 0x0 1392 chr12 56669294 56670401 − CS 0x0 1393 chr12 56904854 56906036 + RBMS2 0x0 1394 chr12 56983285 56984504 + RBMS2 0x0 1395 chr12 56990790 56991985 − BAZ2A 0x0 1396 chr12 56998428 56999593 − BAZ2A 0x0 1397 chr12 57031567 57032662 − ATP5B 0x0 1398 chr12 57038251 57039453 − ATP5B 0x0 1399 chr12 57038251 57039453 − SNORD59A 0x0 1400 chr12 57057255 57058446 − PTGES3 0x0 1401 chr12 57106012 57107208 − NACA 0x2 1402 chr12 57452030 57453472 − TMEM194A 0x0 1403 chr12 57557543 57558713 + LRP1 0x0 1404 chr12 57650492 57651591 − R3HDM2 0x0 1405 chr12 57677230 57678420 − R3HDM2 0x0 1406 chr12 57764748 57765913 − R3HDM2 0x0 1407 chr12 57923781 57924975 − DCTN2 0x0 1408 chr12 57998635 57999786 + DTX3 0x0 1409 chr12 59270638 59271817 − LRIG3 0x1 1410 chr12 62948534 62949723 − MON2 0x0 1411 chr12 63327834 63329011 − PPM1H 0x0 1412 chr12 63358577 63359800 + MIRLET7I 0x1 1413 chr12 65603419 65604657 − LEMD3 0x0 1414 chr12 67285540 67286640 − GRIP1 0x0 1415 chr12 67296512 67297691 − GRIP1 0x0 1416 chr12 67431752 67432968 − GRIP1 0x0 1417 chr12 67698510 67699685 + CAND1 0x0 1418 chr12 69005201 69006430 + RAP1B 0x0 1419 chr12 69649981 69651119 + CPSF6 0x0 1420 chr12 69994544 69995776 + CCT2 0x0 1421 chr12 70194830 70196046 + RAB3IP 0x0 1422 chr12 70679838 70681070 + CNOT2 0x0 1423 chr12 71896974 71898191 + LGR5 0x0 1424 chr11 72004583 72005719 − ZFC3H1 0x0 1425 chr12 72005992 72007142 − ZFC3H1 0x0 1426 chr12 72180935 72182073 + RAB21 0x0 1427 chr12 74850635 74851794 + ATXN7L3B 0x0 1428 chr12 75679900 75681078 − CAPS2 0x0 1429 chr12 75891366 75892543 + GLIPR1 0x1 1430 chr12 75892900 75894150 − KRR1 0x0 1431 chr12 76430189 76431289 − PHLDA1 0x0 1432 chr12 76439331 76440505 − NAP1L1 0x0 1433 chr12 76443863 76444966 − NAP1L1 0x0 1434 chr12 76451371 76460500 − NAP1L1 0x0 1435 chr12 76461818 76462967 − NAP1L1 0x0 1436 chr12 77224354 77225520 + ZDHHC17 0x1 1437 chr12 77423288 77424487 − E2F7 0x4 1438 chr12 79454116 79455268 − PAWR 0x1 1439 chr12 79545435 79546544 − PAWR 0x1 1440 chr12 80065464 80066629 − PAWR 0x1 1441 chr12 81938745 81939922 − PPFIA2 0x0 1442 chr12 82111266 82112433 − PPFIA2 0x0 1443 chr12 82763997 82765204 + C12orf26 0x0 1444 chr12 83250305 83251851 + TMTC2 0x0 1445 chr12 83445406 83446612 + TMTC2 0x0 1446 chr12 85275664 85276792 − SLC6A15 0x2 1447 chr12 85689617 85690718 + ALX1 0x0 1448 chr12 88478022 88479168 − CEP290 0x0 1449 chr12 88823643 88824885 + TMTC3 0x0 1450 chr12 89912721 89913853 − GALNT4 0x0 1451 chr12 89912721 89913853 − POC1B-GALNT4 0x0 1452 chr12 90013416 90014561 − ATP2B1 0x0 1453 chr12 90082996 90084168 − ATP2B1 0x0 1454 chr12 92120144 92121361 + CLLU1 0x0 1455 chr12 92734804 92736003 + CLLU1 0x0 1456 chr12 93795485 93796681 + NUDT4 0x0 1457 chr12 93795485 93796681 + NUDT4P1 0x0 1458 chr12 93801835 93803801 − UBE2N 0x0 1459 chr12 93895618 93896756 + MRPL42 0x0 1460 chr12 93898154 93899253 + MRPL42 0x0 1461 chr12 93902860 93904057 + MRPL42 0x0 1462 chr12 94033987 94035163 − LOC144481 0x0 1463 chr12 94270786 94271995 + CRADD 0x0 1464 chr12 95449301 95450478 − NR2C1 0x0 1465 chr12 95694283 95695450 + VEZT 0x0 1466 chr12 95838385 95839584 − USP44 0x0 1467 chr12 95907272 95908503 + METAP2 0x2 1468 chr12 95945210 95946388 − USP44 0x0 1469 chr12 96131748 96132931 − NTN4 0x0 1470 chr12 96679370 96680544 − CDK17 0x0 1471 chr12 98896705 98897950 + TMPO 0x0 1472 chr12 98909061 98910417 + TMPO 0x0 1473 chr12 98928615 98929958 + TMPO 0x0 1474 chr12 98988112 98989361 + SLC25A3 0x0 1475 chr12 98992887 98994230 + SLC25A3 0x0 1476 chr12 98992887 98994230 + SNORA53 0x0 1477 chr12 99477048 99478198 − ANKS1B 0x0 1478 chr12 100497710 100498916 − UHRF1BP1L 0x0 1479 chr12 100562243 100563428 − GOLGA2P5 0x0 1480 chr12 100672654 100673917 + SCYL2 0x0 1481 chr12 102599508 102600903 + PARPBP 0x0 1482 chr12 102606561 102607720 − PARPBP 0x0 1483 chr12 102819646 102820849 − IGF1 0x0 1484 chr12 104167901 104169068 − NTSDCS 0x0 1485 chr12 104324745 104325987 + HSP90B1 0x0 1486 chr12 104381637 104382863 + TDG 0x2 1487 chr12 104658682 104659889 + TXNRD1 0x0 1488 chr12 104714376 104715825 + TXNRD1 0x0 1489 chr12 104732514 104733718 + TXNRD1 0x0 1490 chr12 104742733 104744033 + TXNRD1 0x0 1491 chr12 105283361 105284557 + C12orf45 0x0 1492 chr12 105392116 105393273 + C12orf45 0x0 1493 chr12 105397776 105398870 + C12orf45 0x0 1494 chr12 105503187 105504415 + KIAA1033 0x0 1495 chr12 106631295 106632921 − CKAP4 0x0 1496 chr12 106872290 106873478 + POLR3B 0x0 1497 chr12 107347778 107348955 − MTERFD3 0x0 1498 chr12 107384669 107385818 − CRY1 0x0 1499 chr12 107951247 107952444 − BTBD11 0x0 1500 chr12 108917140 108918239 − SART3 0x0 1501 chr12 108953954 108955214 − SART3 0x0 1502 chr12 109038635 109040230 − CORO1C 0x0 1503 chr12 109312158 109313375 + DAO 0x0 1504 chr12 109636634 109637824 + ACACB 0x0 1505 chr12 109724629 109725961 − FOXN4 0x0 1506 chr12 109740686 109741911 − FOXN4 0x0 1507 chr12 109761616 109762830 + ACACB 0x0 1508 chr12 109973462 109974663 + UBE3B 0x0 1509 chr12 109994373 109995568 − MMAB 0x0 1510 chr12 110763655 110764854 + ATP2A2 0x2 1511 chr12 110777915 110779112 + ATP2A2 0x2 1512 chr12 110783912 110785278 + ATP2A2 0x2 1513 chr12 110824490 110826195 − ANAPC7 0x0 1514 chr12 111157924 111159308 − PPP1CC 0x0 1515 chr12 111855661 111856775 + SH2B3 0x0 1516 chr12 111948470 111949661 − ATXN2 0x0 1517 chr12 111958175 111959274 − ATXN2 0x0 1518 chr12 112460151 112461345 + ERP29 0x0 1519 chr12 112466354 112467513 − NAA25 0x0 1520 chr12 112467833 112468970 − NAA25 0x0 1521 chr12 112504368 112505565 − NAA25 0x0 1522 chr12 112510461 112511674 − NAA25 0x0 1523 chr12 112637375 112638555 − C12orf51 0x2 1524 chr12 112704325 112705613 + TRAFD1 0x0 1525 chr12 112746050 112747202 − C12orf51 0x2 1526 chr12 112911069 112912282 + PTPN11 0x2 1527 chr12 112944565 112946176 + PTPN11 0x2 1528 chr12 113673828 113675053 + TPCN1 0x0 1529 chr12 113735248 113736378 + TPCN1 0x0 1530 chr12 113874548 113875949 + SDSL 0x0 1531 chr12 115129856 115131062 + LOC255480 0x0 1532 chr12 116398477 116399619 − MED13L 0x0 1533 chr12 116433823 116435006 − MED13L 0x0 1534 chr12 117152663 117154080 − C12orf49 0x0 1535 chr12 117365284 117366523 + FBXW8 0x0 1536 chr12 118683520 118685251 + PEBP1 0x0 1537 chr12 119266964 119268147 + SRRM4 0x0 1538 chr12 120123558 120130500 − CIT 0x2 1539 chr12 120574832 120576057 − GCN1L1 0x0 1540 chr12 120592597 120594106 − GCN1L1 0x0 1541 chr12 120592597 120594106 − MIR4498 0x0 1542 chr12 120600352 120601529 − GCN1L1 0x0 1543 chr12 120636369 120637807 − RPLPO 0x0 1544 chr12 120659813 120661023 − PXN 0x0 1545 chr12 120719700 120720918 + S1RT4 0x0 1546 chr12 120729010 120730242 − PXN 0x0 1547 chr12 120730321 120731569 − PXN 0x0 1548 chr12 120779154 120780474 − MSI1 0x0 1549 chr12 120875360 120876560 + COX6A1 0x0 1550 chr12 120877815 120879006 + COX6A1 0x0 1551 chr12 120884509 120885705 + GATC 0x0 1552 chr12 120935439 120936770 + DYNLL1 0x0 1553 chr12 121124410 121125575 + MLEC 0x0 1554 chr12 121138015 121139114 + MLEC 0x0 1555 chr12 121159111 121160851 + UNC119B 0x0 1556 chr12 121201895 121203019 − SPPL3 0x0 1557 chr12 121308258 121309467 − SPPL3 0x0 1558 chr12 121314068 121315243 − SPPL3 0x0 1559 chr12 121676294 121677456 − CAMKK2 0x0 1560 chr12 122496860 122497973 + BCL7A 0x2 1561 chr12 122627621 122628772 + MLXIP 0x0 1562 chr12 122779092 122780309 − CLIP1 0x2 1563 chr12 122825134 122826272 − CLIP1 0x2 1564 chr12 123120516 123121672 + KNTC1 0x0 1565 chr12 123444050 123445230 − ABCB9 0x0 1566 chr12 123745288 123746440 − CDK2AP1 0x1 1567 chr12 123801208 123802366 − SBNO1 0x0 1568 chr12 123943066 123944289 + SNRNP35 0x0 1569 chr12 124081212 124082349 + TMED2 0x0 1570 chr12 124100782 124101965 + DDX55 0x0 1571 chr12 124145169 124146424 + GTF2H3 0x0 1572 chr12 124219151 124220344 + ATP6V0A2 0x0 1573 chr12 124854201 124855376 − NCOR2 0x0 1574 chr12 124903987 124905161 − NCOR2 0x0 1575 chr12 124915360 124916735 − NCOR2 0x0 1576 chr12 124922826 124924510 − NCOR2 0x0 1577 chr12 124979296 124980474 − NCOR2 0x0 1578 chr12 125261806 125262989 − SCARB1 0x0 1579 chr12 125339397 125340559 − SCARB1 0x0 1580 chr12 125397675 125398874 − UBC 0x0 1581 chr12 127649925 127651531 − LOC440117 0x0 1582 chr12 131358620 131359786 + RAN 0x0 1583 chr12 131359882 131362107 + RAN 0x0 1584 chr12 132589229 132590362 + EP400NL 0x0 1585 chr12 132638091 132639288 + NOC4L 0x0 1586 chr12 133159939 133161159 + FBRSL1 0x4 1587 chr12 133235503 133236603 − POLE 0x0 1588 chr12 133249065 133250242 − POLE 0x0 1589 chr12 133286628 133287809 + PGAM5 0x0 1590 chr12 133297027 133298212 + PGAM5 0x0 1591 chr12 133302273 133303436 − ANKLE2 0x0 1592 chr12 133340445 133341593 + PGAM5 0x0 1593 chr12 133346386 133347715 − GOLGA3 0x0 1594 chr12 133401746 133403135 + PGAM5 0x0 1595 chr13 20182187 20183387 + MPHOSPH8 0x0 1596 chr13 20198790 20199958 + MPHOSPH8 0x0 1597 chr13 21185776 21187001 + IFT88 0x1 1598 chr13 21535345 21536549 + SAP18 0x0 1599 chr13 21946854 21948041 − ZDHHC20 0x0 1600 chr13 21948636 21949812 − ZDHHC20 0x0 1601 chr13 21994684 21995835 − ZDHHC20 0x0 1602 chr13 23903680 23904855 − SACS 0x0 1603 chr13 23934784 23935912 − SACS 0x0 1604 chr13 24434695 24435873 − MIPEP 0x0 1605 chr13 24699699 24700878 − C1QTNF9B 0x0 1606 chr13 24796585 24798913 + SPATA13 0x2 1607 chr13 25470098 25471258 − CENPJ 0x0 1608 chr13 25670480 25671744 + PABPC3 0x2 1609 chr13 26853541 26854689 + CDK8 0x0 1610 chr13 26936737 26937942 + CDK8 0x0 1611 chr13 27694168 27695357 − USP12 0x0 1612 chr13 27827796 27830192 + RPL21 0x0 1613 chr13 27827796 27830192 + RPL21P28 0x0 1614 chr13 27827796 27830192 + SNORA27 0x0 1615 chr13 27827796 27830192 + SNORD102 0x0 1616 chr13 28007054 28008244 + GTF3A 0x0 1617 chr13 28563055 28564262 − PRHOXNB 0x0 1618 chr13 28712198 28713431 + PAN3 0x0 1619 chr13 30085991 30087580 − SLC7A1 0x0 1620 chr13 30106461 30107604 − SLC7A1 0x0 1621 chr13 30109547 30110829 − SLC7A1 0x0 1622 chr13 30814590 30815735 − KATNAL1 0x0 1623 chr13 31712045 31713225 − HSPH1 0x0 1624 chr13 34410120 34411619 + RFC3 0x0 1625 chr13 34497437 34498845 + RFCS 0x0 1626 chr13 34526824 34527999 + RFCS 0x0 1627 chr13 35939677 35940865 + NBEA 0x0 1628 chr13 37427215 37428396 − SMAD9 0x0 1629 chr13 37439099 37440278 − SMAD9 0x0 1630 chr13 41132450 41133622 − FOXO1 0x1 1631 chr13 41155039 41156154 − FOXO1 0x1 1632 chr13 41494897 41496052 − LOC100616668 0x0 1633 chr13 41494897 41496052 − SUGT1P3 0x0 1634 chr13 42352226 42353364 − KIAA0564 0x0 1635 chr13 42439523 42440727 − KIAA0564 0x0 1636 chr13 42893974 42895101 + AKAP11 0x2 1637 chr13 44168571 44169757 − ENOX1 0x0 1638 chr13 45575759 45576957 + KIAA1704 0x0 1639 chr13 45825141 45826367 + GTF2F2 0x0 1640 chr13 45910549 45912314 − SNORA31 0x0 1641 chr13 45910549 45912314 − TPT1 0x0 1642 chr13 46948034 46949263 − KIAA0226L 0x0 1643 chr13 49561491 49562687 + FNDC3A 0x0 1644 chr13 50587746 50588962 − DLEU2 0x1 1645 chr13 50656526 50657696 + DLEU1 0x1 1646 chr13 51323418 51324638 + RNASEH2B 0x0 1647 chr13 51837909 51839104 + FAM124A 0x0 1648 chr13 52987379 52988940 − VPS36 0x0 1649 chr13 53190495 53191693 + HNRNPA1L2 0x0 1650 chr13 60651419 60652765 − DIAPH3 0x0 1651 chr13 61015885 61017092 + TDRD3 0x0 1652 chr13 61125023 61126193 + TDRD3 0x0 1653 chr13 61363164 61364351 + TDRD3 0x0 1654 chr13 67840715 67841891 − PCDH9 0x0 1655 chr13 72228968 72230115 − DACH1 0x0 1656 chr13 72252217 72253358 − DACH1 0x0 1657 chr13 72388884 72389994 − DACH1 0x0 1658 chr13 72419172 72420352 − DACH1 0x0 1659 chr13 73282402 73283576 − MZT1 0x0 1660 chr13 73301105 73302258 − MZT1 0x0 1661 chr13 73308096 73309322 + BORA 0x0 1662 chr13 74505335 74506483 − KLF12 0x0 1663 chr13 75883686 75884853 − TBC1D4 0x0 1664 chr13 75935627 75936804 − TBC1D4 0x0 1665 chr13 76134337 76135485 + UCHL3 0x0 1666 chr13 76142156 76143379 + UCHL3 0x0 1667 chr13 76179345 76180503 + UCHL3 0x0 1668 chr13 76791681 76792834 + LMO7 0x2 1669 chr13 77459623 77460867 − KCTD12 0x0 1670 chr13 77581326 77582522 − FBXL3 0x0 1671 chr13 77592190 77593366 − FBXL3 0x0 1672 chr13 77730560 77731688 − MYCBP2 0x2 1673 chr13 79176171 79177675 − POU4F1 0x0 1674 chr13 79188083 79189266 − RNF219 0x0 1675 chr13 79888041 79889331 − RBM26 0x0 1676 chr13 79939705 79940928 − RBM26 0x0 1677 chr13 80071204 80072474 + NDFIP2 0x0 1678 chr13 92252899 92254129 + GPC5 0x0 1679 chr13 95840472 95841650 − ABCC4 0x0 1680 chr13 95868999 95870171 − ABCC4 0x0 1681 chr13 96293455 96294610 − DZIP1 0x0 1682 chr13 96855475 96856610 + HS6ST3 0x0 1683 chr13 97601125 97602326 − OXGR1 0x0 1684 chr13 98652227 98653437 + IPO5 0x0 1685 chr13 99104245 99105441 − STK24 0x0 1686 chr13 99205745 99206936 − STK24 0x0 1687 chr13 99323732 99324883 + FARP1 0x0 1688 chr13 99857416 99858783 + UBAC2 0x0 1689 chr13 99866861 99868315 − MIR548AN 0x0 1690 chr13 102651242 102652440 + ITGBL1 0x0 1691 chr13 103278915 103280017 − TPP2 0x0 1692 chr13 103355620 103356795 − METTL21C 0x0 1693 chr13 107210710 107211839 − ARGLU1 0x0 1694 chr13 108076427 108077608 − FAM155A 0x0 1695 chr13 108161143 108162342 − FAM155A 0x0 1696 chr13 108264790 108265967 − FAM155A 0x0 1697 chr13 108299224 108300407 − FAM155A 0x0 1698 chr13 109513961 109515157 − LIG4 0x0 1699 chr13 110435906 110437076 − IRS2 0x0 1700 chr13 110566925 110568267 + COL4A2 0x2 1701 chr13 111348428 111349606 − CARS2 0x0 1702 chr13 113598283 113599440 − MCF2L-AS1 0x0 1703 chr13 113833527 113834684 − PCID2 0x0 1704 chr13 113917507 113918650 + CUL4A 0x1 1705 chr13 113931038 113932264 + CUL4A 0x1 1706 chr13 114183681 114184915 + TMCO3 0x0 1707 chr13 114294691 114295879 + TFDP1 0x0 1708 chr14 20742356 20743528 − TTC5 0x0 1709 chr14 20790801 20792085 − CCNB1IP1 0x0 1710 chr14 20810712 20812122 − RPPH1 0x0 1711 chr14 20882556 20883783 + APEX1 0x0 1712 chr14 21081438 21082537 − RNASE12 0x0 1713 chr14 21100650 21101887 + ANG 0x0 1714 chr14 21120694 21121938 − OR6S1 0x0 1715 chr14 21127573 21128700 − OR6S1 0x0 1716 chr14 21130773 21132001 − OR6S1 0x0 1717 chr14 21149336 21150513 + ANG 0x0 1718 chr14 21150862 21152183 + ANG 0x0 1719 chr14 21701758 21702922 − HNRNPC 0x0 1720 chr14 21819168 21820374 − SUPT16H 0x0 1721 chr14 21883441 21884661 − CHD8 0x0 1722 chr14 21927022 21928341 − RAB2B 0x0 1723 chr14 21970840 21972169 − METTL3 0x2 1724 chr14 23398370 23399587 + REM2 0x0 1725 chr14 23534766 23535940 − ACIN1 0x2 1726 chr14 23539764 23541105 − ACIN1 0x2 1727 chr14 23794361 23795539 + BCL2L2-PABPN1 0x0 1728 chr14 23794361 23795539 + PABPN1 0x0 1729 chr14 23947343 23948545 + NGDN 0x0 1730 chr14 24736302 24737477 − RABGGTA 0x0 1731 chr14 24783279 24784402 + LTB4R 0x0 1732 chr14 24842532 24843745 + NFATC4 0x0 1733 chr14 24910543 24911763 − SDR39U1 0x0 1734 chr14 26150011 26151194 − 5TXBP6 0x0 1735 chr14 28733778 28735048 + FOXG1 0x4 1736 chr14 30270786 30271961 − PRKD1 0x2 1737 chr14 31070268 31071668 + G2E3 0x0 1738 chr14 31481080 31482291 − MIR624 0x0 1739 chr14 31585380 31586544 − HECTD1 0x0 1740 chr14 31919046 31920232 − C14orf126 0x0 1741 chr14 32589428 32590647 + ARHGAP5 0x0 1742 chr14 32803437 32804634 + AKAP6 0x2 1743 chr14 32853729 32854962 + AKAP6 0x2 1744 chr14 34929007 34930135 − SPTSSA 0x0 1745 chr14 35328000 35329104 + BAZ1A 0x0 1746 chr14 35857231 35858622 − NFKBIA 0x2 1747 chr14 36231437 36232687 − RALGAPA1 0x0 1748 chr14 39455981 39457143 + GEMIN2 0x0 1749 chr14 39617080 39618404 − TRAPPC6B 0x0 1750 chr14 39650236 39651971 + PNN 0x1 1751 chr14 39837183 39838385 + CTAGE5 0x0 1752 chr14 44660534 44661689 − FSCB 0x0 1753 chr14 45429705 45430918 − KLHL28 0x0 1754 chr14 45513128 45514344 + FAM179B 0x0 1755 chr14 45571192 45572327 + PRPF39 0x0 1756 chr14 45669258 45670454 + FANCM 0x2 1757 chr14 45860772 45861964 + FANCM 0x2 1758 chr14 50052744 50054179 + LRR1 0x0 1759 chr14 50072238 50073452 + LRR1 0x0 1760 chr14 50252419 50253619 − NEMF 0x0 1761 chr14 50283121 50284320 − NEMF 0x0 1762 chr14 50319903 50321149 − NEMF 0x0 1763 chr14 50328727 50329939 − NEMF 0x0 1764 chr14 50534715 50536100 + ARF6 0x0 1765 chr14 50867418 50868611 − CDKL1 0x0 1766 chr14 51255767 51256946 − NIN 0x2 1767 chr14 51464045 51465182 − TRIM9 0x0 1768 chr14 51574132 51575351 + TMX1 0x0 1769 chr14 51712422 51713625 + TMX1 0x0 1770 chr14 51715602 51716791 + TMX1 0x0 1771 chr14 51721809 51723001 + TMX1 0x0 1772 chr14 53010501 53011643 − TXNDC16 0x0 1773 chr14 53052610 53053853 + GPR137C 0x0 1774 chr14 53084258 53085453 + GPR137C 0x0 1775 chr14 53517339 53518466 − DDHD1 0x0 1776 chr14 54893869 54895013 − CNIH 0x0 1777 chr14 55119067 55120298 + SAMD4A 0x0 1778 chr14 56166774 56167972 + KTN1 0x2 1779 chr14 57746954 57748160 + MUDENG 0x0 1780 chr14 58645963 58647181 + ACTR10 0x0 1781 chr14 58706021 58707218 − FLJ31306 0x0 1782 chr14 60582184 60583444 + C14orf135 0x0 1783 chr14 60590498 60591850 + C14orf135 0x0 1784 chr14 60715423 60716633 + PPM1A 0x0 1785 chr14 60728399 60729605 + PPM1A 0x0 1786 chr14 63589788 63590983 + RHOJ 0x0 1787 chr14 64481686 64482836 + SYNE2 0x0 1788 chr14 64595923 64597126 + SYNE2 0x0 1789 chr14 64640181 64641308 + SYNE2 0x0 1790 chr14 64749029 64750351 − ESR2 0x1 1791 chr14 65590559 65591762 − MAX 0x0 1792 chr14 68265192 68266392 + RAD51B 0x2 1793 chr14 69259066 69260239 − ZFP36L1 0x2 1794 chr14 70235277 70236409 + SR5F5 0x0 1795 chr14 70827039 70828233 + ADAM21 0x0 1796 chr14 71050827 71051971 − MEDS 0x0 1797 chr14 73395835 73397193 − DPF3 0x0 1798 chr14 73637050 73638259 + PSEN1 0x0 1799 chr14 73658933 73660059 + PSEN1 0x0 1800 chr14 73750395 73751600 − NUMB 0x0 1801 chr14 75068529 75069738 − LTBP2 0x2 1802 chr14 75358451 75359654 + DLST 0x0 1803 chr14 75496694 75497909 − MLH3 0x0 1804 chr14 75575913 75577091 − NEK9 0x2 1805 chr14 75600401 75601539 − TMED10 0x0 1806 chr14 76528971 76530189 + IFT43 0x0 1807 chr14 76637656 76638879 + C14orf118 0x0 1808 chr14 76663629 76664745 + C14orf118 0x0 1809 chr14 77256334 77257559 − ANGEL1 0x0 1810 chr14 78173934 78175091 + SLIRP 0x0 1811 chr14 81668501 81669733 − SNORA79 0x0 1812 chr14 85737717 85738922 + FLRT2 0x0 1813 chr14 89043389 89044605 + ZC3H14 0x0 1814 chr14 89078709 89079907 + ZC3H14 0x0 1815 chr14 89299285 89300522 + TTC8 0x0 1816 chr14 90051483 90052669 + PRO1768 0x0 1817 chr14 90178358 90179578 + PRO1768 0x0 1818 chr14 90564181 90565327 − EFCAB11 0x0 1819 chr14 91816631 91817828 − CCDC88C 0x0 1820 chr14 93406578 93408201 − ITPK1 0x0 1821 chr14 95192789 95194001 + SERPINA13 0x0 1822 chr14 95999181 96000528 − SCARNA13 0x0 1823 chr14 95999181 96000528 − SNHG10 0x0 1824 chr14 96428328 96429515 − TCL1A 0x0 1825 chr14 96788184 96789377 − ATG2B 0x0 1826 chr14 96850446 96851673 + C14orf129 0x0 1827 chr14 97003083 97004318 + PAPOLA 0x0 1828 chr14 97299331 97300523 + VRK1 0x0 1829 chr14 97303953 97305166 + VRK1 0x0 1830 chr14 97588455 97589675 + VRK1 0x0 1831 chr14 99438779 99440087 − BCL11B 0x2 1832 chr14 99871011 99872156 − SETD3 0x0 1833 chr14 99927008 99928201 − SETD3 0x0 1834 chr14 99978119 99979271 − CCDC85C 0x0 1835 chr14 99980306 99981513 − CCDC85C 0x0 1836 chr14 100704883 100706065 + YY1 0x0 1837 chr14 102451533 102452778 + DYNC1H1 0x0 1838 chr14 102485774 102486912 + DYNC1H1 0x0 1839 chr14 102513570 102514767 + DYNC1H1 0x0 1840 chr14 102515579 102516643 + DYNC1H1 0x0 1841 chr14 102547003 102548556 − HSP90AA1 0x2 1842 chr14 102551792 102552968 − HSP90AA1 0x2 1843 chr14 102792163 102793304 + ZNF839 0x0 1844 chr14 102797439 102798576 + ZNF839 0x0 1845 chr14 102972147 102973298 − ANKRD9 0x0 1846 chr14 103284894 103286072 + TRAF3 0x2 1847 chr14 103375057 103376164 + TRAF3 0x2 1848 chr14 103601516 103602707 + TNFAIP2 0x0 1849 chr14 103803650 103804881 + EIF5 0x0 1850 chr14 103803650 103804881 + SNORA28 0x0 1851 chr14 103985494 103987405 − CKB 0x0 1852 chr14 104131617 104132836 − KLC1 0x0 1853 chr14 104378332 104379524 − C14orf2 0x0 1854 chr14 104479474 104480652 + TDRD9 0x0 1855 chr14 105235359 105236649 − AKT1 0x2 1856 chr14 105715971 105717135 − BRF1 0x1 1857 chr14 105716708 105717810 + BTBD6 0x0 1858 chr14 105752951 105754079 − BRF1 0x1 1859 chr14 105849686 105850785 + PACS2 0x0 1860 chr14 105926114 105927310 + MTA1 0x2 1861 chr14 105934900 105936046 + MTA1 0x2 1862 chr15 21936754 21937923 − LOC646214 0x0 1863 chr15 24925724 24926901 + C15orf2 0x2 1864 chr15 25683452 25684651 − UBE3A 0x4 1865 chr15 25781530 25782728 + SNORD109A 0x4 1866 chr15 25781530 25782728 + SNORD109B 0x4 1867 chr15 28491389 28492502 − HERC2 0x2 1868 chr15 28505439 28506582 − HERC2 0x2 1869 chr15 29335946 29337183 + APBA2 0x0 1870 chr15 29345646 29346846 + APBA2 0x0 1871 chr15 31745052 31746201 − OTUD7A 0x0 1872 chr15 34251063 34252240 − AVEN 0x0 1873 chr15 34633527 34634962 − NOP10 0x0 1874 chr15 34781617 34782779 − GOLGA8B 0x0 1875 chr15 37014652 37015883 + C15orf41 0x0 1876 chr15 37255197 37256324 − MEIS2 0x0 1877 chr15 40833292 40834457 − MRPL42P5 0x0 1878 chr15 41036799 41038022 − FAM82A2 0x0 1879 chr15 41270810 41271987 − INO80 0x0 1880 chr15 41315423 41316571 − INO80 0x0 1881 chr15 41683649 41684911 − NDUFAF1 0x0 1882 chr15 41987838 41989218 + MGA 0x2 1883 chr15 42002771 42004041 + MGA 0x2 1884 chr15 42620396 42621594 − GANC 0x0 1885 chr15 42706180 42707487 − ZFP106 0x0 1886 chr15 42962748 42963944 + STARD9 0x0 1887 chr15 43283722 43284928 − UBR1 0x2 1888 chr15 44038200 44039385 + PDIA3 0x0 1889 chr15 44093201 44094397 + C15orf63 0x0 1890 chr15 44093201 44094397 + SERF2-C15ORF63 0x0 1891 chr15 44243568 44244787 − FRMD5 0x0 1892 chr15 44707143 44708328 + CASC4 0x0 1893 chr15 44853224 44854435 + EIF3J 0x0 1894 chr15 44855288 44856463 + EIF3J 0x0 1895 chr15 45039370 45040570 + TRIM69 0x0 1896 chr15 45490204 45491403 − SHF 0x0 1897 chr15 45492010 45493176 − SHF 0x0 1898 chr15 45492781 45493978 + DUOX1 0x0 1899 chr15 47619874 47621023 + SEMA6D 0x0 1900 chr15 47699587 47700788 + SEMA6D 0x0 1901 chr15 48729413 48730591 − FBN1 0x0 1902 chr15 49170975 49172607 + EID1 0x2 1903 chr15 51223596 51224840 + AP4E1 0x0 1904 chr15 52841907 52843027 − ARPP13 0x0 1905 chr15 55874281 55875380 − PYGO1 0x0 1906 chr15 59040732 59041932 − ADAM10 0x2 1907 chr15 59431774 59432875 + CCNB2 0x0 1908 chr15 59968844 59970052 − BNIP2 0x0 1909 chr15 60576764 60577938 + FOXB1 0x0 1910 chr15 61501060 61510500 + RORA 0x0 1911 chr15 64791589 64792900 + ZNF609 0x0 1912 chr15 64856192 64857385 + ZNF609 0x0 1913 chr15 65587813 65589092 + KBTBD13 0x0 1914 chr15 65596449 65597712 + KBTBD13 0x0 1915 chr15 66433059 66434274 − MEGF11 0x0 1916 chr15 66496826 66498012 − MEGF11 0x0 1917 chr15 66637503 66638647 − SCARNA14 0x0 1918 chr15 66639053 66640252 − SCARNA14 0x0 1919 chr15 66792791 66794211 − RPL4 0x0 1920 chr15 66792791 66794211 − SNORD18C 0x0 1921 chr15 66794418 66796231 − RPL4 0x0 1922 chr15 66794418 66796231 − SNORD16 0x0 1923 chr15 66794418 66796231 − SNORD18A 0x0 1924 chr15 66794418 66796231 − SNORD18B 0x0 1925 chr15 67511428 67512557 − AAGAB 0x0 1926 chr15 68496759 68497953 − CALML4 0x0 1927 chr15 68499340 68500439 − CLN6 0x0 1928 chr15 68572922 68574070 + FEM1B 0x0 1929 chr15 69070758 69072796 − ANP32A 0x1 1930 chr15 69079609 69080756 − ANP32A 0x1 1931 chr15 69100468 69101612 − ANP32A-IT1 0x0 1932 chr15 69494074 69495240 + MIR548H4 0x0 1933 chr15 69738521 69739744 + KIF23 0x0 1934 chr15 69747224 69748423 + RPLP1 0x0 1935 chr15 70389486 70390685 − TLE3 0x0 1936 chr15 70481875 70483051 + C15orf50 0x0 1937 chr15 71456865 71458080 − CT62 0x0 1938 chr15 72337357 72338555 + SENP8 0x0 1939 chr15 72486311 72487490 − GRAMD2 0x0 1940 chr15 72490926 72492479 − PKM2 0x0 1941 chr15 72546097 72547249 − PARP6 0x0 1942 chr15 72766136 72767238 + ARIH1 0x0 1943 chr15 73043229 73044383 − ADPGK 0x0 1944 chr15 73408453 73409650 + NEO1 0x1 1945 chr15 74851876 74853097 + ARID3B 0x1 1946 chr15 75132127 75133316 − ULK3 0x0 1947 chr15 75628401 75629629 + COMMD4 0x0 1948 chr15 76584313 76585531 − ETFA 0x0 1949 chr15 77224273 77225393 + RCN2 0x1 1950 chr15 77337848 77339156 − TSPAN3 0x0 1951 chr15 77362838 77363961 − TSPAN3 0x0 1952 chr15 77969913 77971109 − LINGO1 0x0 1953 chr15 78833666 78834832 + PSMA4 0x0 1954 chr15 78881867 78883066 + CHRNA5 0x0 1955 chr15 78884931 78886120 + CHRNA5 0x0 1956 chr15 79152336 79153574 + MORF4L1 0x0 1957 chr15 80993689 80994882 + FAM108C1 0x0 1958 chr15 81270066 81271359 − MESDC2 0x0 1959 chr15 81557467 81558641 − STARD5 0x0 1960 chr15 82466075 82467253 − EFTUD1 0x0 1961 chr15 83684818 83686067 − BTBD1 0x0 1962 chr15 83857545 83858740 − HDGFRP3 0x0 1963 chr15 84515575 84516733 − LOC388152 0x0 1964 chr15 84819674 84820905 + LOC100505679 0x0 1965 chr15 85234210 85235385 − SEC11A 0x0 1966 chr15 85337100 85338312 + ZNF592 0x0 1967 chr15 85628321 85629513 + PDE8A 0x0 1968 chr15 86111157 86112347 + AKAP13 0x2 1969 chr15 86260146 86261296 + AKAP13 0x2 1970 chr15 88654304 88655504 + LOC283738 0x0 1971 chr15 89743411 89744512 + ABHD2 0x0 1972 chr15 89825525 89826904 + FANCI 0x0 1973 chr15 89859503 89860736 + FANCI 0x0 1974 chr15 89877748 89878974 + FANCI 0x0 1975 chr15 90146668 90147889 + C15orf42 0x0 1976 chr15 90610429 90611599 + ZNF710 0x0 1977 chr15 90814312 90815850 + NGRN 0x0 1978 chr15 90907212 90908788 + ZNF774 0x0 1979 chr15 91185812 91187013 + CRTC3 0x2 1980 chr15 91425207 91426364 + FURIN 0x0 1981 chr15 91432876 91434053 − HDDC3 0x0 1982 chr15 91478248 91479432 + UNC45A 0x0 1983 chr15 91516850 91517974 − PRC1 0x2 1984 chr15 93255471 93256642 + ASB9P1 0x0 1985 chr15 93586832 93588055 − RGMA 0x0 1986 chr15 96288506 96289758 + LOC145820 0x0 1987 chr15 100648661 100649816 − ADAMTS17 0x0 1988 chr15 100765299 100766413 − ADAMTS17 0x0 1989 chr15 100870564 100871790 − ADAMTS17 0x0 1990 chr15 101480773 101482171 + LRRK1 0x2 1991 chr15 101825007 101826228 − SNRPA1 0x0 1992 chr15 102181636 102182846 − TM2D3 0x0 1993 chr16 143816 144957 + MPG 0x0 1994 chr16 235472 236640 − LUC7L 0x0 1995 chr16 342848 344050 − AXIN1 0x1 1996 chr16 396145 397340 − AXIN1 0x1 1997 chr16 448859 451026 + NME4 0x0 1998 chr16 589506 590634 + MIR3176 0x0 1999 chr16 595185 596399 + SOLH 0x0 2000 chr16 601507 602707 + SOLH 0x0 2001 chr16 683792 685117 − C16orf13 0x0 2002 chr16 723557 724706 + RHOT2 0x0 2003 chr16 733573 734707 − JMJD8 0x0 2004 chr16 733573 734707 − WDR24 0x0 2005 chr16 783112 784246 − NARFL 0x0 2006 chr16 787182 788296 − NARFL 0x0 2007 chr16 841316 842543 + CHTF18 0x0 2008 chr16 941830 943035 − LMF1 0x0 2009 chr16 1419680 1420859 − UNKL 0x0 2010 chr16 1509920 1511053 − CLCN7 0x0 2011 chr16 1793752 1795078 + MAPK8IP3 0x2 2012 chr16 2011358 2012506 + NDUFB10 0x0 2013 chr16 2012334 2013692 − RPS2 0x0 2014 chr16 2012334 2013692 − SNORA10 0x0 2015 chr16 2012334 2013692 − SNORA64 0x0 2016 chr16 2127155 2128344 + TSC2 0x1 2017 chr16 2129738 2130819 + TSC2 0x1 2018 chr16 2204448 2205682 − SNORD60 0x0 2019 chr16 2262814 2263925 − PGP 0x0 2020 chr16 2302820 2304024 − RNPS1 0x0 2021 chr16 2325778 2326930 − ABCA3 0x0 2022 chr16 2507661 2508867 + CCNF 0x0 2023 chr16 2551481 2552720 + TBC1D24 0x0 2024 chr16 2669190 2670380 − ERVK13-1 0x0 202S chr16 2816749 2818757 + SRRM2 0x0 2026 chr16 3103594 3104769 − CCDC64B 0x0 2027 chr16 3135604 3136834 + IL32 0x0 2028 chr16 3183893 3185039 − MGC3771 0x0 2029 chr16 3206822 3207998 − MGC3771 0x0 2030 chr16 3707612 3708771 − TRAP1 0x0 2031 chr16 3738655 3739754 − TRAP1 0x0 2032 chr16 3776638 3777807 − CREBBP 0x1 2033 chr16 3853492 3854682 − CREBBP 0x1 2034 chr16 3899742 3901495 − CREBBP 0x1 2035 chr16 4312072 4313247 − TFAP4 0x0 2036 chr16 4585148 4586317 − C16orf5 0x0 2037 chr16 4631453 4632577 − FAM100A 0x0 2038 chr16 4780498 4781691 − ANKS3 0x0 2039 chr16 4809968 4811154 − ZNF500 0x0 2040 chr16 4930725 4931953 + UBN1 0x0 2041 chr16 9202390 9203489 + C16orf72 0x0 2042 chr16 9732686 9733886 + MIR548X 0x0 2043 chr16 10623788 10625100 − EMP2 0x0 2044 chr16 11118150 11119355 + CLEC16A 0x0 2045 chr16 11795285 11796473 − TXNDC11 0x0 2046 chr16 11982629 11983709 − GSPT1 0x0 2047 chr16 11989914 11991031 − GSPT1 0x0 2048 chr16 14247481 14248682 + MKL2 0x0 2049 chr16 15154201 15155400 − RRN3 0x0 2050 chr16 15224518 15225828 − MIR3180-4 0x0 2051 chr16 15959530 15960686 − FOPNL 0x0 2052 chr16 16103077 16104257 + ABCC1 0x0 2053 chr16 16180120 16181312 + ABCC1 0x0 2054 chr16 16231673 16232855 + ABCC1 0x0 2055 chr16 18367186 18368355 + ABCC6P1 0x0 2056 chr16 18795494 18796703 − RPS15A 0x0 2057 chr16 21964106 21965352 − UQCRC2 0x2 2058 chr16 22206429 22207666 − CDR2 0x0 2059 chr16 22236504 22237625 − EEF2K 0x0 2060 chr16 23154325 23155505 − USP31 0x0 2061 chr16 23443115 23444292 + SCNN1B 0x0 2062 chr16 23455520 23456673 − COG7 0x0 2063 chr16 23518784 23519913 − GGA2 0x0 2064 chr16 26772167 26773347 − NSMCE1 0x0 2065 chr16 28109306 28110513 − XPO6 0x0 2066 chr16 28165013 28166113 − XPO6 0x0 2067 chr16 28172868 28174090 + SBK1 0x0 2068 chr16 28178211 28179388 − XPO6 0x0 2069 chr16 28222170 28223312 − XPO6 0x0 2070 chr16 28488127 28489342 − CLN3 0x0 2071 chr16 28502619 28503773 − CLN3 0x0 2072 chr16 28735596 28736768 + EIF3C 0x0 2073 chr16 28735596 28736768 + EIF3CL 0x0 2074 chr16 29620126 29621279 − SLC7A5P1 0x0 2075 chr16 29818410 29819625 + MAZ 0x0 2076 chr16 29821157 29822740 + MAZ 0x0 2077 chr16 29830643 29831878 + C16orf53 0x0 2078 chr16 29830643 29831878 + MVP 0x0 2079 chr16 30076596 30077792 + ALDOA 0x0 2080 chr16 30078033 30079171 + ALDOA 0x0 2081 chr16 30079608 30080725 + ALDOA 0x0 2082 chr16 30345960 30347162 − LOC595101 0x0 2083 chr16 30367895 30369061 − TBC1D10B 0x0 2084 chr16 30369950 30371830 − TBC1D10B 0x0 2085 chr16 30482481 30483615 + ITGAL 0x0 2086 chr16 30662533 30663730 + PRR14 0x0 2087 chr16 30680929 30682096 + FBRS 0x0 2088 chr16 30721321 30722534 + SNORA30 0x0 2089 chr16 30721321 30722534 + SRCAP 0x0 2090 chr16 30734492 30735698 + SRCAP 0x0 2091 chr16 30749886 30751115 + SRCAP 0x0 2092 chr16 30762261 30763449 + PHKG2 0x0 2093 chr16 30785855 30786949 + RNF40 0x0 2094 chr16 30898461 30899560 − BCL7C 0x0 2095 chr16 30995147 30996395 + SETD1A 0x0 2096 chr16 31055455 31056660 + STX4 0x0 2097 chr16 31101627 31103190 − VKORC1 0x0 2098 chr16 33959014 33960199 − LINC00273 0x0 2099 chr16 33963060 33964589 + LOC283914 0x0 2100 chr16 46946475 46947651 + GPT2 0x0 2101 chr16 46949560 46950994 + GPT2 0x0 2102 chr16 47161753 47162900 − NETO2 0x0 2103 chr16 47176155 47177315 − NETO2 0x0 2104 chr16 47502596 47503917 + PHKB 0x0 2105 chr16 47530809 47531908 + PHKB 0x0 2106 chr16 48277848 48278972 + LONP2 0x0 2107 chr16 48387030 48388180 + LONP2 0x0 2108 chr16 49557027 49558211 − ZNF423 0x0 2109 chr16 49604532 49605679 − ZNF423 0x0 2110 chr16 50138880 50140042 + HEATR3 0x0 2111 chr16 53468212 53469426 + RBL2 0x1 2112 chr16 54018126 54019355 + FTO 0x0 2113 chr16 57333351 57334551 + ARL2BP 0x0 2114 chr16 57333796 57335000 − PLLP 0x0 2115 chr16 57770451 57771687 + KATNB1 0x0 2116 chr16 58194850 58196051 − CSNK2A2 0x0 2117 chr16 58506204 58507370 + NDRG4 0x1 2118 chr16 58581850 58583095 − SNORA46 0x0 2119 chr16 58593207 58594416 − CNOT1 0x2 2120 chr16 58593207 58594416 − SNORA50 0x0 2121 chr16 58636236 58637361 − CNOT1 0x2 2122 chr16 59573507 59574718 + SETD6 0x0 2123 chr16 61776537 61777739 − CDH8 0x0 2124 chr16 66583830 66585064 + CKLF 0x0 2125 chr16 66583830 66585064 + CKLF-CMTM1 0x0 2126 chr16 66651623 66652756 − CMTM4 0x0 2127 chr16 66857453 66858552 − NAE1 0x0 2128 chr16 67355018 67356243 − KCTD19 0x0 2129 chr16 67644395 67645577 − ACD 0x4 2130 chr16 67644742 67646514 + CTCF 0x1 2131 chr16 67670055 67671257 + CTCF 0x1 2132 chr16 68155794 68157476 + NFATC3 0x0 2133 chr16 68537173 68538388 + ZFP90 0x0 2134 chr16 69362090 69363244 − COG8 0x0 2135 chr16 69362090 69363244 − PDF 0x0 2136 chr16 69375976 69377216 + NIP7 0x0 2137 chr16 69641676 69642775 + NFAT5 0x0 2138 chr16 70282376 70283535 − EXOSC6 0x0 2139 chr16 70380666 70382034 + DDX19A 0x0 2140 chr16 70412278 70413437 − ST3GAL2 0x0 2141 chr16 70567748 70568934 + SF3B3 0x0 2142 chr16 70598735 70599882 + SF3B3 0x0 2143 chr16 70600812 70601947 + SF3B3 0x0 2144 chr16 70724351 70725450 − VAC14 0x0 2145 chr16 72238271 72239450 − PMFBP1 0x0 2146 chr16 72984070 72985255 − ZFHX3 0x1 2147 chr16 72990914 72992079 − ZFHX3 0x1 2148 chr16 72992940 72994069 − ZFHX3 0x1 2149 chr16 73047809 73049165 − ZFHX3 0x1 2150 chr16 74714271 74715389 − MLKL 0x0 2151 chr16 75289855 75291011 − BCAR1 0x0 2152 chr16 79630494 79631584 − MAF 0x1 2153 chr16 81030333 81031467 − CMC2 0x0 2154 chr16 81744479 81745663 + CMIP 0x0 2155 chr16 81995033 81996350 + PLCG2 0x2 2156 chr16 82195015 82196190 − MPHOSPH6 0x0 2157 chr16 84216501 84217600 − TAF1C 0x0 2158 chr16 84734892 84736093 + USP10 0x0 2159 chr16 84778008 84779365 + USP10 0x0 2160 chr16 85244625 85245831 + LOC400548 0x0 2161 chr16 85394186 85395412 + LINC00311 0x0 2162 chr16 85443986 85445195 + LINC00311 0x0 2163 chr16 85660061 85661260 + KIAA0182 0x0 2164 chr16 85808485 85809616 − COX4NB 0x0 2165 chr16 87364296 87365490 − FBXO31 0x1 2166 chr16 87398201 87399306 − FBXO31 0x1 2167 chr16 87469465 87470642 − ZCCHC14 0x0 2168 chr16 87737922 87739118 − KLHDC4 0x0 2169 chr16 88060540 88061765 + BANP 0x1 2170 chr16 88083221 88084320 + BANP 0x1 2171 chr16 88817646 88818825 − PIEZO1 0x0 2172 chr16 88872808 88873963 + CDT1 0x0 2173 chr16 89164503 89165709 + ACSF3 0x0 2174 chr16 89371092 89372297 − ANKRD11 0x0 2175 chr16 89497144 89498290 − ANKRD11 0x0 2176 chr16 89543379 89550500 − ANKRD11 0x0 2177 chr16 89595342 89596458 + SPG7 0x0 2178 chr16 89627259 89628503 + RPL13 0x0 2179 chr16 89627259 89628503 + SNORD68 0x0 2180 chr16 89629746 89630946 + RPL13 0x0 2181 chr16 89720957 89722136 + C16orf55 0x0 2182 chr16 89759982 89761224 + CDK10 0x0 2183 chr16 89762227 89763431 − SPATA2L 0x0 2184 chr16 89783657 89784775 + LOC100128881 0x0 2185 chr16 89803908 89805002 + ZNF276 0x0 2186 chr16 89804541 89805669 − FANCA 0x2 2187 chr16 89830638 89831758 − FANCA 0x2 2188 chr16 89835725 89837364 − FANCA 0x2 2189 chr16 89851003 89852132 − FANCA 0x2 2190 chr16 89960891 89962086 + TCF25 0x0 2191 chr16 89966465 89967671 + TCF25 0x0 2192 chr16 89975246 89976652 − TCF25 0x0 2193 chr16 90019017 90020436 + DEF8 0x0 2194 chr16 90027401 90028606 + DEF8 0x0 2195 chr16 90071461 90072626 − DBNDD1 0x0 2196 chr16 90094687 90095934 + GAS8 0x0 2197 chr17 420039 421215 − VPS53 0x1 2198 chr17 421588 422752 − VPS53 0x1 2199 chr17 809734 810881 − NXN 0x0 2200 chr17 877224 878419 + TIMM22 0x0 2201 chr17 906054 907251 + TIMM22 0x0 2202 chr17 907914 909091 − ABR 0x0 2203 chr17 975303 976505 − ABR 0x0 2204 chr17 1247548 1249295 − YWHAE 0x2 2205 chr17 1302901 1304079 − YWHAE 0x2 2206 chr17 1367797 1369135 − MYO1C 0x0 2207 chr17 1870297 1871457 − RTN4RL1 0x0 2208 chr17 2091648 2092874 + SRR 0x0 2209 chr17 2202637 2203736 − SMG6 0x0 2210 chr17 2231890 2233069 − SNORD91B 0x0 2211 chr17 2231890 2233069 − TSR1 0x0 2212 chr17 2289272 2290479 − MNT 0x0 2213 chr17 2758169 2759392 + RAP1GAP2 0x0 2214 chr17 3727428 3728604 − C17orf85 0x0 2215 chr17 3774868 3776203 − CAMKK1 0x0 2216 chr17 3989255 3990394 − ZZEF1 0x2 2217 chr17 4848985 4850149 − PFN1 0x1 2218 chr17 4927219 4928332 + KIF1C 0x2 2219 chr17 5011951 5013308 − ZNF232 0x0 2220 chr17 5192114 5193285 + RABEP1 0x2 2221 chr17 5347087 5348274 − DHX33 0x0 2222 chr17 7128624 7130033 − DVL2 0x0 2223 chr17 7143329 7144561 − GABARAP 0x1 2224 chr17 7214768 7215867 + EIF5A 0x2 2225 chr17 7310728 7311838 + NLGN2 0x0 2226 chr17 7477573 7478698 + EIF4A1 0x0 2227 chr17 7477573 7478598 + SENP3-EIF4A1 0x0 2228 chr17 7477573 7478698 + SNORA48 0x0 2229 chr17 7479570 7481901 + EIF4A1 0x0 2230 chr17 7479570 7481901 + SENP3-EIF4A1 0x0 2231 chr17 7479570 7481901 + SNORA67 0x0 2232 chr17 7479570 7481901 + SNORD10 0x0 2233 chr17 7571798 7572976 − TP53 0x1 2234 chr17 7759946 7761139 − LSMD1 0x0 2235 chr17 7809090 7810209 + CHD3 0x2 2236 chr17 7809090 7810209 + SCARNA21 0x0 2237 chr17 7848570 7849762 + CNTROB 0x0 2238 chr17 8023063 8024273 − HES7 0x0 2239 chr17 8023683 8024894 + MIR4314 0x0 2240 chr17 8076195 8077469 − TMEM107 0x0 2241 chr17 8089692 8090869 + MIR3676 0x0 2242 chr17 8089692 8090869 + MIR4521 0x0 2243 chr17 8377996 8379137 − MYH10 0x0 2244 chr17 14608210 14609470 − CDRT15 0x0 2245 chr17 15918092 15919219 + TTC19 0x0 2246 chr17 16132196 16133391 + PIGL 0x0 2247 chr17 16343991 16345208 + C17orf76-AS1 0x0 2248 chr17 16343991 16345208 + SNORD65 0x0 2249 chr17 17089072 17090238 + MPRIP 0x0 2250 chr17 17286493 17287902 − C0PS3 0x2 2251 chr17 17634942 17636091 + RAI1 0x0 2252 chr17 17999746 18000896 + DRG2 0x0 2253 chr17 18111909 18113101 + ALKBH5 0x0 2254 chr17 18177405 18178544 − TOP3A 0x0 2255 chr17 18562696 18563882 + ZNF286B 0x0 2256 chr17 18964696 18965964 + SLC5A10 0x0 2257 chr17 19015303 19016503 − GRAP 0x0 2258 chr17 19090777 19092061 + GRAPL 0x0 2259 chr17 19092840 19094050 − GRAP 0x0 2260 chr17 19349188 19350394 − MFAP4 0x0 2261 chr17 19355037 19356234 + RNF112 0x0 2262 chr17 19568464 19569565 + ALDH3A2 0x0 2263 chr17 20903023 20904171 − USP22 0x0 2264 chr17 26368250 26369432 + NLK 0x0 2265 chr17 26794566 26795779 + SLC13A2 0x0 2266 chr17 26918992 26920362 − SPAG5 0x0 2267 chr17 26959602 26960700 − KIAA0100 0x0 2268 chr17 27047016 27048207 + RPL23A 0x0 2269 chr17 27047016 27048207 + SNORD42B 0x0 2270 chr17 27049068 27051266 + RPL23A 0x0 2271 chr17 27049068 27051266 + SNORD42A 0x0 2272 chr17 27049068 27051266 + SNORD4A 0x0 2273 chr17 27049068 27051266 + SNORD4B 0x0 2274 chr17 27076052 27077263 + TRAF4 0x0 2275 chr17 27134427 27135693 − C17orf63 0x0 2276 chr17 27206815 27207989 − FLOT2 0x0 2277 chr17 27250434 27251617 − PHF12 0x0 2278 chr17 27330860 27332058 − SEZ6 0x0 2279 chr17 27586017 27587151 − NUFIP2 0x0 2280 chr17 27589485 27590890 − NUFIP2 0x0 2281 chr17 27597552 27598763 − NUFIP2 0x0 2282 chr17 27613073 27614247 − NUFIP2 0x0 2283 chr17 27620125 27621304 − NUFIP2 0x0 2284 chr17 27876749 27877967 + TAOK1 0x0 2285 chr17 28793244 28794488 + CPD 0x2 2286 chr17 29151064 29152280 − CRLF3 0x0 2287 chr17 29876577 29877796 + MIR193A 0x0 2288 chr17 30178363 30179685 − C17orf79 0x0 2289 chr17 30322093 30323192 + SUZ12 0x2 2290 chr17 30323258 30324460 + SUZ12 0x2 2291 chr17 30327053 30328256 + SUZ12 0x2 2292 chr17 30701748 30703107 + ZNF207 0x0 2293 chr17 30729721 30730945 + ZNF207 0x0 2294 chr17 31149233 31150434 + TMEM98 0x0 2295 chr17 33338521 33339709 − RAD51L3-RFFL 0x0 2296 chr17 33338521 33339709 − RFFL 0x0 2297 chr17 33477601 33478846 − NLE1 0x0 2298 chr17 34005816 34007062 + AP281 0x0 2299 chr17 34051812 34052960 + AP281 0x0 2300 chr17 34216112 34217346 + TAF15 0x0 2301 chr17 34867890 34869254 − MYO19 0x0 2302 chr17 35463729 35464880 − ACACA 0x0 2303 chr17 35609261 35610459 − ACACA 0x0 2304 chr17 36907500 36908659 − PCGF2 0x1 2305 chr17 36923201 36924315 − PIP4K2B 0x0 2306 chr17 36933509 36934767 − PIP4K2B 0x0 2307 chr17 37008384 37009879 − RPL23 0x0 2308 chr17 37008384 37009879 − SNORA21 0x0 2309 chr17 37310065 37311369 − ARL5C 0x0 2310 chr17 37360307 37361530 + RPL19 0x0 2311 chr17 38187243 38188407 − MED24 0x0 2312 chr17 38292372 38293524 + MSL1 0x0 2313 chr17 38544516 38546023 − TOP2A 0x0 2314 chr17 38546963 38548087 − TOP2A 0x0 2315 chr17 38555669 38556813 − TOP2A 0x0 2316 chr17 39623661 39624919 + LOC100505782 0x0 2317 chr17 39682054 39683217 − KRT19 0x0 2318 chr17 39919253 39920390 − JUP 0x1 2319 chr17 39976137 39977291 + FKBP10 0x0 2320 chr17 40022691 40023931 − ACLY 0x0 2321 chr17 40041357 40042582 − ACLY 0x0 2322 chr17 40051029 40052128 − ACLY 0x0 2323 chr17 40066060 40067304 − ACLY 0x0 2324 chr17 40150541 40151724 − DNAJC7 0x0 2325 chr17 40276463 40277602 − RAB5C 0x0 2326 chr17 40997873 40999063 + AOC2 0x0 2327 chr17 41166535 41167621 − VAT1 0x0 2328 chr17 41464126 41465330 − LOC100130581 0x0 2329 chr17 41477626 41478857 + ARL4D 0x0 2330 chr17 41893195 41894405 − MPP3 0x1 2331 chr17 42124839 42126012 − LSM12 0x0 2332 chr17 42143070 42144243 − LSM12 0x0 2333 chr17 42269530 42270800 − ATXN7L3 0x0 2334 chr17 42283758 42284942 − UBTF 0x0 2335 chr17 42291123 42292222 − UBTF 0x0 2336 chr17 42429663 42430895 − GRN 0x0 2337 chr17 42472130 42475225 − GPATCH8 0x0 2338 chr17 42563669 42564836 − GPATCH8 0x0 2339 chr17 42858464 42859563 − ADAM11 0x0 2340 chr17 42927693 42928792 − EFTUD2 0x0 2341 chr17 43011561 43012778 − KIF18B 0x0 2342 chr17 43112655 43113866 − DCAKD 0x0 2343 chr17 43127402 43129550 − DCAKD 0x0 2344 chr17 43158651 43159849 + NMT1 0x0 2345 chr17 43188503 43189680 − PLCD3 0x0 2346 chr17 43552039 43553599 − MIR4315-1 0x0 2347 chr17 43552039 43553599 − MIR4315-2 0x0 2348 chr17 43552039 43553599 − PLEKHM1 0x0 2349 chr17 44107289 44109182 − KANSL1 0x0 2350 chr17 44121458 44122619 − KANSL1 0x0 2351 chr17 44143350 44144558 − KANSL1 0x0 2352 chr17 44235813 44236965 − KANSL1 0x0 2353 chr17 44248825 44250127 − KANSL1 0x0 2354 chr17 44892011 44893187 + WNT9B 0x0 2355 chr17 45700639 45701871 + NPEPPS 0x0 2356 chr17 45740976 45743040 + KPNB1 0x0 2357 chr17 45749870 45751463 + KPNB1 0x0 2358 chr17 45759557 45760750 + KPNB1 0x0 2359 chr17 46048089 46049200 + CDK5RAP3 0x0 2360 chr17 46146996 46148371 − CBX1 0x0 2361 chr17 46555948 46557104 + HOXB-AS3 0x0 2362 chr17 46672630 46673780 − HOXB6 0x0 2363 chr17 46674823 46676013 − HOXB6 0x0 2364 chr17 46689629 46690750 − HOXB8 0x0 2365 chr17 46698671 46699886 − HOXB9 0x0 2366 chr17 47026177 47027373 − SNF8 0x0 2367 chr17 47102139 47103238 + IGF2BP1 0x0 2368 chr17 47103331 47104443 + IGF2BP1 0x0 2369 chr17 47128290 47131034 + IGF2BP1 0x0 2370 chr17 47269322 47270552 + ABI3 0x2 2371 chr17 47370381 47371514 − ZNF652 0x0 2372 chr17 47438823 47439984 − ZNF652 0x0 2373 chr17 47698699 47699875 − SPOP 0x2 2374 chr17 48211639 48212824 − PPP1R9B 0x0 2375 chr17 48458394 48459935 − LRRC59 0x0 2376 chr17 49238557 49239765 + NME1 0x1 2377 chr17 49238557 49239765 + NME1-NME2 0x0 2378 chr17 49243309 49244511 + NME1-NME2 0x0 2379 chr17 49243309 49244511 + NME2 0x0 2380 chr17 50173256 50174452 + UTP18 0x0 2381 chr17 54908462 54909643 − C17orf67 0x0 2382 chr17 54965631 54966927 − TRIM25 0x0 2383 chr17 55536824 55538020 + MSI2 0x0 2384 chr17 55756729 55757945 + MSI2 0x0 2385 chr17 55760969 55762149 + MSI2 0x0 2386 chr17 55866332 55867485 + MSI2 0x0 2387 chr17 56078023 56079230 − SRSF1 0x2 2388 chr17 56081814 56083329 − SRSF1 0x2 2389 chr17 56083848 56084941 − SRSF1 0x2 2390 chr17 56566533 56567635 − MTMR4 0x0 2391 chr17 56902493 56903592 + PPM1E 0x2 2392 chr17 57188247 57189567 − SKA2 0x0 2393 chr17 57317303 57318598 + GDPD1 0x0 2394 chr17 57474126 57475693 + YPEL2 0x0 2395 chr17 57684974 57686173 + DHX40 0x0 2396 chr17 57771333 57772704 + CLTC 0x2 2397 chr17 57808269 57809459 + VMP1 0x0 2398 chr17 57957769 57958998 − TUBD1 0x0 2399 chr17 58010067 58011229 + RPS6KB1 0x2 2400 chr17 58308321 58309557 − SCARNA20 0x0 2401 chr17 58448595 58449725 − USP32 0x0 2402 chr17 58710732 58711871 + PPM1D 0x2 2403 chr17 59275968 59277116 + BCAS3 0x0 2404 chr17 59316760 59318001 + BCAS3 0x0 2405 chr17 59432076 59433255 − NACA2 0x0 2406 chr17 59821357 59822521 − BRIP1 0x2 2407 chr17 60023113 60024212 − MED13 0x0 2408 chr17 60086819 60087918 − MED13 0x0 2409 chr17 60100732 60101884 − MED13 0x0 2410 chr17 60458542 60459757 + EFCAB3 0x0 2411 chr17 60480366 60481496 − TBC1D3P2 0x0 2412 chr17 60555248 60556357 − TBC1D3P2 0x0 2413 chr17 60610210 60611437 + TLK2 0x0 2414 chr17 60641806 60643010 + TLK2 0x0 2415 chr17 61043429 61044634 + TANC2 0x0 2416 chr17 61554766 61555995 − ACE 0x2 2417 chr17 61668036 61669123 + DCAF7 0x0 2418 chr17 61706281 61707494 − MAP3K3 0x0 2419 chr17 61799111 61800221 − STRADA 0x0 2420 chr17 61823148 61824382 − CCDC47 0x0 2421 chr17 61909439 61910644 − SMARCD2 0x0 2422 chr17 62134563 62135698 − ERN1 0x0 2423 chr17 62222870 62224324 + SNORA76 0x0 2424 chr17 62222870 62224324 + SNORD104 0x0 2425 chr17 62247937 62249096 − TEX2 0x0 2426 chr17 62496606 62498485 − DDX5 0x2 2427 chr17 62496606 62498485 − MIR3064 0x0 2428 chr17 62496606 62498485 − MIR5047 0x0 2429 chr17 62498499 62499684 − DDX5 0x2 2430 chr17 62575922 62577102 − SMURF2 0x2 2431 chr17 62942866 62944035 − AMZ2P1 0x0 2432 chr17 64263301 64264539 + PRKCA 0x0 2433 chr17 64436881 64438060 + PRKCA 0x0 2434 chr17 64530427 64531606 + PRKCA 0x0 2435 chr17 65168688 65169857 − HELZ 0x0 2436 chr17 65292355 65293532 − PSMD12 0x0 2437 chr17 65336211 65337416 − PSMD12 0x0 2438 chr17 65409593 65410812 + PITPNC1 0x0 2439 chr17 65736243 65737466 + SNORA38B 0x0 2440 chr17 65821694 65822893 + BPTF 0x2 2441 chr17 65849813 65851009 + BPTF 0x2 2442 chr17 65959757 65960975 + BPTF 0x2 2443 chr17 66015434 66016611 − C17orf58 0x0 2444 chr17 66042188 66043393 + KPNA2 0x0 2445 chr17 66122069 66123217 + LOC100499466 0x0 2446 chr17 66527202 66528626 + PRKAR1A 0x1 2447 chr17 72199262 72200454 + RPL38 0x0 2448 chr17 72833367 72834565 + TMEM104 0x0 2449 chr17 73029927 73031118 − ATP5H 0x0 2450 chr17 73037405 73038494 + KCTD2 0x0 2451 chr17 73131557 73132694 − HN1 0x0 2452 chr17 73178426 73179605 − SUMO2 0x0 2453 chr17 73218498 73219694 + NUP85 0x0 2454 chr17 73227391 73228588 + NUP85 0x0 2455 chr17 73313814 73314889 − GRB2 0x2 2456 chr17 73455722 73456919 + KIAA0195 0x0 2457 chr17 73773957 73775044 − H3F3B 0x0 2458 chr17 73807721 73808921 + UNK 0x0 2459 chr17 73895087 73896240 − MRPL38 0x0 2460 chr17 73937435 73938595 − ACOX1 0x0 2461 chr17 74077015 74078380 − EXOC7 0x0 2462 chr17 74084980 74086079 − EXOC7 0x0 2463 chr17 74086438 74087537 − EXOC7 0x0 2464 chr17 74138610 74139786 − RNF157 0x0 2465 chr17 74140038 74141515 − RNF157 0x0 2466 chr17 74288029 74289169 − QRICH2 0x0 2467 chr17 74326348 74327468 − PRPSAP1 0x0 2468 chr17 74391748 74392886 − UBE2O 0x2 2469 chr17 74554334 74555523 + LOC100507246 0x0 2470 chr17 74554334 74555523 + SNORD1C 0x0 2471 chr17 74559655 74561651 + LOC100507246 0x0 2472 chr17 74670186 74671261 − MXRA7 0x0 2473 chr17 74671792 74672890 − MXRA7 0x0 2474 chr17 74731497 74732605 − MIR636 0x0 2475 chr17 74731497 74732605 − SRSF2 0x2 2476 chr17 75084818 75086125 + LINC00338 0x0 2477 chr17 75084818 75086125 + SCARNA16 0x0 2478 chr17 75084818 75086125 + SEC14L1 0x0 2479 chr17 75157550 75158929 − MIR4316 0x0 2480 chr17 75437613 75438794 + SEPT9 0x2 2481 chr17 75495129 75496821 + SEPT9 0x2 2482 chr17 75816292 75817394 + FLJ45079 0x0 2483 chr17 76027252 76028462 + TNRC6C 0x0 2484 chr17 76105054 76106203 + TNRC6C 0x0 2485 chr17 76219271 76221106 + BIRC5 0x0 2486 chr17 76396238 76397436 + PGS1 0x0 2487 chr17 76670230 76671405 − CYTH1 0x0 2488 chr17 76706536 76707691 − CYTH1 0x0 2489 chr17 76810010 76811142 − USP36 0x0 2490 chr17 76848640 76849834 − TIMP2 0x0 2491 chr17 76968262 76969430 − LGALS3BP 0x0 2492 chr17 76987582 76988709 − CANT1 0x2 2493 chr17 77081695 77082911 + ENGASE 0x0 2494 chr17 77751447 77752559 + CBX2 0x0 2495 chr17 77908923 77910604 − TBC1D16 0x0 2496 chr17 77911036 77912202 − TBC1D16 0x0 2497 chr17 78079141 78080240 + GAA 0x0 2498 chr17 78441438 78444535 − NPTX1 0x0 2499 chr17 78518341 78519546 + RPTOR 0x0 2500 chr17 78521208 78522403 + RPTOR 0x0 2501 chr17 78900830 78902034 + RPTOR 0x0 2502 chr17 79180215 79181398 − AZI1 0x0 2503 chr17 79222243 79223442 + C17orf89 0x0 2504 chr17 79224181 79225386 − SLC38A10 0x0 2505 chr17 79231888 79233044 − SLC38A10 0x0 2506 chr17 79249251 79250465 − SLC38A10 0x0 2507 chr17 79362635 79363814 − MIR4740 0x0 2508 chr17 79431650 79432774 + BAHCC1 0x0 2509 chr17 79476602 79478114 − ACTG1 0x0 2510 chr17 79480417 79481633 − ACTG1 0x0 2511 chr17 79503071 79504238 − C17orf70 0x0 2512 chr17 79516997 79518173 − C17orf70 0x0 2513 chr17 79524060 79525921 − NPLOC4 0x0 2514 chr17 79538509 79539655 − NPLOC4 0x0 2515 chr17 79571064 79572231 − NPLOC4 0x0 2516 chr17 79660352 79661562 + HGS 0x0 2517 chr17 79668356 79669552 + HGS 0x0 2518 chr17 79686704 79687912 + SLC25A10 0x0 2519 chr17 79766882 79768094 + GCGR 0x0 2520 chr17 79779775 79780909 − FAM195B 0x0 2521 chr17 79785791 79787099 − FAM195B 0x0 2522 chr17 79800553 79801723 − P4HB 0x0 2523 chr17 79802990 79804345 − P4HB 0x0 2524 chr17 79824534 79825654 + ANAPC11 0x0 2525 chr17 79839418 79840516 − ALYREF 0x0 2526 chr17 79842416 79844483 − ALYREF 0x0 2527 chr17 79845379 79846425 − ALYREF 0x0 2528 chr17 79851805 79853110 + ANAPC11 0x0 2529 chr17 79872229 79873547 − SIRT7 0x0 2530 chr17 79957605 79958704 + ASPSCR1 0x0 2531 chr17 79990233 79991418 + RAC3 0x0 2532 chr17 80007055 80008185 − RFNG 0x0 2533 chr17 80008514 80009655 − RFNG 0x0 2534 chr17 80020966 80022173 − DUS1L 0x0 2535 chr17 80035753 80036898 − FASN 0x0 2536 chr17 80038577 80039772 − FASN 0x0 2537 chr17 80041094 80042193 − FASN 0x0 2538 chr17 80048397 80049582 − FASN 0x0 2539 chr17 80051030 80052507 − FASN 0x0 2540 chr17 80055526 80056564 − FASN 0x0 2541 chr17 80093530 80094678 − CCDC57 0x0 2542 chr17 80111293 80112455 − CCDC57 0x0 2543 chr17 80203472 80204534 − CSNK1D 0x0 2544 chr17 80212410 80213512 − CSNK1D 0x0 2545 chr17 80221639 80222776 − CSNK1D 0x0 2546 chr17 80540194 80541386 + FOXK2 0x0 2547 chr17 80552134 80553370 + FOXK2 0x0 2548 chr17 80559523 80560801 + FOXK2 0x0 2549 chr17 80572648 80573867 − WDR45L 0x0 2550 chr17 80675431 80676530 + FN3KRP 0x0 2551 chr17 80723624 80724793 + TBCD 0x0 2552 chr17 80725741 80726938 + TBCD 0x0 2553 chr17 80879768 80880945 + TBCD 0x0 2554 chr17 80922711 80923915 − B3GNTL1 0x0 2555 chr18 261064 262183 − THOC1 0x0 2556 chr18 319122 320335 − COLEC12 0x0 2557 chr18 421767 422978 − COLEC12 0x0 2558 chr18 721629 722906 − YES1 0x0 2559 chr18 759931 761128 − YES1 0x0 2560 chr18 2380851 2382070 + NDC80 0x2 2561 chr18 5840188 5841409 + MIR3976 0x0 2562 chr18 6301429 6302684 − L3MBTL4 0x1 2563 chr18 6310997 6312174 − L3MBTL4 0x1 2564 chr18 9399920 9401153 + TWSG1 0x0 2565 chr18 9524016 9525208 + RALBP1 0x0 2566 chr18 9535748 9536953 + RALBP1 0x0 2567 chr18 9569916 9571148 − PPP4R1 0x0 2568 chr18 9710586 9711734 + RAB31 0x0 2569 chr18 9861621 9862813 + RAB31 0x0 2570 chr18 9953971 9955154 + VAPA 0x0 2571 chr18 10532844 10534018 + NAPG 0x0 2572 chr18 12309965 12311147 + TUBB6 0x0 2573 chr18 12446096 12447328 − SPIRE1 0x0 2574 chr18 12455237 12456416 − SPIRE1 0x0 2575 chr18 12546141 12547368 − SPIRE1 0x0 2576 chr18 12934265 12935389 + SEH1L 0x0 2577 chr18 13681472 13682627 − FAM210A 0x0 2578 chr18 19348091 19349274 + MIB1 0x0 2579 chr18 19353015 19354226 + MIB1 0x0 2580 chr18 19358990 19360117 + MIB1 0x0 2581 chr18 19409262 19410364 + MIB1 0x0 2582 chr18 19446390 19447573 + MIB1 0x0 2583 chr18 20714978 20716166 + CABLES1 0x1 2584 chr18 20780816 20782005 + CABLES1 0x1 2585 chr18 21191142 21192365 + LAMA3 0x0 2586 chr18 21938451 21939627 − OSBPL1A 0x0 2587 chr18 23597385 23598512 − SS18 0x0 2588 chr18 29204767 29205899 − B4GALT6 0x0 2589 chr18 29298411 29299551 + TTR 0x0 2590 chr18 29451847 29452976 − TRAPPC8 0x0 2591 chr18 29691209 29692408 + RNF138 0x0 2592 chr18 31433808 31435029 − NOL4 0x0 2593 chr18 31608188 31609387 − ASXL3 0x0 2594 chr18 32470630 32471818 + DTNA 0x2 2595 chr18 33571402 33572486 − RPRD1A 0x0 2596 chr18 33594761 33595888 − RPRD1A 0x0 2597 chr18 34478931 34480136 + KIAA1328 0x0 2598 chr18 34701645 34702810 + KIAA1328 0x0 2599 chr18 36880605 36881780 − LOC647946 0x0 2600 chr18 37308446 37309672 − LOC647946 0x0 2601 chr18 37324791 37325970 − LOC647946 0x0 2602 chr18 42374366 42375584 − SETBP1 0x0 2603 chr18 43668976 43670384 − ATP5A1 0x0 2604 chr18 43671168 43672337 − ATP5A1 0x0 2605 chr18 43953766 43954965 + RNF165 0x0 2606 chr18 45422404 45423676 − SMAD2 0x1 2607 chr18 47015074 47016220 − RPL17 0x0 2608 chr18 47015074 47016220 − RPL17-C18ORF32 0x0 2609 chr18 47015074 47016220 − SNORD58C 0x0 2610 chr18 47017102 47018645 − RPL17 0x0 2611 chr18 47017102 47018645 − RPL17-C18ORF32 0x0 2612 chr18 47017102 47018645 − SNORD58A 0x0 2613 chr18 47017102 47018645 − SNORD58B 0x0 2614 chr18 47340026 47341285 + SCARNA17 0x0 2615 chr18 48558068 48559169 + SMAD4 0x1 2616 chr18 48702628 48703803 − MEX3C 0x0 2617 chr18 51748117 51749303 − SNORA37 0x0 2618 chr18 54269694 54270879 − TXNL1 0x0 2619 chr18 54433380 54434591 + WDR7 0x0 2620 chr18 55143632 55144824 + ONECUT2 0x0 2621 chr18 55150433 55151555 + ONECUT2 0x0 2622 chr18 55269173 55270333 − NARS 0x0 2623 chr18 56806600 56807800 + SEC11C 0x0 2624 chr18 56995198 56996412 − LMAN1 0x0 2625 chr18 60865174 60866368 − BCL2 0x2 2626 chr18 60997925 60999189 − KDSR 0x0 2627 chr18 61056709 61057890 − VPS4B 0x0 2628 chr18 65183056 65184215 − DSEL 0x0 2629 chr18 66525652 66526789 + CCDC102B 0x0 2630 chr18 67140788 67141996 + DOK6 0x0 2631 chr18 68179463 68180631 + SOCS6 0x0 2632 chr18 71958541 71959718 − CYB5A 0x0 2633 chr18 72370379 72371580 + ZNF407 0x2 2634 chr18 72673866 72675068 + ZNF407 0x2 2635 chr18 74153275 74154425 − ZNF516 0x0 2636 chr18 77169917 77171163 + NFATC1 0x0 2637 chr18 77226859 77228067 + NFATC1 0x0 2638 chr18 77740134 77741271 − TXNL4A 0x0 2639 chr18 77772388 77773636 + RBFA 0x0 2640 chr18 77869933 77871914 + ADNP2 0x0 2641 chr19 433713 434965 − SHC2 0x0 2642 chr19 572067 573237 + BSG 0x0 2643 chr19 582401 583822 + BSG 0x0 2644 chr19 647243 648413 − RNF126 0x0 2645 chr19 660054 661181 − RNF126 0x0 2646 chr19 738533 739809 + PALM 0x0 2647 chr19 797449 798548 + PTBP1 0x0 2648 chr19 807100 808347 + PTBP1 0x0 2649 chr19 811324 812518 + PTBP1 0x0 2650 chr19 863453 864557 − MED16 0x0 2651 chr19 864586 865775 − MED16 0x0 2652 chr19 876524 877713 − MED16 0x0 2653 chr19 896103 897244 − R3HDM4 0x0 2654 chr19 916775 917954 + KISS1R 0x0 2655 chr19 974159 975320 + ARID3A 0x0 2656 chr19 1009824 1010928 − C19orf6 0x0 2657 chr19 1087248 1088492 − POLR2E 0x0 2658 chr19 1106011 1107109 + GPX4 0x0 2659 chr19 1144281 1145432 − SBNO2 0x0 2660 chr19 1159004 1160170 − SBNO2 0x0 2661 chr19 1231861 1233081 − C19orf26 0x0 2662 chr19 1252042 1253161 − C19orf26 0x0 2663 chr19 1258064 1259192 + MIDN 0x0 2664 chr19 1271892 1273420 + CIRBP 0x0 2665 chr19 1383048 1384244 + NDUFS7 0x0 2666 chr19 1408226 1409407 + DAZAP1 0x0 2667 chr19 1576222 1578329 − MBD3 0x0 2668 chr19 1584613 1587222 − MBD3 0x0 2669 chr19 1591066 1592308 − MBD3 0x0 2670 chr19 1609021 1611339 − TCF3 0x2 2671 chr19 1852619 1853804 − KLF16 0x0 2672 chr19 1985081 1986305 − BTBD2 0x0 2673 chr19 2037117 2039388 − MKNK2 0x0 2674 chr19 2194712 2195943 + DOT1L 0x0 2675 chr19 2206903 2208036 + DOT1L 0x0 2676 chr19 2230429 2232621 + DOT1L 0x0 2677 chr19 2232946 2234118 − MIR1227 0x0 2678 chr19 2232946 2234118 − PLEKHJ1 0x0 2679 chr19 2248798 2250016 + AMH 0x1 2680 chr19 2271337 2273780 + OAZ1 0x0 2681 chr19 2323614 2324827 − LSM7 0x0 2682 chr19 2327666 2328831 − LSM7 0x0 2683 chr19 2426336 2427443 − TIMM13 0x0 2684 chr19 2428253 2431164 − LMNB2 0x0 2685 chr19 2754228 2756106 − SGTA 0x0 2686 chr19 3023431 3024607 − TLE2 0x0 2687 chr19 3121993 3123177 + GNA11 0x2 2688 chr19 3208205 3209304 + NCLN 0x0 2689 chr19 3434561 3435750 + NFIC 0x0 2690 chr19 3621899 3623077 − C19orf29 0x0 2691 chr19 3660460 3661587 − PIP5K1C 0x0 2692 chr19 3975699 3978729 − EEF2 0x0 2693 chr19 3978771 3979956 − EEF2 0x0 2694 chr19 3980845 3983477 − EEF2 0x0 2695 chr19 3980845 3983477 − SNORD37 0x0 2696 chr19 4027433 4028579 + PIAS4 0x0 2697 chr19 4034724 4035823 + PIAS4 0x0 2698 chr19 4047304 4048448 − ZBTB7A 0x0 2699 chr19 4055272 4056464 − ZBTB7A 0x0 2700 chr19 4062229 4063364 − ZBTB7A 0x0 2701 chr19 4101878 4102995 − MAP2K2 0x0 2702 chr19 4110028 4111458 − MAP2K2 0x0 2703 chr19 4116961 4118119 − MAP2K2 0x0 2704 chr19 4310496 4311645 + FSD1 0x0 2705 chr19 4322332 4323445 + FSD1 0x0 2706 chr19 4359894 4360966 − SH3GL1 0x2 2707 chr19 4366582 4367670 − SH3GL1 0x2 2708 chr19 4429995 4431094 + CHAF1A 0x0 2709 chr19 4440953 4442054 + CHAF1A 0x0 2710 chr19 4561124 4562302 − SEMA6B 0x0 2711 chr19 4654640 4655802 + TNFAIP8L1 0x0 2712 chr19 4657317 4658465 − C19orf10 0x0 2713 chr19 4917576 4918740 + UHRF1 0x0 2714 chr19 4939459 4940559 + UHRF1 0x0 2715 chr19 4944246 4945392 + UHRF1 0x0 2716 chr19 4985938 4987096 + KDM4B 0x0 2717 chr19 5046939 5048139 + KDM4B 0x0 2718 chr19 5133469 5134656 + KDM4B 0x0 2719 chr19 5134771 5135966 + KDM4B 0x0 2720 chr19 5205586 5206716 − PTPRS 0x2 2721 chr19 5266837 5267994 − PTPRS 0x2 2722 chr19 5273735 5274901 − PTPRS 0x2 2723 chr19 5325308 5326490 − PTPRS 0x2 2724 chr19 5336090 5337290 − PTPRS 0x2 2725 chr19 5566085 5567294 − PLAC2 0x0 2726 chr19 5652831 5654001 + SAFB 0x1 2727 chr19 5667676 5668949 + SAFB 0x1 2728 chr19 5667701 5668881 − C19orf70 0x0 2729 chr19 5679163 5680303 − C19orf70 0x0 2730 chr19 5689972 5692190 + RPL36 0x0 2731 chr19 5709498 5710708 − LONP1 0x0 2732 chr19 5805513 5806703 + NRTN 0x0 2733 chr19 6012390 6013607 − RFX2 0x2 2734 chr19 6210117 6211258 − MLLT1 0x2 2735 chr19 6211446 6213296 − MLLT1 0x2 2736 chr19 6221935 6223135 − MLLT1 0x2 2737 chr19 6413133 6415362 − KHSRP 0x2 2738 chr19 6453951 6455214 − SLC25A23 0x0 2739 chr19 6493985 6495204 − TUBB4A 0x0 2740 chr19 7114169 7115339 − INSR 0x0 2741 chr19 7124438 7125655 − INSR 0x0 2742 chr19 7988914 7990981 − CTXN1 0x0 2743 chr19 7991707 7992856 − TIMM44 0x0 2744 chr19 8024767 8025863 − ELAVL1 0x0 2745 chr19 8026719 8028012 − ELAVL1 0x0 2746 chr19 8468497 8469678 + RAB11B 0x0 2747 chr19 8553318 8554417 + HNRNPM 0x0 2748 chr19 9680260 9681437 − ZNF121 0x0 2749 chr19 9784612 9785787 − ZNF562 0x0 2750 chr19 9937238 9938414 − FBXL12 0x0 2751 chr19 9938053 9939209 + UBL5 0x0 2752 chr19 9950227 9951326 + PIN1 0x0 2753 chr19 10217776 10218974 + PPAN 0x0 2754 chr19 10217776 10218974 + PPAN-P2RY11 0x0 2755 chr19 10217776 10218974 + SNORD105 0x0 2756 chr19 10227061 10228280 − EIF3G 0x0 2757 chr19 10243711 10244899 − DNMT1 0x4 2758 chr19 10250997 10252088 − DNMT1 0x4 2759 chr19 10369710 10370861 + MRPL4 0x0 2760 chr19 10421479 10422676 − FDX1L 0x0 2761 chr19 10427503 10428656 − RAVER1 0x0 2762 chr19 10463325 10464506 − TYK2 0x0 2763 chr19 10501355 10502667 − CDC37 0x0 2764 chr19 10777886 10779078 + ILF3 0x0 2765 chr19 10795337 10796433 + ILF3 0x0 2766 chr19 10800973 10802039 + ILF3 0x0 2767 chr19 11032246 11033452 + CARM1 0x0 2768 chr19 11082469 11083677 + SMARCA4 0x1 2769 chr19 11107671 11108841 + SMARCA4 0x1 2770 chr19 11133693 11134778 + SMARCA4 0x1 2771 chr19 11223722 11224919 + LDLR 0x0 2772 chr19 11257228 11258356 − SPC24 0x0 2773 chr19 11455424 11456815 − TMEM205 0x0 2774 chr19 11474649 11475822 + LPPR2 0x0 2775 chr19 11518907 11520144 + PRKCSH 0x0 2776 chr19 11546281 11547487 + PRKCSH 0x0 2777 chr19 11560498 11562101 + PRKCSH 0x0 2778 chr19 11663922 11665073 − ELOF1 0x0 2779 chr19 11925496 11926700 + ZNF440 0x0 2780 chr19 12698834 12699974 − ZNF490 0x0 2781 chr19 12809813 12812031 − TNPO2 0x0 2782 chr19 12813855 12815063 − TNPO2 0x0 2783 chr19 12821562 12822732 − TNPO2 0x0 2784 chr19 12825352 12826594 − TNPO2 0x0 2785 chr19 12840942 12842171 − C19orf43 0x0 2786 chr19 13038666 13039865 − FARSA 0x0 2787 chr19 13040558 13041695 − FARSA 0x0 2788 chr19 13054508 13055694 + CALR 0x2 2789 chr19 13135373 13136566 + NFIX 0x0 2790 chr19 13219864 13221182 − TRMT1 0x0 2791 chr19 13229656 13230815 + NACC1 0x0 2792 chr19 13249505 13250603 + NACC1 0x0 2793 chr19 13264394 13265575 + IER2 0x0 2794 chr19 13883248 13884372 + MRI1 0x0 2795 chr19 13923224 13924434 + ZSWIM4 0x0 2796 chr19 14198159 14199558 − SAMD1 0x0 2797 chr19 14200909 14202105 − SAMD1 0x0 2798 chr19 14293844 14294997 − LPHN1 0x2 2799 chr19 14579728 14580828 + PKN1 0x2 2800 chr19 14581976 14583102 + PKN1 0x2 2801 chr19 14588668 14589819 − GIPC1 0x0 2802 chr19 14625659 14625906 − DNAJB1 0x0 2803 chr19 14732536 14733997 + CLEC17A 0x0 2804 chr19 15270591 15271715 − NOTCH3 0x0 2805 chr19 15465179 15466371 − AKAP8 0x2 2806 chr19 15468886 15470088 − AKAP8 0x2 2807 chr19 15513523 15514703 − AKAP8L 0x0 2808 chr19 16212928 16214130 + TPM4 0x0 2809 chr19 16345227 16346378 + AP1M1 0x0 2810 chr19 16376027 16377201 − CIB3 0x0 2811 chr19 16470042 16471169 − EPS15L1 0x0 2812 chr19 16651975 16653236 − CHERP 0x0 2813 chr19 16737773 16738944 − MED26 0x0 2814 chr19 16790289 16791467 + TMEM38A 0x0 2815 chr19 17212335 17213596 + MYO9B 0x0 2816 chr19 17391547 17392710 + ANKLE1 0x0 2817 chr19 17416651 17417847 + MRPL34 0x0 2818 chr19 17692166 17693768 + GLT25D1 0x0 2819 chr19 17874502 17875704 + FCHO1 0x0 2820 chr19 17972879 17974106 + RPL18A 0x0 2821 chr19 17972879 17974106 + SNORA68 0x0 2822 chr19 18245096 18246253 + MAST3 0x0 2823 chr19 18390080 18391372 − JUND 0x0 2824 chr19 18418226 18419383 − LSM4 0x0 2825 chr19 18546682 18547816 − ISYNA1 0x0 2826 chr19 18649873 18651098 − FKBP8 0x0 2827 chr19 18652180 18653326 − FKBP8 0x0 2828 chr19 18679220 18680543 + KXD1 0x0 2829 chr19 18884271 18885435 + CRTC1 0x2 2830 chr19 19035880 19037084 + DDX49 0x0 2831 chr19 19108089 19109247 − SUGP2 0x0 2832 chr19 19120195 19121638 − SUGP2 0x0 2833 chr19 19152147 19153382 + ARMC6 0x0 2834 chr19 19170255 19171474 + ARMC6 0x0 2835 chr19 19246414 19248580 − TMEM161A 0x0 2836 chr19 19407380 19408591 − SUGP1 0x0 2837 chr19 19515851 19517059 + GATAD2A 0x0 2838 chr19 19565218 19566440 + GATAD2A 0x0 2839 chr19 19606355 19607510 + GATAD2A 0x0 2840 chr19 19618774 19619862 + GATAD2A 0x0 2841 chr19 19641808 19642907 + YJEFN3 0x0 2842 chr19 19709318 19710495 − PBX4 0x0 2843 chr19 21207859 21209170 + ZNF430 0x0 2844 chr19 21289831 21291024 + ZNF714 0x0 2845 chr19 22877044 22878262 − ZNF99 0x0 2846 chr19 24009538 24011365 + RPSAP58 0x0 2847 chr19 24183115 24184722 − LOC100101266 0x0 2848 chr19 30499618 30500671 + URI1 0x0 2849 chr19 30824657 30825856 + ZNF536 0x2 2850 chr19 33077622 33078844 + PDCD5 0x0 2851 chr19 33188805 33189954 + NUDT19 0x0 2852 chr19 33460137 33461317 − CEP89 0x0 2853 chr19 33791628 33792820 − CEBPA 0x1 2854 chr19 34304490 34305768 + KCTD15 0x0 2855 chr19 34718119 34719264 + LSM14A 0x0 2856 chr19 34858984 34860104 + GPI 0x0 2857 chr19 34890809 34892921 + GPI 0x0 2858 chr19 34925241 34926410 + UBA2 0x0 2859 chr19 34940655 34941844 + UBA2 0x0 2860 chr19 35503647 35504748 − GRAMD1A 0x0 2861 chr19 35769770 35771106 + USF2 0x0 2862 chr19 36065946 36067217 + TMEM147 0x0 2863 chr19 36123827 36124926 + RBM42 0x0 2864 chr19 36148991 36150113 + COX6B1 0x0 2865 chr19 36212927 36214148 + MLL4 0x0 2866 chr19 36582377 36583533 + WDR62 0x0 2867 chr19 36631344 36632542 + CAPNS1 0x0 2868 chr19 38431494 38432690 + SIPA1L3 0x0 2869 chr19 39326617 39327844 − HNRNPL 0x0 2870 chr19 39337434 39338533 − HNRNPL 0x0 2871 chr19 39410724 39412282 − SARS2 0x0 2872 chr19 39676724 39677915 + PAK4 0x0 2873 chr19 39797108 39798331 − LRFN1 0x0 2874 chr19 39888164 39889343 + MED29 0x2 2875 chr19 39902265 39903407 − MIR4530 0x0 2876 chr19 39923315 39924524 − RPS16 0x0 2877 chr19 39976373 39977573 + TIMM50 0x0 2878 chr19 40324585 40325684 − DYRK1B 0x0 2879 chr19 40324585 40325684 − FBI 0x0 2880 chr19 40697581 40698898 + MAP3K10 0x0 2881 chr19 40738955 40740117 − AKT2 0x2 2882 chr19 40783554 40784768 − MIR641 0x0 2883 chr19 40784791 40786415 − MIR641 0x0 2884 chr19 40789643 40791062 − AKT2 0x2 2885 chr19 40821326 40822426 − C19orf47 0x0 2886 chr19 40826618 40827833 − C19orf47 0x0 2887 chr19 40871081 40872319 + PLD3 0x0 2888 chr19 41307405 41308504 − EGLN2 0x0 2889 chr19 41307405 41308504 + RAB4B-EGLN2 0x0 2890 chr19 41313315 41314483 + EGLN2 0x0 2891 chr19 41313315 41314483 + RAB4B-EGLN2 0x0 2892 chr19 41784451 41785650 + HNRNPUL1 0x0 2893 chr19 41800880 41802017 + HNRNPUL1 0x0 2894 chr19 41812393 41813671 + HNRNPUL1 0x0 2895 chr19 41815425 41816747 − TGFB1 0x1 2896 chr19 41829951 41831140 − CCDC97 0x0 2897 chr19 42069747 42070918 − CEACAM4 0x0 2898 chr19 42364262 42365484 + RPS19 0x0 2899 chr19 42375951 42377127 + RPS19 0x0 2900 chr19 42751641 42752823 − ERF 0x1 2901 chr19 42792581 42793913 + CIC 0x2 2902 chr19 42838329 42840427 + MEGF8 0x0 2903 chr19 42853211 42854995 + MEGF8 0x0 2904 chr19 42881170 42882304 + MEGF8 0x0 2905 chr19 42937196 42938377 + MEGF8 0x0 2906 chr19 43909808 43910977 + TEX101 0x0 2907 chr19 44046898 44048117 − XRCC1 0x0 2908 chr19 44111103 44112238 − ZNF428 0x0 2909 chr19 44677729 44678937 + ZNF226 0x2 2910 chr19 45489903 45491113 + CLPTM1 0x0 2911 chr19 45637271 45638417 + PPP1R37 0x0 2912 chr19 45981284 45982504 − RTN2 0x0 2913 chr19 46055463 46056676 − OPA3 0x0 2914 chr19 46191155 46192341 − SNRPD2 0x0 2915 chr19 46285399 46290500 − DMPK 0x0 2916 chr19 46285399 46290500 − DMWD 0x0 2917 chr19 46361925 46363145 + FOXA3 0x0 2918 chr19 45403964 46405141 − MYPOP 0x0 2919 chr19 46441853 46443027 − NOVA2 0x0 2920 chr19 47112545 47113889 + CALM3 0x0 2921 chr19 47219629 47220775 − PRKD2 0x0 2922 chr19 47230409 47231590 − STRN4 0x0 2923 chr19 47234518 47235724 − STRN4 0x0 2924 chr19 47277768 47279296 − SLC1A5 0x0 2925 chr19 47287026 47288125 − SLC1A5 0x0 2926 chr19 47290828 47292007 − SLC1A5 0x0 2927 chr19 47421491 47422610 + ARHGAP35 0x1 2928 chr19 47505828 47507452 + ARHGAP35 0x1 2929 chr19 47571603 47572761 − ZC3H4 0x0 2930 chr19 47633618 47634854 + SAE1 0x0 2931 chr19 47857790 47859035 + DHX34 0x0 2932 chr19 47884204 47885407 + DHX34 0x0 2933 chr19 47995135 47996311 − NAPA 0x0 2934 chr19 48179700 48180894 + GLTSCR1 0x1 2935 chr19 48258914 48260113 + GLTSCR2 0x1 2936 chr19 48258914 48260113 + SNORD23 0x0 2937 chr19 48287091 48288282 + SEPW1 0x0 2938 chr19 48426524 48427748 + SNAR-A10 0x0 2939 chr19 48426524 48427748 + SNAR-A11 0x0 2940 chr19 48426524 48427748 + SNAR-A14 0x0 2941 chr19 48426524 48427748 + SNAR-A3 0x0 2942 chr19 48426524 48427748 + SNAR-A4 0x0 2943 chr19 48426524 48427748 + SNAR-A5 0x0 2944 chr19 48426524 48427748 + SNAR-A6 0x0 2945 chr19 48426524 48427748 + SNAR-A7 0x0 2946 chr19 48426524 48427748 + SNAR-A8 0x0 2947 chr19 48426524 48427748 + SNAR-A9 0x0 2948 chr19 48638772 48639948 − LIG1 0x0 2949 chr19 48640427 48641526 − LIG1 0x0 2950 chr19 48642529 48643725 − LIG1 0x0 2951 chr19 48704862 48706055 − CARD8 0x0 2952 chr19 48885682 48886906 − KDELR1 0x0 2953 chr19 48893193 48894425 − KDELR1 0x0 2954 chr19 49118619 49120644 − RPL18 0x0 2955 chr19 49297824 49298967 − BCAT2 0x0 2956 chr19 49303599 49304778 − BCAT2 0x0 2957 chr19 49425423 49426724 + NUCB1 0x0 2958 chr19 49469028 49470166 + FTL 0x0 2959 chr19 49471950 49473128 − GYS1 0x0 2960 chr19 49588237 49589435 + SNRNP70 0x0 2961 chr19 49592075 49593223 + SNRNP70 0x0 2962 chr19 49607258 49608427 + SNRNP70 0x0 2963 chr19 49645121 49646312 + PPFIA3 0x0 2964 chr19 49670843 49672015 + TRPM4 0x0 2965 chr19 49863523 49864822 − TEAD2 0x0 2966 chr19 49955965 49957142 + ALDH16A1 0x0 2967 chr19 49992705 49993802 + RPL13A 0x0 2968 chr19 49992705 49993802 + RPL13AP5 0x0 2969 chr19 49992705 49993802 + SNORD32A 0x0 2970 chr19 49994537 49995624 + RPL13A 0x0 2971 chr19 49994537 49995624 + RPL13AP5 0x0 2972 chr19 50000608 50001855 + RPS11 0x0 2973 chr19 50000608 50001855 + SNORD35B 0x0 2974 chr19 50002222 50003374 + RPS11 0x0 2975 chr19 50028948 50030116 + FCGRT 0x0 2976 chr19 50098847 50100070 − PRR12 0x0 2977 chr19 50104606 50105797 + PRR12 0x0 2978 chr19 50125677 50126919 + PRR12 0x0 2979 chr19 50359518 50362672 − PTOV1 0x0 2980 chr19 50409664 50411091 − NUP62 0x0 2981 chr19 52381165 52382302 − ZNF577 0x0 2982 chr19 52729015 52730190 + PPP2R1A 0x2 2983 chr19 53226284 53227434 − ZNF611 0x0 2984 chr19 54462756 54463932 + CACNG8 0x0 2985 chr19 54605893 54607047 + NDUFA3 0x0 2986 chr19 54704517 54705652 + RPS9 0x0 2987 chr19 54710900 54712000 + RPS9 0x0 2988 chr19 54969341 54970479 + LENG8 0x0 2989 chr19 54972309 54973633 + LENG8 0x0 2990 chr19 55559299 55560476 − RDH13 0x0 2991 chr19 55897400 55898599 + RPL28 0x0 2992 chr19 55899145 55900296 + RPL28 0x0 2993 chr19 55900600 55901783 + RPL28 0x0 2994 chr19 55945818 55947059 + ZNF628 0x0 2995 chr19 55978495 55979717 + ZNF628 0x0 2996 chr19 55997742 55999096 + NAT14 0x0 2997 chr19 56090628 56091988 − ZNF579 0x0 2998 chr19 56172904 56173985 + U2AF2 0x2 2999 chr19 56185234 56186475 + U2AF2 0x2 3000 chr19 56667669 56668775 + ZNF444 0x0 3001 chr19 57725909 57727008 + ZNF264 0x4 3002 chr19 57910640 57911792 + ZNF548 0x0 3003 chr19 57973839 57975442 − ZNF772 0x0 3004 chr19 57979307 57980462 − ZNF772 0x0 3005 chr19 58217480 58218587 + ZNF551 0x0 3006 chr19 58280064 58281258 + ZNF586 0x0 3007 chr19 58295632 58296837 + ZNF586 0x0 3008 chr19 58378068 58379253 + ZNF587 0x0 3009 chr19 58455718 58456894 − ZNF256 0x0 3010 chr19 58874297 58875496 + A1BG-AS1 0x0 3011 chr19 58904215 58905433 + RPS5 0x0 3012 chr19 59024596 59025774 − ZBTB45 0x0 3013 chr19 59061179 59062583 + TRIM28 0x0 3014 chr19 59066969 59068097 − UBE2M 0x0 3015 chr19 59069120 59070278 − UBE2M 0x0 3016 chr2 1216356 1217585 + SNTG2 0x0 3017 chr2 1636731 1637920 − PXDN 0x2 3018 chr2 2363834 2365034 − MYTH 0x0 3019 chr2 3320034 3321188 − TSSC1 0x0 3020 chr2 8869616 8870757 − KIDINS220 0x0 3021 chr2 8994807 8995934 − MBOAT2 0x0 3022 chr2 8997799 8999023 − MBOAT2 0x0 3023 chr2 9757076 9758210 − YWHAQ 0x2 3024 chr2 10586337 10587409 − SNORA80B 0x0 3025 chr2 11724384 11725662 + GREB1 0x0 3026 chr2 11906920 11908110 + LPIN1 0x0 3027 chr2 15653200 15654333 − NBAS 0x0 3028 chr2 16639823 16641013 + MYCN 0x2 3029 chr2 17942106 17943268 + GEN1 0x2 3030 chr2 20232436 20233529 − LAPTM4A 0x0 3031 chr2 20417746 20419143 − SDC1 0x0 3032 chr2 20501494 20502666 − PUM2 0x0 3033 chr2 20680167 20681308 + RHOB 0x1 3034 chr2 23629735 23630885 + KLHL29 0x0 3035 chr2 23644452 23645882 + KLHL29 0x0 3036 chr2 23675495 23676607 + KLHL29 0x0 3037 chr2 24079710 24080888 − ATAD2B 0x0 3038 chr2 24289952 24291126 − SF3B14 0x0 3039 chr2 25004382 25005586 + CENPO 0x0 3040 chr2 25452998 25454097 − DNMT3A 0x2 3041 chr2 25961435 25962615 − ASXL2 0x0 3042 chr2 26250444 26251731 − KIF3C 0x0 3043 chr2 26256446 26257646 + RAB10 0x0 3044 chr2 26617976 26619180 + EPT1 0x0 3045 chr2 27273066 27274339 + AGBL5 0x0 3046 chr2 27355797 27356988 − PREB 0x0 3047 chr2 27456383 27457481 + CAD 0x0 3048 chr2 27477080 27478216 − SLC30A3 0x0 3049 chr2 28974355 28975566 + PPP1CB 0x0 3050 chr2 29135977 29137186 + SNORD92 0x0 3051 chr2 29135977 29137186 + WDR43 0x0 3052 chr2 29148700 29149881 + WDR43 0x0 3053 chr2 29150294 29151499 + WDR43 0x0 3054 chr2 29388281 29389489 + CLIP4 0x0 3055 chr2 30723323 30724519 + LCLAT1 0x0 3056 chr2 32140854 32141953 − MEMO1 0x0 3057 chr2 32248479 32249699 − DPY30 0x0 3058 chr2 33726765 33727887 + RASGRP3 0x0 3059 chr2 33739891 33741064 − FAM98A 0x0 3060 chr2 35845713 35846891 − LOC100288911 0x0 3061 chr2 36667962 36669182 + CRIM1 0x0 3062 chr2 36669204 36670402 + CRIM1 0x0 3063 chr2 37080343 37081493 − STRN 0x0 3064 chr2 37326947 37328278 − EIF2AK2 0x1 3065 chr2 37332097 37333466 − EIF2AK2 0x1 3066 chr2 38708654 38710070 + GALM 0x0 3067 chr2 39220563 39221718 − SOS1 0x2 3068 chr2 39281328 39282494 − SOS1 0x2 3069 chr2 40424638 40425802 − SLC8A1 0x0 3070 chr2 40655162 40656518 − SLC8A1 0x0 3071 chr2 42417346 42418501 + EML4 0x2 3072 chr2 42469322 42470470 + EML4 0x2 3073 chr2 42930426 42931526 + MTA3 0x0 3074 chr2 42991030 42992261 + MTA3 0x0 3075 chr2 43628334 43629550 + LOC100129726 0x0 3076 chr2 43707207 43708335 − THADA 0x0 3077 chr2 43753054 43754275 − THADA 0x0 3078 chr2 44127543 44128682 − LRPPRC 0x0 3079 chr2 44133422 44134551 − LRPPRC 0x0 3080 chr2 44428084 44429242 + PPM1B 0x0 3081 chr2 44588997 44590196 + CAMKMT 0x0 3082 chr2 44842666 44843896 + CAMKMT 0x0 3083 chr2 45704492 45705671 − SRBD1 0x0 3084 chr2 45789231 45790428 − SRBD1 0x0 3085 chr2 46113133 46114336 + PRKCE 0x0 3086 chr2 47387070 47388219 − CALM2 0x0 3087 chr2 47389236 47390372 − CALM2 0x0 3088 chr2 47401791 47404187 − CALM2 0x0 3089 chr2 54084744 54085904 + ERLEC1 0x0 3090 chr2 55198969 55200096 − RTN4 0x0 3091 chr2 55209139 55210248 − RTN4 0x0 3092 chr2 55276912 55278085 − RTN4 0x0 3093 chr2 55455389 55456529 − C2orf63 0x0 3094 chr2 55460782 55461826 + MIR4426 0x0 3095 chr2 55460782 55461826 + RPS27A 0x0 3096 chr2 56256982 56258160 − MIR216B 0x0 3097 chr2 58426661 58427856 − FANCL 0x0 3098 chr2 60775743 60776943 + PAPOLG 0x0 3099 chr2 61105229 61106424 + REL 0x2 3100 chr2 61129741 61130952 + REL 0x2 3101 chr2 61152233 61153452 + REL 0x2 3102 chr2 61441647 61442807 − USP34 0x0 3103 chr2 61718705 61720082 − XPO1 0x2 3104 chr2 61729986 61731165 − XPO1 0x2 3105 chr2 61764394 61765670 − XPO1 0x2 3106 chr2 61891926 61893148 + COMMD1 0x4 3107 chr2 62109913 62111078 − CCT4 0x0 3108 chr2 63185727 63186942 + EHBP1 0x0 3109 chr2 65496944 65498205 + ACTR2 0x0 3110 chr2 65629603 65630801 − SPRED2 0x0 3111 chr2 69266676 69267880 + ANTXR1 0x0 3112 chr2 69977480 69978670 + ANXA4 0x0 3113 chr2 69998942 70000138 + ANXA4 0x0 3114 chr2 70065682 70066781 + GMCL1 0x0 3115 chr2 70130919 70132148 + SNRNP27 0x0 3116 chr2 70166448 70167626 − ASPRV1 0x0 3117 chr2 70439959 70441087 − TIA1 0x0 3118 chr2 70451212 70453245 − TIA1 0x0 3119 chr2 70462729 70463934 − TIA1 0x0 3120 chr2 70475116 70476306 − TIA1 0x0 3121 chr2 70506910 70508076 + PCYOX1 0x0 3122 chr2 71605045 71606241 + 2NF638 0x2 3123 chr2 71660699 71661885 + ZNF638 0x2 3124 chr2 72403769 72404907 − EXOC6B 0x0 3125 chr2 72880523 72881715 − EXOC6B 0x0 3126 chr2 73314836 73316011 − RAB11F1P5 0x0 3127 chr2 73466265 73467475 + CCT7 0x0 3128 chr2 73471196 73472298 + CCT7 0x0 3129 chr2 74379504 74380719 − MOB1A 0x1 3130 chr2 74472451 74473668 − SLC4A5 0x0 3131 chr2 74604733 74605908 − DCTN1 0x0 3132 chr2 74651919 74653107 + WDR54 0x0 3133 chr2 74719416 74720610 + TTC31 0x0 3134 chr2 74756938 74758134 + HTRA2 0x1 3135 chr2 75886605 75887676 + MRPL19 0x0 3136 chr2 76671803 76673078 − LRRTM4 0x0 3137 chr2 78928161 78929528 + REG3G 0x0 3138 chr2 82813926 82815121 + LOC1720 0x0 3139 chr2 85547533 85548789 − TGOLN2 0x0 3140 chr2 85549172 85550284 − TGOLN2 0x0 3141 chr2 85571106 85572305 − RETSAT 0x0 3142 chr2 85596349 85597520 + ELMOD3 0x0 3143 chr2 85768172 85769384 + MAT2A 0x0 3144 chr2 85770203 85771928 + MAT2A 0x0 3145 chr2 86362432 86363688 + PTCD3 0x0 3146 chr2 86362432 86363688 + SNORD94 0x0 3147 chr2 96850183 96852632 − STARD7 0x0 3148 chr2 96873373 96874629 − STARD7 0x0 3149 chr2 96886991 96888202 + LOC285033 0x0 3150 chr2 96917577 96918862 − TMEM127 0x1 3151 chr2 96934086 96935241 − TMEM127 0x1 3152 chr2 96934811 96935966 + CIAO1 0x0 3153 chr2 96939147 96940246 + CIAO1 0x0 3154 chr2 96964067 96965248 − SNRNP200 0x0 3155 chr2 97028996 97030194 + NCAPH 0x0 3156 chr2 97271741 97273016 − KANSL3 0x0 3157 chr2 97504664 97505839 − ANKRD23 0x0 3158 chr2 97528436 97529590 − SEMA4C 0x0 3159 chr2 97532383 97533489 − SEMA4C 0x0 3160 chr2 97688627 97689804 − FAM178B 0x0 3161 chr2 97830818 97832001 + ANKRD36 0x0 3162 chr2 98443952 98445069 + ZAP70 0x0 3163 chr2 98611751 98612927 + VWA3B 0x0 3164 chr2 99213766 99214929 − COA5 0x0 3165 chr2 99327874 99329169 − MGAT4A 0x0 3166 chr2 100505174 100506343 − AFF3 0x2 3167 chr2 101621869 101623334 + RPL31 0x0 3168 chr2 101634848 101636020 + RPL31 0x0 3169 chr2 101753040 101754214 − TBC1D8 0x0 3170 chr2 101914253 101915427 − RNF149 0x0 3171 chr2 102471880 102473077 + MAP4K4 0x2 3172 chr2 105470160 105471496 + POU3F3 0x0 3173 chr2 105546628 105547807 + POU3F3 0x0 3174 chr2 105908127 105909296 − TGFBRAP1 0x0 3175 chr2 109182877 109184117 + LIMS1 0x0 3176 chr2 109350228 109351366 + RANBP2 0x0 3177 chr2 109380433 109381480 + RANBP2 0x0 3178 chr2 111433698 111434876 − BUB1 0x0 3179 chr2 113278429 113279578 + TTL 0x2 3180 chr2 113288452 113289542 + TTL 0x2 3181 chr2 113420264 113421422 + SLC20A1 0x0 3182 chr2 114201793 114202983 + CBWD2 0x0 3183 chr2 114567960 114569149 − SLC35F5 0x0 3184 chr2 114708764 114709972 + ACTR3 0x0 3185 chr2 115694554 115695736 − LOC389023 0x0 3186 chr2 115694749 115695961 + DPP10 0x2 3187 chr2 116999724 117000945 + DPP10 0x2 3188 chr2 121387744 121388900 − LOC84931 0x0 3189 chr2 121498659 121499846 + GLI2 0x0 3190 chr2 121572475 121573681 + GLI2 0x0 3191 chr2 121721345 121722544 + GLI2 0x0 3192 chr2 122158585 122159790 − CLASP1 0x0 3193 chr2 122287903 122289168 − RNU4ATAC 0x0 3194 chr2 122326393 122327567 − CLASP1 0x0 3195 chr2 122363177 122364331 − CLASP1 0x0 3196 chr2 122522653 122523768 + TSN 0x0 3197 chr2 128014354 128015560 − ERCC3 0x2 3198 chr2 128033246 128034430 − ERCC3 0x2 3199 chr2 128144821 128146023 − MIR4783 0x0 3200 chr2 128263658 128264859 − IWS1 0x0 3201 chr2 128605078 128606215 − POLR2D 0x0 3202 chr2 128740898 128742002 − SAP130 0x0 3203 chr2 128916619 128917760 + UGGT1 0x2 3204 chr2 130913803 130915004 − SMPD4 0x0 3205 chr2 130939357 130940573 + MZT2B 0x0 3206 chr2 131094151 131095309 − CCDC115 0x0 3207 chr2 131104509 131105707 + IMP4 0x2 3208 chr2 131132081 131133280 + PTPN18 0x0 3209 chr2 131805917 131807019 − FAM168B 0x0 3210 chr2 131899453 131900659 + PLEKHB2 0x0 3211 chr2 132245207 132246346 − MIR4784 0x0 3212 chr2 132273057 132274242 + LOC150776 0x0 3213 chr2 133011758 133013847 − MIR663B 0x0 3214 chr2 133026440 133027503 − ANKRD30BL 0x0 3215 chr2 133027871 133029879 − ANKRD30BL 0x0 3216 chr2 133741826 133742980 − NCKAP5 0x0 3217 chr2 134916352 134917556 + MIR3679 0x0 3218 chr2 135211232 135212359 + MGAT5 0x0 3219 chr2 136508474 136509745 + UBXN4 0x0 3220 chr2 136613864 136615023 − MCM6 0x0 3221 chr2 138786081 138787300 + HNMT 0x0 3222 chr2 142231057 142232282 + KYNU 0x0 3223 chr2 142246188 142247397 + KYNU 0x0 3224 chr2 142469274 142470500 − LRP1B 0x1 3225 chr2 142536923 142538099 − LRP1B 0x1 3226 chr2 142742729 142743935 − LRP1B 0x1 3227 chr2 148729810 148730961 − ORC4 0x0 3228 chr2 149402018 149403220 + EPC2 0x0 3229 chr2 151218773 151219905 + LYPD6 0x0 3230 chr2 152318973 152320151 + RIF1 0x0 3231 chr2 152802350 152803566 − CACNB4 0x0 3232 chr2 152846132 152847415 − CACNB4 0x0 3233 chr2 153193327 153194477 + FMNL2 0x0 3234 chr2 153205934 153207116 + FMNL2 0x0 3235 chr2 153524942 153526351 − PRPF40A 0x0 3236 chr2 154729764 154730960 + GALNT13 0x0 3237 chr2 154818140 154819320 + GALNT13 0x0 3238 chr2 154819642 154820805 + GALNT13 0x0 3239 chr2 155410346 155411541 + GALNT13 0x0 3240 chr2 157033856 157035046 − NR4A2 0x0 3241 chr2 157312157 157313327 + GPD2 0x0 3242 chr2 158155010 158156187 − ERMN 0x0 3243 chr2 159346768 159348023 + PKP4 0x0 3244 chr2 160087070 160088269 + TANC1 0x0 3245 chr2 161130286 161131453 − RBMS1 0x0 3246 chr2 161264377 161265530 − MIR4785 0x0 3247 chr2 162207621 162208841 + P5MD14 0x0 3248 chr2 162979680 162980900 + SLC4A10 0x2 3249 chr2 164457179 164458356 − FIGN 0x0 3250 chr2 165583619 165584827 − COBLL1 0x0 3251 chr2 166908003 166909181 − SCN1A 0x0 3252 chr2 167036660 167037847 − SCN9A 0x2 3253 chr2 168004968 168006187 + XIRP2 0x2 3254 chr2 168193128 168194318 + XIRP2 0x2 3255 chr2 168810454 168811655 − STK39 0x0 3256 chr2 169629883 169632194 + CERS6 0x0 3257 chr2 169708092 169709241 − SPC25 0x0 3258 chr2 169718770 169719869 − SPC25 0x0 3259 chr2 170745999 170747207 + UBR3 0x2 3260 chr2 170803991 170805188 + UBR3 0x2 3261 chr2 171822195 171823294 + GORASP2 0x0 3262 chr2 172513412 172514608 + DYNC1I2 0x0 3263 chr2 172964494 172965794 − DLX2 0x0 3264 chr2 172973378 172974581 + DLX1 0x0 3265 chr2 174812507 174813692 − SP3 0x0 3266 chr2 175345813 175347006 − GPR155 0x0 3267 chr2 175584480 175585720 + SCRN3 0x0 3268 chr2 176793434 176794543 − KIAA1715 0x0 3269 chr2 176845051 176846246 − KIAA1715 0x0 3270 chr2 176889001 176890223 + HOXD13 0x2 3271 chr2 177039955 177041231 − HOXD-AS1 0x0 3272 chr2 177065262 177066455 − HOXD-AS1 0x0 3273 chr2 178084124 178085352 + HNRNPA3 0x0 3274 chr2 178111555 178112777 − MIR3128 0x0 3275 chr2 178256942 178258132 + AGPS 0x0 3276 chr2 179403300 179404432 + LOC100506866 0x0 3277 chr2 179468434 179469583 + LOC100506866 0x0 3278 chr2 179487035 179488248 + LOC100506866 0x0 3279 chr2 183595170 183596369 + DNAJC10 0x0 3280 chr2 183789780 183790961 − NCKAP1 0x0 3281 chr2 183887963 183889156 − NCKAP1 0x0 3282 chr2 185472545 185473764 − ZNF804A 0x0 3283 chr2 187072084 187073267 − ZSWIM2 0x0 3284 chr2 187167909 187169130 − ZSWIM2 0x0 3285 chr2 187310259 187311409 − ZSWIM2 0x0 3286 chr2 189271930 189273039 − GULP1 0x0 3287 chr2 190317882 190319095 + WDR75 0x0 3288 chr2 191887589 191888807 + GLS 0x0 3289 chr2 197657125 197658291 − GTF3C3 0x2 3290 chr2 197752015 197753239 − PGAP1 0x0 3291 chr2 198256448 198257650 − SF3B1 0x2 3292 chr2 198353229 198354328 − HSPD1 0x0 3293 chr2 198367444 198368643 + HSPE1 0x0 3294 chr2 198399765 198400920 + HSPE1-MOB4 0x0 3295 chr2 198399765 198400920 + MOB4 0x0 3296 chr2 200245869 200247024 − SATB2 0x2 3297 chr2 200297611 200298794 − SATB2 0x2 3298 chr2 201687403 201688597 + BZW1 0x0 3299 chr2 201845865 201847050 − FAM126B 0x0 3300 chr2 202346553 202347750 + STRADB 0x0 3301 chr2 202485617 202487245 − TMEM237 0x0 3302 chr2 202490564 202491687 − TMEM237 0x0 3303 chr2 202625507 202626945 − ALS2 0x2 3304 chr2 203157232 203158427 + NOP58 0x0 3305 chr2 203157232 203158427 − SNORDll 0x0 3306 chr2 203160339 203161446 + NOP58 0x0 3307 chr2 203729600 203730792 − ICA1L 0x0 3308 chr2 203925103 203926329 + NBEAL1 0x0 3309 chr2 204235230 204236550 − ABI2 0x1 3310 chr2 204293056 204294163 + A8I2 0x1 3311 chr2 205628833 205630031 + PARD3B 0x0 3312 chr2 206613569 206614766 + NRP2 0x0 3313 chr2 206765021 206766246 + NRP2 0x0 3314 chr2 206889787 206890980 + EEF1B2 0x0 3315 chr2 206997122 206998292 − NDUFS1 0x0 3316 chr2 207026124 207027613 + EEF1B2 0x0 3317 chr2 207026124 207027613 + SNORA41 0x0 3318 chr2 207026124 207027613 + SNORD51 0x0 3319 chr2 209221075 209222274 + PIKFYVE 0x0 3320 chr2 211512125 211513352 + CPS1 0x2 3321 chr2 212399831 212401039 + CPS1 0x2 3322 chr2 212428216 212429388 − ERBB4 0x1 3323 chr2 213214823 213215916 − MIR548F2 0x0 3324 chr2 213238740 213239938 − MIR548F2 0x0 3325 chr2 213329050 213330269 − MIR548F2 0x0 3326 chr2 213336293 213337490 − MIR548F2 0x0 3327 chr2 213390114 213391313 − ERBB4 0x1 3328 chr2 216995072 216996232 + XRCC5 0x0 3329 chr2 217069580 217070799 + XRCC5 0x0 3330 chr2 217363468 217365329 + RPL37A 0x0 3331 chr2 217365531 217366649 + RPL37A 0x0 3332 chr2 217383074 217384232 + RPL37A 0x0 3333 chr2 217431845 217433045 + IGFBP2 0x0 3334 chr2 217538206 217540299 − IGFBP5 0x1 3335 chr2 218286440 218287567 − DIRC3 0x0 3336 chr2 218400358 218401552 − DIRC3 0x0 3337 chr2 219109965 219111160 + ARPC2 0x0 3338 chr2 219134612 219135878 + PNKD 0x0 3339 chr2 219365160 219366302 − USP37 0x0 3340 chr2 219525952 219527133 + BCS1L 0x0 3341 chr2 220047566 220048764 + FAM134A 0x0 3342 chr2 220083700 220085128 − ABCB6 0x0 3343 chr2 220083700 220085128 − ATG9A 0x0 3344 chr2 220431286 220432550 − OBSL1 0x0 3345 chr2 223084400 223085617 − PAX3 0x2 3346 chr2 223771341 223772508 + ACSL3 0x2 3347 chr2 225337375 225338590 − CUL3 0x1 3348 chr2 225357124 225358316 − CUL3 0x1 3349 chr2 225362717 225363887 − CUL3 0x1 3350 chr2 225449421 225450594 − CUL3 0x1 3351 chr2 228627217 228628393 − SLC19A3 0x0 3352 chr2 230015177 230016385 + FBXO36 0x0 3353 chr2 230723204 230724432 − TRIP12 0x0 3354 chr2 231684657 231685792 + CAB39 0x0 3355 chr2 231742416 231743651 + ITM2C 0x0 3356 chr2 231895330 231896507 − LOC348761 0x0 3357 chr2 232319052 232321792 − NCL 0x0 3358 chr2 232319052 232321792 − SNORA75 0x0 3359 chr2 232319052 232321792 − SNORD20 0x0 3360 chr2 232324517 232325714 − NCL 0x0 3361 chr2 232324517 232325714 − SNORD82 0x0 3362 chr2 232328602 232329702 − NCL 0x0 3363 chr2 232576047 232577235 + PTMA 0x0 3364 chr2 233936152 233937371 + INPP5D 0x0 3365 chr2 234183893 234185136 + SCARNA5 0x0 3366 chr2 234196971 234198139 + SCARNA6 0x0 3367 chr2 234379111 234380348 + DGKD 0x0 3368 chr2 236707724 236708823 + AGAP1 0x0 3369 chr2 237084009 237085207 + AGAP1 0x0 3370 chr2 237828105 237829302 − COL6A3 0x0 3371 chr2 237994178 237995402 + COPS8 0x0 3372 chr2 238640130 238641441 + LRRFIP1 0x2 3373 chr2 238977416 238978680 + SCLY 0x0 3374 chr2 238977416 238978680 + UBE2F-SCLY 0x0 3375 chr2 240566799 240567975 + LOC150935 0x0 3376 chr2 240927842 240929122 − NDUFA10 0x0 3377 chr2 241438874 241440090 − ANKMY1 0x0 3378 chr2 241463023 241464122 − ANKMY1 0x0 3379 chr2 241464673 241465805 − ANKMY1 0x0 3380 chr2 241537146 241538345 + CAPN10 0x0 3381 chr2 241653284 241655521 − KIF1A 0x2 3382 chr2 241680148 241681373 − KIF1A 0x2 3383 chr2 241696785 241697921 − KIF1A 0x2 3384 chr2 242168371 242169557 − HDLBP 0x2 3385 chr2 242172844 242174023 − ANO7 0x0 3386 chr2 242254254 242255441 + SEPT2 0x0 3387 chr2 242280235 242282090 + SEPT2 0x0 3388 chr2 242291056 242292245 + SEPT2 0x0 3389 chr2 242292246 242293356 + SEPT2 0x0 3390 chr2 242434431 242435563 − STK25 0x0 3391 chr2 242684886 242686231 − D2HGDH 0x0 3392 chr2 242699828 242700961 + D2HGDH 0x0 3393 chr20 308144 309463 + SOX12 0x0 3394 chr20 463505 464699 − CSNK2A1 0x0 3395 chr20 1161617 1162788 − TMEM74B 0x0 3396 chr20 1349577 1351191 − FKBP1A 0x0 3397 chr20 1918344 1919624 + SIRPA 0x0 3398 chr20 2443060 2444241 − SNORD119 0x0 3399 chr20 2443060 2444241 − SNRPB 0x0 3400 chr20 2447764 2448925 − SNRPB 0x0 3401 chr20 2635175 2636402 + NOP56 0x0 3402 chr20 2635175 2636402 + SNORA51 0x0 3403 chr20 2637038 2638212 + NOP56 0x0 3404 chr20 2637038 2638212 + SNORD56 0x0 3405 chr20 2637038 2638212 + SNORD57 0x0 3406 chr20 3145220 3146658 − ProSAPiP1 0x0 3407 chr20 3733763 3734862 − C20orf27 0x0 3408 chr20 4004220 4005516 + PANK2 0x0 3409 chr20 4152647 4153818 − ADRA1D 0x0 3410 chr20 5060684 5061856 − C20orf30 0x0 3411 chr20 5164963 5166161 + CDS2 0x0 3412 chr20 6559171 6560272 + BMP2 0x1 3413 chr20 8864641 8865840 + PLCB1 0x0 3414 chr20 9172099 9173278 + PLCB4 0x2 3415 chr20 11905246 11906565 + BTBD3 0x0 3416 chr20 11972785 11974015 + BTBD3 0x0 3417 chr20 17930389 17931587 − SNX5 0x0 3418 chr20 17942784 17944058 − SNORD17 0x0 3419 chr20 18245801 18247009 − DZANK1 0x0 3420 chr20 18485060 18486248 + SEC23B 0x0 3421 chr20 25515364 25516505 − NINL 0x0 3422 chr20 25845882 25847080 + LOC100134868 0x0 3423 chr20 26188218 26190630 − LOC284801 0x0 3424 chr20 26188218 26190630 − MIR663A 0x0 3425 chr20 29620241 29621478 + FRG1B 0x0 3426 chr20 30373619 30374717 + TPX2 0x0 3427 chr20 30754487 30755598 + TM9SF4 0x0 3428 chr20 30927750 30928849 + KIF3B 0x0 3429 chr20 30953660 30954792 + ASXL1 0x1 3430 chr20 31379762 31380979 + DNMT3B 0x0 3431 chr20 31436868 31438511 + MAPRE1 0x0 3432 chr20 31940667 31941815 − CDK5RAP1 0x0 3433 chr20 31974725 31975863 − CDK5RAP1 0x0 3434 chr20 32263513 32264643 − E2F1 0x1 3435 chr20 32273238 32274483 − E2F1 0x1 3436 chr20 32867650 32868912 − AHCY 0x0 3437 chr20 33027471 33028640 − ITCH 0x2 3438 chr20 33361081 33362271 − NCOA6 0x2 3439 chr20 33530007 33531300 − GSS 0x0 3440 chr20 33610313 33611516 − TRPC4AP 0x0 3441 chr20 33866251 33867414 − EIF6 0x0 3442 chr20 34091229 34092435 + CEP250 0x0 3443 chr20 34144721 34145900 + ERGIC3 0x0 3444 chr20 34218394 34219612 + CPNE1 0x0 3445 chr20 34233085 34234229 − RBM12 0x0 3446 chr20 34288156 34289329 + ROMO1 0x0 3447 chr20 34301632 34302837 − RBM39 0x0 3448 chr20 34312012 34313213 − RBM39 0x0 3449 chr20 34430845 34432061 + PHF20 0x0 3450 chr20 34633445 34634576 − LOC647979 0x0 3451 chr20 34636380 34637538 − LOC647979 0x0 3452 chr20 35221533 35222724 + TGIF2 0x0 3453 chr20 35281129 35282335 − NDRG3 0x0 3454 chr20 35422398 35423497 − KIAA0889 0x0 3455 chr20 35443437 35444575 − KIAA0889 0x0 3456 chr20 35466846 35467976 − KIAA0889 0x0 3457 chr20 35485069 35486168 − KIAA0889 0x0 3458 chr20 35519588 35520734 − SAMHD1 0x0 3459 chr20 35857418 35858593 + RPN2 0x0 3460 chr20 36064875 36066076 − BLCAP 0x5 3461 chr20 36145828 36146964 − BLCAP 0x5 3462 chr20 36147195 36148377 − BLCAP 0x5 3463 chr20 36603038 36604247 − TTI1 0x0 3464 chr20 37047754 37049031 − LOC388796 0x0 3465 chr20 37053360 37054538 − SNORA71B 0x0 3466 chr20 37055441 37056553 − SNORA71A 0x0 3467 chr20 37062007 37063212 − LOC388796 0x0 3468 chr20 37062007 37063212 − SNORA71D 0x0 3469 chr20 37189919 37191130 + RALGAPB 0x0 3470 chr20 37389853 37390980 + ACTR5 0x0 3471 chr20 37500902 37502082 + PPP1R16B 0x0 3472 chr20 37960926 37962082 − LOC339568 0x0 3473 chr20 39652337 39653562 + TOP1 0x2 3474 chr20 39751537 39752686 + TOP1 0x2 3475 chr20 39755510 39756646 + TOP1 0x2 3476 chr20 42086469 42087562 + SRSF6 0x2 3477 chr20 42101122 42102269 + SRSF6 0x2 3478 chr20 42139312 42140444 − GTSF1L 0x0 3479 chr20 42142857 42143994 + L3MBTL1 0x0 3480 chr20 42225881 42227031 + IFT52 0x0 3481 chr20 42320252 42321487 + MYBL2 0x0 3482 chr20 42635354 42636553 + TOX2 0x0 3483 chr20 43380554 43381761 − RIMS4 0x0 3484 chr20 43535683 43536777 + YWHAB 0x2 3485 chr20 44469990 44471179 − ACOT8 0x0 3486 chr20 44498416 44499609 + ZSWIM3 0x0 3487 chr20 44557368 44558519 − PLTP 0x0 3488 chr20 45892219 45893412 − ZMYND8 0x0 3489 chr20 47896310 47897875 + SNORD12 0x0 3490 chr20 47896310 47897875 + SNORD12B 0x0 3491 chr20 47896310 47897875 + ZNFX1-AS1 0x0 3492 chr20 47964535 47965725 + ZNFX1-AS1 0x0 3493 chr20 48288304 48289481 − B4GALT5 0x0 3494 chr20 48697546 48698670 − TMEM189-UBE2V1 0x0 3495 chr20 48697546 48698670 − UBE2V1 0x0 3496 chr20 48706461 48707619 − TMEM189-UBE2V1 0x0 3497 chr20 48706461 48707619 − UBE2V1 0x0 3498 chr20 49541256 49542400 − ADNP 0x0 3499 chr20 50216789 50217980 − ATP9A 0x0 3500 chr20 50512575 50513768 − SALL4 0x0 3501 chr20 50556896 50658253 − ZFP64 0x2 3502 chr20 50702728 50703853 − ZFP64 0x2 3503 chr20 50704408 50705579 − ZFP64 0x2 3504 chr20 51687704 51688904 + TSHZ2 0x2 3505 chr20 57022743 57023963 + VAPB 0x0 3506 chr20 57233979 57235189 + STX16 0x0 3507 chr20 57233979 57235189 + STX16-NPEPL1 0x0 3508 chr20 57465380 57466479 + GNAS 0x6 3509 chr20 57479961 57481011 + GNAS 0x6 3510 chr20 57483814 57485692 + GNAS 0x6 3511 chr20 57608841 57609971 − SLMO2 0x0 3512 chr20 60513126 60514302 − MIR1Z57 0x0 3513 chr20 60588238 60589418 − TAF4 0x0 3514 chr20 60639005 60640133 − TAF4 0x0 3515 chr20 60848232 60849342 + OSBPL2 0x0 3516 chr20 60906798 60907895 − LAMA5 0x0 3517 chr20 60906798 60907895 − MIR4758 0x0 3518 chr20 60934764 60935941 − LAMA5 0x0 3519 chr20 60941458 60942635 − LAMA5 0x0 3520 chr20 60962350 60964070 + RPS21 0x0 3521 chr20 61431286 61432436 + C20orf20 0x4 3522 chr20 61478722 61479897 − TCFL5 0x0 3523 chr20 61907455 61908654 + ARFGAP1 0x0 3524 chr20 62289653 62290799 + RTEL1 0x0 3525 chr20 62289653 62290799 + RTEL1-TNFRSF6B 0x0 3526 chr20 62338006 62339157 − ARFRP1 0x0 3527 chr20 62365427 62366595 + ZGPAT 0x0 3528 chr20 62373279 62374403 + SLC2A4RG 0x0 3529 chr20 62527170 62528378 + DNAJC5 0x0 3530 chr20 62545422 62546619 + MIR941-1 0x0 3531 chr20 62573549 62574693 − MIR647 0x0 3532 chr20 62582519 62583704 − UCKL1 0x0 3533 chr20 62599061 62600188 − ZNF512B 0x0 3534 chr20 62612010 62613160 + PRPF6 0x0 3535 chr21 16016413 16017631 + ABCC13 0x0 3536 chr21 17691360 17692529 + LINC00478 0x0 3537 chr21 17923872 17925099 + MIRLET7C 0x1 3538 chr21 18939729 18940861 + CXADR 0x0 3539 chr21 18965434 18966673 − BTG3 0x0 3540 chr21 19808934 19810061 − TMPRSS15 0x0 3541 chr21 20716989 20718110 + CHODL 0x0 3542 chr21 27096387 27097500 − ATP5J 0x0 3543 chr21 27253244 27254417 − APP 0x0 3544 chr21 27422807 27423993 − APP 0x0 3545 chr21 27483816 27484951 − APP 0x0 3546 chr21 27542144 27543260 − APP 0x0 3547 chr21 28127783 28128979 + MIR4759 0x0 3548 chr21 28208989 28210463 − ADAMTS1 0x2 3549 chr21 28216087 28217212 − ADAMTS1 0x2 3550 chr21 28337808 28339033 − ADAMTS5 0x0 3551 chr21 30425923 30427216 + USP16 0x2 3552 chr21 30698361 30699558 + BACH1 0x0 3553 chr21 31014916 31016114 + GRIK1-AS2 0x0 3554 chr21 32638350 32639765 − TIAM1 0x2 3555 chr21 33036141 33037340 + SOD1 0x0 3556 chr21 33040334 33041539 + SOD1 0x0 3557 chr21 33089295 33090522 − SCAF4 0x0 3558 chr21 33748942 33750183 − SNORA80 0x0 3559 chr21 33984133 33985269 − C21orf59 0x0 3560 chr21 34719386 34720535 + IFNAR1 0x0 3561 chr21 35030387 35031585 + ITSN1 0x0 3562 chr21 35127217 35128385 + ITSN1 0x0 3563 chr21 35275722 35276821 − ATP50 0x0 3564 chr21 35466827 35468201 + SLC5A3 0x0 3565 chr21 36145165 36146372 + LOC100506385 0x0 3566 chr21 37717977 37719131 + MORC3 0x0 3567 chr21 37784041 37785217 + CHAF1B 0x0 3568 chr21 37788598 37789672 + CHAF1B 0x0 3569 chr21 38567541 38568686 + TTC3 0x0 3570 chr21 38574002 38575432 + TTC3 0x0 3571 chr21 38596923 38598132 − DSCR3 0x0 3572 chr21 38632627 38633808 − DSCR3 0x0 3573 chr21 40197423 40198595 + ETS2 0x0 3574 chr21 40517282 40518471 − PSMG1 0x0 3575 chr21 40718385 40719530 − HMGN1 0x0 3576 chr21 42749811 42750988 + MX2 0x2 3577 chr21 44268392 44269583 + WDR4 0x0 3578 chr21 44479625 44480758 − CBS 0x0 3579 chr21 44984500 44985920 + RRP1B 0x0 3580 chr21 45090405 45091504 + RRP1B 0x0 3581 chr21 45179520 45180696 + PDXK 0x0 3582 chr21 45221421 45222618 + RRP1 0x0 3583 chr21 45337879 45339028 + AGPAT3 0x0 3584 chr21 45393639 45394947 + AGPAT3 0x0 3585 chr21 45559550 45560770 + C21orf33 0x0 3586 chr21 46188735 46189879 − UBE2G2 0x2 3587 chr21 46225809 46226932 − SUMO3 0x0 3588 chr21 46708339 46709547 + LOC642852 0x0 3589 chr21 46893600 46894927 + COL18A1 0x1 3590 chr21 46949302 46950441 − SLC19A1 0x0 3591 chr21 46952281 46953369 − SLC19A1 0x0 3592 chr21 46955505 46956592 − SLC19A1 0x0 3593 chr21 47424319 47425504 + COL6A1 0x0 3594 chr21 47547608 47548806 + COL6A2 0x0 3595 chr21 47608898 47610162 − LSS 0x0 3596 chr21 47738047 47739198 − C21orf58 0x0 3597 chr22 18314151 18315281 − MICAL3 0x0 3598 chr22 18571125 18572217 + PEX26 0x0 3599 chr22 18954229 18955424 + DGCR5 0x0 3600 chr22 19162785 19163956 − SLC25A1 0x0 3601 chr22 19283535 19284762 + MRPL40 0x0 3602 chr22 19362273 19363409 − HIRA 0x0 3603 chr22 19822965 19824171 − C22orf29 0x0 3604 chr22 19946011 19947236 + COMT 0x0 3605 chr22 19949534 19950733 + COMT 0x0 3606 chr22 19967218 19968536 − ARVCF 0x0 3607 chr22 20842383 20843522 − KLHL22 0x0 3608 chr22 21287555 21289058 + CRKL 0x0 3609 chr22 21306986 21308085 + CRKL 0x0 3610 chr22 21742936 21744308 + RIMBP3B 0x0 3611 chr22 21742936 21744308 + RIMBP3C 0x0 3612 chr22 22210386 22211557 − MAPK1 0x0 3613 chr22 22672503 22673700 + LOC96610 0x0 3614 chr22 23522226 23523427 + BCR 0x1 3615 chr22 23980518 23981697 − GUSBP11 0x0 3616 chr22 24236041 24237608 + MIF 0x0 3617 chr22 24438704 24439858 + CABIN1 0x0 3618 chr22 24907612 24908737 + UPB1 0x0 3619 chr22 24936646 24937830 − C22orf13 0x0 3620 chr22 24967397 24968547 + SNRPD3 0x0 3621 chr22 25529046 25530177 + KIAA1671 0x0 3622 chr22 25776890 25778026 − LRP5L 0x0 3623 chr22 26104005 26105227 + ADRBK2 0x0 3624 chr22 27282576 27283773 − CRYBB1 0x0 3625 chr22 28248228 28249383 − PITPNB 0x0 3626 chr22 28629801 28630944 − TTC28 0x0 3627 chr22 28763509 28764779 − TTC28 0x0 3628 chr22 28814029 28815169 − TTC28 0x0 3629 chr22 28852585 28853737 − TTC28 0x0 3630 chr22 28888395 28889599 − TTC28 0x0 3631 chr22 29356334 29357530 + ZNRF3 0x0 3632 chr22 29538797 29539902 + KREMEN1 0x2 3633 chr22 29541059 29542208 + KREMEN1 0x2 3634 chr22 29725923 29727091 − AP1B1 0x0 3635 chr22 29727713 29730500 − AP1B1 0x0 3636 chr22 29727713 29730500 − MIR3653 0x0 3637 chr22 29727713 29730500 − SNORD125 0x0 3638 chr22 31371430 31372477 + TUG1 0x0 3639 chr22 31556509 31557707 + RNF18S 0x0 3640 chr22 32226093 32227273 − DEPDC5 0x0 3641 chr22 32894134 32895276 + FBXO7 0x0 3642 chr22 33777348 33778521 − LARGE 0x0 3643 chr22 34297389 34298523 − LARGE 0x0 3644 chr22 34315651 34316828 − LARGE 0x0 3645 chr22 35681160 35682395 + HMGXB4 0x0 3646 chr22 35690280 35691464 + HMGXB4 0x0 3647 chr22 35839585 35840776 + MCM5 0x0 3648 chr22 36137244 36138456 − RBFOX2 0x0 3649 chr22 36138942 36140500 − RBFOX2 0x0 3650 chr22 36214874 36216032 − RBFOX2 0x0 3651 chr22 36395321 36396462 − RBFOX2 0x0 3652 chr22 36677011 36678199 − MYH9 0x2 3653 chr22 36680665 36681891 − MYH9 0x2 3654 chr22 36704808 36705986 − MYH9 0x2 3655 chr22 37803544 37804731 − ELFN2 0x0 3656 chr22 38007253 38008489 + GGA1 0x2 3657 chr22 38200770 38201857 + H1F0 0x0 3658 chr22 38313130 38314351 + MICALL1 0x0 3659 chr22 38616456 38617636 − TMEM184B 0x0 3660 chr22 38690099 38691306 − CSNK1E 0x0 3661 chr22 38691643 38692846 − CSNK1E 0x0 3662 chr22 38851091 38852298 + KDELR3 0x0 3663 chr22 38879086 38881782 − DDX17 0x0 3664 chr22 38896636 38897754 − DDX17 0x0 3665 chr22 39079245 39080420 + TOMM22 0x0 3666 chr22 39126436 39127627 + GTPBP1 0x0 3667 chr22 39258060 39259789 − CBX6 0x0 3668 chr22 39709252 39710490 − RP13 0x0 3669 chr22 39709252 39710490 − SNORD83B 0x0 3670 chr22 39710669 39711896 − RPL3 0x0 3671 chr22 39710669 39711896 − SNORD83A 0x0 3672 chr22 39713023 39714106 − RPL3 0x0 3673 chr22 39714525 39715679 − RPL3 0x0 3674 chr22 39714525 39715679 − SNORD43 0x0 3675 chr22 39824331 39825448 + TAB1 0x0 3676 chr22 40603841 40604999 + TNRC6B 0x0 3677 chr22 41032643 41033828 + MCHR1 0x2 3678 chr22 41322022 41323150 + XPNPEP3 0x0 3679 chr22 41348974 41350206 + RBX1 0x1 3680 chr22 41367993 41369234 + RBX1 0x1 3681 chr22 41650943 41652115 − RANGAP1 0x0 3682 chr22 41672402 41673555 − RANGAP1 0x0 3683 chr22 41830391 41831584 − TOB2 0x0 3684 chr22 41921316 41922493 − POLR3H 0x0 3685 chr22 41931206 41932394 − POLR3H 0x0 3686 chr22 41989044 41990224 − PMM1 0x0 3687 chr22 42017457 42018631 + XRCC6 0x0 3688 chr22 42031586 42032802 + XRCC6 0x0 3689 chr22 42070194 42071398 − NHP2L1 0x0 3690 chr22 42205327 42206535 + CCDC134 0x0 3691 chr22 42224006 42225166 + CCDC134 0x0 3692 chr22 42228697 42229797 + SREBF2 0x0 3693 chr22 42244116 42245325 + SREBF2 0x0 3694 chr22 42301585 42303689 + SREBF2 0x0 3695 chr22 42390611 42391960 + SEPTS 0x0 3696 chr22 42605304 42606458 − TCF20 0x0 3697 chr22 42911537 42912665 − RRP7A 0x0 3698 chr22 42960739 42961876 − RRP7B 0x0 3699 chr22 43010681 43011963 + RNU12 0x0 3700 chr22 43014427 43015900 − CYB5R3 0x0 3701 chr22 44403105 44404301 + PARVB 0x0 3702 chr22 45364086 45365225 − PHF21B 0x0 3703 chr22 45568661 45569815 + NUP50 0x0 3704 chr22 45580847 45581958 + NUP50 0x0 3705 chr22 45921134 45922335 + FBLN1 0x0 3706 chr22 46088330 46089523 + ATXN10 0x0 3707 chr22 46124715 46126044 + ATXN10 0x0 3708 chr22 46134049 46135230 + ATXN10 0x0 3709 chr22 46156733 46157865 + MIR4762 0x0 3710 chr22 46268284 46269464 + ATXN10 0x0 3711 chr22 46483698 46484878 + MIRLET7BHG 0x0 3712 chr22 46494420 46495618 + MIRLET7BHG 0x0 3713 chr22 46634509 46635753 + PPARA 0x0 3714 chr22 46781824 46783035 − CELSR1 0x0 3715 chr22 46946646 46947830 − CELSR1 0x0 3716 chr22 47270127 47271321 + TBC1D22A 0x0 3717 chr22 50205194 50206352 − BRD1 0x0 3718 chr22 50210282 50211470 − BRD1 0x0 3719 chr22 50713376 50714569 − PLXNB2 0x0 3720 chr22 50719855 50721037 − PLXNB2 0x0 3721 chr22 50831729 50832913 + PPP6R2 0x0 3722 chr22 50904081 50906314 − SBF1 0x0 3723 chr22 50970887 50972085 + NCAPH2 0x0 3724 chr22 51063279 51064390 − ARSA 0x0 3725 chr3 3186604 3187841 + TRNT1 0x0 3726 chr3 8024180 8025374 − LOC100288428 0x0 3727 chr3 8265114 8266333 + LMCD1 0x0 3728 chr3 9431261 9432805 − LOC440944 0x0 3729 chr3 9486201 9487428 + SETD5 0x0 3730 chr3 9857220 9858434 + TTLL3 0x0 3731 chr3 10167287 10168486 + BRK1 0x0 3732 chr3 10321861 10323056 + TATDN2 0x0 3733 chr3 11401512 11402751 + ATG7 0x0 3734 chr3 11597538 11598649 − VGLL4 0x0 3735 chr3 12064814 12066017 + SYN2 0x2 3736 chr3 12147964 12149112 + SYN2 0x2 3737 chr3 12560059 12561224 + TSEN2 0x0 3738 chr3 12625214 12626361 − RAF1 0x2 3739 chr3 12844503 12845700 + CAND2 0x0 3740 chr3 12881152 12882451 − RPL32 0x0 3741 chr3 12881152 12882451 − SNORA7A 0x0 3742 chr3 12982633 12983771 − IQSEC1 0x0 3743 chr3 13035839 13037016 − IQSEC1 0x0 3744 chr3 13280722 13281919 − NUP210 0x2 3745 chr3 13313379 13314536 − NUP210 0x2 3746 chr3 13357743 13359380 − NUP210 0x2 3747 chr3 13783339 13784537 + LOC285375 0x0 3748 chr3 14199493 14200692 − XPC 0x2 3749 chr3 15483124 15484230 + EAF1 0x0 3750 chr3 15779482 15780795 + BTD 0x0 3751 chr3 15885578 15886855 − ANKRD28 0x0 3752 chr3 16275601 16276775 + GALNTL2 0x0 3753 chr3 16459402 16460560 − RFTN1 0x0 3754 chr3 17052965 17054111 + PICL2 0x0 3755 chr3 20025601 20026775 + RAB5A 0x0 3756 chr3 23383956 23385109 + MIR548AC 0x0 3757 chr3 23436605 23437832 + MIR548AC 0x0 3758 chr3 23925735 23926895 + UBE2E1 0x0 3759 chr3 23932123 23933247 + UBE2E1 0x0 3760 chr3 23960126 23962663 + RPL15 0x0 3761 chr3 23995512 23996762 + NR1D2 0x0 3762 chr3 25639039 25640283 − TOP2B 0x0 3763 chr3 29587021 29588218 + RBMS3 0x0 3764 chr3 31269659 31270890 + STT3B 0x0 3765 chr3 31620850 31622065 + STT3B 0x0 3766 chr3 31699275 31700456 + STT3B 0x0 3767 chr3 31945766 31946935 + OSBPL10 0x0 3768 chr3 32078480 32079674 + ZNF860 0x0 3769 chr3 32411082 32412230 + CMTM8 0x0 3770 chr3 32599973 32601163 − DYNC1LI1 0x0 3771 chr3 32609995 32611224 − DYNC1LI1 0x0 3772 chr3 32938215 32939410 + TRIM71 0x0 3773 chr3 33128714 33129913 − TMPPE 0x0 3774 chr3 33173472 33174713 + CRTAP 0x0 3775 chr3 33643362 33644461 − CLASP2 0x0 3776 chr3 33873618 33874717 + PDCD6IP 0x0 3777 chr3 36726163 36727403 + STAC 0x0 3778 chr3 37080825 37081931 + MLH1 0x1 3779 chr3 37189849 37191014 − LRRFIP2 0x0 3780 chr3 37465287 37466386 + C3orf35 0x0 3781 chr3 38427202 38428303 + XYLB 0x0 3782 chr3 38668691 38669899 − SCN5A 0x2 3783 chr3 39449312 39450619 + RPSA 0x0 3784 chr3 39449312 39450619 + SNORA6 0x0 3785 chr3 39452000 39454062 + RPSA 0x0 3786 chr3 39452000 39454062 + SNORA62 0x0 3787 chr3 40352965 40354173 + EIF1B 0x0 3788 chr3 40504882 40506079 + RPL14 0x0 3789 chr3 40522637 40523826 + ZNF619 0x0 3790 chr3 40713594 40714769 + ZNF621 0x0 3791 chr3 41268246 41269401 + CTNNB1 0x2 3792 chr3 41280979 41282170 + CTNNB1 0x2 3793 chr3 42172215 42173420 + TRAK1 0x0 3794 chr3 42262814 42263984 + TRAK1 0x0 3795 chr3 42627709 42628944 + SS18L2 0x0 3796 chr3 42661569 42662722 + NKTR 0x0 3797 chr3 42825272 42826470 − HIGD1A 0x0 3798 chr3 43369372 43370583 + SNRK 0x0 3799 chr3 43513438 43514642 + SNRK 0x0 3800 chr3 43735287 43736484 + ABHD5 0x0 3801 chr3 44534839 44536016 − ZNF445 0x0 3802 chr3 44672062 44673163 + ZNF197 0x0 3803 chr3 44879232 44880427 + KIF15 0x0 3804 chr3 45532675 45533841 + LARS2 0x0 3805 chr3 45696671 45697833 + LIMD1 0x1 3806 chr3 45729920 45731109 − LOC644714 0x0 3807 chr3 47030877 47031967 + NBEAL2 0x0 3808 chr3 47050355 47051532 + NBEAL2 0x0 3809 chr3 47450648 47451750 + PTPN23 0x0 3810 chr3 47466455 47467633 − SCAP 0x0 3811 chr3 47469475 47470674 − SCAP 0x0 3812 chr3 47529404 47530562 − C3orf75 0x0 3813 chr3 47603307 47604405 − CSPG5 0x0 3814 chr3 47627164 47629184 − SMARCC1 0x0 3815 chr3 47703473 47704650 − SMARCC1 0x0 3816 chr3 47719118 47720319 − SMARCC1 0x0 3817 chr3 47892891 47895011 − MAP4 0x0 3818 chr3 47932060 47933280 − MAP4 0x0 3819 chr3 47985416 47986611 − MAP4 0x0 3820 chr3 48313866 48315070 + ZNF589 0x0 3821 chr3 48455708 48456825 − PLXNB1 0x0 3822 chr3 48460349 48461527 − PLXNB1 0x0 3823 chr3 48730604 48732071 − IP6K2 0x0 3824 chr3 48784557 48786041 − PRKAR2A 0x0 3825 chr3 48978026 48979203 + ARIH2 0x0 3826 chr3 49049998 49051180 + WDR6 0x0 3827 chr3 49059757 49060931 + NDUFAF3 0x0 3828 chr3 49298828 49299995 − C3orf62 0x0 3829 chr3 49306933 49308097 + MIR4271 0x0 3830 chr3 49396629 49397880 − RHOA 0x1 3831 chr3 49462515 49463654 − NICN1 0x0 3832 chr3 49515374 49516569 + DAG1 0x0 3833 chr3 49570399 49571592 + DAG1 0x0 3834 chr3 49736551 49737732 + RNF123 0x0 3835 chr3 50263689 50264867 + SLC38A3 0x2 3836 chr3 50773542 50774742 + DOCK3 0x0 3837 chr3 51042193 51043377 + DOCK3 0x0 3838 chr3 51242911 51244156 + DOCK3 0x0 3839 chr3 51347120 51348316 + DOCK3 0x0 3840 chr3 51572431 51573592 + RAD54L2 0x0 3841 chr3 51697732 51698844 + RAD54L2 0x0 3842 chr3 51727913 51729115 − IQCF6 0x0 3843 chr3 52002235 52003383 − ABHD14B 0x0 3844 chr3 52027879 52028994 − RPL29 0x0 3845 chr3 52561632 52562808 − NT5DC2 0x0 3846 chr3 52569766 52570959 + C3orf78 0x0 3847 chr3 52635477 52636633 − PBRM1 0x1 3848 chr3 52713144 52714273 − PBRM1 0x1 3849 chr3 52728009 52729194 − GLT8D1 0x0 3850 chr3 53260228 53261442 − TKT 0x0 3851 chr3 53327386 53328534 − DCP1A 0x0 3852 chr3 53893275 53894463 − ACTR8 0x0 3853 chr3 56105579 56106778 + CCDC66 0x0 3854 chr3 56253146 56254314 − ERC2 0x0 3855 chr3 56657136 56658267 − FAM208A 0x0 3856 chr3 56692410 56693565 + CCDC66 0x0 3857 chr3 56712433 56713636 − FAM208A 0x0 3858 chr3 58066827 58068032 + FLNB 0x2 3859 chr3 59526653 59527853 − FHIT 0x1 3860 chr3 59803894 59805090 − FHIT 0x1 3861 chr3 60392540 60393686 − FHIT 0x1 3862 chr3 60740685 60741849 − FHIT 0x1 3863 chr3 61079221 61080390 − FHIT 0x1 3864 chr3 61684302 61685482 − ID2B 0x0 3865 chr3 61728103 61729326 − ID2B 0x0 3866 chr3 61781350 61782617 + PTPRG 0x0 3867 chr3 61821361 61822559 + PTPRG 0x0 3868 chr3 62252507 62253654 + PTPRG 0x0 3869 chr3 63530565 63531774 + SYNPR 0x0 3870 chr3 63898015 63899478 + ATXN7 0x0 3871 chr3 64081176 64082354 − PRICKLE2 0x0 3872 chr3 65581623 65582779 − MAGI1 0x0 3873 chr3 69061262 69062419 − C3orf64 0x0 3874 chr3 69109074 69110269 − UBA3 0x0 3875 chr3 69383812 69385009 − FRMD4B 0x0 3876 chr3 69937863 69939029 + MITF 0x2 3877 chr3 71049846 71051051 − FOXP1 0x1 3878 chr3 71310174 71311273 − FOXP1 0x1 3879 chr3 71803897 71805392 + GPR27 0x0 3880 chr3 72440865 72442047 − RYBP 0x0 3881 chr3 73159615 73160858 + PPP4R2 0x0 3882 chr3 75467516 75468695 − FAM86DP 0x0 3883 chr3 75778673 75780352 − ZNF717 0x0 3884 chr3 76067180 76068297 + MIR4273 0x0 3885 chr3 76116679 76117859 + MIR4273 0x0 3886 chr3 77588421 77589624 − ROBO1 0x2 3887 chr3 78210509 78211683 + ROBO2 0x2 3888 chr3 78725364 78726526 − ROBO1 0x2 3889 chr3 78776220 78777399 − ROBO1 0x2 3890 chr3 78965685 78966835 − ROBO1 0x2 3891 chr3 79746721 79747916 + ROBO2 0x2 3892 chr3 87302575 87303778 + CHMP2B 0x2 3893 chr3 88188033 88189234 + ZNF654 0x0 3894 chr3 93845492 93846677 + NSUN3 0x0 3895 chr3 96070305 96071474 + EPHA6 0x0 3896 chr3 96336252 96337451 − MINA 0x0 3897 chr3 96706235 96707403 + EPHA6 0x0 3898 chr3 98298899 98300073 − CPOX 0x0 3899 chr3 98514482 98515659 − DCBLD2 0x0 3900 chr3 99674284 99675721 + C3orf26 0x0 3901 chr3 100083078 100084175 − TOMM70A 0x0 3902 chr3 101294947 101296226 − SENP7 0x0 3903 chr3 101311953 101313173 + PCNP 0x0 3904 chr3 101427409 101428630 + LOC285359 0x0 3905 chr3 101523677 101524892 − FAM55C 0x0 3906 chr3 105577927 105579124 − CBLB 0x2 3907 chr3 112728872 112730023 − C3orf17 0x0 3908 chr3 112731024 112732187 − C3orf17 0x0 3909 chr3 113351035 113352266 + SIDT1 0x0 3910 chr3 113409806 113410988 − KIAA2018 0x0 3911 chr3 113437715 113438865 − NAA50 0x0 3912 chr3 113439795 113440972 − NAA50 0x0 3913 chr3 113528980 113530968 + ATP6V1A 0x0 3914 chr3 113782739 113783838 + QTRTD1 0x0 3915 chr3 114068620 114069796 − ZBTB20 0x0 3916 chr3 119247667 119248873 + TIMMDC1 0x0 3917 chr3 119509622 119510841 + NR1I2 0x0 3918 chr3 119812267 119813380 − GSK3B 0x2 3919 chr3 120434017 120435211 − RABL3 0x0 3920 chr3 120955706 120956915 − POLQ 0x0 3921 chr3 122841602 122842804 + PDIA5 0x0 3922 chr3 124988538 124989715 − ZNF148 0x0 3923 chr3 125165792 125166986 − SNX4 0x2 3924 chr3 125797486 125798706 − SLC41A3 0x0 3925 chr3 125833502 125834789 − ALDH1L1 0x4 3926 chr3 126180019 126181440 − ZXDC 0x0 3927 chr3 126183659 126184858 − ZXDC 0x0 3928 chr3 126322569 126323774 − TXNRD3 0x0 3929 chr3 126707552 126708763 + PLXNA1 0x0 3930 chr3 127380537 127381652 + PODXL2 0x0 3931 chr3 127788558 127790058 + SEC61A1 0x0 3932 chr3 127793410 127794585 − RUVBL1 0x2 3933 chr3 128198861 128200036 − GATA2 0x2 3934 chr3 128207961 128209161 + DNAJB8-AS1 0x0 3935 chr3 128338243 128339419 − RPN1 0x2 3936 chr3 128451591 128452997 + RAB7A 0x0 3937 chr3 128531822 128533064 + RAB7A 0x0 3938 chr3 128953745 128954950 + COPG1 0x0 3939 chr3 129273522 129274695 − PLXND1 0x0 3940 chr3 129296466 129297816 − PLXND1 0x0 3941 chr3 129309709 129310948 + H1FOO 0x2 3942 chr3 130462865 130464003 − P1K3R4 0x0 3943 chr3 131197366 131198647 − SNORA58 0x0 3944 chr3 131947407 131948608 − CPNE4 0x0 3945 chr3 132293236 132294410 − ACAD11 0x0 3946 chr3 132293236 132294410 − NPHP3-ACAD11 0x0 3947 chr3 132394900 132396036 + UBA5 0x0 3948 chr3 132809501 132810699 + TMEM108 0x0 3949 chr3 133361690 133362902 − TOPBP1 0x0 3950 chr3 133875654 133876850 − RYK 0x0 3951 chr3 134501746 134502960 − KY 0x0 3952 chr3 134713228 134714454 + EPHB1 0x2 3953 chr3 136676705 136677925 + IL20RB 0x0 3954 chr3 141324383 141325571 + RASA2 0x0 3955 chr3 141644100 141645202 + ATP1B3 0x0 3956 chr3 142047179 142048291 − XRN1 0x1 3957 chr3 142391861 142393182 + PLS1 0x0 3958 chr3 142774866 142776027 + U2SURP 0x0 3959 chr3 143553099 143554255 − SLC9A9 0x0 3960 chr3 148748280 148749431 − HLTF 0x1 3961 chr3 148757934 148759261 − HLTF 0x1 3962 chr3 149672385 149673561 − PFN2 0x0 3963 chr3 149682334 149684418 − PFN2 0x0 3964 chr3 149685647 149686790 − PFN2 0x0 3965 chr3 149699572 149700765 − PFN2 0x0 3966 chr3 150261659 150262838 − SERP1 0x0 3967 chr3 150381802 150383036 + SELT 0x0 3968 chr3 150905323 150906552 + MED12L 0x2 3969 chr3 152019844 152021041 + MBNL1 0x0 3970 chr3 152525159 152526317 − TMEM14E 0x0 3971 chr3 154006950 154008133 − DHX36 0x0 3972 chr3 154017847 154018991 − DHX36 0x0 3973 chr3 155610832 155611932 + GMPS 0x2 3974 chr3 156258040 156259216 − SSR3 0x0 3975 chr3 156259638 156260819 − SSR3 0x0 3976 chr3 159505029 159506215 + IQCJ-SCHIP1 0x0 3977 chr3 159505029 159506215 + SCHIPl 0x0 3978 chr3 160101112 160102239 − IFT80 0x0 3979 chr3 160135040 160136208 + SMC4 0x0 3980 chr3 160145967 160147164 + SMC4 0x0 3981 chr3 160151049 160152148 + SMC4 0x0 3982 chr3 160232247 160233581 − KPNA4 0x0 3983 chr3 160232247 160233581 − SCARNA7 0x0 3984 chr3 161146335 161147562 − SPTSSB 0x0 3985 chr3 162751663 162752835 + OTOL1 0x0 3986 chr3 167812547 167813770 − GOLIM4 0x0 3987 chr3 168916004 168917153 − MECOM 0x0 3988 chr3 169016868 169018187 − MECOM 0x0 3989 chr3 169248357 169249556 − MECOM 0x0 3990 chr3 169257396 169258572 − MECOM 0x0 3991 chr3 169276218 169277388 − MECOM 0x0 3992 chr3 169300966 169302116 − MECOM 0x0 3993 chr3 169321337 169322504 − MECOM 0x0 3994 chr3 169481843 169483395 − TERC 0x0 3995 chr3 169489439 169490639 + MYNN 0x0 3996 chr3 169712126 169713251 + SEC62 0x0 3997 chr3 169811003 169812221 − PHC3 0x0 3998 chr3 170113003 170114159 + SKIL 0x0 3999 chr3 173662250 173663437 + NLGN1 0x2 4000 chr3 174095052 174096268 + NLGN1 0x2 4001 chr3 174689747 174690921 − SPATA16 0x0 4002 chr3 175180913 175182083 + NAALADL2 0x0 4003 chr3 176738627 176739772 − TBL1XR1 0x2 4004 chr3 178724112 178725336 − ZMAT3 0x0 4005 chr3 178897509 178898703 + PIK3CA 0x2 4006 chr3 179040437 179041633 + ZNF639 0x2 4007 chr3 179089083 179090273 + MFN1 0x0 4008 chr3 179113461 179114610 − GNB4 0x2 4009 chr3 179117003 179118152 − GNB4 0x2 4010 chr3 179305509 179306667 + ACTL6A 0x0 4011 chr3 179879102 179880325 − PEX5L 0x0 4012 chr3 180631103 180632281 − DNAJC19 0x0 4013 chr3 181540082 181541351 − FU46066 0x0 4014 chr3 182582782 182583964 + ATP11B 0x0 4015 chr3 182750101 182751276 − MCCC1 0x0 4016 chr3 183169134 183170340 + LOC100505687 0x0 4017 chr3 183353570 183354694 + KLHL24 0x0 4018 chr3 183398003 183399122 + KLHL24 0x0 4019 chr3 183580621 183581759 − PARL 0x0 4020 chr3 183744592 183745798 − ABCC5 0x0 4021 chr3 183854121 183855271 + EIF2B5 0x0 4022 chr3 183867148 183868604 + EIF2B5 0x0 4023 chr3 183890038 183891239 + DVL3 0x0 4024 chr3 183900738 183902213 + AP2M1 0x0 4025 chr3 184039630 184040778 + EIF4G1 0x0 4026 chr3 184042919 184044133 + EIF4G1 0x0 4027 chr3 184042919 184044133 + SNORD66 0x0 4028 chr3 184051974 184053512 + EIF4G1 0x0 4029 chr3 184084326 184085542 + POLR2H 0x0 4030 chr3 184427867 184429119 − MAGEF1 0x0 4031 chr3 184429133 184430288 − MAGEF1 0x0 4032 chr3 184563055 184564277 + VPS8 0x0 4033 chr3 185347678 185348961 + SENP2 0x0 4034 chr3 185361867 185363192 − IGF2BP2 0x0 4035 chr3 185439837 185441123 − IGF2BP2 0x0 4036 chr3 185505712 185506895 − IGF2BP2 0x0 4037 chr3 185634368 185635555 − TRA2B 0x0 4038 chr3 185649515 185650644 − TRA2B 0x0 4039 chr3 185653526 185654615 − TRA2B 0x0 4040 chr3 186503929 186505190 + EIF4A2 0x2 4041 chr3 186503929 186505190 + MIR1248 0x0 4042 chr3 186503929 186505190 + SNORA63 0x0 4043 chr3 186503929 186505190 + SNORA81 0x0 4044 chr3 186507201 186508333 − RFC4 0x0 4045 chr3 186617309 186618709 + ST6GAL1 0x0 4046 chr3 186759892 186761084 + ST6GAL1 0x0 4047 chr3 187388143 187389326 + LOC100131635 0x0 4048 chr3 192515576 192516752 − MB21D2 0x0 4049 chr3 193855605 193856801 + HES1 0x4 4050 chr3 194125256 194126390 − ATP13A3 0x0 4051 chr3 194171170 194172310 − ATP13A3 0x0 4052 chr3 194386411 194387704 − LSG1 0x0 4053 chr3 195776095 195777234 − TFRC 0x2 4054 chr3 195962385 195963505 − PCYT1A 0x0 4055 chr3 196074014 196075163 − UBXN7 0x0 4056 chr3 196081421 196082538 − UBXN7 0x0 4057 chr3 196118165 196119364 − UBXN7 0x0 4058 chr3 196119861 196121051 − UBXN7 0x0 4059 chr3 196511321 196512475 − CEP19 0x0 4060 chr3 196728214 196729390 − MFI2 0x0 4061 chr3 196842301 196843472 − DLG1 0x1 4062 chr3 197281533 197282691 + FYTTD1 0x0 4063 chr3 197679722 197680920 + RPL35A 0x0 4064 chr3 197682245 197683345 + RPL35A 0x0 4065 chr4 1209320 1210535 − CTBP1 0x1 4066 chr4 1218742 1219931 − CTBP1 0x1 4067 chr4 1231531 1232630 − CTBP1 0x1 4068 chr4 1234606 1235835 − CTBP1 0x1 4069 chr4 1342835 1343966 + KIAA1530 0x4 4070 chr4 1672052 1673244 − FAM53A 0x0 4071 chr4 1694014 1695533 − SLBP 0x0 4072 chr4 1713372 1714566 − SLBP 0x0 4073 chr4 1726499 1727631 + TACC3 0x0 4074 chr4 1738532 1739923 + TACC3 0x0 4075 chr4 1746121 1747254 + TACC3 0x0 4076 chr4 1805357 1806534 + FGFR3 0x2 4077 chr4 1813767 1815003 − LETM1 0x2 4078 chr4 1824830 1826025 − LETM1 0x2 4079 chr4 1918109 1919304 + WHSC1 0x2 4080 chr4 1936420 1937586 + WHSC1 0x2 4081 chr4 1957214 1958422 + WHSC1 0x2 4082 chr4 1975823 1977043 + SCARNA22 0x0 4083 chr4 1975823 1977043 + WHSC1 0x2 4084 chr4 1981796 1982993 + WHSC1 0x2 4085 chr4 2067921 2069165 + NAT8L 0x0 4086 chr4 2077034 2078212 − POLN 0x0 4087 chr4 2248957 2250057 − MXD4 0x0 4088 chr4 2581395 2582619 + FAM193A 0x0 4089 chr4 2827638 2829176 + SH3BP2 0x0 4090 chr4 2906074 2907292 + ADD1 0x0 4091 chr4 2940758 2941861 − NOP14 0x0 4092 chr4 3252082 3253256 − HTT-AS1 0x0 4093 chr4 4683894 4685085 + LOC100507266 0x0 4094 chr4 5818067 5819249 + EVC 0x0 4095 chr4 6200362 6201539 − JAKMIP1 0x0 4096 chr4 6642990 6644560 + MRFAP1 0x0 4097 chr4 6709345 6710474 − MRFAP1L1 0x0 4098 chr4 6998419 6999606 + TBC1D14 0x0 4099 chr4 7033051 7034321 + TBC1D14 0x0 4100 chr4 7583649 7584931 + SORCS2 0x0 4101 chr4 8459163 8460338 + METTL19 0x0 4102 chr4 11684050 11685227 − HS3ST1 0x0 4103 chr4 13426350 13427562 − RAB28 0x0 4104 chr4 13731061 13732284 + LOC152742 0x0 4105 chr4 17625172 17626370 + MED28 0x0 4106 chr4 17819468 17820625 + NCAPG 0x0 4107 chr4 17838682 17839842 + NCAPG 0x0 4108 chr4 17841200 17842430 + NCAPG 0x0 4109 chr4 18013434 18014610 − LCORL 0x0 4110 chr4 18576184 18577360 − LCORL 0x0 4111 chr4 20253069 20255107 + SLIT2 0x1 4112 chr4 20357968 20359022 + SLIT2-IT1 0x0 4113 chr4 20377297 20378395 + SLIT2-IT1 0x0 4114 chr4 20414007 20415155 + SLIT2-IT1 0x0 4115 chr4 20420764 20421861 + SLIT2-IT1 0x0 4116 chr4 20526965 20528169 + SLIT2 0x1 4117 chr4 20554935 20556122 + SLIT2 0x1 4118 chr4 20590724 20591907 + SLIT2 0x1 4119 chr4 20621379 20622480 + SLIT2 0x1 4120 chr4 25251620 25252796 + PI4K2B 0x0 4121 chr4 25278154 25279346 + PI4K2B 0x0 4122 chr4 25748638 25749824 − SEL1L3 0x0 4123 chr4 26416536 26417741 + RBPJ 0x0 4124 chr4 27023705 27024866 + STIM2 0x0 4125 chr4 30525911 30527106 − CCKAR 0x2 4126 chr4 30724060 30725257 + PCDH7 0x2 4127 chr4 30732429 30733530 + PCDH7 0x2 4128 chr4 30737453 30738629 + PCDH7 0x2 4129 chr4 30755239 30756386 + PCDH7 0x2 4130 chr4 37437853 37439050 − RELL1 0x0 4131 chr4 37634961 37637224 − RELL1 0x0 4132 chr4 38618668 38619867 + KLF3 0x0 4133 chr4 39114266 39115366 + KLHL5 0x0 4134 chr4 39276035 39277181 + WDR19 0x0 4135 chr4 39286725 39287909 + WDR19 0x0 4136 chr4 39708907 39710122 + UBE2K 0x0 4137 chr4 39782183 39783294 + UBE2K 0x0 4138 chr4 39978528 39979627 − PDS5A 0x0 4139 chr4 40601188 40602333 − RBM47 0x0 4140 chr4 41259046 41260283 + UCHL1 0x1 4141 chr4 41264120 41265319 + UCHL1 0x1 4142 chr4 41269710 41270980 + UCHL1 0x1 4143 chr4 42088879 42090056 + SLC30A9 0x0 4144 chr4 42202449 42203618 + SLC30A9 0x0 4145 chr4 43411605 43412801 − ATP8A1 0x0 4146 chr4 46893136 46894294 − COX7B2 0x0 4147 chr4 47708099 47709348 + ATP10D 0x0 4148 chr4 47882394 47883542 − NFXL1 0x0 4149 chr4 48413731 48414890 + SLAIN2 0x0 4150 chr4 48438539 48439739 + SLAIN2 0x0 4151 chr4 48862472 48863658 + OCIAD1 0x0 4152 chr4 52734129 52735328 + DCUN1D4 0x0 4153 chr4 53461921 53463125 − USP46 0x0 4154 chr4 54283388 54284590 + FIP1L1 0x2 4155 chr4 54953571 54954744 + GSX2 0x0 4156 chr4 55841774 55842881 − KDR 0x2 4157 chr4 56280443 56281494 + TMEM165 0x0 4158 chr4 56962978 56964223 + CEP135 0x0 4159 chr4 57325750 57327992 + PAICS 0x0 4160 chr4 58383343 58384447 + LOC255130 0x0 4161 chr4 59221215 59222390 − IGFBP7 0x1 4162 chr4 62093328 62094523 + LPHN3 0x2 4163 chr4 62551899 62553121 + LPHN3 0x2 4164 chr4 62774206 62775380 + LPHN3 0x2 4165 chr4 66438864 66440463 + LOC100144602 0x0 4166 chr4 68294835 68295976 − CENPC1 0x0 4167 chr4 68321540 68322718 − CENPC1 0x0 4168 chr4 69097071 69098228 − TMPRSS11B 0x0 4169 chr4 70296091 70297349 − UGT2B4 0x0 4170 chr4 71553746 71554940 + UTP3 0x0 4171 chr4 73941209 73942338 − ANKRD17 0x0 4172 chr4 73955544 73957661 − ANKRD17 0x0 4173 chr4 73986039 73987204 − ANKRD17 0x0 4174 chr4 74079369 74080510 − ANKRD17 0x0 4175 chr4 74102690 74103817 − ANKRD17 0x0 4176 chr4 74109735 74110834 − ANKRD17 0x0 4177 chr4 76569124 76570342 − G3BP2 0x0 4178 chr4 76648143 76649358 − G3BP2 0x0 4179 chr4 76660425 76661657 + USO1 0x0 4180 chr4 76733874 76735088 + USO1 0x0 4181 chr4 76806599 76808121 + USO1 0x0 4182 chr4 77265081 77266329 + FAM47E-STBD1 0x0 4183 chr4 77265081 77266329 + STBD1 0x0 4184 chr4 77372618 77373794 + SHROOM3 0x2 4185 chr4 77766703 77767861 − SOWAHB 0x0 4186 chr4 77768802 77770022 + SHROOM3 0x2 4187 chr4 77958275 77959447 + SEPT11 0x0 4188 chr4 77967833 77969064 − CCNI 0x0 4189 chr4 77969179 77970319 − CCNI 0x0 4190 chr4 77976650 77978723 − CCNI 0x0 4191 chr4 79053658 79054798 − CNOT6L 0x0 4192 chr4 79175849 79177015 + FRAS1 0x0 4193 chr4 79205034 79206238 + FRAS1 0x0 4194 chr4 79410767 79411878 + FRAS1 0x0 4195 chr4 79438573 79439806 + FRAS1 0x0 4196 chr4 79734146 79735341 + BMP2K 0x0 4197 chr4 79840005 79841132 − PAQR3 0x0 4198 chr4 80274113 80275302 − NAA11 0x0 4199 chr4 83268298 83269488 − HNRNPD 0x0 4200 chr4 83274558 83275765 − HNRNPD 0x0 4201 chr4 83280150 83281278 − HNRNPD 0x0 4202 chr4 83343963 83345140 − HNRPDL 0x0 4203 chr4 83347069 83348169 − HNRPDL 0x0 4204 chr4 83550678 83551963 − SCD5 0x0 4205 chr4 83818751 83819908 − LOC100499177 0x0 4206 chr4 86021366 86022519 + WDFY3-AS2 0x0 4207 chr4 87393257 87394403 − MAPK10 0x0 4208 chr4 87515041 87516221 + PTPN13 0x0 4209 chr4 87653247 87654357 + PTPN13 0x0 4210 chr4 87870545 87871718 − LOC100506746 0x0 4211 chr4 87940038 87941259 + AFF1 0x0 4212 chr4 88099083 88100238 − KLHL8 0x0 4213 chr4 88137806 88138917 − KLHL8 0x0 4214 chr4 89777339 89778499 − FAM13A 0x2 4215 chr4 89954916 89956116 − FAM13A 0x2 4216 chr4 90663937 90665134 + LOC644248 0x0 4217 chr4 93531591 93532768 + GRID2 0x0 4218 chr4 95416050 95417252 + PDLIM5 0x0 4219 chr4 95575127 95576327 + PDLIM5 0x0 4220 chr4 96396095 96397271 − UNC5C 0x1 4221 chr4 99563213 99564313 − TSPAN5 0x0 4222 chr4 99850331 99851505 + METAP1 0x0 4223 chr4 100868849 100870090 − H2AFZ 0x0 4224 chr4 103717651 103719025 − UBE2D3 0x0 4225 chr4 104725398 104726574 − TACR3 0x0 4226 chr4 106026648 106027830 + TET2 0x1 4227 chr4 106057841 106059021 − PPA2 0x0 4228 chr4 106344162 106345353 − PPA2 0x0 4229 chr4 106852779 106853976 + NPNT 0x0 4230 chr4 107208670 107209801 − TBCK 0x0 4231 chr4 107868851 107870051 − DKK2 0x2 4232 chr4 107923941 107925121 − DKK2 0x2 4233 chr4 109564721 109565921 + OSTC 0x0 4234 chr4 109760830 109762023 − COL25A1 0x2 4235 chr4 110104521 110105697 − COL25A1 0x2 4236 chr4 110608918 110610063 + CCDC109B 0x0 4237 chr4 110650525 110651689 − PLA2G12A 0x0 4238 chr4 111068841 111070012 − EL0VL6 0x2 4239 chr4 113708823 113709979 − MIR3O2B 0x0 4240 chr4 113785324 113786500 + ANK2 0x2 4241 chr4 114146722 114148054 + ANK2 0x2 4242 chr4 114341014 114342181 + ANK2 0x2 4243 chr4 114437818 114438997 − CAMK2D 0x0 4244 chr4 114662153 114663347 − CAMK2D 0x0 4245 chr4 119199757 119201059 + SNHG8 0x0 4246 chr4 119199757 119201059 + SNORA24 0x0 4247 chr4 120157972 120159202 + USP53 0x0 4248 chr4 120476269 120477447 − PDE5A 0x0 4249 chr4 121587880 121589054 + PP12613 0x0 4250 chr4 122588643 122590042 − ANXA5 0x0 4251 chr4 122606909 122608071 − ANXA5 0x0 4252 chr4 123750558 123751842 + FGF2 0x0 4253 chr4 128754661 128755882 + HSPA4L 0x0 4254 chr4 128850808 128851989 − MFSD8 0x0 4255 chr4 136916515 136917744 − PCDH18 0x2 4256 chr4 140045828 140047021 − ELF2 0x0 4257 chr4 140300081 140301298 − NAA15 0x0 4258 chr4 140427948 140429133 − SETD7 0x0 4259 chr4 140429601 140430909 − SETD7 0x0 4260 chr4 140618700 140619799 − MAML3 0x0 4261 chr4 140805551 140806871 − MAML3 0x0 4262 chr4 141349704 141350880 − CLGN 0x0 4263 chr4 142154608 142155762 + ZNF330 0x0 4264 chr4 143315717 143316925 − INPP4B 0x1 4265 chr4 144257623 144258821 + GAB1 0x6 4266 chr4 144270075 144271461 − FREM3 0x0 4267 chr4 144346149 144347318 + GAB1 0x6 4268 chr4 146018918 146020143 + ABCE1 0x2 4269 chr4 146427241 146428425 + SMAD1 0x0 4270 chr4 146822800 146823918 − ZNF827 0x0 4271 chr4 149180417 149181814 − NR3C2 0x0 4272 chr4 149265208 149266372 − NR3C2 0x0 4273 chr4 149356392 149357576 − NR3C2 0x0 4274 chr4 151185305 151186711 − LRBA 0x0 4275 chr4 151871001 151872180 − LRBA 0x0 4276 chr4 152024415 152025614 + RPS3A 0x0 4277 chr4 152024415 152025614 + SNORD73A 0x0 4278 chr4 152041252 152042409 − SH3D19 0x0 4279 chr4 152591367 152592570 − PET112 0x0 4280 chr4 153448757 153449897 − FBXW7 0x1 4281 chr4 154169920 154171208 + TRIM2 0x0 4282 chr4 154472765 154473974 + KIAA0922 0x0 4283 chr4 155457250 155458379 − PLRG1 0x0 4284 chr4 158688599 158689776 − FAM198B 0x0 4285 chr4 159636841 159637978 − PPID 0x0 4286 chr4 164045004 164046132 − NAF1 0x0 4287 chr4 164077750 164078946 − NAF1 0x0 4288 chr4 166213819 166215040 − GK3P 0x0 4289 chr4 166263567 166264776 + MSMO1 0x0 4290 chr4 167021877 167023098 + TLL1 0x0 4291 chr4 167063135 167064378 + TLL1 0x0 4292 chr4 169925827 169927030 + PALLD 0x0 4293 chr4 170332145 170333366 − NEK1 0x0 4294 chr4 170427527 170428695 − NEK1 0x0 4295 chr4 174252351 174253786 − HMGB2 0x0 4296 chr4 174254588 174255755 − HMGB2 0x0 4297 chr4 175219945 175221126 + CEP44 0x0 4298 chr4 175275109 175276324 + CEP44 0x0 4299 chr4 176423626 176424847 + ADAM29 0x2 4300 chr4 176842074 176843173 − GPM6A 0x0 4301 chr4 177240631 177241730 + SPCS3 0x0 4302 chr4 177252721 177253795 + SPCS3 0x0 4303 chr4 177495908 177497008 − VEGFC 0x0 4304 chr4 181405460 181406582 − LINC00290 0x0 4305 chr4 183403106 183404347 + ODZ3 0x0 4306 chr4 183608768 183609957 + ODZ3 0x0 4307 chr4 184185650 184186805 + WWC2 0x0 4308 chr4 184206594 184207757 + WWC2 0x0 4309 chr4 184236991 184238138 + WWC2 0x0 4310 chr4 185598395 185599560 + CCDC111 0x0 4311 chr4 185612026 185613243 + CCDC111 0x0 4312 chr4 186284166 186285356 + SNX25 0x0 4313 chr4 187548781 187550336 − FAT1 0x1 4314 chr4 187595179 187596294 − FAT1 0x1 4315 chr4 187627324 187628579 − FAT1 0x1 4316 chr4 187628672 187630961 − FAT1 0x1 4317 chr5 256042 257241 + SDHA 0x1 4318 chr5 465016 466156 + EXOC3 0x0 4319 chr5 475184 476283 + EXOC3 0x0 4320 chr5 616400 617529 + CEP72 0x0 4321 chr5 619661 620917 + CEP72 0x0 4322 chr5 855260 856450 − ZDHHC11 0x0 4323 chr5 881928 883115 − BRD9 0x0 4324 chr5 984575 985775 − LOC100506688 0x0 4325 chr5 1011265 1012552 + NKD2 0x0 4326 chr5 1059288 1060478 + NKD2 0x0 4327 chr5 1317484 1318925 − CLPTM1L 0x0 4328 chr5 2099419 2100621 + NDUFS6 0x0 4329 chr5 5433872 5435049 + KIAA0947 0x0 4330 chr5 6367854 6369079 + MED10 0x0 4331 chr5 6599311 6600462 − NSUN2 0x0 4332 chr5 6732256 6733453 + PAPD7 0x0 4333 chr5 6742830 6744075 + PAPD7 0x0 4334 chr5 6847884 6849102 − MIR4278 0x0 4335 chr5 7054525 7055680 − MIR4454 0x0 4336 chr5 10277925 10279202 − CMBL 0x0 4337 chr5 10374162 10375376 + MARCH6 0x0 4338 chr5 10379681 10380780 + MARCH6 0x0 4339 chr5 10400598 10401855 + MARCH6 0x0 4340 chr5 10415135 10416313 + MARCH6 0x0 4341 chr5 10425959 10427183 + MARCH6 0x0 4342 chr5 14420879 14422105 + TRIO 0x0 4343 chr5 14482958 14484167 + TRIO 0x0 4344 chr5 14508432 14509594 + TRIO 0x0 4345 chr5 14701374 14702535 − ANKH 0x0 4346 chr5 14750666 14751845 − ANKH 0x0 4347 chr5 15822964 15824180 + FBXL7 0x0 4348 chr5 18800477 18801690 + BASP1 0x0 4349 chr5 20304100 20305276 − CDH18 0x4 4350 chr5 21527696 21528894 + GUSBP1 0x0 4351 chr5 31455998 31457175 − DROSHA 0x2 4352 chr5 31488619 31489794 − DROSHA 0x2 4353 chr5 32124537 32125869 − GOLPH3 0x0 4354 chr5 32143298 32144538 − GOLPH3 0x0 4355 chr5 32378698 32379827 − ZFR 0x0 4356 chr5 32601050 32602364 + SUB1 0x0 4357 chr5 33161873 33163111 + LOC340113 0x0 4358 chr5 33452823 33453991 + TARS 0x0 4359 chr5 34068024 34069192 − C1QTNF3 0x0 4360 chr5 34801788 34803022 + RAI14 0x0 4361 chr5 36146478 36147695 − MIR580 0x0 4362 chr5 36931288 36932498 + NIPBL 0x0 4363 chr5 37107160 37108354 − C5orf42 0x0 4364 chr5 37290557 37291656 − NUP155 0x0 4365 chr5 37644395 37645575 + WDR70 0x0 4366 chr5 38966651 38967862 − RICTOR 0x0 4367 chr5 40714019 40715191 − PE33 0x0 4368 chr5 40834076 40835225 − RPL37 0x0 4369 chr5 41920550 41921732 + C5orf51 0x0 4370 chr5 43290478 43291600 − HMGCS1 0x0 4371 chr5 44816488 44817669 + MRPS30 0x0 4372 chr5 53348060 53349257 − ARL15 0x0 4373 chr5 54964571 54965747 − SLC38A9 0x0 4374 chr5 55281035 55282211 − IL6ST 0x2 4375 chr5 56239517 56240829 − MIER3 0x2 4376 chr5 56464363 56465567 − MIER3 0x2 4377 chr5 60163431 60164583 − ERCC8 0x0 4378 chr5 60195168 60196367 − ERCC8 0x0 4379 chr5 60280264 60281431 + NDUFAF2 0x0 4380 chr5 60454911 60456125 − C5orf43 0x0 4381 chr5 60629614 60630713 + ZSWIM6 0x0 4382 chr5 60778117 60779343 + ZSWIM6 0x0 4383 chr5 60838057 60839254 + ZSWIM6 0x0 4384 chr5 64017997 64019153 − SREK1IP1 0x0 4385 chr5 64826677 64827834 − CENPK 0x0 4386 chr5 64854223 64855425 − CENPK 0x0 4387 chr5 65474521 65475620 + SREK1 0x0 4388 chr5 65929854 65931080 + MAST4 0x0 4389 chr5 68169262 68170459 + SLC30A5 0x0 4390 chr5 68470301 68471848 + CCNB1 0x0 4391 chr5 68534620 68535809 + CDK7 0x0 4392 chr5 71146171 71147505 + CARTPT 0x0 4393 chr5 71501197 71502296 + MAP1B 0x2 4394 chr5 71558941 71560151 − MRPS27 0x0 4395 chr5 72153426 72154546 + TNPO1 0x2 4396 chr5 72188374 72189602 + TNPO1 0x2 4397 chr5 72206009 72207217 + TNPO1 0x2 4398 chr5 72293664 72294858 + FCHO2 0x0 4399 chr5 72798331 72799514 + BTF3 0x0 4400 chr5 73923248 73924390 − ENC1 0x0 4401 chr5 75630962 75632158 − F2RL2 0x2 4402 chr5 75775909 75777085 − F2RL2 0x2 4403 chr5 76375769 76376916 − SNORA47 0x0 4404 chr5 76727954 76729712 − WDR41 0x0 4405 chr5 77301561 77302684 − AP3B1 0x0 4406 chr5 77435096 77436266 − AP3B1 0x0 4407 chr5 77528492 77529643 − AP3B1 0x0 4408 chr5 78734358 78735466 − HOMER1 0x0 4409 chr5 79548465 79549683 + SPZ1 0x0 4410 chr5 80183593 80184748 + MSH3 0x2 4411 chr5 80484785 80485962 − LOC100131067 0x0 4412 chr5 80628317 80629455 − ACOT12 0x0 4413 chr5 81570830 81571946 − RPS23 0x0 4414 chr5 81573146 81574245 − RPS23 0x0 4415 chr5 82254994 82256171 − TMEM167A 0x0 4416 chr5 82359469 82360601 − SCARNA18 0x0 4417 chr5 86569424 86570609 + RASA1 0x2 4418 chr5 89768753 89769931 − M8LAC2 0x0 4419 chr5 90105888 90107164 + GPR98 0x0 4420 chr5 92929548 92930740 + NR2F1 0x0 4421 chr5 93018311 93019965 − POUSF2 0x0 4422 chr5 93131269 93132417 − FAM172A 0x0 4423 chr5 94173902 94175063 − MCTP1 0x0 4424 chr5 95158511 95159640 + RHOBTB3 0x0 4425 chr5 95239923 95241132 − ELL2 0x0 4426 chr5 96323354 96324453 + INPEP 0x0 4427 chr5 100068452 100069649 + FAM174A 0x0 4428 chr5 101637845 101639040 + PAM 0x0 4429 chr5 102087133 102088329 − SLCO6A1 0x0 4430 chr5 102212164 102213379 + PAM 0x0 4431 chr5 107002182 107003311 − EFNA5 0x1 4432 chr5 108229675 108230841 − HP07349 0x0 4433 chr5 108349997 108351209 − HP07349 0x0 4434 chr5 109034853 109036078 − PJA2 0x0 4435 chr5 109146662 109147860 + MAN2A1 0x0 4436 chr5 109930841 109932041 + TMEM232 0x0 4437 chr5 110458675 110459862 + WDR36 0x0 4438 chr5 111496683 111497883 + EPB41L4A-AS1 0x0 4439 chr5 111496683 111497883 + SNORA13 0x0 4440 chr5 112349145 112350420 + DCP2 0x0 4441 chr5 112382879 112384028 − MCC 0x1 4442 chr5 112599748 112600940 − MCC 0x1 4443 chr5 118172992 118174184 − DTWD2 0x0 4444 chr5 118417262 118418446 + DMXL1 0x0 4445 chr5 118499717 118500922 + DMXL1 0x0 4446 chr5 122358764 122359921 − PPIC 0x0 4447 chr5 122698012 122699206 − CEP120 0x0 4448 chr5 122880801 122882021 + CSNK1G3 0x0 4449 chr5 122990432 122991632 + CSNK1G3 0x0 4450 chr5 123981877 123983264 − ZNF608 0x0 4451 chr5 123998470 123999607 − ZNF608 0x0 4452 chr5 126112381 126113578 + LMNB1 0x0 4453 chr5 126153331 126154530 + LMNB1 0x0 4454 chr5 126889467 126890663 + PRRC1 0x0 4455 chr5 127276736 127277912 − FLJ33630 0x0 4456 chr5 129449539 129450732 + CHSY3 0x0 <4457 chr5 130524747 130525947 + LYRM7 0x0 4458 chr5 130746679 130747856 − RAPGEF6 0x0 4459 chr5 130760870 130762039 − RAPGEF6 0x0 4460 chr5 130771334 130772508 − RAPGEF6 0x0 4461 chr5 130959540 130960717 − RAPGEF6 0x0 4462 chr5 130977720 130978819 − FNIP1 0x0 4463 chr5 131515897 131517099 + PDLIM4 0x1 4464 chr5 131803299 131804500 + C5orf56 0x0 4465 chr5 132202774 132203870 + UQCRQ 0x0 4466 chr5 133307460 133308834 − VDAC1 0x0 4467 chr5 133311749 133312912 − VDAC1 0x0 4468 chr5 133492617 133493834 − SKP1 0x0 4469 chr5 133532291 133533413 − PPP2CA 0x0 4470 chr5 134076563 134077772 + CAMLG 0x0 4471 chr5 134115176 134117473 + DDX46 0x0 4472 chr5 134159669 134160855 + DDX46 0x0 4473 chr5 134259234 134260405 + MIR4461 0x0 4474 chr5 134262142 134263369 − PITX1 0x0 4475 chr5 134355468 134356654 − PITX1 0x0 4476 chr5 134570673 134571870 + CATSPER3 0x0 4477 chr5 134669500 134670677 − H2AFY 0x0 4478 chr5 137033418 137034620 − KLHL3 0x0 4479 chr5 137087973 137089077 − HNRNPAO 0x0 4480 chr5 137289730 137290854 − FAM13B 0x0 4481 chr5 137666391 137667527 − CDC25C 0x2 4482 chr5 137771267 137772439 + KDM3B 0x1 4483 chr5 137781466 137783078 + REEP2 0x0 4484 chr5 137842197 137843338 − ETF1 0x0 4485 chr5 137896165 137897367 − HSPA9 0x0 4486 chr5 137896165 137897367 − SNORD63 0x0 4487 chr5 138119261 138120454 + CTNNA1 0x0 4488 chr5 138613928 138615224 + MATR3 0x0 4489 chr5 138613928 138615224 + SNHG4 0x0 4490 chr5 138613928 138615224 + SNORA74A 0x0 4491 chr5 138664683 138665785 + MATR3 0x0 4492 chr5 138697052 138698264 + PAIP2 0x0 4493 chr5 138955660 138956759 + UBE2D2 0x0 4494 chr5 139907953 139909087 + ANKHD1 0x0 4495 chr5 139907953 139909087 + ANKHD1-EIF4EBP3 0x0 4496 chr5 139935676 139936843 − SRA1 0x0 4497 chr5 139942922 139944119 − APBB3 0x0 4498 chr5 139947150 139948368 + SLC35A4 0x0 4499 chr5 140026517 140027657 − NDUFA2 0x0 4500 chr5 140090322 140091532 + VTRNA1-1 0x0 4501 chr5 140097951 140099191 + VTRNA1-2 0x0 4502 chr5 140105202 140106473 + VTRNA1-3 0x0 4503 chr5 140697652 140699013 − TAF7 0x0 4504 chr5 140882980 140884167 + PCDHGA1 0x0 4505 chr5 140882980 140884167 + PCDHGA10 0x0 4506 chr5 140882980 140884167 + PCDHGA11 0x0 4507 chr5 140882980 140884167 + PCDHGA12 0x0 4508 chr5 140882980 140884167 + PCDHGA2 0x0 4509 chr5 140882980 140884167 + PCDHGA3 0x0 4510 chr5 140882980 140884167 + PCDHGA4 0x0 4511 chr5 140882980 140884167 + PCDHGA5 0x0 4512 chr5 140882980 140884167 + PCDHGA6 0x0 4513 chr5 140882980 140884167 + PCDHGA7 0x0 4514 chr5 140882980 140884167 + PCDHGA8 0x0 4515 chr5 140882980 140884167 + PCDHGA9 0x0 4516 chr5 140882980 140884167 + PCDHGB1 0x0 4517 chr5 140882980 140884167 + PCDHGB2 0x0 4518 chr5 140882980 140884167 + PCDHGB3 0x0 4519 chr5 140882980 140884167 + PCDHGB4 0x0 4520 chr5 140882980 140884167 + PCDHGB5 0x0 4521 chr5 140882980 140884167 + PCDHGB6 0x0 4522 chr5 140882980 140884167 + PCDHGB7 0x0 4523 chr5 140882980 140884167 + PCDHGC3 0x0 4524 chr5 140882980 140884167 + PCDHGC4 0x0 4525 chr5 140882980 140884167 + PCDHGC5 0x2 4526 chr5 140894240 140895404 − DIAPH1 0x2 4527 chr5 140958099 140959290 − DIAPH1 0x2 4528 chr5 141005206 141006359 − HDAC3 0x1 4529 chr5 141313659 141314784 + KIAA0141 0x0 4530 chr5 141379710 141380830 − GNPDA1 0x0 4531 chr5 142659520 142660619 − NR3C1 0x0 4532 chr5 145485049 145486259 − PLAC8L1 0x0 4533 chr5 145828942 145830154 + TCERG1 0x2 4534 chr5 145934974 145936167 + TCERG1 0x2 4535 chr5 146770912 146772858 − DPYSL3 0x0 4536 chr5 147695170 147696363 + SPINK7 0x1 4537 chr5 149221294 149222492 + PPARGC1B 0x0 4538 chr5 149379189 149380405 + HMGXB3 0x0 4539 chr5 149391310 149392467 + HMGXB3 0x0 4540 chr5 149409668 149410825 + HMGXB3 0x0 4541 chr5 149823257 149824472 − RPS14 0x0 4542 chr5 149826726 149827839 − RPS14 0x0 4543 chr5 149933323 149934522 + NDST1 0x0 4544 chr5 150088157 150089605 − DCTN4 0x0 4545 chr5 150305903 150307127 + IRGM 0x0 4546 chr5 151166977 151168088 + G3BP1 0x2 4547 chr5 151176282 151177428 + G3BP1 0x2 4548 chr5 151183068 151184445 + G3BP1 0x2 4549 chr5 151988029 151989202 + G3BP1 0x2 4550 chr5 154184861 154185960 + LARP1 0x0 4551 chr5 154194245 154195970 + LARP1 0x0 4552 chr5 155271898 155273116 + SGCD 0x0 4553 chr5 157258473 157259663 − CLINT1 0x0 4554 chr5 157403274 157404503 − CLINT1 0x0 4555 chr5 159519658 159520837 − PWWP2A 0x0 4556 chr5 162917770 162918943 + HMMR 0x0 4557 chr5 164286793 164287987 + MAT2B 0x0 4558 chr5 167979735 167980834 − PANK3 0x0 4559 chr5 170532740 170533963 + RANBP17 0x2 4560 chr5 170631767 170632976 + RANBP17 0x2 4561 chr5 170650569 170651816 + RANBP17 0x2 4562 chr5 170814307 170815505 + NPM1 0x2 4563 chr5 170833000 170834240 + NPM1 0x2 4564 chr5 170836987 170838202 + NPM1 0x2 4565 chr5 170864262 170865494 + FGF18 0x0 4566 chr5 171636089 171637261 − UBTD2 0x0 4567 chr5 172402266 172403402 + RPL26L1 0x0 4568 chr5 172447180 172448424 + ATP6V0E1 0x0 4569 chr5 172447180 172448424 + SNORA74B 0x0 4570 chr5 174541243 174542729 − FLI16171 0x0 4571 chr5 174954262 174955476 + SFXN1 0x0 4572 chr5 175046803 175047922 − DRD1 0x0 4573 chr5 176348311 176349451 − UIMC1 0x0 4574 chr5 176729779 176730956 − RAB24 0x2 4575 chr5 176868941 176870106 + GRK6 0x0 4576 chr5 176881538 176882733 + PRR7 0x0 4577 chr5 176883596 176884716 − DBN1 0x2 4578 chr5 176964393 176966567 − FAM193B 0x0 4579 chr5 177058987 177060287 − LOC202181 0x0 4580 chr5 177310372 177311573 + LOC728554 0x0 4581 chr5 177379634 177380812 + FAM153C 0x0 4582 chr5 177656564 177657732 − AGXT2L2 0x0 4583 chr5 179049534 179050703 − HNRNPH1 0x0 4584 chr5 179132092 179133317 + CANX 0x0 4585 chr5 179155733 179157832 + CANX 0x0 4586 chr5 179251620 179252771 + SQSTM1 0x0 4587 chr5 179673716 179674848 − MAPK9 0x0 4588 chr5 180206560 180207717 − MGAT1 0x0 4589 chr5 180528261 180529516 + BTNL9 0x0 4590 chr5 180634178 180635408 + TRIM41 0x0 4591 chr5 180644693 180645829 − MIR4638 0x0 4592 chr5 180665592 180666691 − GNB2L1 0x0 4593 chr5 180667997 180669448 − GN82L1 0x0 4594 chr5 180667997 180669448 − SNORD96A 0x0 4595 chr5 180669745 180671450 − GN82L1 0x0 4596 chr5 180669745 180671450 − SNORD95 0x0 4597 chr6 350525 351808 + DUSP22 0x1 4598 chr6 694363 695593 + IRF4 0x2 4599 chr6 1392055 1393297 + FOXF2 0x0 4600 chr6 2249565 2250764 + LOC100508120 0x0 4601 chr6 2959958 2961063 − SERPINB6 0x0 4602 chr6 2999751 3000981 + NQO2 0x0 4603 chr6 3224108 3225372 − TUBB2B 0x0 4604 chr6 3343107 3344230 + SLC22A23 0x0 4605 chr6 4061321 4062476 + PRPF4B 0x2 4606 chr6 4427628 4428908 + CDYL 0x2 4607 chr6 4891386 4893097 + CDYL 0x2 4608 chr6 5305109 5306287 − LYRM4 0x0 4609 chr6 5819194 5820380 + FARS2 0x0 4610 chr6 6006440 6007652 − NRN1 0x0 4611 chr6 7281986 7283116 − SSR1 0x0 4612 chr6 7289208 7290341 − SSR1 0x0 4613 chr6 7312770 7313892 − SSR1 0x0 4614 chr6 7338944 7340205 − CAGE1 0x0 4615 chr6 7417091 7418291 + RIOK1 0x0 4616 chr6 7567486 7568687 + DSP 0x0 4617 chr6 10397277 10398503 − TFAP2A 0x1 4618 chr6 10790794 10791948 + TMEM14B 0x0 4619 chr6 11120447 11121644 + C6orf228 0x0 4620 chr6 11135447 11136546 + C6orf228 0x0 4621 chr6 12094830 12095971 + HIVEP1 0x0 4622 chr6 12513934 12515138 + PHACTR1 0x0 4623 chr6 13213750 13214999 + PHACTR1 0x0 4624 chr6 13374363 13375494 − GFOD1 0x0 4625 chr6 13486586 13487751 − GFOD1 0x0 4626 chr6 13646093 13647202 − RANBP9 0x0 4627 chr6 13787360 13788567 − CCDC90A 0x0 4628 chr6 15011581 15012776 + JAR1D2 0x2 4629 chr6 15416602 15417810 + JARID2 0x2 4630 chr6 16326605 16327827 − ATXN1 0x0 4631 chr6 16747172 16748334 − ATXN1 0x0 4632 chr6 17615189 17616505 − NUP153 0x0 4633 chr6 18224189 18225654 − DEK 0x2 4634 chr6 18264094 18265258 − DEK 0x2 4635 chr6 19839163 19840388 + ID4 0x1 4636 chr6 20452761 20453860 + E2F3 0x2 4637 chr6 20556060 20557162 + CDKAL1 0x0 4638 chr6 21593746 21594950 + SOX4 0x0 4639 chr6 21595334 21596486 + SOX4 0x0 4640 chr6 24417797 24418997 + MRS2 0x0 4641 chr6 24718988 24720133 − C6orf62 0x0 4642 chr6 26020508 26021702 + HIST1H3A 0x0 4643 chr6 26026615 26027821 − HIST1H4B 0x0 4644 chr6 26031448 26032740 − HIST1H3B 0x0 4645 chr6 26056020 26057248 − HIST1H1C 0x2 4646 chr6 26103864 26105124 + H1ST1H4C 0x0 4647 chr6 26156035 26157248 + HIST1H1E 0x2 4648 chr6 26157864 26159045 + HIST1H2BD 0x0 4649 chr6 26198776 26199974 − HIST1H2AD 0x0 4650 chr6 26198776 26199974 − HIST1H3D 0x0 4651 chr6 26204313 26205679 + HIST1H4E 0x0 4652 chr6 26216601 26217833 + HIST1H2AE 0x0 4653 chr6 26250095 26251233 − HIST1H3F 0x0 4654 chr6 26284906 26286305 − HIST1H4H 0x0 4655 chr6 26305137 26306335 − HIST1H4H 0x0 4656 chr6 26327842 26329088 + BTN3A2 0x0 4657 chr6 26520899 26522108 + HCG11 0x0 4658 chr6 26537187 26538396 + HMGN4 0x0 4659 chr6 26553894 26554993 + HMGN4 0x0 4660 chr6 26556236 26557446 + HMGN4 0x0 4661 chr6 26568500 26569739 + HMGN4 0x0 4662 chr6 26575282 26576489 + ABT1 0x0 4663 chr6 26576788 26577992 + ABT1 0x0 4664 chr6 26594507 26595750 + ABT1 0x0 4665 chr6 27077095 27078239 − HIST1H2BJ 0x0 4666 chr6 27100256 27101388 + HIST1H2AG 0x0 4667 chr6 27114034 27115196 − HIST1H2BK 0x0 4668 chr6 27125338 27126535 + MIR3143 0x0 4669 chr6 27177100 27178332 + PRSS16 0x0 4670 chr6 27181083 27182248 − HIST1H2BK 0x0 4671 chr6 27182391 27183627 + PRSS16 0x0 4672 chr6 27197707 27198928 − POM121L2 0x0 4673 chr6 27261107 27262319 + VN1R10P 0x0 4674 chr6 27262686 27263839 + VN1R10P 0x0 4675 chr6 27265242 27266405 + VN1R10P 0x0 4676 chr6 27470978 27472096 + ZNF391 0x2 4677 chr6 27514942 27516154 − ZNF184 0x0 4678 chr6 27520641 27521851 − ZNF184 0x0 4679 chr6 27550661 27551841 − ZNF184 0x0 4680 chr6 27569815 27570892 − ZNF184 0x0 4681 chr6 27572845 27574055 − ZNF184 0x0 4682 chr6 27618069 27619288 − HIST1H2BL 0x0 4683 chr6 27637768 27638977 − HIST1H2BL 0x0 4684 chr6 27758556 27759782 − HIST1H2BL 0x0 4685 chr6 27860016 27861423 − HIST1H2AM 0x0 4686 chr6 27860839 27861988 + HIST1H2BO 0x2 4687 chr6 28180242 28181509 + ZNF193 0x0 4688 chr6 28426989 28428187 − ZSCAN23 0x0 4689 chr6 28625465 28626614 − SCAND3 0x0 4690 chr6 28641012 28642197 − SCAND3 0x0 4691 chr6 28663157 28664356 − SCAND3 0x0 4692 chr6 28677791 28678990 + GPX5 0x0 4693 chr6 28696501 28697715 + GPX5 0x0 4694 chr6 28702649 28703851 − LOC401242 0x0 4695 chr6 28714933 28716164 + GPX5 0x0 4696 chr6 28725595 28726811 − LOC401242 0x0 4697 chr6 28757006 28758172 − LOC401242 0x0 4698 chr6 28769969 28771216 − LOC401242 0x0 4699 chr6 28784408 28785655 − LOC401242 0x0 4700 chr6 28863440 28864678 − TRIM27 0x2 4701 chr6 28865423 28866591 − TRIM27 0x2 4702 chr6 28908284 28909530 + LOC100129636 0x0 4703 chr6 28911814 28913011 + LOC100129636 0x0 4704 chr6 28918286 28919467 + LOC100129636 0x0 4705 chr6 29593377 29594477 − GABBR1 0x2 4706 chr6 29912705 29913935 + HLA-A 0x2 4707 chr6 30174258 30175638 − TRIM26 0x0 4708 chr6 30513886 30515122 − GNL1 0x0 4709 chr6 30680109 30681208 − MDC1 0x0 4710 chr6 30681230 30682456 − MDC1 0x0 4711 chr6 30691823 30693561 + TUBB 0x2 4712 chr6 30831650 30832824 + DDR1 0x0 4713 chr6 30846909 30848085 + DDR1 0x0 4714 chr6 31130402 31131596 + TCF19 0x0 4715 chr6 31496068 31497234 − ATP6V1G2-DDX39B 0x0 4716 chr6 31496068 31497234 − DDX39B 0x0 4717 chr6 31501739 31502906 − ATP6V1G2-DDX39B 0x0 4718 chr6 31501739 31502906 − DDX39B 0x0 4719 chr6 31507750 31508843 − ATP6V1G2-DDX39B 0x0 4720 chr6 31507750 31508843 − DDX39B 0x0 4721 chr6 31588657 31589786 + PRRC2A 0x0 4722 chr6 31590298 31591538 + PRRC2A 0x0 4723 chr6 31590298 31591538 + SNORA38 0x0 4724 chr6 31613730 31614837 − BAG6 0x0 4725 chr6 31703631 31704808 − CLIC1 0x0 4726 chr6 31746849 31748039 − VARS 0x0 4727 chr6 31760008 31761205 − VARS 0x0 4728 chr6 31782864 31784065 + HSPA1A 0x0 4729 chr6 31784919 31786234 + HSPA1A 0x0 4730 chr6 31797179 31798469 + HSPA1B 0x0 4731 chr6 31804278 31805485 + C6orf48 0x0 4732 chr6 31804278 31805485 + SNORD52 0x0 4733 chr6 32086135 32087386 − ATF6B 0x0 4734 chr6 32148451 32149554 + RNF5 0x0 4735 chr6 32148451 32149554 + RNF5P1 0x0 4736 chr6 33239916 33241022 + RPS18 0x0 4737 chr6 33243018 33244197 + RPS18 0x0 4738 chr6 33266967 33268141 − RGL2 0x0 4739 chr6 33266967 33268141 − TAPBP 0x0 4740 chr6 33654767 33655866 + ITPR3 0x2 4741 chr6 33738948 33740183 − LEMD2 0x0 4742 chr6 34204449 34205642 + HMGA1 0x2 4743 chr6 34213068 34214379 + HMGA1 0x2 4744 chr6 34249271 34250682 − NUDT3 0x0 4745 chr6 34249271 34250682 − RPS10-NUDT3 0x0 4746 chr6 34388259 34389415 − RPS10 0x0 4747 chr6 34388259 34389415 − RPS10-NUDT3 0x0 4748 chr6 34390262 34391440 − RPS10 0x0 4749 chr6 34390262 34391440 − RPS10-NUDT3 0x0 4750 chr6 34556452 34557600 − C6orf106 0x0 4751 chr6 34826547 34827779 + UHRF1BP1 0x0 4752 chr6 35032311 35033701 + ANKS1A 0x0 4753 chr6 35451550 35452727 − TEAD3 0x0 4754 chr6 35523396 35524603 + RPL10A 0x0 4755 chr6 35853153 35854414 − SRPK1 0x0 4756 chr6 36198642 36199909 + BRPF3 0x0 4757 chr6 36569808 36571036 + SRSF3 0x2 4758 chr6 36894856 36896000 + C6orf89 0x0 4759 chr6 37358228 37359440 + RNF8 0x0 4760 chr6 38041182 38042392 + ZFAND3 0x0 4761 chr6 41761912 41763042 − USP49 0x0 4762 chr6 42236613 42237790 − TRERF1 0x0 4763 chr6 42423307 42424509 + UBR2 0x0 4764 chr6 42856085 42857313 + RPL7L1 0x0 4765 chr6 42923667 42925068 − PEX6 0x0 4766 chr6 42988024 42989312 − KLHDC3 0x0 4767 chr6 43025492 43027669 − MRPL2 0x0 4768 chr6 43037667 43038876 + KLC4 0x0 4769 chr6 43095792 43096991 + PTK7 0x0 4770 chr6 43171690 43172872 + CUL9 0x0 4771 chr6 44081319 44082523 − MRPL14 0x0 4772 chr6 44094272 44095453 − MRPL14 0x0 4773 chr6 44219220 44220481 + HSP90AB1 0x2 4774 chr6 44266391 44267567 − AARS2 0x0 4775 chr6 44408477 44410722 + CDC5L 0x0 4776 chr6 44995610 44996776 − SUPT3H 0x0 4777 chr6 46111643 46112793 + ENPP4 0x0 4778 chr6 46622408 46623507 + SLC25A27 0x0 4779 chr6 47251283 47252411 − TNFRSF21 0x0 4780 chr6 47253341 47254576 − TNFRSF21 0x0 4781 chr6 52349296 52350448 + EFHC1 0x0 4782 chr6 52849480 52850704 − GSTA4 0x0 4783 chr6 52855044 52856169 − GSTA4 0x0 4784 chr6 52859885 52861330 + FBXO9 0x0 4785 chr6 52957213 52958430 + FBXO9 0x0 4786 chr6 53083552 53084753 + FBXO9 0x0 4787 chr6 53132185 53133289 − ELOVL5 0x0 4788 chr6 56399463 56400610 − OST 0x2 4789 chr6 57034314 57035512 + ZNF451 0x0 4790 chr6 57053896 57055230 − RAB23 0x2 4791 chr6 63921356 63922581 + PTP4A1 0x0 4792 chr6 64290668 64291881 + PTP4A1 0x0 4793 chr6 71225073 71226176 + FAM135A 0x0 4794 chr6 73448473 73449706 + KCNQ5 0x2 4795 chr6 74197008 74198113 − EEF1A1 0x1 4796 chr6 74227963 74229055 − EEF1A1 0x1 4797 chr6 74229688 74230876 − EEF1A1 0x1 4798 chr6 74309553 74310681 − SLC17A5 0x2 4799 chr6 75946972 75948118 − COX7A2 0x0 4800 chr6 77993678 77994796 − HTR1B 0x0 4801 chr6 79665318 79666472 − PHIP 0x2 4802 chr6 79769656 79770833 − PHIP 0x2 4803 chr6 80656541 80657733 − ELOVL4 0x0 4804 chr6 80751306 80752707 + TTK 0x2 4805 chr6 83706974 83708136 − UBE3D 0x0 4806 chr6 83787687 83788905 + DOPEY1 0x0 4807 chr6 84942245 84943434 − KIAA1009 0x0 4808 chr6 86323454 86325410 − SYNCRIP 0x0 4809 chr6 86333179 86334327 − SYNCRIP 0x0 4810 chr6 86339754 86340907 − SYNCRIP 0x0 4811 chr6 86386454 86387828 − SNHG5 0x0 4812 chr6 86386454 86387828 − SNORD50A 0x1 4813 chr6 86385454 86387828 − SNORD50B 0x0 4814 chr6 87896838 87898031 + ZNF292 0x0 4815 chr6 88268955 88270163 − RARS2 0x0 4816 chr6 88271871 88273026 − RARS2 0x0 4817 chr6 89512421 89513595 − RNGTT 0x0 4818 chr6 89772705 89773936 − SRSF12 0x0 4819 chr6 90036427 90037576 − UBE2J1 0x0 4820 chr6 90103175 90104299 − RRAGD 0x0 4821 chr6 90180489 90181711 + ANKRD6 0x0 4822 chr6 90190795 90191990 + ANKRD6 0x0 4823 chr6 90319964 90321150 + ANKRD6 0x0 4824 chr6 90352660 90354462 − MDN1 0x0 4825 chr6 90377219 90378421 − MDN1 0x0 4826 chr6 91224962 91226062 − MAP3K7 0x0 4827 chr6 91327958 91329132 + MIR4464 0x0 4828 chr6 94045719 94046894 − EPHA7 0x2 4829 chr6 94268127 94269325 + TSG1 0x0 4830 chr6 97632526 97633664 − MMS22L 0x0 4831 chr6 97683639 97684802 − IMMS22L 0x0 4832 chr6 97685918 97687017 − MMS22L 0x0 4833 chr6 97719552 97720728 − MMS22L 0x0 4834 chr6 100028547 100029746 − CCNC 0x1 4835 chr6 100905416 100906563 − SIM1 0x0 4836 chr6 101135519 101136729 − ASCC3 0x0 4837 chr6 101146910 101148133 − ASCC3 0x0 4838 chr6 105544496 105545608 − BVES 0x0 4839 chr6 106730913 106732080 − ATG5 0x0 4840 chr6 106896710 106897932 + AIM1 0x4 4841 chr6 107388384 107389560 − BEND3 0x0 4842 chr6 107969104 107970332 + SOBP 0x0 4843 chr6 108984597 108986174 + FOXO3 0x1 4844 chr6 109688249 109689435 − CD164 0x0 4845 chr6 111193860 111195060 + AMD1 0x0 4846 chr6 111210899 111212106 + AMD1 0x0 4847 chr6 111588017 111589142 + KIAA1919 0x0 4848 chr6 111653808 111654975 − REV3L 0x0 4849 chr6 111793412 111794582 − REV3L 0x0 4850 chr6 111904428 111905605 + TRAF3IP2-AS1 0x0 4851 chr6 111982194 111983390 − FYN 0x0 4852 chr6 113292154 113293373 + RFPL4B 0x0 4853 chr6 114178112 114179330 + MARCKS 0x0 4854 chr6 114181875 114183039 + MARCKS 0x0 4855 chr6 116579247 116580527 − TSPYL4 0x0 4856 chr6 116598668 116599891 − TSPYL1 0x0 4857 chr6 117034886 117036007 + KPNA5 0x2 4858 chr6 118031778 118032913 + NUS1 0x0 4859 chr6 118332249 118333446 + SLC35F1 0x0 4860 chr6 118554121 118555276 − CEP85L 0x0 4861 chr6 119177072 119178279 − MCM9 0x0 4862 chr6 119393192 119394423 − MIR548B 0x0 4863 chr6 121007221 121008447 + GJA1 0x1 4864 chr6 121769727 121770978 + GJA1 0x1 4865 chr6 121900967 121902148 − C6orf170 0x2 4866 chr6 123065973 123067206 + PKIB 0x0 4867 chr6 124217186 124218234 + NKAIN2 0x0 4868 chr6 125596639 125597850 − HDDC2 0x0 4869 chr6 126299287 126300490 + HINT3 0x0 4870 chr6 126359698 126360815 + TRMT11 0x0 4871 chr6 126371294 126372445 + TRMT11 0x0 4872 chr6 126500603 126501839 + TRMT11 0x0 4873 chr6 126524483 126525677 + CENPW 0x0 4874 chr6 131215651 131216815 − EPB41L2 0x0 4875 chr6 131337192 131338291 − EPB41L2 0x0 4876 chr6 131517695 131518893 + AKAP7 0x0 4877 chr6 131978592 131979749 + ENPP3 0x0 4878 chr6 132381098 132382233 + LOC100507254 0x0 4879 chr6 133135538 133137071 + RPS12 0x0 4880 chr6 133135538 133137071 + SNORD101 0x0 4881 chr6 133137377 133138573 + RPS12 0x0 4882 chr6 133137377 133138573 + SNORA33 0x0 4883 chr6 133137377 133138573 + SNORD100 0x0 4884 chr6 135776476 135777666 − AHI1 0x0 4885 chr6 135792205 135793369 − AHI1 0x0 4886 chr6 136580786 136583058 − BCLAF1 0x2 4887 chr6 136609769 136610922 − BCLAF1 0x2 4888 chr6 136950837 136951945 + PEX7 0x0 4889 chr6 136985366 136986559 − MAP3K5 0x2 4890 chr6 137516718 137517919 + IFNGR1 0x0 4891 chr6 138411876 138413053 − PERP 0x0 4892 chr6 139471071 139472211 + HECA 0x1 4893 chr6 143770410 143771612 + PEX3 0x0 4894 chr6 144024630 144025793 + PHACTR2 0x0 4895 chr6 144080177 144081352 + PHACTR2 0x0 4896 chr6 144092907 144094059 + PHACTR2 0x0 4897 chr6 144415589 144416776 − SF3B5 0x0 4898 chr6 144691525 144692844 − SF3B5 0x0 4899 chr6 145503291 145504468 + UTRN 0x0 4900 chr6 148180382 148181555 + SAMDS 0x0 4901 chr6 148864652 148865751 + SASH1 0x1 4902 chr6 149114303 149115527 + UST 0x0 4903 chr6 149373105 149374324 − UST 0x0 4904 chr6 149731584 149732938 − TAB2 0x0 4905 chr6 149771073 149772242 − ZC3H12D 0x0 4906 chr6 149887280 149888487 + C6orf72 0x0 4907 chr6 150070386 150071604 + PCMT1 0x0 4908 chr6 150131824 150133021 + PCMT1 0x0 4909 chr6 151007810 151008958 + PLEKHG1 0x0 4910 chr6 151230797 151231991 − MTHFD1L 0x0 4911 chr6 151715338 151716552 + AKAP12 0x1 4912 chr6 153602990 153604390 − RGS17 0x0 4913 chr6 153741015 153742253 + OPRM1 0x0 4914 chr6 154510891 154512064 + OPRM1 0x0 4915 chr6 157099272 157100482 + ARID1B 0x2 4916 chr6 157297408 157298585 + ARID1B 0x2 4917 chr6 158501709 158502885 + SYNJ2 0x0 4918 chr6 158732582 158734565 + TULP4 0x0 4919 chr6 158836738 158837951 + TULP4 0x0 4920 chr6 159005798 159006993 + TMEM181 0x0 4921 chr6 159010147 159011345 + TMEM181 0x0 4922 chr6 159222196 159223361 − EZR 0x2 4923 chr6 160100679 160101871 − SOD2 0x1 4924 chr6 160147489 160148641 − LOC100129518 0x0 4925 chr6 160199235 160200470 − TCP1 0x0 4926 chr6 160200704 160201944 − SNORA20 0x0 4927 chr6 160200704 160201944 − TCP1 0x0 4928 chr6 161574255 161575389 − AGPAT4 0x0 4929 chr6 161693681 161694857 − AGPAT4 0x0 4930 chr6 163729635 163730813 − LOC285796 0x0 4931 chr6 163992894 163994954 + QKI 0x0 4932 chr6 167096615 167097792 − RPS6KA2 0x1 4933 chr6 167232349 167233545 − RPS6KA2 0x1 4934 chr6 167431288 167432414 + FGFR1OP 0x2 4935 chr6 169717516 169718713 − THBS2 0x0 4936 chr6 169959010 169960179 − WDR27 0x0 4937 chr6 170063733 170065042 − WDR27 0x0 4938 chr6 170107201 170108322 − PHF10 0x0 4939 chr6 170108331 170109430 − PHF10 0x0 4940 chr6 170109684 170110800 − PHF10 0x0 4941 chr6 170715138 170716380 − FAM120B 0x0 4942 chr6 170793708 170794808 − TBP 0x0 4943 chr7 716322 717533 − PRKAR1B 0x0 4944 chr7 793397 794759 − HEATR2 0x0 4945 chr7 882031 883164 + SUN1 0x0 4946 chr7 1114643 1115856 − C7orf50 0x0 4947 chr7 1148073 1149265 − C7or(50 0x0 4948 chr7 2209517 2210716 − MAD1L1 0x1 4949 chr7 2335042 2336261 − SNX8 0x0 4950 chr7 2419510 2420742 + EIF3B 0x0 4951 chr7 2653169 2654343 + IQCE 0x0 4952 chr7 2702439 2704021 + TTYH3 0x0 4953 chr7 2762696 2763886 − GNA12 0x0 4954 chr7 2765610 2766723 − GNA12 0x0 4955 chr7 3038321 3039532 + AMZ1 0x0 4956 chr7 3152398 3153597 − CARD11 0x2 4957 chr7 3297158 3298337 − CARD11 0x2 4958 chr7 3347392 3348543 + SDK1 0x0 4959 chr7 3613078 3614275 + SDK1 0x0 4960 chr7 3998820 4000014 + SDK1 0x0 4961 chr7 4118598 4119714 + SDK1 0x0 4962 chr7 5253679 5254827 + WIPI2 0x0 4963 chr7 5269929 5271252 + WIPI2 0x0 4964 chr7 5347601 5348689 − TNRC18 0x0 4965 chr7 5351989 5353124 − TNRC18 0x0 4966 chr7 5395880 5397015 − TNRC18 0x0 4967 chr7 5433553 5434723 − TNRC18 0x0 4968 chr7 5450755 5451944 − TNRC18 0x0 4969 chr7 5536480 5537661 − MIR589 0x0 4970 chr7 5540860 5542057 − FBXL18 0x0 4971 chr7 5566668 5567958 − ACTB 0x2 4972 chr7 5685864 5687035 − RNF216 0x0 4973 chr7 6025876 6027098 − PMS2 0x1 4974 chr7 6098042 6099244 − EIF2AK1 0x0 4975 chr7 6380025 6381233 − C7orf70 0x0 4976 chr7 6441838 6444007 + RAC1 0x0 4977 chr7 6500568 6501811 − KDELR2 0x0 4978 chr7 7882404 7883601 + LOC729852 0x0 4979 chr7 8112486 8113702 + GLCCI1 0x0 4980 chr7 8127283 8128479 + GLCCI1 0x0 4981 chr7 11137465 11138681 + PHF14 0x0 4982 chr7 12024744 12025924 − THSD7A 0x0 4983 chr7 12915824 12917060 + ARL4A 0x0 4984 chr7 15781909 15783031 − LOC100506025 0x0 4985 chr7 16739862 16741056 − BZW2 0x0 4986 chr7 16823462 16824630 + TSPAN13 0x0 4987 chr7 22895658 22896857 + SNORD93 0x0 4988 chr7 23224278 23225503 + NUPL2 0x0 4989 chr7 23239252 23240488 − NUPL2 0x0 4990 chr7 23446198 23447358 − IGF2BP3 0x0 4991 chr7 23530465 23531648 + RPS2P32 0x0 4992 chr7 24731533 24732682 + MPP6 0x0 4993 chr7 25988340 25989530 − MIR148A 0x0 4994 chr7 26230917 26232469 − HNRNPA2B1 0x2 4995 chr7 26236459 26237797 − HNRNPA2B1 0x2 4996 chr7 26239671 26241083 − HNRNPA2B1 0x2 4997 chr7 26241519 26242615 + CBX3 0x0 4998 chr7 26364063 26365261 + SNX10 0x0 4999 chr7 26706811 26708082 − SKAP2 0x0 5000 chr7 27202973 27204085 − HOXA10-HOXA9 0x0 5001 chr7 27202973 27204085 − HOXA9 0x2 5002 chr7 27205067 27206183 − HOXA9 0x2 5003 chr7 28081190 28082374 − JAZF1 0x2 5004 chr7 28179077 28180280 − JAZF1 0x2 5005 chr7 28832876 28834100 + CREB5 0x0 5006 chr7 28843490 28844709 + CREB5 0x0 5007 chr7 29960439 29961649 − SCRN1 0x0 5008 chr7 30199055 30200368 + C7orf41 0x0 5009 chr7 30201709 30202892 + C7or(41 0x0 5010 chr7 30401633 30402869 + ZNRF2 0x0 5011 chr7 32602085 32603255 + AVL9 0x0 5012 chr7 32768061 32769271 + ZNRF2P1 0x0 5013 chr7 34970565 34971769 − DPY19L1 0x0 5014 chr7 35187334 35188527 − DPY19L2P1 0x0 5015 chr7 35943851 35945050 + SEPT7 0x0 5016 chr7 37474190 37475366 + GPR141 0x0 5017 chr7 38764683 38766032 − VPS41 0x0 5018 chr7 38767749 38768941 − VPS41 0x0 5019 chr7 40046956 40048149 + CDK13 0x0 5020 chr7 40122300 40123482 + CDK13 0x0 5021 chr7 40716495 40717647 + C7orf10 0x0 5022 chr7 43664776 43665987 − C7orf44 0x0 5023 chr7 43676994 43678133 − C7orf44 0x0 5024 chr7 43688077 43689239 − C7orf44 0x0 5025 chr7 43755954 43757114 − C7orf44 0x0 5026 chr7 44017403 44018614 − POLR2J4 0x0 5027 chr7 44156210 44157388 − POLD2 0x0 5028 chr7 44252240 44253901 + YKT6 0x0 5029 chr7 44422977 44425078 − NUDCD3 0x0 5030 chr7 44506929 44508226 + OGDH 0x0 5031 chr7 44615133 44616293 − DDX56 0x0 5032 chr7 44867630 44869296 − H2AFV 0x0 5033 chr7 44869491 44870653 − H2AFV 0x0 5034 chr7 44871384 44872476 − H2AFV 0x0 5035 chr7 45024431 45025655 − SNHG15 0x0 5036 chr7 45024431 45025655 − SNORA9 0x0 5037 chr7 45055716 45056839 + CCM2 0x0 5038 chr7 45143432 45145126 − SNORA5A 0x0 5039 chr7 45143432 45145126 − SNORA5C 0x0 5040 chr7 45143432 45145126 − TBRG4 0x0 5041 chr7 45631850 45633046 + ADCY1 0x2 5042 chr7 45687751 45688961 + ADCY1 0x2 5043 chr7 47883015 47884214 − PKD1L1 0x0 5044 chr7 48329866 48330965 + ABCA13 0x0 5045 chr7 51125959 51127160 − COBL 0x0 5046 chr7 51140419 51141571 + COBL 0x0 5047 chr7 53573745 53575001 + POM121L12 0x0 5048 chr7 53843321 53844539 + POM121L12 0x0 5049 chr7 55712928 55714027 + LANCL2 0x0 5050 chr7 55992166 55993377 + ZNF713 0x0 5051 chr7 56047818 56048984 + GBAS 0x0 5052 chr7 56050957 56052136 + GBAS 0x0 5053 chr7 56066418 56067572 + GBAS 0x0 5054 chr7 56111114 56112302 − PSPH 0x0 5055 chr7 56122829 56124002 + CCT6A 0x0 5056 chr7 56125566 56126665 + CCT6A 0x0 5057 chr7 56130833 56132038 + CCT6A 0x0 5058 chr7 56130833 56132038 + SUMF2 0x0 5059 chr7 56168775 56169951 − CHCHD2 0x0 5060 chr7 63806388 63807524 + ZNF736 0x0 5061 chr7 64512487 64513689 + CCT6P3 0x0 5062 chr7 65220022 65221173 + CCT6P1 0x0 5063 chr7 65220022 65221173 + SNORA22 0x0 5064 chr7 66444580 66445777 + TYW1 0x0 5065 chr7 66452731 66453910 − SBDS 0x2 5066 chr7 66461505 66462727 + TYW1 0x0 5067 chr7 66696321 66697506 − PMS2P4 0x0 5068 chr7 66732088 66733253 − PMS2P4 0x0 5069 chr7 68526830 68528282 + AUTS2 0x0 5070 chr7 69137623 69139895 + AUTS2 0x0 5071 chr7 69150855 69152052 + AUTS2 0x0 5072 chr7 69890680 69891884 + AUTS2 0x0 5073 chr7 69944884 69946122 + AUTS2 0x0 5074 chr7 70095006 70096231 + AUTS2 0x0 5075 chr7 70158630 70159729 + AUTS2 0x0 5076 chr7 70162406 70163506 + AUTS2 0x0 5077 chr7 70228678 70229863 + AUTS2 0x0 5078 chr7 72210226 72211362 − TYW1B 0x0 5079 chr7 72384475 72385573 + POM 121 0x0 5080 chr7 72855521 72856620 − BAZ1B 0x0 5081 chr7 72892223 72893442 − BAZ1B 0x0 5082 chr7 73028896 73030065 − MLXIPL 0x0 5083 chr7 73609735 73611412 + EIF4H 0x0 5084 chr7 74011007 74012204 + GTF21RD1 0x0 5085 chr7 75013767 75014967 + TRIM73 0x0 5086 chr7 75013767 75014967 + TRIM74 0x0 5087 chr7 75616282 75617424 − TMEM120A 0x0 5088 chr7 75677085 75678284 + MDH2 0x0 5089 chr7 75695075 75696451 + MDH2 0x0 5090 chr7 76183802 76184974 + LOC100133091 0x0 5091 chr7 77288076 77289291 + PTPN12 0x1 5092 chr7 77325584 77329262 + RSBN1L 0x0 5093 chr7 77409754 77411102 + RSBN1L 0x0 5094 chr7 77444662 77445817 + PHTF2 0x0 5095 chr7 77819775 77820999 + RPL13AP17 0x0 5096 chr7 84217800 84218994 − SEMA3A 0x0 5097 chr7 85957572 85958791 + GRM3 0x2 5098 chr7 91745871 91747042 − CYP51A1 0x0 5099 chr7 92121693 92122871 − PEX1 0x0 5100 chr7 94259800 94260938 − SGCE 0x4 5101 chr7 94277985 94279186 − SGCE 0x4 5102 chr7 95182157 95183355 + ASB4 0x4 5103 chr7 97500925 97502164 − ASNS 0x0 5104 chr7 97822980 97824146 + LMTK2 0x0 5105 chr7 98571475 98572623 + TRRAP 0x2 5106 chr7 98580407 98581636 + TRRAP 0x2 5107 chr7 99040246 99041345 − CPSF4 0x0 5108 chr7 99055334 99056509 − ATP5J2 0x0 5109 chr7 99063102 99064286 − ATP5J2 0x0 5110 chr7 99063102 99064286 − ATP5J2-PTCD1 0x0 5111 chr7 99070753 99071852 + ZNF789 0x0 5112 chr7 99090314 99091491 − ZNF394 0x0 5113 chr7 99164579 99165769 + ZNF655 0x0 5114 chr7 99620568 99621775 + ZKSCAN1 0x0 5115 chr7 99696493 99697583 − MCM7 0x0 5116 chr7 99766778 99767983 − GPC2 0x0 5117 chr7 100027125 100028311 + MEPCE 0x0 5118 chr7 100171876 100172981 − LRCH4 0x0 5119 chr7 100177762 100178920 − LRCH4 0x0 5120 chr7 100880641 100881974 − CLDN15 0x0 5121 chr7 100895195 100896397 + ZNHIT1 0x0 5122 chr7 101518509 101519697 − CUX1 0x2 5123 chr7 101614007 101615204 + CUX1 0x2 5124 chr7 101870302 101871497 + CUX1 0x2 5125 chr7 102090409 102091726 + ORAI2 0x0 5126 chr7 102103915 102105079 − ALKBH4 0x0 5127 chr7 102273284 102274466 − POLR2J2 0x0 5128 chr7 102776284 102777472 − RPL19P12 0x0 5129 chr7 102956740 102957866 − DNAJC2 0x0 5130 chr7 102959728 102960926 − DNAJC2 0x0 5131 chr7 102987648 102988747 + PSMC2 0x0 5132 chr7 103017293 103018395 + PSMC2 0x0 5133 chr7 104183926 104185102 − LOC645591 0x0 5134 chr7 104989419 104990519 − SRPK2 0x0 5135 chr7 105130826 105131959 − PUS7 0x0 5136 chr7 105730920 105732237 − SYPL1 0x0 5137 chr7 106966970 106968196 − COG5 0x0 5138 chr7 107392326 107393492 + CBLL1 0x0 5139 chr7 107579969 107581118 − LAMB1 0x0 5140 chr7 107604477 107605657 − LAMB1 0x0 5141 chr7 107641647 107642890 − LAMB1 0x0 5142 chr7 107788055 107789246 − NRCAM 0x1 5143 chr7 109647779 109648956 − EIF3IP1 0x0 5144 chr7 111928314 111929569 + ZNF277 0x0 5145 chr7 112094112 112095341 + IFRD1 0x0 5146 chr7 113813661 113814849 + FOXP2 0x0 5147 chr7 113873613 113874725 + FOXP2 0x0 5148 chr7 116655877 116657135 + ST7-OT4 0x0 5149 chr7 116864291 116865488 − ST7 0x1 5150 chr7 121022060 121023221 − FAM3C 0x0 5151 chr7 123181470 123182631 − NDUFA5 0x0 5152 chr7 126826996 126828167 − GRM8 0x2 5153 chr7 127002369 127003478 − ZNF800 0x0 5154 chr7 127011169 127012346 − ZNF800 0x0 5155 chr7 127292221 127293424 + SND1 0x0 5156 chr7 127304238 127305368 − SND1 0x0 5157 chr7 127717944 127719181 − SND1 0x0 5158 chr7 128045356 128046535 − IMPDH1 0x0 5159 chr7 128144617 128145843 − METTL2B 0x0 5160 chr7 128268899 128270067 + FU45340 0x0 5161 chr7 128294201 128295432 + FU4S340 0x0 5162 chr7 128336957 128338351 + FAM71F2 0x0 5163 chr7 128410338 128411503 + CALU 0x0 5164 chr7 128626267 128627427 − TNPO3 0x0 5165 chr7 128804197 128805297 + TSPAN33 0x0 5166 chr7 128828291 128829490 + SMO 0x1 5167 chr7 128844598 128846620 + SMO 0x1 5168 chr7 128956910 128958109 + AHCYL2 0x0 5169 chr7 129249052 129250217 − MIR182 0x0 5170 chr7 129771754 129772914 + KLHDC10 0x0 5171 chr7 132719105 132721265 − CHCHD3 0x0 5172 chr7 134126762 134127961 − AKR1B1 0x1 5173 chr7 134446424 134447609 − AKR1B1 0x1 5174 chr7 134653877 134655027 + CALD1 0x0 5175 chr7 135262978 135264232 + NUP205 0x0 5176 chr7 135299192 135300395 − NUP205 0x0 5177 chr7 135564469 135565613 − LUZP6 0x0 5178 chr7 135564469 135565613 − MTPN 0x0 5179 chr7 135612497 135613615 − LUZP6 0x0 5180 chr7 135612497 135613615 − MTPN 0x0 5181 chr7 135631923 135633117 − LUZP6 0x0 5182 chr7 135631923 135633117 − MTPN 0x0 5183 chr7 137561561 137562688 − CREB3L2 0x2 5184 chr7 137593795 137594957 − CREB3L2 0x2 5185 chr7 137641335 137642504 − CREB3L2 0x2 5186 chr7 138229348 138230509 + TRIM24 0x1 5187 chr7 138601353 138602530 − KIAA1549 0x0 5188 chr7 138708377 138709573 − ZC3HAV1L 0x0 5189 chr7 139060142 139061336 + LUC7L2 0x0 5190 chr7 139091472 139092571 + LUC7L2 0x0 5191 chr7 139163207 139164420 − KLRG2 0x0 5192 chr7 139252540 139254304 − HIPK2 0x1 5193 chr7 139255381 139257357 − HIPK2 0x1 5194 chr7 139415555 139417089 − HIPK2 0x1 5195 chr7 139991958 139993146 − SLC37A3 0x0 5196 chr7 140578969 140580149 − BRAF 0x2 5197 chr7 140608227 140609407 − BRAF 0x2 5198 chr7 140949281 140950478 + LOC100507421 0x0 5199 chr7 140989729 140990945 + LOC100507421 0x0 5200 chr7 141427256 141428517 − WEE2 0x0 5201 chr7 142828739 142829949 − OR6W1P 0x0 5202 chr7 148517064 148518265 − EZH2 0x2 5203 chr7 148637989 148639256 + CUL1 0x1 5204 chr7 148683652 148684931 − PDIA4 0x2 5205 chr7 148815628 148816762 − ZNF425 0x0 5206 chr7 148822219 148823398 − ZNF425 0x0 5207 chr7 148875639 148876808 + ZNF398 0x0 5208 chr7 149187521 149188679 − ZNF746 0x0 5209 chr7 149281240 149282410 + KRBA1 0x0 5210 chr7 149361344 149362611 + KRBA1 0x0 5211 chr7 149387704 149388911 − ZNF767 0x0 5212 chr7 149411854 149413217 + KRBA1 0x0 5213 chr7 149575886 149577679 + ATP6V0E2 0x0 5214 chr7 150070282 150071455 + REPIN1 0x0 5215 chr7 150815954 150817053 + AGAP3 0x0 5216 chr7 150910175 150911551 − ABCF2 0x0 5217 chr7 150967839 150969008 − SMARCD3 0x0 5218 chr7 151215094 151216312 − RHEB 0x0 5219 chr7 151921067 151922240 − MLL3 0x2 5220 chr7 152097427 152098632 − MLL3 0x2 5221 chr7 155099915 155101047 + INSIG1 0x0 5222 chr7 155250236 155251340 + EN2 0x0 5223 chr7 155572294 155573527 + RBM33 0x0 5224 chr7 156473215 156474319 − LMBR1 0x0 5225 chr7 157131140 157132337 + DNAJB6 0x0 5226 chr7 157207302 157208421 + DNAJB6 0x0 5227 chr7 158482226 158483355 − NCAPG2 0x0 5228 chr7 158523818 158524891 − ESYT2 0x0 5229 chr7 158526068 158527207 − ESYT2 0x0 5230 chr8 171812 172992 − RPL23AP53 0x0 5231 chr8 650437 651644 − ERICH1 0x0 5232 chr8 1728071 1729269 + CLN8 0x2 5233 chr8 1851872 1853143 + ARHGEF10 0x2 5234 chr8 1892421 1893656 + ARHGEF10 0x2 5235 chr8 8719116 8720272 − MFHAS1 0x1 5236 chr8 9522657 9523873 + TNKS 0x0 5237 chr8 10543587 10544750 + C8orf74 0x0 5238 chr8 10553225 10554430 − SOX7 0x1 5239 chr8 10989659 10990816 − XKR6 0x0 5240 chr8 11018991 11020365 − XKR6 0x0 5241 chr8 11179720 11180920 + MTMR9 0x0 5242 chr8 14088163 14089374 − SGCZ 0x0 5243 chr8 14466831 14468007 − SGCZ 0x0 5244 chr8 15608483 15609698 + TUSC3 0x1 5245 chr8 16969800 16970982 + EFHA2 0x0 5246 chr8 16973468 16974591 + EFHA2 0x0 5247 chr8 17020725 17021901 + ZDHHC2 0x1 5248 chr8 17528806 17529982 − MTUS1 0x1 5249 chr8 17600589 17601753 − MTUS1 0x1 5250 chr8 21783081 21784262 + XPO7 0x2 5251 chr8 22273079 22274302 + SLC39A14 0x0 5252 chr8 22278525 22279701 + SLC39A14 0x0 5253 chr8 22993341 22994750 − TNFRSF10D 0x0 5254 chr8 23001245 23002452 − TNFRSF10D 0x0 5255 chr8 23118432 23119876 + CHMP7 0x0 5256 chr8 23933949 23935207 − STC1 0x2 5257 chr8 26466443 26467884 + DPYSL2 0x0 5258 chr8 26513085 26514287 + DPYSL2 0x0 5259 chr8 27626561 27627757 − CCDC25 0x0 5260 chr8 27642609 27643794 + ESCO2 0x0 5261 chr8 27661194 27662353 + ESCO2 0x0 5262 chr8 28610258 28611360 + EXTL3 0x1 5263 chr8 28925365 28926640 − K1F13B 0x0 5264 chr8 28973920 28975219 − KIF13B 0x0 5265 chr8 29191850 29193027 − DUSP4 0x0 5266 chr8 29926842 29927959 − TMEM66 0x0 5267 chr8 30535411 30536703 − GSR 0x0 5268 chr8 30918443 30919643 + WRN 0x2 5269 chr8 30941596 30942794 + WRN 0x2 5270 chr8 30973889 30975103 + WRN 0x2 5271 chr8 33307984 33309159 − FUT10 0x0 5272 chr8 33370435 33371696 + MAK16 0x0 5273 chr8 33405399 33406500 − RNF122 0x0 5274 chr8 37351279 37352488 − LOC728024 0x0 5275 chr8 37548760 37549962 − LOC728024 0x0 5276 chr8 37555657 37556832 + ZNF703 0x0 5277 chr8 37610997 37612138 + ERLIN2 0x0 5278 chr8 37734373 37735537 − RAB11FIP1 0x0 5279 chr8 37896767 37897965 + EIF4EBP1 0x0 5280 chr8 37964730 37965937 + ASH2L 0x0 5281 chr8 38238788 38240521 − WHSC1L1 0x1 5282 chr8 41789279 41790380 − KAT6A 0x2 5283 chr8 42069466 42070659 + AP3M2 0x0 5284 chr8 42751527 42752702 − RNF170 0x0 5285 chr8 48454145 48455421 + KIAA0146 0x0 5286 chr8 48690474 48691581 − PRKDC 0x0 5287 chr8 48719526 48720712 − PRKDC 0x0 5288 chr8 56698693 56699907 + TGS1 0x0 5289 chr8 56702837 56704080 + TGS1 0x0 5290 chr8 56792545 56793692 + LYN 0x0 5291 chr8 56986406 56987620 − RPS20 0x0 5292 chr8 56986406 56987620 − SNORD54 0x0 5293 chr8 59361453 59362789 + UBXN2B 0x0 5294 chr8 59495823 59497028 − NSMAF 0x0 5295 chr8 60367861 60369092 + SDCBP 0x0 5296 chr8 61141149 61142305 − CAS 0x0 5297 chr8 61380988 61382139 − CA8 0x0 5298 chr8 61428976 61430164 + RAB2A 0x0 5299 chr8 62558694 62559890 − ASPH 0x0 5300 chr8 65062889 65064025 − LOC401463 0x0 5301 chr8 67025014 67026251 + DNAJC5B 0x0 5302 chr8 67834131 67835343 − SNHG6 0x0 5303 chr8 67834131 67835343 − SNORD87 0x0 5304 chr8 67854441 67855579 − TCF24 0x0 5305 chr8 69218262 69219475 + C8orf34 0x0 5306 chr8 69628958 69630158 + C8orf34 0x0 5307 chr8 70601758 70603154 − SLC05A1 0x0 5308 chr8 71015648 71016846 − NCOA2 0x2 5309 chr8 71485199 71486420 − TRAM1 0x0 5310 chr8 72549549 72550725 − MSC 0x0 5311 chr8 73557323 73558542 + KCNB2 0x0 5312 chr8 74558696 74559805 − STAU2 0x0 5313 chr8 77776192 77777558 + ZFHX4 0x2 5314 chr8 80676493 80677670 − HEY1 0x2 5315 chr8 80708218 80709377 + STMN2 0x0 5316 chr8 81039463 81040687 − TPD52 0x0 5317 chr8 84510943 84512141 − C8orf59 0x0 5318 chr8 86191435 86192537 + CAB 0x0 5319 chr8 87528903 87530098 + CPNE3 0x0 5320 chr8 95406717 95407924 − RAD54B 0x0 5321 chr8 95854520 95855619 + INTS8 0x0 5322 chr8 98672727 98573911 + MTDH 0x0 5323 chr8 98817057 98818222 + LAPTM4B 0x0 5324 chr8 98827727 98828903 + LAPTM4B 0x0 5325 chr8 101485556 101486759 − ANKRD46 0x0 5326 chr8 101714872 101716041 − PABPC1 0x2 5327 chr8 101724361 101725581 − PABPC1 0x2 5328 chr8 101727184 101728357 − PABPC1 0x2 5329 chr8 101729540 101730664 − PABPC1 0x2 5330 chr8 101733058 101734450 − PABPC1 0x2 5331 chr8 102149814 102150984 + FU42969 0x0 5332 chr8 103423528 103424664 − UBR5 0x2 5333 chr8 103845897 103847028 − AZIN1 0x0 5334 chr8 106914349 106915532 − ABRA 0x0 5335 chr8 107709298 107710494 − ABRA 0x0 5336 chr8 110281595 110282791 − NUDCD1 0x0 5337 chr8 110353471 110354647 + ENY2 0x0 5338 chr8 116563419 116564599 − TRPS1 0x0 5339 chr8 119396638 119397854 − SAMD12 0x0 5340 chr8 120743496 120744716 − TAF2 0x2 5341 chr8 120874372 120875604 + DEPTOR 0x0 5342 chr8 121501990 121503167 + MTBP 0x0 5343 chr8 124025136 124026313 − DERL1 0x0 5344 chr8 124053823 124055003 − DERL1 0x0 5345 chr8 124095937 124097121 + WDR67 0x0 5346 chr8 124250286 124251573 − C8orf76 0x0 5347 chr8 124250286 124251573 − ZHX1-C8ORF76 0x0 5348 chr8 124511119 124512309 − FBXO32 0x1 5349 chr8 124826019 124827118 + FAM91A1 0x0 5350 chr8 125503049 125504257 + RNF139 0x0 5351 chr8 126257758 126258960 + NSMCE2 0x0 5352 chr8 126467614 126468814 + TRIB1 0x2 5353 chr8 126584427 126585626 + TRIB1 0x2 5354 chr8 128752709 128753881 + MYC 0x2 5355 chr8 128878369 128879800 + PVT1 0x0 5356 chr8 128902427 128903666 + PVT1 0x0 5357 chr8 129006031 129007240 + PVT1 0x0 5358 chr8 129232188 129233396 + MIR1208 0x0 5359 chr8 131369782 131370944 − ASAP1 0x0 5360 chr8 134249222 134250405 − NDRG1 0x1 5361 chr8 135602264 135603445 − ZFAT 0x4 5362 chr8 136484515 136485664 + KHDRBS3 0x0 5363 chr8 141539629 141540966 − EIF2C2 0x0 5364 chr8 141706964 141708108 − PTK2 0x0 5365 chr8 144390951 144392074 − TOP1MT 0x0 5366 chr8 144589736 144590895 − ZC3H3 0x0 5367 chr8 144623760 144624957 + GSDMD 0x0 5368 chr8 144656550 144657716 − NAPRT1 0x0 5369 chr8 144665432 144666631 − EEF1D 0x0 5370 chr8 144668416 144669512 − EEF1D 0x0 5371 chr8 144671344 144672503 − EEF1D 0x0 5372 chr8 144872867 144874212 − SCRIB 0x1 5373 chr8 144995170 144996345 − PLEC 0x0 5374 chr8 144996673 144997860 − PLEC 0x0 5375 chr8 145512299 145513597 − BOP1 0x0 5376 chr8 145514906 145516064 + HSF1 0x0 5377 chr8 145735164 145736323 + MFSD3 0x0 5378 chr8 145975673 145976844 − ZNF251 0x0 5379 chr8 146014646 146015821 − RPL8 0x0 5380 chr8 146016941 146018035 − RPL8 0x0 5381 chr9 579222 580422 + KANK1 0x1 5382 chr9 583912 585146 + KANK1 0x1 5383 chr9 2358753 2359971 − SMARCA2 0x1 5384 chr9 3214212 3215432 − KCNV2 0x0 5385 chr9 3508378 3509541 − RFX3 0x0 5386 chr9 4826335 4827507 + RCL1 0x0 5387 chr9 4833549 4834747 − RCL1 0x0 5388 chr9 5734043 5735202 + KIAA1432 0x0 5389 chr9 9441508 9442749 − KDM4C 0x0 5390 chr9 13124573 13125772 − MPDZ 0x0 5391 chr9 14611622 14612784 − ZDHHC21 0x0 5392 chr9 14640065 14641279 − ZDHHC21 0x0 5393 chr9 14921661 14922812 − FREM1 0x0 5394 chr9 15482841 15484138 − PSIP1 0x2 5395 chr9 15505342 15506551 − PSIP1 0x2 5396 chr9 16828016 16829203 − BNC2 0x0 5397 chr9 17413189 17414414 − CNTLN 0x0 5398 chr9 17440398 17441554 − BNC2 0x0 5399 chr9 19055113 19056309 − HAUS6 0x0 5400 chr9 19063173 19064362 − HAUS6 0x0 5401 chr9 19063173 19064362 − SCARNA8 0x0 5402 chr9 19372260 19373473 + DENNO4C 0x0 5403 chr9 19375853 19377070 − RPS6 0x0 5404 chr9 19377873 19380410 − RPS6 0x0 5405 chr9 19383288 19384499 + DENND4C 0x0 5406 chr9 20429737 20430924 − MLLT3 0x2 5407 chr9 20548245 20549446 − MIR4474 0x0 5408 chr9 20786340 20787535 + KIAA1797 0x0 5409 chr9 20810807 20811984 − MLLT3 0x2 5410 chr9 20896813 20898020 + KIAA1797 0x0 5411 chr9 20923117 20924315 + KIAA1797 0x0 5412 chr9 21332177 21333335 − KLHL9 0x0 5413 chr9 21698742 21700024 + MTAP 0x1 5414 chr9 21861943 21863042 + MTAP 0x1 5415 chr9 21867924 21869151 + MTAP 0x1 5416 chr9 21903931 21905084 + MTAP 0x1 5417 chr9 22081029 22082228 + CDKN2B-AS1 0x0 5418 chr9 25676769 25677898 − TUSC1 0x0 5419 chr9 26658888 26660011 + IFT74 0x0 5420 chr9 26935048 26936169 − PLAA 0x0 5421 chr9 28707158 28708331 − LINGO2 0x0 5422 chr9 28846936 28848152 − MIR876 0x0 5423 chr9 33011499 33012677 − APTX 0x0 5424 chr9 33023893 33025172 − SMU1 0x0 5425 chr9 33038376 33039941 + DNAJA1 0x0 5426 chr9 33318207 33319380 + NFX1 0x0 5427 chr9 33916595 33917697 + UBE2R2 0x0 5428 chr9 33952273 33953373 − SNORD121A 0x0 5429 chr9 33952273 33953373 − UBAP2 0x0 5430 chr9 33955557 33956731 − UBAP2 0x0 5431 chr9 33960256 33961456 − UBAP2 0x0 5432 chr9 33963170 33964252 − UBAP2 0x0 5433 chr9 34011964 34013151 − UBAP2 0x0 5434 chr9 34016524 34017695 − UBAP2 0x0 5435 chr9 34049409 34050630 − SNORD121B 0x0 5436 chr9 34087271 34088491 − DCAF12 0x0 5437 chr9 34185383 34186545 − UBAP1 0x0 5438 chr9 34282012 34283214 − KIF24 0x0 5439 chr9 34634177 34635546 − SIGMAR1 0x0 5440 chr9 35101379 35102543 − STOML2 0x0 5441 chr9 35398409 35399768 + UNC13B 0x0 5442 chr9 35547214 35548291 + RUSC2 0x0 5443 chr9 35657197 35658583 − RMRP 0x0 5444 chr9 35705464 35707665 − TLN1 0x2 5445 chr9 35712376 35713551 − TLN1 0x2 5446 chr9 35737757 35738923 − GBA2 0x0 5447 chr9 35748405 35749597 − GBA2 0x0 5448 chr9 36211270 36212469 − CLTA 0x0 5449 chr9 36215412 36216592 − GNE 0x0 5450 chr9 37161890 37162980 + ZCCHC7 0x0 5451 chr9 37180719 37181818 − ZCCHC7 0x0 5452 chr9 37394697 37395893 + GRHPR 0x0 5453 chr9 37425972 37427149 + GRHPR 0x0 5454 chr9 37757009 37758131 + RG9MTD3 0x0 5455 chr9 37776759 37777892 − EXOSC3 0x0 5456 chr9 38392326 38393556 + ALDH1B1 0x0 5457 chr9 38406249 38407526 − IGFBPL1 0x1 5458 chr9 38408287 38409466 − IGFBPL1 0x1 5459 chr9 38542057 38543182 − ANKRD18A 0x0 5460 chr9 38548716 38549888 − ANKRD18A 0x0 5461 chr9 45454163 45455328 + FAM27A 0x0 5462 chr9 66862489 66863606 − LOC286297 0x0 5463 chr9 72276359 72277573 − APBA1 0x4 5464 chr9 72802958 72804155 − LOC100507244 0x0 5465 chr9 74319441 74320649 − TMEM2 0x0 5466 chr9 77639260 77640400 − C9orf41 0x0 5467 chr9 79000589 79001744 − RFK 0x0 5468 chr9 79186185 79187441 + GCNT1 0x0 5469 chr9 80333954 80335131 − GNAQ 0x2 5470 chr9 80461575 80462760 − GNAQ 0x2 5471 chr9 80526971 80528160 − GNAQ 0x2 5472 chr9 80624392 80625619 − GNAQ 0x2 5473 chr9 81149233 81150432 + PSAT1 0x0 5474 chr9 82201319 82202535 + TIE4 0x2 5475 chr9 84036070 84037267 + FAM75D5 0x0 5476 chr9 84250539 84251853 − TLE1 0x0 5477 chr9 84486792 84487991 − TLE1 0x0 5478 chr9 85827443 85828601 − FRMD3 0x0 5479 chr9 86186741 86188057 − FRMD3 0x0 5480 chr9 86292867 86294079 − UBQIN1 0x0 5481 chr9 86582599 86583805 − HNRNPK 0x0 5482 chr9 86598602 86599787 + RMI1 0x0 5483 chr9 88260737 88261915 − AGTPBP1 0x0 5484 chr9 88307117 88308237 − AGTPBP1 0x0 5485 chr9 90115188 90116387 + DAPK1 0x1 5486 chr9 91925658 91926817 + CKS2 0x0 5487 chr9 94053627 94054823 − AUH 0x0 5488 chr9 94666775 94667954 − ROR2 0x0 5489 chr9 95017779 95019585 − IARS 0x0 5490 chr9 95026780 95027945 − IARS 0x0 5491 chr9 95148146 95149332 + CENPP 0x0 5492 chr9 95289868 95290971 + CENPP 0x0 5493 chr9 96054324 96055449 + WNK2 0x1 5494 chr9 96259226 96260410 + FAM120A 0x1 5495 chr9 96260521 96261610 + FAM120A 0x1 5496 chr9 96304540 96306154 + FAM120A 0x1 5497 chr9 96425818 96426994 + PHF2 0x0 5498 chr9 97626912 97628116 + MIR2278 0x0 5499 chr9 97747161 97748371 + C9orf3 0x0 5500 chr9 98205195 98206341 − PTCH1 0x1 5501 chr9 98665745 98667943 + C9orf102 0x0 5502 chr9 98703213 98704414 + C9orf102 0x0 5503 chr9 98864832 98866024 − LOC158434 0x0 5504 chr9 99541077 99542255 − ZNF510 0x0 5505 chr9 100434963 100436183 + NCBP1 0x0 5506 chr9 100443119 100444445 + NCBP1 0x0 5507 chr9 100777282 100778579 + ANP32B 0x0 5508 chr9 101495339 101496482 − ANKS6 0x0 5509 chr9 103086818 103087997 − TEX10 0x0 5510 chr9 105967533 105968751 + CYLC2 0x0 5511 chr9 108456322 108457519 + TMEM38B 0x0 5512 chr9 108535853 108537110 + TMEM38B 0x0 5513 chr9 108651081 108652249 + TMEM38B 0x0 5514 chr9 110089577 110090784 + RAD23B 0x0 5515 chr9 111650030 111651171 − IKBKAP 0x0 5516 chr9 111778364 111779477 − C9orf5 0x0 5517 chr9 111780160 111781373 − C9orf5 0x0 5518 chr9 111790148 111791333 − C9orf5 0x0 5519 chr9 111812360 111813518 − C9orf5 0x0 5520 chr9 113016565 113017668 − TXN 0x0 5521 chr9 113170031 113171232 + AKAP2 0x0 5522 chr9 113170031 113171232 + PALM2-AKAP2 0x0 5523 chr9 113740724 113741947 − LPAR1 0x0 5524 chr9 114176345 114177492 − KIAA0368 0x0 5525 chr9 114696644 114697810 + UGCG 0x0 5526 chr9 114796115 114797308 − SUSD1 0x0 5527 chr9 114802856 114804030 − SUSD1 0x0 5528 chr9 114980670 114981806 − PTBP3 0x0 5529 chr9 114993295 114994445 − PTBP3 0x0 5530 chr9 115013987 115015217 + HSDL2 0x0 5531 chr9 115248759 115249937 + KIAA1958 0x0 5532 chr9 115260536 115261678 + KIAA1958 0x0 5533 chr9 115335902 115337364 + KIAA1958 0x0 5534 chr9 115346600 115347807 + KIAA1958 0x0 5535 chr9 115424721 115426125 + KIAA1958 0x0 5536 chr9 115448029 115450211 − C9orf80 0x0 5537 chr9 115469920 115471091 − C9orf80 0x0 5538 chr9 115531377 115532567 + SNX30 0x0 5539 chr9 115682177 115683415 + SNX30 0x0 5540 chr9 116023582 116024730 + SLC31A1 0x0 5541 chr9 116792285 116793484 + ZNF618 0x0 5542 chr9 116815803 116817028 + ZNF618 0x0 5543 chr9 116991103 116992232 + COL27A1 0x0 5544 chr9 117068821 117069994 + COL27A1 0x0 5545 chr9 117359969 117361206 + ATP6V1G1 0x0 5546 chr9 117370634 117371856 − LOC100S0S478 0x0 5547 chr9 120844756 120846132 − ASTN2 0x0 5548 chr9 123227241 123228507 − CDK5RAP2 0x0 5549 chr9 123618193 123619372 − PHF19 0x0 5550 chr9 124101279 124102449 − STOM 0x0 5551 chr9 124544477 124545706 + DAB2IP 0x1 5552 chr9 124546847 124548061 + DAB2IP 0x1 5553 chr9 125641926 125643151 − RC3H2 0x0 5554 chr9 125641926 125643151 − SNORD90 0x0 5555 chr9 125842673 125843822 + RABGAP1 0x0 5556 chr9 126021388 126022620 − STRBP 0x0 5557 chr9 127115305 127116453 − PSMB7 0x0 5558 chr9 127194668 127195860 + GPR144 0x0 5559 chr9 127362373 127363500 + NR6A1 0x0 5560 chr9 127619641 127620905 − RPL35 0x0 5561 chr9 128099141 128100376 + GAPVD1 0x0 5562 chr9 128620793 128622016 + PBX3 0x0 5563 chr9 128985818 128987014 − NRON 0x0 5564 chr9 129456477 129457634 + LMX1B 0x4 5565 chr9 129461350 129462503 + LMX1B 0x4 5566 chr9 129567385 129568582 + ZBTB43 0x0 5567 chr9 130209656 130210776 − RPL12 0x0 5568 chr9 130547783 130548996 + CDK9 0x0 5569 chr9 130547783 130548996 + MIR2861 0x0 5570 chr9 130547783 130548996 + MIR3960 0x0 5571 chr9 130630132 130631339 − AK1 0x0 5572 chr9 130647627 130648808 − ST6GALNAC6 0x0 5573 chr9 130886273 130887511 − PTGES2 0x0 5574 chr9 131101823 131103019 − TRUB2 0x0 5575 chr9 131369703 131371031 + SPTAN1 0x2 5576 chr9 131457332 131458528 + SET 0x2 5577 chr9 131517208 131518346 − ZER1 0x0 5578 chr9 131668747 131669926 + LRRC8A 0x0 5579 chr9 131679585 131680770 + LRRC8A 0x0 5580 chr9 131727918 131729140 + NUP188 0x0 5581 chr9 131732532 131733679 + NUP188 0x0 5582 chr9 131770371 131771456 − SH3GLB2 0x0 5583 chr9 131773181 131774253 − SH3GLB2 0x0 5584 chr9 131832278 131833404 + FAM73B 0x0 5585 chr9 132266292 132267491 + LOC100506190 0x0 5586 chr9 132395806 132396981 + METTLUA 0x0 5587 chr9 132400461 132402140 − ASB6 0x0 5588 chr9 132650535 132651858 − FNBP1 0x2 5589 chr9 132899707 132901024 + GPR107 0x0 5590 chr9 132995682 132998198 + NCS1 0x0 5591 chr9 133576846 133578028 + EXOSC2 0x0 5592 chr9 133580429 133581619 + EXOSC2 0x0 5593 chr9 133690736 133691950 + ABL1 0x2 5594 chr9 133924803 133925919 + LAMC3 0x0 5595 chr9 133996060 133997384 + AIF1L 0x0 5596 chr9 134287069 134288195 + PRRC2B 0x0 5597 chr9 134304953 134306142 + PRRC2B 0x0 5598 chr9 134313808 134315037 + PRRC2B 0x0 5599 chr9 134319022 134320189 + PRRC2B 0x0 5600 chr9 134371214 134373009 + PRRC2B 0x0 5601 chr9 134374644 134375968 + PRRC2B 0x0 5602 chr9 134451766 134453602 − RAPGEF1 0x0 5603 chr9 134857136 134858315 − MED27 0x0 5604 chr9 134913794 134914897 − MED27 0x0 5605 chr9 135139556 135140719 − SETX 0x0 5606 chr9 135275910 135277087 − TTF1 0x0 5607 chr9 135483943 135485086 − DDX31 0x0 5608 chr9 135784782 135785881 − TSC1 0x1 5609 chr9 135924729 135925906 − GTF3C5 0x0 5610 chr9 135973592 135974691 − RALGDS 0x2 5611 chr9 135998700 136000170 − RALGDS 0x2 5612 chr9 136020317 136021667 − RALGDS 0x2 5613 chr9 136203824 136205001 − SURF6 0x0 5614 chr9 136216397 136217914 + RPL7A 0x0 5615 chr9 136216397 136217914 + SNORD36A 0x0 5616 chr9 136216397 136217914 + SNORD36B 0x0 5617 chr9 136216397 136217914 + SNORD36C 0x0 5618 chr9 136228108 136230784 − SURF4 0x0 5619 chr9 136474800 136475979 − FAM163B 0x0 5620 chr9 137023421 137024790 + WDR5 0x0 5621 chr9 137029029 137030228 − RNU6ATAC 0x0 5622 chr9 137305770 137306997 − RXRA 0x0 5623 chr9 138264957 138266133 + PPP1R26 0x0 5624 chr9 138651228 138652408 − CAMSAP1 0x0 5625 chr9 138772916 138775474 − CAMSAP1 0x0 5626 chr9 138835556 138836655 − UBAC1 0x0 5627 chr9 139098581 139099758 − QSOX2 0x0 5628 chr9 139248624 139249755 + GPSM1 0x0 5629 chr9 139252436 139253615 + GPSM1 0x0 5630 chr9 139270387 139271514 − SNAPC4 0x0 5631 chr9 139300843 139302303 − SDCCAG3 0x0 5632 chr9 139306000 139307223 + PMPCA 0x0 5633 chr9 139326284 139327462 − INPP5E 0x0 5634 chr9 139334317 139335518 − SEC16A 0x0 5635 chr9 139355237 139356585 − SEC16A 0x0 5636 chr9 139369167 139370266 − SEC16A 0x0 5637 chr9 139608470 139609690 + FAM69B 0x0 5638 chr9 139618664 139619796 − SNHG7 0x0 5639 chr9 139620014 139621238 − SNHG7 0x0 5640 chr9 139620014 139621238 − SNORA17 0x0 5641 chr9 139620014 139621238 − SNORA43 0x0 5642 chr9 139686353 139687562 + TMEM141 0x0 5643 chr9 139716292 139717458 + C9orf86 0x0 5644 chr9 139725678 139726811 + C9orf86 0x0 5645 chr9 139734812 139735981 + C9orf86 0x0 5646 chr9 139743402 139744501 + PHPT1 0x4 5647 chr9 139827010 139828223 + TRAF2 0x0 5648 chr9 139901384 139902524 − ABCA2 0x0 5649 chr9 139904579 139905686 − ABCA2 0x0 5650 chr9 139908105 139909204 − ABCA2 0x0 5651 chr9 139911510 139912639 − ABCA2 0x0 5652 chr9 139916992 139918141 − ABCA2 0x0 5653 chr9 139936983 139939048 − NPDC1 0x0 5654 chr9 139939110 139940262 − NPDC1 0x0 5655 chr9 139956840 139958016 − SAPCD2 0x0 5656 chr9 139972957 139974872 + UAP1L1 0x0 5657 chr9 140001474 140002681 + MAN1B1 0x0 5658 chr9 140078233 140079809 − ANAPC2 0x0 5659 chr9 140082995 140084194 + SSNA1 0x0 5660 chr9 140100452 140101634 + NDOR1 0x0 5661 chr9 140136707 140137882 + TUBB4B 0x0 5662 chr9 140147472 140148671 + C9orf173 0x0 5663 chr9 140169601 140170815 + C9orf167 0x0 5664 chr9 140279070 140280213 − EXD3 0x0 5665 chr9 140342309 140343845 − NELF 0x0 5666 chr9 140351347 140352478 − NELF 0x0 5667 chr9 140375375 140376591 − PNPLA7 0x0 5668 chr9 140481200 140482329 − ZMYND19 0x0 5669 chr9 140484130 140485265 − ZMYND19 0x0 5670 chr9 140637806 140638965 + EHMT1 0x0 5671 chr9 140729130 140730908 + EHMT1 0x0 5672 chr9 141054281 141055394 + TUBBP5 0x0 5673 chr9 141132390 141133605 + FAM157B 0x0 5674 chrX 3522243 3523476 − PRKX 0x2 5675 chrX 6340101 6341264 − MIR4770 0x0 5676 chrX 8326354 8327513 + VCX3B 0x2 5677 chrX 9543660 9544882 + TBL1X 0x0 5678 chrX 9571405 9572643 + TBL1X 0x0 5679 chrX 9862050 9863191 + SHROOM2 0x0 5680 chrX 11010346 11011488 − ARHGAP6 0x0 5681 chrX 14629215 14630428 − FANCB 0x0 5682 chrX 14876727 14877909 − FANCB 0x0 5683 chrX 15421374 15422561 − PIR-FIGF 0x0 5684 chrX 17091194 17092417 + REP52 0x0 5685 chrX 17300438 17301635 + NHS 0x0 5686 chrX 18372174 18373364 − SCML2 0x0 5687 chrX 20153607 20154922 − EIF1AX 0x0 5688 chrX 20153607 20154922 − SCARNA9L 0x0 5689 chrX 21576566 21577762 + CNKSR2 0x0 5690 chrX 22229861 22231058 + PHEX 0x0 5691 chrX 24095005 24096156 + EIF2S3 0x0 5692 chrX 24175280 24176442 + ZFX 0x0 5693 chrX 24196894 24198305 + ZFX 0x0 5694 chrX 24761177 24763241 + POLA1 0x0 5695 chrX 24761177 24763241 + SCARNA23 0x0 5696 chrX 24977492 24978688 + POLA1 0x0 5697 chrX 27399828 27401046 − SMEK3P 0x0 5698 chrX 29000399 29001566 − DCAF8L1 0x0 5699 chrX 30648152 30649398 + GK 0x0 5700 chrX 34233500 34234721 + FAM47B 0x0 5701 chrX 39645752 39646886 − BCOR 0x2 5702 chrX 40464569 40465726 + ATP6AP2 0x0 5703 chrX 41092038 41093252 + USP9X 0x0 5704 chrX 41207726 41208825 + DDX3X 0x1 5705 chrX 44736213 44737379 + KDM6A 0x2 5706 chrX 46299524 46300707 − ZNF674 0x0 5707 chrX 47081266 47082479 + CDK16 0x0 5708 chrX 47088062 47089227 + CDK16 0x0 5709 chrX 47495209 47496359 − ELK1 0x0 5710 chrX 47665780 47667007 + ZNF81 0x0 5711 chrX 47746834 47748055 + ZNF81 0x0 5712 chrX 48435453 48436647 + RBM3 0x0 5713 chrX 48462703 48463818 + WDR13 0x0 5714 chrX 48831187 48832583 − GRIPAP1 0x0 5715 chrX 49126721 49127934 − PPP1R3F 0x0 5716 chrX 49857672 49858823 + CLCN5 0x2 5717 chrX 51936036 51937238 + MAGED4 0x0 5718 chrX 51936036 51937238 + MAGED4B 0x0 5719 chrX 53106605 53107796 + GPR173 0x0 5720 chrX 53134334 53135497 + TSPYL2 0x0 5721 chrX 53405372 53407332 − SMC1A 0x0 5722 chrX 53569946 53571046 − HUWE1 0x0 5723 chrX 53618943 53620070 − HUWE1 0x0 5724 chrX 53673766 53675041 − HUWE1 0x0 5725 chrX 53792619 53793775 − HUWE1 0x0 5726 chrX 54594744 54595938 + GNL3L 0x0 5727 chrX 54596140 54597311 + GNL3L 0x0 5728 chrX 56992161 56993336 − SPIN3 0x0 5729 chrX 68004807 68006025 + EFNB1 0x0 5730 chrX 68379551 68380728 − PJA1 0x0 5731 chrX 68891771 68893024 + EDA 0x0 5732 chrX 69380277 69381519 + IGBP1 0x0 5733 chrX 69531191 69532421 + KIF4A 0x0 5734 chrX 69691179 69692344 + DLG3 0x2 5735 chrX 69720649 69721848 + DLG3 0x2 5736 chrX 70182424 70183623 + FOXO4 0x1 5737 chrX 70507281 70508462 − ZMYM3 0x0 5738 chrX 70520333 70521503 + NONO 0x2 5739 chrX 70602894 70604095 + TAF1 0x2 5740 chrX 70861969 70863207 + ACRC 0x0 5741 chrX 71570013 71571157 − HDAC8 0x0 5742 chrX 71596356 71597548 − HDAC8 0x0 5743 chrX 71769793 71770972 − HDAC8 0x0 5744 chrX 73046559 73048327 − XIST 0x4 5745 chrX 73052516 73053845 − XIST 0x4 5746 chrX 73057033 73059270 − XIST 0x4 5747 chrX 73062806 73063994 − XIST 0x4 5748 chrX 73069685 73073030 − XIST 0x4 5749 chrX 73170342 73171562 + JPX 0x0 5750 chrX 73430482 73431552 − MIR421 0x0 5751 chrX 73436680 73437810 − MIR421 0x0 5752 chrX 73482382 73483604 − FTX 0x0 5753 chrX 73494914 73496013 − FTX 0x0 5754 chrX 76923431 76924656 − ATRX 0x2 5755 chrX 77081697 77082848 − MAGT1 0x0 5756 chrX 77105733 77106914 − MAGT1 0x0 5757 chrX 79927079 79928302 − BRWD3 0x0 5758 chrX 81950478 81951677 − RPS6KA6 0x1 5759 chrX 85340420 85341609 − CHM 0x0 5760 chrX 96438715 96439906 + DIAPH2 0x0 5761 chrX 99410666 99411825 − PCDH19 0x0 5762 chrX 100289732 100290890 − TRMT2B 0x0 5763 chrX 100654698 100655907 − GLA 0x0 5764 chrX 100668386 100669571 + HNRNPH2 0x0 5765 chrX 100668386 100669571 + RPL36A-HNRNPH2 0x0 5766 chrX 100678736 100679933 + ARMCX4 0x0 5767 chrX 102108868 102110010 + LOC100287765 0x0 5768 chrX 102185541 102186736 + RAB40AL 0x0 5769 chrX 102632229 102633433 + NGFRAP1 0x0 5770 chrX 102930316 102931634 − MORF4L2 0x0 5771 chrX 103407200 103408423 + FAM199X 0x0 5772 chrX 103416323 103417521 + FAM199X 0x0 5773 chrX 105855261 105856451 + CXorf57 0x0 5774 chrX 106164212 106165373 − R1PPLY1 0x0 5775 chrX 106184082 106185253 − MORC4 0x0 5776 chrX 106236843 106238032 − MORC4 0x0 5777 chrX 106296930 106298133 − RBM41 0x0 5778 chrX 106312517 106313695 − RBM41 0x0 5779 chrX 106351735 106352899 − RBM41 0x0 5780 chrX 106956061 106957210 − TSC22D3 0x0 5781 chrX 107083544 107084738 + MID2 0x0 5782 chrX 107330418 107331641 − PSMD10 0x0 5783 chrX 107692109 107693273 + COL4A5 0x0 5784 chrX 107755369 107756586 + COL4A5 0x0 5785 chrX 107962711 107965128 − IRS4 0x2 5786 chrX 107965833 107966886 + IRS4 0x2 5787 chrX 107978161 107979977 − IRS4 0x2 5788 chrX 108296815 108298321 + COL4A5 0x0 5789 chrX 108885425 108886557 − ACSL4 0x0 5790 chrX 109418043 109419259 + TMEM164 0x0 5791 chrX 109419535 109421324 + TMEM164 0x0 5792 chrX 109440950 109442127 − AMMECR1 0x0 5793 chrX 110928049 110929158 + ALG13 0x0 5794 chrX 111556247 111557485 − ZCCHC16 0x0 5795 chrX 112018825 112019925 − AMOT 0x0 5796 chrX 112832649 112833826 − AMOT 0x0 5797 chrX 114388539 114389720 − LRCH2 0x0 5798 chrX 114860238 114861417 − LRCH2 0x0 5799 chrX 114883597 114884758 + PLS3 0x0 5800 chrX 114937422 114938740 + PLS3 0x0 5801 chrX 114952760 114953901 − LRCH2 0x0 5802 chrX 115033924 115035353 − CXorf61 0x0 5803 chrX 115051152 115052326 − cxorf61 0x0 5804 chrX 115108241 115109440 − CXorf61 0x0 5805 chrX 117333430 117334585 − KLHL13 0x0 5806 chrX 117512110 117513293 + WDR44 0x0 5807 chrX 118151592 118152740 + LONRF3 0x0 5808 chrX 118377285 118378507 + PGRMC1 0x0 5809 chrX 118557172 118558436 + SLC25A43 0x0 5810 chrX 118603146 118604243 + SLC25A5 0x0 5811 chrX 118717249 118718392 + UBE2A 0x2 5812 chrX 118919904 118921072 − RPL39 0x0 5813 chrX 119005351 119006450 + NDUFA1 0x0 5814 chrX 119390792 119391981 + ZBTB33 0x0 5815 chrX 119658057 119660511 − CUL4B 0x0 5816 chrX 122736393 122737568 − THOC2 0x0 5817 chrX 123041693 123042887 + XIAP 0x0 5818 chrX 123095598 123096767 + STAG2 0x0 5819 chrX 123234731 123236864 + STAG2 0x0 5820 chrX 128705605 128706804 + OCRL 0x0 5821 chrX 128725857 128727037 + OCRL 0x0 5822 chrX 129065075 129066245 − ZDHHC9 0x0 5823 chrX 129535551 129536727 − GPR119 0x0 5824 chrX 129538199 129539389 + RBMX2 0x0 5825 chrX 130882834 130884008 − LOC286467 0x0 5826 chrX 130889093 130890323 − LOC286467 0x0 5827 chrX 130902059 130903202 − LOC286467 0x0 5828 chrX 130917396 130918579 − LOC286467 0x0 5829 chrX 130927787 130929004 − LOC286467 0x0 5830 chrX 131198110 131199259 + MST4 0x0 5831 chrX 131337023 131338180 − RAP2C 0x0 5832 chrX 131512145 131513234 − MBNL3 0x0 5833 chrX 131760858 131762133 − HS6ST2 0x0 5834 chrX 132081206 132082401 − HS6ST2 0x0 5835 chrX 132435951 132437179 − GPC4 0x0 5836 chrX 132804697 132805894 + CCDC160 0x0 5837 chrX 133682855 133684020 − MIR424 0x0 5838 chrX 133683746 133684962 + LOC100506757 0x0 5839 chrX 133693934 133695138 + LOC100506757 0x0 5840 chrX 133750415 133751607 − PLAC1 0x0 5841 chrX 133904208 133905344 − FAM122B 0x0 5842 chrX 134169327 134170543 + FAM127A 0x0 5843 chrX 134685389 134686586 + DDX26B 0x0 5844 chrX 134700591 134701697 + DDX26B 0x0 5845 chrX 134704442 134705586 + DDX26B 0x0 5846 chrX 135044994 135047017 − MMGT1 0x0 5847 chrX 135292161 135293316 + FHL1 0x0 5848 chrX 135894541 135895736 − ARHGEF6 0x0 5849 chrX 135960801 135962006 − RBMX 0x1 5850 chrX 135960801 135962006 − SNORD61 0x0 5851 chrX 138051867 138053046 + LOC100129662 0x0 5852 chrX 138822633 138823803 − ATP11C 0x0 5853 chrX 139806745 139807946 + RP1-177G62 0x0 5854 chrX 144138226 144139456 + SPANXN1 0x0 5855 chrX 147024021 147025185 + FMR1 0x0 5856 chrX 147743371 147744594 + AFF2 0x2 5857 chrX 148615669 148616861 − LOC100131434 0x0 5858 chrX 148622764 148623954 + CXorf40A 0x0 5859 chrX 149101387 149102530 − CXorf40B 0x0 5860 chrX 149283200 149284299 + LOC100272228 0x0 5861 chrX 149932765 149933963 + MTMR1 0x0 5862 chrX 149934398 149936217 − CD99L2 0x0 5863 chrX 150156335 150157614 + HMGB3 0x0 5864 chrX 150347357 150348535 + GPR50 0x0 5865 chrX 152138729 152139828 + ZNF185 0x0 5866 chrX 152615120 152616281 + ZNF275 0x0 5867 chrX 152712573 152713786 − HAUS7 0x0 5868 chrX 152907741 152908844 + DUSP9 0x2 5869 chrX 152931282 152932454 + DUSP9 0x2 5870 chrX 152961002 152962294 + SLC6A8 0x0 5871 chrX 153061339 153062580 + SSR4 0x0 5872 chrX 153212601 153214292 − HCFC1 0x0 5873 chrX 153229508 153230711 − HCFC1 0x0 5874 chrX 153275908 153277630 − IRAK1 0x0 5875 chrX 153282970 153284121 − IRAK1 0x0 5876 chrX 153290837 153291997 − MECP2 0x0 5877 chrX 153329200 153330332 − MECP2 0x0 5878 chrX 153582804 153583968 − FLNA 0x2 5879 chrX 153590352 153591533 − FLNA 0x2 5880 chrX 153607528 153608725 + EMD 0x0 5881 chrX 153626228 153627408 + RPL10 0x1 5882 chrX 153648801 153649993 + TAZ 0x0 5883 chrX 153656522 153657630 + ATP6AP1 0x0 5884 chrX 153663803 153666133 + ATP6AP1 0x0 5885 chrX 153663803 153666133 + GDI1 0x0 5886 chrX 153670936 153672130 + GDI1 0x0 5887 chrX 153677138 153678294 + FAM50A 0x0 5888 chrX 153736962 153738109 − FAM3A 0x0 5889 chrX 153743942 153745077 − FAM3A 0x0 5890 chrX 153996235 153997439 + DKC1 0x0 5891 chrX 153996235 153997439 + SNORA36A 0x0 5892 chrX 154002693 154003854 + DKC1 0x0 5893 chrX 154002693 154003854 + SNORA56 0x0

Lengthy table referenced here US20220403380A1-20221222-T00001 Please refer to the end of the specification for access instructions.

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

LENGTHY TABLES The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20220403380A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

1.-36. (canceled)
 37. A method of reducing expression of a target interleukin 1 receptor-associated kinase 1 (IRAK1) gene in a cell, the method comprising delivering to the cell a single stranded oligonucleotide of 15 to 40 nucleotides in length having a region of complementarity that is complementary with at least 15 contiguous nucleotides of an IRAK1 RNA, wherein the oligonucleotide binds to or within 500 nt of SEQ ID NOs: 5874, 5875, 17389, 17390, or 17391, wherein PRC1 binding to the IRAK1 RNA is disrupted. 38.-41. (canceled)
 42. The method of claim 37, wherein the cell is in vitro.
 43. The method of claim 37, wherein the cell is in vivo.
 44. The method of claim 37, wherein at least one nucleotide of the oligonucleotide is a modified nucleotide. 45.-48. (canceled)
 49. The method of claim 37, wherein the oligonucleotide has complementarity to the IRAK1 RNA in a region of the IRAK1 RNA that forms a stem-loop structure.
 50. (canceled)
 51. The method of claim 37, wherein at least one nucleotide of the oligonucleotide is a ribonucleic acid analogue comprising a ribose ring having a bridge between its 2′-oxygen and 4′-carbon.
 52. The method of claim 51, wherein the ribonucleic acid analogue comprises a methylene bridge between the 2′-oxygen and the 4′-carbon.
 53. The method of claim 37, wherein at least one nucleotide of the oligonucleotide comprises a modified sugar moiety.
 54. The method of claim 53, wherein the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety.
 55. The method of claim 37, wherein the oligonucleotide comprises at least one modified internucleoside linkage.
 56. The method of claim 55, wherein the at least one modified internucleoside linkage is selected from phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
 57. The method of claim 37, wherein the oligonucleotide is configured such that hybridization of the single stranded oligonucleotide to the PRC1-binding RNA does not activate an RNAse H pathway in the cell. 58.-61. (canceled)
 62. The method of claim 37, wherein the cell is a cell of a male subject. 63.-67. (canceled)
 68. A method of isolating RNA sequences that interact with a selected protein, e.g., with chromatin complexes, in a cell, the method comprising: providing a cell expressing (i) a biotin ligase, e.g., BirA, and (ii) the protein of interest comprising a biotinylation sequence; exposing the cells to UV-crosslinking; lysing the cells, isolating protein-RNA complexes from the lysed cells, e.g., using avidin purification, e.g., streptavidin beads; washing the complexes in protein-denaturing conditions, e.g., high salt and detergent, e.g., using 8 M urea+0.1% SDS; and isolating the protein-RNA complexes. 69.-75. (canceled)
 76. A method for treating a subject with systemic lupus erythematosis, the method comprising administering a therapeutically effective amount of an inhibitory nucleic acid targeting a PRC1-binding region on IRAK1 RNA, preferably wherein the PRC1 binding region comprises SEQ ID NO:5874, 5875, or 17389-17391.
 77. The method of claim 76, comprising administering an inhibitory nucleic acid targeting a sequence within the 3′UTR of IRAK1.
 78. (canceled)
 79. The method of claim 76, wherein the inhibitory nucleic acid comprises at least one locked nucleotide (LNA). 80.-83. (canceled)
 84. The method of claim 37, wherein the oligonucleotide binds to or within 100 nt of SEQ ID NOs:5874, 5875, 17389, 17390, or
 17391. 85. The method of claim 37, wherein the oligonucleotide binds to or within SEQ ID NOs: 5874, 5875, 17389, 17390, or
 17391. 